{"79ce2380f14bdb096dba4ec433e6e851303b02b8": [["plasma from convalescent donors should be recovered rapidly after symptoms resolution.", [["plasma", "ANATOMY", 0, 6], ["plasma", "ORGANISM_SUBSTANCE", 0, 6], ["donors", "ORGANISM", 25, 31], ["convalescent donors", "TREATMENT", 12, 31], ["symptoms resolution", "PROBLEM", 66, 85]]], ["48MAIN TEXT 51Until an efficient vaccine to protect from SARS-CoV-2 infection is available, alternative 52 approaches to treat or prevent acute COVID-19 are urgently needed.", [["SARS-CoV-2 infection", "DISEASE", 57, 77], ["SARS-CoV-2", "ORGANISM", 57, 67], ["CoV-2", "SPECIES", 62, 67], ["SARS-CoV-2", "SPECIES", 57, 67], ["an efficient vaccine", "TREATMENT", 20, 40], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 infection", "PROBLEM", 66, 77], ["acute COVID", "PROBLEM", 138, 149]]], ["A promising approach is the 53 use of convalescent plasma containing anti-SARS-CoV-2 antibodies collected from donors who 54 have recovered from COVID-19 (1).", [["plasma", "ANATOMY", 51, 57], ["COVID-19", "CHEMICAL", 145, 153], ["convalescent", "ORGANISM", 38, 50], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["anti-SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 69, 95], ["donors", "ORGANISM", 111, 117], ["anti-SARS-CoV-2 antibodies", "PROTEIN", 69, 95], ["convalescent plasma", "TEST", 38, 57], ["anti-SARS", "TEST", 69, 78], ["CoV-2 antibodies", "TEST", 79, 95], ["COVID", "TEST", 145, 150]]], ["Convalescent plasma therapy was successfully used in the 55 treatment of SARS, MERS and influenza H1N1 pandemics and was associated with 56 improvement of clinical outcomes (2-4).", [["plasma", "ANATOMY", 13, 19], ["SARS", "DISEASE", 73, 77], ["MERS", "DISEASE", 79, 83], ["influenza H1N1 pandemics", "DISEASE", 88, 112], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["Convalescent plasma therapy", "TREATMENT", 0, 27], ["SARS", "PROBLEM", 73, 77], ["MERS", "PROBLEM", 79, 83], ["influenza H1N1 pandemics", "PROBLEM", 88, 112], ["plasma therapy", "OBSERVATION", 13, 27]]], ["Experience to date shows that the passive transfer of 57 convalescent plasma to acute COVID-19 patients has been shown to be well tolerated and 58 presented some hopeful signs (5-9).", [["plasma", "ANATOMY", 70, 76], ["convalescent", "ORGANISM", 57, 69], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["acute COVID", "TEST", 80, 91]]], ["In one study, the convalescent plasma used had high titers of 59MAIN TEXT 51IgG to SARS-CoV-2 (at least 1:1640), which correlated positively with neutralizing activity (10).", [["plasma", "ANATOMY", 31, 37], ["convalescent", "ORGANISM", 18, 30], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["SARS-CoV", "SPECIES", 83, 91], ["one study", "TEST", 3, 12], ["the convalescent plasma", "TEST", 14, 37], ["high titers", "TEST", 47, 58], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["neutralizing activity", "OBSERVATION", 146, 167]]], ["60MAIN TEXT 51While it remains to be formally demonstrated, neutralizing activity is considered an important 61 determinant of convalescent plasma efficacy (11) and regulatory agencies have been 62 recommending specific thresholds for qualifying convalescent plasma prior to its release.", [["plasma", "ANATOMY", 140, 146], ["plasma", "ANATOMY", 259, 265], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["plasma", "ORGANISM_SUBSTANCE", 259, 265], ["convalescent plasma efficacy", "TEST", 127, 155], ["qualifying convalescent plasma", "TREATMENT", 235, 265]]], ["While 63 neutralizing function has been associated with protection against reinfection in rhesus macaques 64 expressing VSV-G.", [["rhesus macaques", "ORGANISM", 90, 105], ["VSV-G.", "ORGANISM", 120, 126], ["rhesus macaques", "SPECIES", 90, 105], ["rhesus macaques", "SPECIES", 90, 105], ["VSV-G.", "SPECIES", 120, 126], ["reinfection", "PROBLEM", 75, 86]]], ["Neutralizing activity against pseudoparticles bearing the SARS-CoV S 120 glycoprotein was detected in only 25% of convalescent plasma and exhibited low potency, as 121 previously reported (Figure 2) (14) .", [["plasma", "ANATOMY", 127, 133], ["SARS", "DISEASE", 58, 62], ["SARS-CoV S 120 glycoprotein", "GENE_OR_GENE_PRODUCT", 58, 85], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["SARS-CoV S 120 glycoprotein", "PROTEIN", 58, 85], ["SARS-CoV", "SPECIES", 58, 66], ["the SARS", "TEST", 54, 62], ["CoV S", "TEST", 63, 68], ["glycoprotein", "TEST", 73, 85], ["convalescent plasma", "TEST", 114, 133], ["low potency", "OBSERVATION_MODIFIER", 148, 159]]], ["Of note, while we observed enhanced infectivity for the 122 D614G variant compared to its WT SARS-CoV-2 S counterpart ( Figure S3A ), no major 123 differences in neutralization with convalescent plasma were detected at both time-points ( Figure 124 S3B), thus suggesting that the D614G change does not affect the overall conformation of the 125 Spike, in agreement with recent findings (18) .", [["plasma", "ANATOMY", 195, 201], ["D614G", "GENE_OR_GENE_PRODUCT", 60, 65], ["plasma", "ORGANISM_SUBSTANCE", 195, 201], ["Spike", "GENE_OR_GENE_PRODUCT", 345, 350], ["122 D614G variant", "PROTEIN", 56, 73], ["125 Spike", "PROTEIN", 341, 350], ["enhanced infectivity", "PROBLEM", 27, 47], ["its WT SARS", "TEST", 86, 97], ["CoV", "TEST", 98, 101], ["major 123 differences in neutralization", "PROBLEM", 137, 176], ["convalescent plasma", "TEST", 182, 201], ["the D614G change", "PROBLEM", 276, 292]]], ["126 127 The capacity to neutralize SARS-CoV-2 S WT or D614G-pseudotyped particles 128 significantly correlated with the presence of RBD-specific IgG, IgM and anti-S antibodies 129 ( Figure S4 ).", [["SARS-CoV-2 S WT", "ORGANISM", 35, 50], ["D614G", "GENE_OR_GENE_PRODUCT", 54, 59], ["pseudotyped", "ORGANISM", 60, 71], ["RBD", "GENE_OR_GENE_PRODUCT", 132, 135], ["IgG", "GENE_OR_GENE_PRODUCT", 145, 148], ["IgM", "GENE_OR_GENE_PRODUCT", 150, 153], ["RBD", "PROTEIN", 132, 135], ["IgG", "PROTEIN", 145, 148], ["IgM", "PROTEIN", 150, 153], ["anti-S antibodies 129", "PROTEIN", 158, 179], ["The capacity", "TEST", 8, 20], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["WT", "TEST", 48, 50], ["D614G-pseudotyped particles", "TEST", 54, 81], ["RBD", "TEST", 132, 135], ["specific IgG", "TEST", 136, 148], ["IgM", "TEST", 150, 153], ["anti-S antibodies", "TEST", 158, 175]]], ["Interestingly, we observed a pronounced decrease (20-30%) in the percentage of 130 patients able to neutralize pseudoparticles bearing SARS-CoV-2 S glycoprotein between 6 and 131 10 weeks after symptoms onset.", [["patients", "ORGANISM", 83, 91], ["SARS-CoV-2 S glycoprotein", "PROTEIN", 135, 160], ["patients", "SPECIES", 83, 91], ["a pronounced decrease", "PROBLEM", 27, 48], ["CoV", "TEST", 140, 143], ["symptoms", "PROBLEM", 194, 202], ["pronounced", "OBSERVATION_MODIFIER", 29, 39], ["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["Moreover, with plasma that still neutralized, the neutralization 132 activity significantly decreased between these two time-points ( Figure 2C ).", [["plasma", "ANATOMY", 15, 21], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["the neutralization", "TEST", 46, 64]]], ["Interestingly, RBD-133 specific IgM and neutralizing activity declined more significantly in convalescent plasma 134 overtime compared to RBD-specific IgG and anti-S Abs ( Figure S5A , B).", [["plasma", "ANATOMY", 106, 112], ["RBD-133", "GENE_OR_GENE_PRODUCT", 15, 22], ["IgM", "GENE_OR_GENE_PRODUCT", 32, 35], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["B", "GENE_OR_GENE_PRODUCT", 185, 186], ["RBD", "PROTEIN", 15, 18], ["IgM", "PROTEIN", 32, 35], ["RBD", "PROTEIN", 138, 141], ["IgG", "PROTEIN", 151, 154], ["anti-S Abs", "PROTEIN", 159, 169], ["Figure S5A , B", "PROTEIN", 172, 186], ["RBD", "TEST", 15, 18], ["specific IgM", "TEST", 23, 35], ["neutralizing activity", "TEST", 40, 61], ["convalescent plasma", "TEST", 93, 112], ["RBD", "TEST", 138, 141], ["specific IgG", "TEST", 142, 154], ["anti-S Abs", "TEST", 159, 169]]], ["Moreover, while the 135 loss of neutralizing activity on the WT and D614G pseudoparticles over time correlated with the 136 loss of anti-RBD IgM and IgG antibodies, the correlation was higher for IgM than IgG ( Figure 137 S5C, D), suggesting that at least part of the neutralizing activity could be mediated by IgM, as 138 recently proposed (13, 14) .", [["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 132, 144], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 149, 163], ["IgM", "GENE_OR_GENE_PRODUCT", 196, 199], ["IgM", "GENE_OR_GENE_PRODUCT", 311, 314], ["RBD IgM", "PROTEIN", 137, 144], ["IgG antibodies", "PROTEIN", 149, 163], ["IgM", "PROTEIN", 196, 199], ["IgG", "PROTEIN", 205, 208], ["IgM", "PROTEIN", 311, 314], ["neutralizing activity", "PROBLEM", 32, 53], ["the WT and D614G pseudoparticles", "TREATMENT", 57, 89], ["anti-RBD IgM", "TEST", 132, 144], ["IgG antibodies", "TEST", 149, 163], ["IgM", "TEST", 196, 199], ["IgG", "TEST", 205, 208], ["Figure", "TEST", 211, 217], ["the neutralizing activity", "PROBLEM", 264, 289], ["IgM", "TEST", 311, 314], ["neutralizing activity", "OBSERVATION", 268, 289]]], ["139140In summary, our study indicates that plasma neutralization activity keeps decreasing 141 passed the sixth week of symptom onset (14).", [["plasma", "ANATOMY", 43, 49], ["139140", "CHEMICAL", 0, 6], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["139140", "SPECIES", 0, 6], ["our study", "TEST", 18, 27], ["plasma neutralization activity", "TEST", 43, 73]]], ["It is currently unknown whether neutralizing activity is truly driving the efficacy of convalescent plasma in acute Figure S3 .", [["plasma", "ANATOMY", 100, 106], ["plasma", "ORGANISM_SUBSTANCE", 100, 106], ["convalescent plasma in acute Figure S3", "PROBLEM", 87, 125], ["neutralizing", "OBSERVATION", 32, 44], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["Figure S3", "OBSERVATION", 116, 125]]], ["D614G mutation enhances SARS-CoV-2 infectivity but does not affect its susceptibility to plasma neutralization.(A) Reverse Transcriptase normalized levels of pseudoviral particles bearing the SARS-CoV-2 S WT or D614G variant were used to infect 293T/ACE2 cells and infectivity measured 48h later by luciferase activity.", [["plasma", "ANATOMY", 89, 95], ["293T/ACE2 cells", "ANATOMY", 245, 260], ["D614G", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["plasma", "ORGANISM_SUBSTANCE", 89, 95], ["SARS-CoV-2 S WT", "ORGANISM", 192, 207], ["D614G", "GENE_OR_GENE_PRODUCT", 211, 216], ["293T", "CELL", 245, 249], ["ACE2", "GENE_OR_GENE_PRODUCT", 250, 254], ["luciferase", "GENE_OR_GENE_PRODUCT", 299, 309], ["Reverse Transcriptase", "PROTEIN", 115, 136], ["293T", "CELL_LINE", 245, 249], ["ACE2 cells", "CELL_LINE", 250, 260], ["luciferase", "PROTEIN", 299, 309], ["SARS-CoV", "SPECIES", 192, 200], ["plasma neutralization", "TEST", 89, 110], ["pseudoviral particles", "PROBLEM", 158, 179], ["the SARS", "TEST", 188, 196], ["CoV", "TEST", 197, 200], ["D614G variant", "PROBLEM", 211, 224], ["ACE2 cells", "TEST", 250, 260], ["infectivity", "TEST", 265, 276]]], ["Graph shown represents the percentage of infectivity relative to pseudoviral particle bearing the SARS-CoV-2 S WT.", [["SARS-CoV-2 S WT", "ORGANISM", 98, 113], ["infectivity", "PROBLEM", 41, 52], ["the SARS", "TEST", 94, 102], ["percentage", "OBSERVATION_MODIFIER", 27, 37], ["infectivity", "OBSERVATION", 41, 52], ["pseudoviral particle", "OBSERVATION", 65, 85]]], ["(B) Comparison between the neutralization ID 50 from pseudoparticles bearing SARS-CoV-2 S WT and SARS-CoV-2 S D614G.", [["SARS-CoV-2 S D614G", "DNA", 97, 115], ["SARS-CoV", "SPECIES", 97, 105], ["the neutralization ID", "TEST", 23, 44], ["pseudoparticles bearing SARS", "TEST", 53, 81], ["CoV", "TEST", 82, 85], ["WT", "TEST", 90, 92], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105]]], ["Statistical significance was tested using Wilcoxon matched-pairs signed rank test. (ns, not significant).", [["significant", "OBSERVATION_MODIFIER", 92, 103]]]], "e540a478a53e0a612773e9238ab0d99ad1398777": [["especially the elderly and those with pre-existing health issues or immunocompromised, COVID-19 can progress from mild symptoms or signs, such as low-grade fever, h e a d a c h e , c o n j u n c t i v i t i s , r h i n o r r h e a , a n o s m i a , pharyngodynia, ageusia, cough, chills, myalgia, asthenia, skin rash, nausea vomiting, and diarrhea, to pneumonia, acute respiratory distress syndrome, renal insufficiency, disseminate intravascular coagulation, and multiple organ failure [1] .", [["skin", "ANATOMY", 307, 311], ["respiratory", "ANATOMY", 369, 380], ["renal", "ANATOMY", 400, 405], ["intravascular", "ANATOMY", 433, 446], ["organ", "ANATOMY", 473, 478], ["low-grade fever", "DISEASE", 146, 161], ["pharyngodynia", "DISEASE", 249, 262], ["ageusia", "DISEASE", 264, 271], ["cough", "DISEASE", 273, 278], ["chills", "DISEASE", 280, 286], ["myalgia", "DISEASE", 288, 295], ["asthenia", "DISEASE", 297, 305], ["skin rash", "DISEASE", 307, 316], ["nausea vomiting", "DISEASE", 318, 333], ["diarrhea", "DISEASE", 339, 347], ["pneumonia", "DISEASE", 352, 361], ["acute respiratory distress syndrome", "DISEASE", 363, 398], ["renal insufficiency", "DISEASE", 400, 419], ["intravascular coagulation", "DISEASE", 433, 458], ["organ failure", "DISEASE", 473, 486], ["skin", "ORGAN", 307, 311], ["renal", "ORGAN", 400, 405], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 433, 446], ["organ", "ORGAN", 473, 478], ["immunocompromised", "PROBLEM", 68, 85], ["mild symptoms", "PROBLEM", 114, 127], ["signs, such as low-grade fever", "PROBLEM", 131, 161], ["a", "PROBLEM", 245, 246], ["pharyngodynia", "PROBLEM", 249, 262], ["ageusia", "PROBLEM", 264, 271], ["cough", "PROBLEM", 273, 278], ["chills", "PROBLEM", 280, 286], ["myalgia", "PROBLEM", 288, 295], ["asthenia", "PROBLEM", 297, 305], ["skin rash", "PROBLEM", 307, 316], ["nausea", "PROBLEM", 318, 324], ["vomiting", "PROBLEM", 325, 333], ["diarrhea", "PROBLEM", 339, 347], ["pneumonia", "PROBLEM", 352, 361], ["acute respiratory distress syndrome", "PROBLEM", 363, 398], ["renal insufficiency", "PROBLEM", 400, 419], ["disseminate intravascular coagulation", "PROBLEM", 421, 458], ["multiple organ failure", "PROBLEM", 464, 486], ["ageusia", "ANATOMY", 264, 271], ["skin", "ANATOMY", 307, 311], ["rash", "OBSERVATION", 312, 316], ["diarrhea", "OBSERVATION", 339, 347], ["pneumonia", "OBSERVATION", 352, 361], ["acute", "OBSERVATION_MODIFIER", 363, 368], ["respiratory distress", "OBSERVATION", 369, 389], ["syndrome", "OBSERVATION", 390, 398], ["renal", "ANATOMY", 400, 405], ["insufficiency", "OBSERVATION", 406, 419], ["intravascular coagulation", "OBSERVATION", 433, 458], ["multiple", "OBSERVATION_MODIFIER", 464, 472], ["organ", "ANATOMY", 473, 478], ["failure", "OBSERVATION", 479, 486]]], ["A marked lymphopenia has been observed in the most serious cases of the disease [2] .", [["lymphopenia", "DISEASE", 9, 20], ["A marked lymphopenia", "PROBLEM", 0, 20], ["the disease", "PROBLEM", 68, 79], ["marked", "OBSERVATION_MODIFIER", 2, 8], ["lymphopenia", "OBSERVATION", 9, 20], ["most serious", "OBSERVATION_MODIFIER", 46, 58], ["disease", "OBSERVATION", 72, 79]]], ["EBV belongs to the Herpesviridae family and causes infectious mononucleosis as well as chronic active infections; besides, it can induce various pre-cancerous or cancerous lymphoproliferative disorders, such as mucocutaneous ulcer, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B cell lymphoma, plasmablastic lymphoma, plasma cell myeloma, angioimmunoblastic T cell lymphoma, follicular T cell lymphoma, extranodal NK/T cell lymphoma, and aggressive NK cell leukemia, particularly in immunodeficient and/or post-transplanted patients [3] .", [["pre-cancerous", "ANATOMY", 145, 158], ["cancerous lymphoproliferative", "ANATOMY", 162, 191], ["mucocutaneous ulcer", "ANATOMY", 211, 230], ["Hodgkin lymphoma", "ANATOMY", 232, 248], ["Burkitt lymphoma", "ANATOMY", 250, 266], ["diffuse large B cell lymphoma", "ANATOMY", 268, 297], ["plasmablastic lymphoma", "ANATOMY", 299, 321], ["plasma cell myeloma", "ANATOMY", 323, 342], ["angioimmunoblastic T cell lymphoma", "ANATOMY", 344, 378], ["follicular T cell lymphoma", "ANATOMY", 380, 406], ["extranodal NK/T cell lymphoma", "ANATOMY", 408, 437], ["NK cell leukemia", "ANATOMY", 454, 470], ["infectious mononucleosis", "DISEASE", 51, 75], ["chronic active infections", "DISEASE", 87, 112], ["lymphoproliferative disorders", "DISEASE", 172, 201], ["mucocutaneous ulcer", "DISEASE", 211, 230], ["Hodgkin lymphoma", "DISEASE", 232, 248], ["Burkitt lymphoma", "DISEASE", 250, 266], ["large B cell lymphoma", "DISEASE", 276, 297], ["plasmablastic lymphoma", "DISEASE", 299, 321], ["plasma cell myeloma", "DISEASE", 323, 342], ["angioimmunoblastic T cell lymphoma", "DISEASE", 344, 378], ["follicular T cell lymphoma", "DISEASE", 380, 406], ["NK/T cell lymphoma", "DISEASE", 419, 437], ["NK cell leukemia", "DISEASE", 454, 470], ["EBV", "ORGANISM", 0, 3], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 19, 32], ["mucocutaneous ulcer", "PATHOLOGICAL_FORMATION", 211, 230], ["Hodgkin lymphoma", "CANCER", 232, 248], ["Burkitt lymphoma", "CANCER", 250, 266], ["diffuse large B cell lymphoma", "CANCER", 268, 297], ["plasmablastic lymphoma", "CANCER", 299, 321], ["plasma cell myeloma", "CANCER", 323, 342], ["angioimmunoblastic T cell lymphoma", "CANCER", 344, 378], ["follicular T cell lymphoma", "CANCER", 380, 406], ["extranodal NK/T cell lymphoma", "CANCER", 408, 437], ["NK cell leukemia", "CANCER", 454, 470], ["patients", "ORGANISM", 529, 537], ["patients", "SPECIES", 529, 537], ["infectious mononucleosis", "PROBLEM", 51, 75], ["chronic active infections", "PROBLEM", 87, 112], ["various pre-cancerous or cancerous lymphoproliferative disorders", "PROBLEM", 137, 201], ["mucocutaneous ulcer", "PROBLEM", 211, 230], ["Hodgkin lymphoma", "PROBLEM", 232, 248], ["Burkitt lymphoma", "PROBLEM", 250, 266], ["diffuse large B cell lymphoma", "PROBLEM", 268, 297], ["plasmablastic lymphoma", "PROBLEM", 299, 321], ["plasma cell myeloma", "PROBLEM", 323, 342], ["angioimmunoblastic T cell lymphoma", "PROBLEM", 344, 378], ["follicular T cell lymphoma", "PROBLEM", 380, 406], ["extranodal NK/T cell lymphoma", "PROBLEM", 408, 437], ["aggressive NK cell leukemia", "PROBLEM", 443, 470], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["active", "OBSERVATION_MODIFIER", 95, 101], ["infections", "OBSERVATION", 102, 112], ["cancerous lymphoproliferative disorders", "OBSERVATION", 162, 201], ["mucocutaneous", "OBSERVATION_MODIFIER", 211, 224], ["ulcer", "OBSERVATION", 225, 230], ["Hodgkin lymphoma", "OBSERVATION", 232, 248], ["Burkitt lymphoma", "OBSERVATION", 250, 266], ["diffuse", "OBSERVATION_MODIFIER", 268, 275], ["large", "OBSERVATION_MODIFIER", 276, 281], ["B cell lymphoma", "OBSERVATION", 282, 297], ["plasmablastic lymphoma", "OBSERVATION", 299, 321], ["plasma cell myeloma", "OBSERVATION", 323, 342], ["angioimmunoblastic T cell lymphoma", "OBSERVATION", 344, 378], ["follicular T cell lymphoma", "OBSERVATION", 380, 406], ["extranodal NK", "OBSERVATION", 408, 421], ["T cell lymphoma", "OBSERVATION", 422, 437], ["aggressive", "OBSERVATION_MODIFIER", 443, 453], ["NK cell leukemia", "OBSERVATION", 454, 470]]], ["In these subjects, the synergic action of EBV and SARS-CoV-2 is assumed to be burden by a very high fatality rate.", [["SARS", "DISEASE", 50, 54], ["EBV", "ORGANISM", 42, 45], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["EBV", "PROBLEM", 42, 45], ["SARS", "PROBLEM", 50, 54], ["a very high fatality rate", "PROBLEM", 88, 113]]]], "51f0c030960b63911b3af89389bedc621813c442": [["IntroductionCoxiella burnetii is a Gram-negative bacterium that causes Q fever in humans.", [["Coxiella burnetii", "DISEASE", 12, 29], ["Q fever", "DISEASE", 71, 78], ["Coxiella burnetii", "ORGANISM", 12, 29], ["Gram-", "GENE_OR_GENE_PRODUCT", 35, 40], ["humans", "ORGANISM", 82, 88], ["Coxiella burnetii", "SPECIES", 12, 29], ["humans", "SPECIES", 82, 88], ["Coxiella burnetii", "SPECIES", 12, 29], ["humans", "SPECIES", 82, 88], ["Coxiella burnetii", "PROBLEM", 12, 29], ["a Gram-negative bacterium", "PROBLEM", 33, 58], ["Q fever in humans", "PROBLEM", 71, 88]]], ["It targets macrophage cells of body tissues (e.g., lymph nodes, spleen, lungs, and liver) and circulating monocytes (Eldin et al., 2017) .", [["macrophage cells", "ANATOMY", 11, 27], ["body tissues", "ANATOMY", 31, 43], ["lymph nodes", "ANATOMY", 51, 62], ["spleen", "ANATOMY", 64, 70], ["lungs", "ANATOMY", 72, 77], ["liver", "ANATOMY", 83, 88], ["monocytes", "ANATOMY", 106, 115], ["macrophage cells", "CELL", 11, 27], ["body tissues", "TISSUE", 31, 43], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 51, 62], ["spleen", "ORGAN", 64, 70], ["lungs", "ORGAN", 72, 77], ["liver", "ORGAN", 83, 88], ["monocytes", "CELL", 106, 115], ["macrophage cells", "CELL_TYPE", 11, 27], ["circulating monocytes", "CELL_TYPE", 94, 115], ["body tissues", "TEST", 31, 43], ["lymph nodes", "TEST", 51, 62], ["macrophage cells", "OBSERVATION", 11, 27], ["body tissues", "ANATOMY", 31, 43], ["lymph nodes", "OBSERVATION", 51, 62], ["spleen", "ANATOMY", 64, 70], ["lungs", "ANATOMY", 72, 77], ["liver", "ANATOMY", 83, 88], ["circulating monocytes", "ANATOMY", 94, 115]]], ["Several genetic studies have been performed on C. burnetii strains showing that the chromosomes varied in size from 1.5 to 2.4 base pairs and were highly variable among different strains.", [["chromosomes", "ANATOMY", 84, 95], ["C. burnetii", "ORGANISM", 47, 58], ["chromosomes", "CELLULAR_COMPONENT", 84, 95], ["chromosomes", "DNA", 84, 95], ["C. burnetii", "SPECIES", 47, 58], ["C. burnetii", "SPECIES", 47, 58], ["Several genetic studies", "TEST", 0, 23], ["C. burnetii strains", "PROBLEM", 47, 66], ["the chromosomes", "TEST", 80, 95], ["base pairs", "TEST", 127, 137], ["varied", "OBSERVATION_MODIFIER", 96, 102], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["Indeed, recent data showed that genetic variation had an apparent closer connection with the geographical source of the isolate with clinical presentation (Honarmand, 2012) .", [["genetic variation", "PROBLEM", 32, 49]]], ["Furthermore, host factors are reasonably more important than genomic variation in developing acute or chronic disease (Porter et al., 2011) . at first it was detected as a rickettsia-like organism in the spleen and liver of mice treated with the urine of the slaughterhouse workers (Porter et al., 2011; Mitscherlich and Marth, 2012) .", [["spleen", "ANATOMY", 204, 210], ["liver", "ANATOMY", 215, 220], ["urine", "ANATOMY", 246, 251], ["acute or chronic disease", "DISEASE", 93, 117], ["spleen", "ORGAN", 204, 210], ["liver", "ORGAN", 215, 220], ["mice", "ORGANISM", 224, 228], ["urine", "ORGANISM_SUBSTANCE", 246, 251], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 224, 228], ["developing acute or chronic disease", "PROBLEM", 82, 117], ["a rickettsia", "PROBLEM", 170, 182], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["disease", "OBSERVATION", 110, 117], ["rickettsia", "OBSERVATION", 172, 182], ["spleen", "ANATOMY", 204, 210], ["liver", "ANATOMY", 215, 220]]], ["Human Q fever usually has a subclinical course or a mild course characterized by transient flu-like symptoms.", [["Q fever", "DISEASE", 6, 13], ["flu-like symptoms", "DISEASE", 91, 108], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human Q fever", "PROBLEM", 0, 13], ["a mild course", "PROBLEM", 50, 63], ["transient flu-like symptoms", "PROBLEM", 81, 108], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["transient", "OBSERVATION_MODIFIER", 81, 90], ["flu", "OBSERVATION", 91, 94]]], ["Rarely, more severe conditions such as pneumonia, endocarditis, hepatitis, and miscarriage may develop.", [["pneumonia", "DISEASE", 39, 48], ["endocarditis", "DISEASE", 50, 62], ["hepatitis", "DISEASE", 64, 73], ["miscarriage", "DISEASE", 79, 90], ["more severe conditions", "PROBLEM", 8, 30], ["pneumonia", "PROBLEM", 39, 48], ["endocarditis", "PROBLEM", 50, 62], ["hepatitis", "PROBLEM", 64, 73], ["miscarriage", "PROBLEM", 79, 90], ["more", "OBSERVATION_MODIFIER", 8, 12], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["conditions", "OBSERVATION", 20, 30], ["pneumonia", "OBSERVATION", 39, 48], ["endocarditis", "OBSERVATION", 50, 62], ["hepatitis", "OBSERVATION", 64, 73]]], ["C. burnetii can infect a wide range of animals and Q fever is a known abortifacient in domestic ruminants (Agerholm et al., 2015) .", [["Q fever", "DISEASE", 51, 58], ["C. burnetii", "ORGANISM", 0, 11], ["Q fever", "ORGANISM", 51, 58], ["C. burnetii", "SPECIES", 0, 11], ["C. burnetii", "SPECIES", 0, 11], ["C. burnetii", "PROBLEM", 0, 11], ["Q fever", "PROBLEM", 51, 58], ["burnetii", "OBSERVATION", 3, 11], ["wide", "OBSERVATION_MODIFIER", 25, 29], ["range", "OBSERVATION_MODIFIER", 30, 35]]], ["The infection may cause abortion, premature delivery, and stillbirth, particularly in goats and sheep while such incidents seem to be rare in cattle (Agerholm, 2013) .", [["infection", "DISEASE", 4, 13], ["abortion", "DISEASE", 24, 32], ["stillbirth", "DISEASE", 58, 68], ["goats", "ORGANISM", 86, 91], ["sheep", "ORGANISM", 96, 101], ["cattle", "ORGANISM", 142, 148], ["goats", "SPECIES", 86, 91], ["sheep", "SPECIES", 96, 101], ["cattle", "SPECIES", 142, 148], ["goats", "SPECIES", 86, 91], ["sheep", "SPECIES", 96, 101], ["cattle", "SPECIES", 142, 148], ["The infection", "PROBLEM", 0, 13], ["abortion", "PROBLEM", 24, 32], ["premature delivery", "PROBLEM", 34, 52], ["infection", "OBSERVATION", 4, 13], ["may cause", "UNCERTAINTY", 14, 23]]], ["The infection is highly prevalent in Danish cattle, where 60-80% of dairy herds had antibodies in the bulk tank milk J o u r n a l P r e -p r o o f (Agger et al., 2010; Agger and Paul, 2014) and 4.1% of slaughtered beef cattle were seropositive .IntroductionC. burnetii infection has been reported less frequently in several other domestic or wild mammals, including horses, rabbits, swine, camels, water buffalo, rats, and mice (Porter et al., 2011; Gunther et al., 2019; Wood et al., 2019; Ma et al., 2020) .", [["infection", "DISEASE", 4, 13], ["burnetii infection", "DISEASE", 261, 279], ["cattle", "ORGANISM", 220, 226], ["burnetii", "ORGANISM", 261, 269], ["horses", "ORGANISM_SUBDIVISION", 367, 373], ["rabbits", "ORGANISM", 375, 382], ["swine", "ORGANISM", 384, 389], ["camels", "ORGANISM_SUBDIVISION", 391, 397], ["water buffalo", "ORGANISM", 399, 412], ["rats", "ORGANISM", 414, 418], ["mice", "ORGANISM", 424, 428], ["antibodies", "PROTEIN", 84, 94], ["cattle", "SPECIES", 44, 50], ["beef", "SPECIES", 215, 219], ["cattle", "SPECIES", 220, 226], ["burnetii", "SPECIES", 261, 269], ["horses", "SPECIES", 367, 373], ["rabbits", "SPECIES", 375, 382], ["swine", "SPECIES", 384, 389], ["rats", "SPECIES", 414, 418], ["mice", "SPECIES", 424, 428], ["cattle", "SPECIES", 44, 50], ["beef", "SPECIES", 215, 219], ["cattle", "SPECIES", 220, 226], ["burnetii", "SPECIES", 261, 269], ["rabbits", "SPECIES", 375, 382], ["swine", "SPECIES", 384, 389], ["buffalo", "SPECIES", 405, 412], ["mice", "SPECIES", 424, 428], ["The infection", "PROBLEM", 0, 13], ["Agger", "TEST", 169, 174], ["slaughtered beef cattle", "TEST", 203, 226], ["seropositive", "PROBLEM", 232, 244], ["burnetii infection", "PROBLEM", 261, 279], ["infection", "OBSERVATION", 4, 13], ["infection", "OBSERVATION", 270, 279], ["less frequently", "OBSERVATION_MODIFIER", 298, 313]]], ["Due to the wide range of hosts for C. burnetii, horses may also become infected although the significance of the infection needs to be further investigated.", [["infection", "DISEASE", 113, 122], ["C. burnetii", "ORGANISM", 35, 46], ["horses", "ORGANISM", 48, 54], ["C. burnetii", "SPECIES", 35, 46], ["C. burnetii", "SPECIES", 35, 46], ["horses", "SPECIES", 48, 54], ["C. burnetii", "PROBLEM", 35, 46], ["the infection", "PROBLEM", 109, 122], ["infected", "OBSERVATION", 71, 79], ["infection", "OBSERVATION", 113, 122]]], ["Two older experimental studies performed in non-pregnant horses have shown that horses may develop fever, conjunctivitis, respiratory and gastrointestinal symptoms after inoculation (Agerholm, 2013).IntroductionC. burnetii infection can be demonstrated in different ways, depending on the type of sample and the purpose of the investigations.", [["respiratory", "ANATOMY", 122, 133], ["gastrointestinal", "ANATOMY", 138, 154], ["fever", "DISEASE", 99, 104], ["conjunctivitis", "DISEASE", 106, 120], ["respiratory and gastrointestinal symptoms", "DISEASE", 122, 163], ["burnetii infection", "DISEASE", 214, 232], ["horses", "ORGANISM", 57, 63], ["horses", "ORGANISM", 80, 86], ["gastrointestinal", "ORGAN", 138, 154], ["burnetii", "ORGANISM", 214, 222], ["burnetii", "SPECIES", 214, 222], ["horses", "SPECIES", 80, 86], ["burnetii", "SPECIES", 214, 222], ["Two older experimental studies", "TEST", 0, 30], ["fever", "PROBLEM", 99, 104], ["conjunctivitis", "PROBLEM", 106, 120], ["respiratory and gastrointestinal symptoms", "PROBLEM", 122, 163], ["burnetii infection", "PROBLEM", 214, 232], ["the investigations", "TEST", 323, 341], ["conjunctivitis", "OBSERVATION", 106, 120], ["respiratory", "ANATOMY", 122, 133], ["gastrointestinal", "ANATOMY", 138, 154], ["infection", "OBSERVATION", 223, 232]]], ["Serological tests are used especially for screening herds or flocks and to detect previous exposure to the bacterium but they are not appropriate for determining the infectivity status of individual animals.", [["Serological tests", "TEST", 0, 17], ["screening herds", "TEST", 42, 57], ["flocks", "PROBLEM", 61, 67], ["previous exposure to the bacterium", "PROBLEM", 82, 116]]], ["On the other hand, isolation of the causal agent in cell culture or embryonated eggs is laborious and time consuming, while its detection using stained smears has a low sensitivity.", [["cell culture", "ANATOMY", 52, 64], ["eggs", "ANATOMY", 80, 84], ["cell culture", "CELL", 52, 64], ["cell culture", "CELL_LINE", 52, 64], ["cell culture", "TEST", 52, 64], ["embryonated eggs", "PROBLEM", 68, 84], ["stained smears", "TEST", 144, 158], ["a low sensitivity", "PROBLEM", 163, 180], ["low sensitivity", "OBSERVATION_MODIFIER", 165, 180]]], ["Consequently, several PCR based diagnostic assays have recently been developed to detect C. burnetii DNA in clinical samples.", [["samples", "ANATOMY", 117, 124], ["C. burnetii", "ORGANISM", 89, 100], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["samples", "CANCER", 117, 124], ["C. burnetii", "SPECIES", 89, 100], ["C. burnetii", "SPECIES", 89, 100], ["several PCR", "TEST", 14, 25], ["diagnostic assays", "TEST", 32, 49], ["C. burnetii DNA in clinical samples", "PROBLEM", 89, 124], ["burnetii DNA", "OBSERVATION", 92, 104]]], ["Techniques targeting genes of a substantial copy number, like the insertion sequence IS1111, were demonstrated to be especially sensitive (Berri et al., 2000; Marenzoni et al., 2013) .", [["insertion sequence IS1111", "DNA", 66, 91], ["the insertion sequence IS1111", "TEST", 62, 91], ["substantial", "OBSERVATION_MODIFIER", 32, 43]]], ["Based on previous literatures, PCR is a wellapproved laboratory method for diagnosing C. burnetii.", [["C. burnetii", "DISEASE", 86, 97], ["C. burnetii", "ORGANISM", 86, 97], ["C. burnetii", "SPECIES", 86, 97], ["C. burnetii", "SPECIES", 86, 97], ["PCR", "TEST", 31, 34], ["C. burnetii", "PROBLEM", 86, 97]]], ["Trans-PCR (transposon like element) is particularly sensitive to the detection of C. burnetii using primers targeting IS1111.", [["C. burnetii", "ORGANISM", 82, 93], ["Trans-PCR (transposon like element", "DNA", 0, 34], ["IS1111", "DNA", 118, 124], ["C. burnetii", "SPECIES", 82, 93], ["C. burnetii", "SPECIES", 82, 93], ["Trans-PCR", "TEST", 0, 9], ["C. burnetii", "PROBLEM", 82, 93]]], ["Due to the presence of at least 56 copies of the insertion sequence in the genome, it increases the sensitivity of the diagnosis (Massung et al., 2012; Mares-Guia et al., 2018; Dhaka et al., 2019) .", [["insertion sequence", "DNA", 49, 67], ["the insertion sequence", "TREATMENT", 45, 67]]], ["Trans-PCR technique used is capable of direct detection of C. burnetii in genital swabs, milk and fecal J o u r n a l P r e -p r o o f specimens in less than 6 h on various biological samples (Berri et al., 2000) .", [["genital swabs", "ANATOMY", 74, 87], ["milk", "ANATOMY", 89, 93], ["specimens", "ANATOMY", 135, 144], ["C. burnetii", "ORGANISM", 59, 70], ["genital swabs", "ORGANISM_SUBSTANCE", 74, 87], ["milk", "ORGANISM_SUBSTANCE", 89, 93], ["C. burnetii", "SPECIES", 59, 70], ["C. burnetii", "SPECIES", 59, 70], ["PCR technique", "TEST", 6, 19], ["direct detection", "TEST", 39, 55], ["C. burnetii in genital swabs", "PROBLEM", 59, 87], ["a l P r e -p r o o f specimens", "TEST", 114, 144], ["burnetii", "OBSERVATION", 62, 70], ["genital swabs", "ANATOMY", 74, 87]]], ["Although still controversial, PCR performed on serum sample may be used to diagnose acute Q fever in the first 2 weeks of the disease (Honarmand, 2012) .", [["serum sample", "ANATOMY", 47, 59], ["acute Q fever", "DISEASE", 84, 97], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["PCR", "TEST", 30, 33], ["serum sample", "TEST", 47, 59], ["acute Q fever", "PROBLEM", 84, 97], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["disease", "OBSERVATION", 126, 133]]], ["Comparison of the sensitivities of the two PCR methods was made using serially diluted C. burnetii pure genomic DNA.", [["DNA", "CELLULAR_COMPONENT", 112, 115], ["C. burnetii pure genomic DNA", "DNA", 87, 115], ["C. burnetii", "SPECIES", 87, 98], ["C. burnetii", "SPECIES", 87, 98], ["the two PCR methods", "TEST", 35, 54], ["serially diluted C. burnetii pure genomic DNA", "TREATMENT", 70, 115]]], ["Our protocol enhanced sensitivity over the Trans PCR in detecting C. burnetii by 10-to 100-fold and it proved to be an effective tool for the diagnosis of animal coxiellosis (Parisi et al., 2006) .IntroductionIran has about 155,000 horses.", [["coxiellosis", "DISEASE", 162, 173], ["C. burnetii", "ORGANISM", 66, 77], ["C. burnetii", "SPECIES", 66, 77], ["C. burnetii", "SPECIES", 66, 77], ["Our protocol enhanced sensitivity", "TEST", 0, 33], ["the Trans PCR", "TEST", 39, 52], ["C. burnetii", "PROBLEM", 66, 77], ["animal coxiellosis", "PROBLEM", 155, 173], ["burnetii", "OBSERVATION", 69, 77]]], ["The main reason for choosing Golestan province for this study is the use of breeds in this province in terms of economic importance and its important use in equestrian competitions (Willi et al., 2006) .IntroductionAlthough Q fever occurs infrequently in Iran, (Mostafavi et al.) .", [["Q fever", "DISEASE", 224, 231], ["this study", "TEST", 51, 61], ["Q fever", "PROBLEM", 224, 231], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Also, according reports regarding the prevalence of Q fever among domestic and wild animals, Q fever is endemic in Iran.", [["Q fever", "DISEASE", 52, 59], ["Q fever", "DISEASE", 93, 100], ["Q fever", "PROBLEM", 52, 59], ["fever", "PROBLEM", 95, 100], ["endemic", "OBSERVATION_MODIFIER", 104, 111]]], ["Q fever cases are not diagnosed in Iran for >40 years due to a lack of diagnostic facilities and the relatively low level of awareness with in the Iranian health care system.IntroductionAlthough several studies have investigated C. burnetii infection in dairy cattle, sheep and goats in Iran (Khademi et al., 2014; Khademi et al., 2019 ., Khademi et al., 2020 , no studies reported on the occurrence of C. burnetii in horses.", [["fever", "DISEASE", 2, 7], ["C. burnetii infection", "DISEASE", 229, 250], ["C. burnetii", "DISEASE", 403, 414], ["C. burnetii", "ORGANISM", 229, 240], ["sheep", "ORGANISM", 268, 273], ["goats", "ORGANISM", 278, 283], ["C. burnetii", "ORGANISM", 403, 414], ["horses", "ORGANISM", 418, 424], ["C. burnetii", "SPECIES", 229, 240], ["cattle", "SPECIES", 260, 266], ["sheep", "SPECIES", 268, 273], ["goats", "SPECIES", 278, 283], ["C. burnetii", "SPECIES", 403, 414], ["C. burnetii", "SPECIES", 229, 240], ["cattle", "SPECIES", 260, 266], ["sheep", "SPECIES", 268, 273], ["goats", "SPECIES", 278, 283], ["C. burnetii", "SPECIES", 403, 414], ["fever cases", "PROBLEM", 2, 13], ["several studies", "TEST", 195, 210], ["C. burnetii infection", "PROBLEM", 229, 250], ["C. burnetii in horses", "PROBLEM", 403, 424], ["burnetii infection", "OBSERVATION", 232, 250], ["burnetii", "OBSERVATION", 406, 414]]], ["Recently, it showed a boom in the horse international trade in Iran.", [["horse", "ORGANISM", 34, 39], ["horse", "SPECIES", 34, 39], ["boom", "OBSERVATION_MODIFIER", 22, 26]]], ["The risk of Coxiella spp. transmission to humans maybe increase after exposure to infected horses during horseback riding and horse keeping.", [["Coxiella spp.", "DISEASE", 12, 25], ["Coxiella spp.", "ORGANISM", 12, 25], ["humans", "ORGANISM", 42, 48], ["horses", "ORGANISM", 91, 97], ["horse", "ORGANISM_SUBDIVISION", 126, 131], ["Coxiella spp.", "SPECIES", 12, 25], ["humans", "SPECIES", 42, 48], ["horse", "SPECIES", 126, 131], ["Coxiella spp.", "SPECIES", 12, 25], ["humans", "SPECIES", 42, 48], ["Coxiella spp.", "PROBLEM", 12, 25], ["infected horses", "PROBLEM", 82, 97], ["Coxiella spp.", "OBSERVATION", 12, 25], ["increase", "OBSERVATION_MODIFIER", 55, 63]]], ["This study aimed to investigate the prevalence of C. burnetii in horse serum by using Trans-PCR method (for the first time in Iran) in Golestan Province, Iran.Field sampling Study areaThis study was carried out in Golestan Province located in the north of Iran, [geographically located between 36\u00b0 50\u2032 21.48\u2033 N, 54\u00b0 26\u2032 39.84\u2033 E (https://tools.wmflabs.org)].", [["serum", "ANATOMY", 71, 76], ["C. burnetii", "ORGANISM", 50, 61], ["horse", "ORGANISM", 65, 70], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["C. burnetii", "SPECIES", 50, 61], ["horse", "SPECIES", 65, 70], ["C. burnetii", "SPECIES", 50, 61], ["horse", "SPECIES", 65, 70], ["This study", "TEST", 0, 10], ["C. burnetii", "PROBLEM", 50, 61], ["Trans-PCR method", "TREATMENT", 86, 102], ["Field sampling Study areaThis study", "TEST", 159, 194], ["burnetii", "OBSERVATION", 53, 61]]], ["(Fig. 1 ).Sera collection:In 2017-2018, Two hundred Blood samples were collected, in two geographical regions of Golestan Province (Kalaleh County (n=121), Gonbad Kavus (n=79).", [["Blood samples", "ANATOMY", 52, 65], ["Sera", "ORGANISM_SUBSTANCE", 10, 14], ["Blood samples", "CANCER", 52, 65], ["Sera collection", "TEST", 10, 25], ["Blood samples", "TEST", 52, 65]]], ["The study population represented 4 breeds.", [["The study population", "TEST", 0, 20]]], ["Most horses were Turkmen (n = 50) followed by Akhal-Teke (n=51), Turkmen Dokhun (n=50), and Yamut Turkmen (n=49) horses.", [["horses", "ORGANISM", 5, 11], ["horses", "ORGANISM", 113, 119], ["Akhal", "TEST", 46, 51]]], ["Sampled animals were grouped into two different age groups ( 6 years old (p-value <0.05, 95%, CI: 7% -19.8%) is higher than the age group 6 years old (14.15%) (p-value <0.05, 95%, CI: 8.5% -23%) age group for C. burnetii infection. this result revealed that age may be a risk factor for C. burnetii in horses.", [["C. burnetii infection", "DISEASE", 209, 230], ["C. burnetii", "DISEASE", 287, 298], ["C. burnetii", "ORGANISM", 209, 220], ["C. burnetii", "ORGANISM", 287, 298], ["horses", "ORGANISM", 302, 308], ["C. burnetii", "SPECIES", 209, 220], ["C. burnetii", "SPECIES", 287, 298], ["C. burnetii", "SPECIES", 209, 220], ["C. burnetii", "SPECIES", 287, 298], ["p-value", "TEST", 74, 81], ["CI", "TEST", 94, 96], ["p-value", "TEST", 160, 167], ["CI", "TEST", 180, 182], ["C. burnetii infection", "PROBLEM", 209, 230], ["C. burnetii in horses", "PROBLEM", 287, 308], ["burnetii infection", "OBSERVATION", 212, 230], ["burnetii", "OBSERVATION", 290, 298]]], ["The difference may be explained as a consequence of a higher probability of contact (Filioussis et al., 2017; Li et al., 2020) .DiscussionOther factors apart from species, such as farm densities of animals, seasonality of births or management, could explain the higher frequency of C. burnetii infection in ruminants.", [["C. burnetii infection", "DISEASE", 282, 303], ["C. burnetii", "ORGANISM", 282, 293], ["C. burnetii", "SPECIES", 282, 293], ["C. burnetii", "SPECIES", 282, 293], ["species", "PROBLEM", 163, 170], ["management", "TREATMENT", 232, 242], ["C. burnetii infection", "PROBLEM", 282, 303], ["may be explained", "UNCERTAINTY", 15, 31], ["burnetii infection", "OBSERVATION", 285, 303]]], ["The risk factors identified for C. burnetii infection in ruminants should also be examined when studying the infection in horses.", [["C. burnetii infection", "DISEASE", 32, 53], ["infection", "DISEASE", 109, 118], ["C. burnetii", "ORGANISM", 32, 43], ["ruminants", "ORGANISM", 57, 66], ["horses", "ORGANISM", 122, 128], ["C. burnetii", "SPECIES", 32, 43], ["C. burnetii", "SPECIES", 32, 43], ["The risk factors", "PROBLEM", 0, 16], ["C. burnetii infection", "PROBLEM", 32, 53], ["the infection in horses", "PROBLEM", 105, 128], ["burnetii", "OBSERVATION_MODIFIER", 35, 43], ["infection", "OBSERVATION", 44, 53], ["infection", "OBSERVATION", 109, 118]]], ["Moreover, different C. burnetii infections may have differing epidemiologic characteristics depending on the nature of specific outbreaks (Georgiev et al., 2013) .DiscussionThe most important diagnostic problems of C. burnetii is collection and storage of specimens.DiscussionC. burnetii is a very infectious intracellular bacterium.", [["specimens", "ANATOMY", 256, 265], ["intracellular", "ANATOMY", 309, 322], ["C. burnetii infections", "DISEASE", 20, 42], ["C. burnetii", "ORGANISM", 20, 31], ["C. burnetii", "ORGANISM", 215, 226], ["specimens", "CANCER", 256, 265], ["burnetii", "ORGANISM", 279, 287], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 322], ["C. burnetii", "SPECIES", 20, 31], ["C. burnetii", "SPECIES", 215, 226], ["burnetii", "SPECIES", 279, 287], ["C. burnetii", "SPECIES", 20, 31], ["C. burnetii", "SPECIES", 215, 226], ["burnetii", "SPECIES", 279, 287], ["different C. burnetii infections", "PROBLEM", 10, 42], ["C. burnetii", "PROBLEM", 215, 226], ["burnetii", "PROBLEM", 279, 287], ["a very infectious intracellular bacterium", "PROBLEM", 291, 332], ["burnetii infections", "OBSERVATION", 23, 42], ["burnetii", "OBSERVATION", 218, 226], ["very", "OBSERVATION_MODIFIER", 293, 297], ["infectious", "OBSERVATION_MODIFIER", 298, 308], ["bacterium", "OBSERVATION", 323, 332]]], ["Thus, only biosafety level 3 laboratories and experienced personnel should be allowed to manipulate contaminated specimens and cultivate this microorganism from clinical samples (Fournier et al., 1998; Anderson et al., 2013) .", [["specimens", "ANATOMY", 113, 122], ["contaminated specimens", "TEST", 100, 122]]], ["There were many limitations in this research that we point as: no any history about abortion in horse J o u r n a l P r e -p r o o f herds, no accessible facilities for bacterial cell culturing and many limitations related with occurrence of Covid-19 pandemic.DiscussionFinally, because Q fever is not a notifiable disease and many human cases could have been misdiagnosed as some other infection, the public health impact of C. burnetii infection will be not understood until suitable epidemiologic surveillance is effectively employed in Iran.ConclusionTo conclude, horses can play an important role in the epidemiology of Q fever as reservoir for C.Conclusionburnetii.", [["cell", "ANATOMY", 179, 183], ["fever", "DISEASE", 289, 294], ["infection", "DISEASE", 387, 396], ["C. burnetii infection", "DISEASE", 426, 447], ["Q fever", "DISEASE", 625, 632], ["horse", "ORGANISM", 96, 101], ["cell", "CELL", 179, 183], ["Covid-19", "ORGANISM", 242, 250], ["human", "ORGANISM", 332, 337], ["C. burnetii", "ORGANISM", 426, 437], ["horses", "ORGANISM", 568, 574], ["horse", "SPECIES", 96, 101], ["human", "SPECIES", 332, 337], ["C. burnetii", "SPECIES", 426, 437], ["human", "SPECIES", 332, 337], ["C. burnetii", "SPECIES", 426, 437], ["abortion", "PROBLEM", 84, 92], ["herds", "PROBLEM", 133, 138], ["bacterial cell culturing", "PROBLEM", 169, 193], ["Covid", "TEST", 242, 247], ["pandemic", "PROBLEM", 251, 259], ["Q fever", "PROBLEM", 287, 294], ["a notifiable disease", "PROBLEM", 302, 322], ["some other infection", "PROBLEM", 376, 396], ["C. burnetii infection", "PROBLEM", 426, 447], ["fever", "PROBLEM", 627, 632], ["bacterial cell", "OBSERVATION", 169, 183], ["infection", "OBSERVATION", 387, 396], ["burnetii infection", "OBSERVATION", 429, 447]]], ["Attained data show that PCR can be used as an easy and reliable approach for detecting Q fever causative agent.", [["fever", "DISEASE", 89, 94], ["PCR", "TEST", 24, 27], ["Q fever causative agent", "PROBLEM", 87, 110]]], ["Therefore, decreasing the risk of Q fever transmission from horse to other animals and humans is followed.", [["fever", "DISEASE", 36, 41], ["horse", "ORGANISM", 60, 65], ["humans", "ORGANISM", 87, 93], ["horse", "SPECIES", 60, 65], ["humans", "SPECIES", 87, 93], ["horse", "SPECIES", 60, 65], ["humans", "SPECIES", 87, 93], ["Q fever transmission", "PROBLEM", 34, 54]]], ["Our study shows that the impact of Q fever disease on horses' health status in the studied area appears to be low, but quite important.", [["fever", "DISEASE", 37, 42], ["Our study", "TEST", 0, 9], ["Q fever disease", "PROBLEM", 35, 50], ["low", "OBSERVATION", 110, 113]]], ["One of the limitations of our study was little number of positive cases that made it impossible for us to properly analyze the risk factors Statistical and epidemiologically.", [["our study", "TEST", 26, 35]]], ["The authors suggest application of PCR based method to reliable diagnosis of Q fever in animal with all kind of samples such as serum sample.Conflicts of interest:The authors have not conflicts of interest to disclose.", [["samples", "ANATOMY", 112, 119], ["serum sample", "ANATOMY", 128, 140], ["Q fever", "DISEASE", 77, 84], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["PCR", "TREATMENT", 35, 38], ["Q fever", "PROBLEM", 77, 84], ["serum sample", "TEST", 128, 140]]]], "PMC7357975": [["Advances in Organ Chip TechnologyOrgan Chips are engineered microfluidic devices which, when populated with human cells, offer the possibility to replicate the complex structures and physiological functions of major functional units of human organs, both alone and when coupled together fluidically to create human body-on-chips systems [1,2].", [["cells", "ANATOMY", 114, 119], ["organs", "ANATOMY", 242, 248], ["body", "ANATOMY", 315, 319], ["human", "ORGANISM", 108, 113], ["cells", "CELL", 114, 119], ["human", "ORGANISM", 236, 241], ["organs", "ORGAN", 242, 248], ["human", "ORGANISM", 309, 314], ["body", "ORGANISM_SUBDIVISION", 315, 319], ["human cells", "CELL_TYPE", 108, 119], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 309, 314], ["Chips", "TREATMENT", 39, 44], ["engineered microfluidic devices", "TREATMENT", 49, 80], ["human cells", "TREATMENT", 108, 119], ["microfluidic devices", "OBSERVATION", 60, 80]]], ["They may complement, or even represent alternatives to, some animal models and conventional 2D and 3D culture systems by providing greater physiological relevance and mimicry of human organ-specific responses [3., 4., 5.].", [["organ", "ANATOMY", 184, 189], ["human", "ORGANISM", 178, 183], ["organ", "ORGAN", 184, 189], ["2D and 3D culture systems", "CELL_LINE", 92, 117], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["3D culture systems", "TEST", 99, 117]]], ["It has been postulated that Organ Chip technology could help to reduce the high failure rate in current drug development pipelines where many drugs that are found to be safe and effective in laboratory animals fail when they enter human clinical trials [6,7].", [["human", "ORGANISM", 231, 236], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 231, 236], ["Organ Chip technology", "TREATMENT", 28, 49], ["the high failure rate", "PROBLEM", 71, 92], ["many drugs", "TREATMENT", 137, 147], ["high", "OBSERVATION_MODIFIER", 75, 79], ["failure", "OBSERVATION", 80, 87]]], ["Thus, successful Organ Chips could help to reverse the increasing cost of drug development.Advances in Organ Chip TechnologySince 2010, when the first physiological relevant Organ Chip model of the lung alveolus was reported [1,2], numerous other Organ Chips have been developed and applied to study disease biology and drug analysis.", [["lung alveolus", "ANATOMY", 198, 211], ["lung alveolus", "MULTI-TISSUE_STRUCTURE", 198, 211], ["successful Organ Chips", "TREATMENT", 6, 28], ["drug development", "PROBLEM", 74, 90], ["numerous other Organ Chips", "PROBLEM", 232, 258], ["drug analysis", "TEST", 320, 333], ["increasing", "OBSERVATION_MODIFIER", 55, 65], ["cost", "OBSERVATION", 66, 70], ["lung", "ANATOMY", 198, 202], ["alveolus", "ANATOMY_MODIFIER", 203, 211], ["Organ", "ANATOMY", 247, 252], ["Chips", "OBSERVATION", 253, 258]]], ["These Organ Chips minimally include one tissue type and generally feature an interface with an extracellular matrix (ECM) and a neighboring vascular and/or connective tissue [2,8., 9., 10.].", [["tissue", "ANATOMY", 40, 46], ["extracellular matrix", "ANATOMY", 95, 115], ["ECM", "ANATOMY", 117, 120], ["vascular", "ANATOMY", 140, 148], ["connective tissue", "ANATOMY", 156, 173], ["tissue", "TISSUE", 40, 46], ["extracellular matrix", "CELLULAR_COMPONENT", 95, 115], ["ECM", "CELLULAR_COMPONENT", 117, 120], ["vascular", "MULTI-TISSUE_STRUCTURE", 140, 148], ["connective tissue", "TISSUE", 156, 173], ["a neighboring vascular and/or connective tissue", "PROBLEM", 126, 173], ["Organ", "ANATOMY", 6, 11], ["Chips", "OBSERVATION", 12, 17], ["one tissue", "OBSERVATION_MODIFIER", 36, 46], ["type", "OBSERVATION_MODIFIER", 47, 51], ["interface", "OBSERVATION", 77, 86], ["extracellular matrix", "OBSERVATION", 95, 115], ["neighboring", "ANATOMY_MODIFIER", 128, 139], ["vascular", "ANATOMY", 140, 148], ["connective tissue", "ANATOMY", 156, 173]]], ["There are many chip designs available, both commercially and as prototypes from academic institutions, which allow various readouts of cell-, tissue-, and organ-level behaviors.", [["cell", "ANATOMY", 135, 139], ["tissue", "ANATOMY", 142, 148], ["organ", "ANATOMY", 155, 160], ["cell", "CELL", 135, 139], ["tissue", "TISSUE", 142, 148], ["organ", "ORGAN", 155, 160], ["many", "OBSERVATION_MODIFIER", 10, 14], ["chip", "OBSERVATION", 15, 19]]], ["These range from in situ imaging (i.e., optical or mass spectrometric) to built-in electrodes for quantification of transepithelial electrical resistance (TEER) and integrated pH and O2 sensors to sampling liquid flowing through the channels of the devices [11., 12., 13., 14.].", [["transepithelial", "ANATOMY", 116, 131], ["O2", "CHEMICAL", 183, 185], ["O2", "SIMPLE_CHEMICAL", 183, 185], ["situ imaging", "TEST", 20, 32], ["transepithelial electrical resistance", "PROBLEM", 116, 153], ["integrated pH", "TEST", 165, 178], ["O2 sensors", "TEST", 183, 193], ["sampling liquid", "TEST", 197, 212], ["the devices", "TREATMENT", 245, 256], ["transepithelial electrical resistance", "OBSERVATION", 116, 153]]], ["Chip-based disease models are thus becoming important research tools in numerous applications [10,20].", [["Chip-based disease models", "PROBLEM", 0, 25], ["disease", "OBSERVATION", 11, 18]]], ["Examples include, but are not limited to, diabetic nephropathy and drug toxicities in a kidney glomerulus chip [21,22], intravascular thrombosis in a lung alveolus chip [23], Alzheimer's disease in a brain chip [24], and radiation and drug toxicities, as well as modeling a rare genetic disease in a bone marrow chip [25].", [["kidney glomerulus", "ANATOMY", 88, 105], ["intravascular", "ANATOMY", 120, 133], ["lung alveolus", "ANATOMY", 150, 163], ["brain", "ANATOMY", 200, 205], ["bone marrow", "ANATOMY", 300, 311], ["diabetic nephropathy", "DISEASE", 42, 62], ["toxicities", "DISEASE", 72, 82], ["intravascular thrombosis", "DISEASE", 120, 144], ["Alzheimer's disease", "DISEASE", 175, 194], ["toxicities", "DISEASE", 240, 250], ["kidney", "ORGAN", 88, 94], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 133], ["lung alveolus", "MULTI-TISSUE_STRUCTURE", 150, 163], ["brain", "ORGAN", 200, 205], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 300, 311], ["diabetic nephropathy", "PROBLEM", 42, 62], ["drug toxicities", "PROBLEM", 67, 82], ["a kidney glomerulus chip", "TREATMENT", 86, 110], ["intravascular thrombosis", "PROBLEM", 120, 144], ["a lung alveolus chip", "PROBLEM", 148, 168], ["Alzheimer's disease", "PROBLEM", 175, 194], ["a brain chip", "TREATMENT", 198, 210], ["radiation", "TREATMENT", 221, 230], ["drug toxicities", "PROBLEM", 235, 250], ["a rare genetic disease", "PROBLEM", 272, 294], ["a bone marrow chip", "TREATMENT", 298, 316], ["diabetic", "OBSERVATION_MODIFIER", 42, 50], ["nephropathy", "OBSERVATION", 51, 62], ["kidney", "ANATOMY", 88, 94], ["glomerulus", "ANATOMY_MODIFIER", 95, 105], ["intravascular", "OBSERVATION_MODIFIER", 120, 133], ["thrombosis", "OBSERVATION", 134, 144], ["lung", "ANATOMY", 150, 154], ["alveolus", "ANATOMY_MODIFIER", 155, 163], ["brain", "ANATOMY", 200, 205], ["bone", "ANATOMY", 300, 304]]], ["As these disease and toxicity models emerge, new opportunities for drug development are created that may contribute to reducing the number of failed clinical trials.", [["toxicity", "DISEASE", 21, 29], ["these disease and toxicity models emerge", "PROBLEM", 3, 43], ["drug development", "PROBLEM", 67, 83], ["disease", "OBSERVATION", 9, 16]]], ["Several Organ Chips have been developed that model drug pharmacokinetics and pharmacodynamics across tissues, yet their predictive values largely remain to be validated with clinical data.", [["tissues", "ANATOMY", 101, 108], ["tissues", "TISSUE", 101, 108], ["Several Organ Chips", "PROBLEM", 0, 19], ["pharmacodynamics across tissues", "PROBLEM", 77, 108], ["Organ", "ANATOMY", 8, 13], ["Chips", "OBSERVATION", 14, 19]]], ["However, in one recent study, fluidically coupled human Organ Chips have been used to qualitatively predict the drug pharmacokinetic responses in patients [26,27].Advances in Organ Chip TechnologyTo mimic host\u2013microbe interactions specifically, several Organ Chip platforms have been developed that allow study of both pathogenic and nonpathogenic bacteria, and most recently, viral infections.", [["viral infections", "DISEASE", 377, 393], ["human", "ORGANISM", 50, 55], ["patients", "ORGANISM", 146, 154], ["human", "SPECIES", 50, 55], ["patients", "SPECIES", 146, 154], ["human", "SPECIES", 50, 55], ["one recent study", "TEST", 12, 28], ["fluidically coupled human Organ Chips", "TREATMENT", 30, 67], ["several Organ Chip platforms", "PROBLEM", 245, 273], ["both pathogenic and nonpathogenic bacteria", "PROBLEM", 314, 356], ["viral infections", "PROBLEM", 377, 393], ["nonpathogenic", "OBSERVATION_MODIFIER", 334, 347], ["bacteria", "OBSERVATION", 348, 356], ["viral", "OBSERVATION_MODIFIER", 377, 382], ["infections", "OBSERVATION", 383, 393]]], ["Among the possibilities being explored are the use of Organ Chip to study infection kinetics, virus\u2013host interactions, viral pathogenesis and evolution, drug responses, and the development of resistance to drugs and vaccines.", [["infection", "DISEASE", 74, 83], ["Organ Chip", "TREATMENT", 54, 64], ["infection kinetics", "PROBLEM", 74, 92], ["virus\u2013host interactions", "PROBLEM", 94, 117], ["viral pathogenesis", "PROBLEM", 119, 137], ["drugs", "TREATMENT", 206, 211], ["vaccines", "TREATMENT", 216, 224]]], ["Here, we provide an overview of Organ Chip technologies described for virology application to date and we discuss opportunities and challenges that lie ahead (Figure 1).Liver Chip ::: Modeling Viral Diseases in Organ Chips", [["Liver", "ANATOMY", 169, 174], ["Viral Diseases", "DISEASE", 193, 207], ["Liver", "ORGAN", 169, 174], ["Organ Chip technologies", "TREATMENT", 32, 55], ["Modeling Viral Diseases", "PROBLEM", 184, 207], ["Organ Chips", "TREATMENT", 211, 222], ["Chip", "OBSERVATION", 175, 179], ["Viral Diseases", "OBSERVATION", 193, 207]]]], "f0091767c83187459e6681b4624083279410463e": [["They believed that cleanliness would lead to good health and made links between causes of disease and methods of prevention.", [["disease", "PROBLEM", 90, 97], ["methods of prevention", "TREATMENT", 102, 123]]], ["For example, during this time an association was made between the increased death rate of persons living near swamps and sewage, and as a result the Roman Empire began working on two major public health projects in sanitation control: the building of aqueducts to supply clean water to the city and a sewage system to eliminate waste from the streets.", [["death", "DISEASE", 76, 81], ["persons", "ORGANISM", 90, 97], ["persons", "SPECIES", 90, 97], ["the increased death rate", "PROBLEM", 62, 86], ["a sewage system", "TREATMENT", 299, 314], ["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["The impact of interventions has been great.", [["interventions", "TREATMENT", 14, 27], ["great", "OBSERVATION_MODIFIER", 37, 42]]], ["Vaccination programs, meaning the eradication of smallpox; elimination of poliomyelitis in the Americas; and control of measles, rubella, tetanus, diphtheria, and other diseases around the world 2.", [["smallpox", "DISEASE", 49, 57], ["poliomyelitis", "DISEASE", 74, 87], ["measles", "DISEASE", 120, 127], ["rubella, tetanus, diphtheria", "DISEASE", 129, 157], ["Vaccination programs", "TREATMENT", 0, 20], ["smallpox", "TREATMENT", 49, 57], ["poliomyelitis", "PROBLEM", 74, 87], ["measles", "PROBLEM", 120, 127], ["rubella", "PROBLEM", 129, 136], ["tetanus", "PROBLEM", 138, 145], ["diphtheria", "PROBLEM", 147, 157], ["other diseases", "PROBLEM", 163, 177], ["poliomyelitis", "OBSERVATION", 74, 87], ["diseases", "OBSERVATION", 169, 177]]], ["Control of infectious diseases 5.", [["infectious diseases", "DISEASE", 11, 30], ["infectious diseases", "PROBLEM", 11, 30], ["infectious", "OBSERVATION", 11, 21]]], ["Decline in deaths from coronary heart disease and stroke 6.", [["coronary", "ANATOMY", 23, 31], ["heart", "ANATOMY", 32, 37], ["deaths", "DISEASE", 11, 17], ["coronary heart disease", "DISEASE", 23, 45], ["stroke", "DISEASE", 50, 56], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 23, 37], ["coronary heart disease", "PROBLEM", 23, 45], ["stroke", "PROBLEM", 50, 56], ["coronary heart", "ANATOMY", 23, 37], ["disease", "OBSERVATION", 38, 45], ["stroke", "OBSERVATION", 50, 56]]], ["Recognition of tobacco use as a health hazard Public health is founded on the efforts of a society to protect, promote, and restore the health of its citizens.", [["tobacco", "ORGANISM", 15, 22], ["tobacco", "SPECIES", 15, 22]]], ["Public health programs and services emphasize the prevention of disease and administration of health needs to the population as an entity, versus the study and treatment of a single patient, as is found in the discipline of medicine.Today, public health is defined as \"the science and the art of preventing disease, prolonging life, and promoting physical health and mental health and efficiency through organized community efforts . . . and the development of the social machinery to ensure to every individual in the community a standard of living adequate for the maintenance of health.\" 2 The mission of public health is to fulfill society's desire to create conditions so that people can be healthy.", [["patient", "ORGANISM", 182, 189], ["people", "ORGANISM", 682, 688], ["patient", "SPECIES", 182, 189], ["people", "SPECIES", 682, 688], ["disease", "PROBLEM", 64, 71], ["the study", "TEST", 146, 155], ["treatment", "TREATMENT", 160, 169], ["preventing disease", "PROBLEM", 296, 314]]], ["Public health is divided into the staple pillars of assessment, policy development, and assurance.", [["assessment", "TEST", 52, 62], ["staple pillars", "OBSERVATION", 34, 48]]], ["3 All three of these pillars are interdependent and cyclical.", [["pillars", "OBSERVATION", 21, 28], ["cyclical", "OBSERVATION_MODIFIER", 52, 60]]], ["3 Like traditional programs in public health, ranging from maternal and reproductive health to injury control and prevention, the public health response to disasters also fulfills the same basic tenets of assessment, policy development, and assurance.", [["injury control", "TREATMENT", 95, 109], ["assessment", "TEST", 205, 215]]], ["Public health seeks to mitigate hazards such as explosions, chemical exposures, natural disasters like floods and earthquakes, and infectious disease, as well as reducing vulnerabilities of the infrastructure such as weak assets, resources, personnel, and science.", [["earthquakes", "DISEASE", 114, 125], ["infectious disease", "DISEASE", 131, 149], ["infectious disease", "PROBLEM", 131, 149]]], ["One form of mitigation may be hardening structures against blast, but also can be the placement of surveillance systems to increase early detection of infectious diseases in a hospital setting, for example.", [["infectious diseases", "DISEASE", 151, 170], ["blast", "PROBLEM", 59, 64], ["surveillance systems", "TEST", 99, 119], ["infectious diseases", "PROBLEM", 151, 170], ["mitigation", "OBSERVATION", 12, 22], ["may be", "UNCERTAINTY", 23, 29], ["infectious", "OBSERVATION", 151, 161]]], ["Today, these systems, as well as reporting parameters, are being put into place across the country to both recognize and protect populations from a bioterrorism event.", [["a bioterrorism event", "PROBLEM", 146, 166]]], ["Early warning offers the benefit of a rapid response and reduction in morbidity and mortality.PUBLIC HEALTH RESPONSE CYCLEPreparedness is the process of developing a formal program of response.", [["a rapid response", "PROBLEM", 36, 52], ["morbidity", "PROBLEM", 70, 79], ["reduction", "OBSERVATION_MODIFIER", 57, 66], ["morbidity", "OBSERVATION", 70, 79]]], ["Preparedness has many components, including: training and staff development; identification and classification of public health resources including personnel, supplies, and facilities; development of standard operating procedures (SOPs), emergency response plans, and communications plans; and preplacement of key supplies and protective equipment.", [["protective equipment", "TREATMENT", 327, 347]]], ["This phase should also include the participation in tabletop and functional exercises.", [["functional exercises", "TREATMENT", 65, 85]]], ["Public health personnel must be integrated and participate with other response agencies during drills and exercises to better familiarize each stakeholder with their respective roles and abilities.", [["drills and exercises", "TREATMENT", 95, 115]]], ["In addition, this is the phase in which public health agencies would develop interagency agreements, memoranda of understanding (MOUs), and external support contracts.PUBLIC HEALTH RESPONSE CYCLEThe Centers for Disease Control and Prevention (CDC) is one reference source where planners can obtain basic guidelines for disaster preparedness.These include:PUBLIC HEALTH RESPONSE CYCLE1.", [["external support contracts", "TREATMENT", 140, 166], ["Disease Control", "TREATMENT", 211, 226], ["disaster preparedness", "TREATMENT", 319, 340]]], ["Conduct a hazard and risk assessment.", [["risk assessment", "TEST", 21, 36]]], ["Conduct a capacity assessment, identifying resources in your system.", [["a capacity assessment", "TEST", 8, 29]]], ["Develop surveillance, registries, and data archiving systems.", [["surveillance", "TEST", 8, 20]]], ["Orientation for volunteers and personnel on procedures, guidelines, and command and management systems.", [["procedures", "TREATMENT", 44, 54]]], ["For example, in response to a biologic or chemical terrorist event, public health agencies would respond by conducting site surveys, recommending public safety measures and communicating risk, providing epidemiologic investigations, providing medical treatment of prophylaxis for those exposed, and initiating disease prevention and environmental decontamination measures.", [["public safety measures", "TREATMENT", 146, 168], ["epidemiologic investigations", "TEST", 203, 231], ["medical treatment", "TREATMENT", 243, 260], ["prophylaxis", "TREATMENT", 264, 275], ["disease prevention", "TREATMENT", 310, 328], ["environmental decontamination measures", "TREATMENT", 333, 371]]], ["5RECOVERYPublic health agencies must identify what resources may be available to assist in restoring the operation as well as address other physically and emotionally affected populations.", [["the operation", "TREATMENT", 101, 114]]], ["Furthermore, recovery efforts comprise several components, some of which are Search and Rescue (SAR) in the case of an earthquake, bombing, or landslide; reinstitution of medical services if clinics and hospitals are destroyed; and establishment of corrupted lifelines like sanitation, electricity, and water.", [["earthquake", "DISEASE", 119, 129], ["several", "OBSERVATION_MODIFIER", 39, 46], ["components", "OBSERVATION_MODIFIER", 47, 57]]], ["Those affected by the horrendous Tsunami disaster-that killed hundreds of thousands in Indonesia,Thailand,India,and so many other nations-demonstrated the international public health relief operation: an extreme example of multilateral, global relief spanning commercial and government sectors.The recovery from this disaster is ongoing and likely will last several years.DISASTER POLICYFor weeks after the 2004 tsunami, survivors on makeshift rafts were miraculously saved and brought back to shore.", [["survivors on makeshift rafts", "TREATMENT", 421, 449], ["global", "OBSERVATION_MODIFIER", 237, 243], ["relief", "OBSERVATION_MODIFIER", 244, 250]]], ["Thirteen people were trapped and 6 died from LOCAL PUBLIC HEALTH RESPONSE TO THE WORST TERRORIST ATTACK IN U.S. HISTORY On Sept. 11, 2001, two commercial jets that were hijacked by terrorists crashed into the two towers of the World Trade Center in New York City.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["Within 90 minutes, both 110-story towers had collapsed.", [["collapsed", "PROBLEM", 45, 54], ["collapsed", "OBSERVATION", 45, 54]]], ["The New York State Department of Health (NYS DOH) had pre-established Emergency Operations Center committees that came together and began working within 30 minutes of the attack.", [["New", "OBSERVATION_MODIFIER", 4, 7]]], ["NYS DOH nursing staff assisted in triaging and treating injured persons at an emergency triage center.", [["persons", "ORGANISM", 64, 71], ["persons", "SPECIES", 64, 71]]], ["Within the disaster site and surrounding commu-nity, DOH performed environmental monitoring.", [["DOH", "CHEMICAL", 53, 56], ["environmental monitoring", "TEST", 67, 91]]], ["With losses in power and water as well as having tons of airborne contaminants in the area, DOH had its hands full with monitoring both the general public and emergency responders in addition to performing its daily activities.", [["DOH", "CHEMICAL", 92, 95], ["losses", "OBSERVATION_MODIFIER", 5, 11], ["airborne contaminants", "OBSERVATION", 57, 78]]], ["Additionally, the DOH initiated four disease and injury surveillance systems after the disaster, with assistance from the CDC. mudslides in La Conchita, California; and a train disaster in Graniteville, South Carolina released concentrated chlorine fumes, leading to 9 deaths and 250 hospitalizations.", [["DOH", "CHEMICAL", 18, 21], ["chlorine", "CHEMICAL", 240, 248], ["deaths", "DISEASE", 269, 275], ["chlorine", "CHEMICAL", 240, 248], ["four disease", "PROBLEM", 32, 44], ["injury surveillance systems", "PROBLEM", 49, 76], ["La Conchita", "ANATOMY", 140, 151], ["California", "OBSERVATION_MODIFIER", 153, 163], ["chlorine fumes", "OBSERVATION", 240, 254]]], ["Finally, in the fall of 2005 Hurricane Katrina devastated the Gulf coast of the United States, resulting in the flooding and complete evacuation of New Orleans.", [["the flooding", "PROBLEM", 108, 120], ["New", "OBSERVATION_MODIFIER", 148, 151], ["Orleans", "OBSERVATION", 152, 159]]], ["Although these disasters are not on the same scale in terms of death, injury, social loss, and destruction as the tsunami, they still maintain criteria that classify them as disasters.DISASTER POLICYWhat determines whether an event is treated as a federal disaster?", [["death", "DISEASE", 63, 68], ["injury", "DISEASE", 70, 76], ["social loss", "DISEASE", 78, 89], ["death", "PROBLEM", 63, 68], ["injury", "PROBLEM", 70, 76], ["social loss", "PROBLEM", 78, 89], ["destruction", "PROBLEM", 95, 106], ["disasters", "OBSERVATION", 15, 24], ["injury", "OBSERVATION", 70, 76], ["social loss", "OBSERVATION", 78, 89]]], ["7 The Stafford Disaster Relief and Emergency Assistant Act's definition of a major disaster is stated in the following 7 :DISASTER POLICYAny natural catastrophe (including any hurricane,tornado,storm,high water, wind-driven water, tidal wave, tsunami, earthquake, volcanic eruption, landslide, mudslide, snowstorm, or drought), or, regardless of cause, any fire, flood, or explosion in any part of the United States, which in the determination of the President causes damage of sufficient severity and magnitude to warrant major disaster assistance under this Act to supplement the efforts and available resources of states, local governments, and disaster relief organizations in alleviating the damage, loss, hardship, or suffering caused thereby.DISASTER POLICYA major disaster declaration makes available all federal disaster relief assistance to affected communities.", [["tornado", "DISEASE", 186, 193], ["earthquake", "DISEASE", 252, 262], ["eruption", "DISEASE", 273, 281], ["landslide", "DISEASE", 283, 292], ["natural catastrophe", "PROBLEM", 141, 160], ["volcanic eruption", "PROBLEM", 264, 281], ["damage of sufficient severity", "PROBLEM", 468, 497], ["major disaster assistance", "TREATMENT", 523, 548], ["disaster relief organizations", "TREATMENT", 648, 677], ["the damage", "PROBLEM", 693, 703]]], ["This can include repair, replacement, and reconstruction of public and nonprofit facilities; cash grants for personal victim needs; temporary housing vouchers or replacement accommodations; and unemployment assistance.", [["repair", "TREATMENT", 17, 23], ["replacement", "TREATMENT", 25, 36], ["reconstruction", "TREATMENT", 42, 56], ["replacement accommodations", "TREATMENT", 162, 188], ["repair", "OBSERVATION", 17, 23], ["replacement", "OBSERVATION_MODIFIER", 25, 36]]], ["8 Following the Sept. 11 attacks in 2001, the President declared the Homeland Security Presidential Directive (HSPD)-5, in which he called for the development of a new National Response Plan (NRP) \"to align Federal coordination structures, capabilities, and resources into a unified, all-discipline, and all-hazards approach to domestic incident management.\" 6 The premise of this robust plan is to standardize and make seamless the manner of operations for all levels of disaster response from local to federal, as well as private and public, agencies.", [["domestic incident management", "TREATMENT", 328, 356]]], ["Upon full implementation of the NRP, it will supersede the Initial National Response Plan (INRP), the Federal Response Plan (FRP), the U.S. Governmental Interagency Domestic Terrorism Concept of Operations Plan (CONPLAN), and Federal Radiological Emergency Response Plan (FRERP).DISASTER POLICYThe NRP also provides for guidance to initiate long-term community recovery and mitigation.", [["mitigation", "TREATMENT", 374, 384]]], ["6 The NRP stipulates that the coordinator and the primary agency is the Department of Health and Human Services.OPERATING PUBLIC HEALTHThe American Public Health Association (APHA) provides principles to guide public health's response toward terrorism.", [["Human", "ORGANISM", 97, 102], ["Human", "SPECIES", 97, 102]]], ["11 From a list of 12 principles, the following seven are of specific interest to this chapter:OPERATING PUBLIC HEALTH1.", [["HEALTH1", "PROTEIN", 111, 118]]], ["Ensure the availability of and accessibility to health care, including medications and vaccines, for individuals exposed, infected, made ill, or injured in terrorist attacks.", [["medications", "TREATMENT", 71, 82], ["vaccines", "TREATMENT", 87, 95]]], ["Educate and inform health professionals and the public to better identify, respond to, and prevent the health consequences of terrorism and promote the visibility and availability of health professionals in the communities that they serve.OPERATING PUBLIC HEALTH4.", [["HEALTH4", "PROTEIN", 256, 263]]], ["Build and sustain the public health capacity to develop systems to collect data about the health and mental health consequences of terrorism and other disasters on victims, responders, and communities and develop uniform definitions and standardized data classifications systems of death and injury resulting from terrorism and other disasters.OPERATING PUBLIC HEALTHThis chapter introduces basic concepts, discussions, and recommendations regarding the following key issues arising from these selected APHA principles: (1) public health infrastructure; (2) medical services, including the distribution of drugs and supplies; (3) education, training, and communications; (4) environmental health and precautions; (5) mental health; (6) worker safety and first responders; and (7) data collection and analysis.PUBLIC HEALTH INFRASTRUCTUREFormal public health programs in the United States have existed for well over 200 years.", [["death", "DISEASE", 282, 287], ["death", "PROBLEM", 282, 287], ["injury", "PROBLEM", 292, 298], ["terrorism", "PROBLEM", 314, 323], ["data collection and analysis", "TEST", 780, 808]]], ["Working alongside its other federal partners and state agencies, including the DHHS (and its agencies, such as the CDC, the Food and Drug Administration [FDA]), and the U.S. Department of Agriculture (USDA), the USPHS continues to be an active partner in the nationwide system of public health at the federal level and to influence public health on a national scale.", [["a national scale", "TREATMENT", 349, 365], ["active", "OBSERVATION", 237, 243]]], ["The USPHS has, until recently, provided active support and direction to the NDMS (now directly under FEMA).", [["active support", "TREATMENT", 40, 54]]], ["The USPHS continues to respond to and support operations as a partner of NDMS, providing expertise in several areas.PUBLIC HEALTH INFRASTRUCTUREThe U.S. public health system encompasses a broad integration of commercial, public, government, and nongovernment entities.", [["NDMS", "DISEASE", 73, 77], ["support operations", "TREATMENT", 38, 56], ["NDMS", "PROBLEM", 73, 77], ["broad", "OBSERVATION_MODIFIER", 188, 193]]], ["3 Public health is also augmented by its partnerships and increasing collaboration with expert military health institutions, such as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and other defense agencies; national institutions such as the National Institute for Allergy and Infectious Disease (NIAID), under the National Institutes of Health (NIH); law enforcement and emergency responder communities on federal (Federal Bureau of Investigation) and local levels; and the medicolegal community, which is composed of national medical examiners offices and forensic scientists.PUBLIC HEALTH INFRASTRUCTUREPublic health response is not centralized (for better or worse) and incorporates multiple government agencies, ranging from those involved in research and development (e.g., Bioshield at DHHS) to victim assistance (e.g., NDMS at DHS).", [["Infectious Diseases", "DISEASE", 177, 196], ["Allergy and Infectious Disease", "DISEASE", 293, 323]]], ["9 The DHHS alone elicits responses from its agencies: the Agency for Healthcare Research and Quality ( 9 Different agencies function to deliver services to varying target audiences.", [["DHHS", "CHEMICAL", 6, 10]]], ["In terms of activities, the CDC provides grants, technical support, and performance standards to support preparedness and response planning for bioterrorism; chemical and radiological incidents; natural disasters; and terrorist incidents, such as explosions, that may yield significant physical trauma.", [["trauma", "DISEASE", 295, 301], ["bioterrorism", "PROBLEM", 144, 156], ["significant physical trauma", "PROBLEM", 274, 301], ["trauma", "OBSERVATION", 295, 301]]], ["9 The OEP enhances medical response capabilities, such as early identification of a biologic incident, mass prophylaxis, mass casualty care, and mass fatality management.", [["mass prophylaxis", "TREATMENT", 103, 119], ["mass casualty care", "TREATMENT", 121, 139], ["mass fatality management", "TREATMENT", 145, 169]]], ["9 The DOJ helps states develop strategic plans and funds training, the obtaining of equipment, and the planning of drills and exercises for fire, law enforcement, emergency medical and hazardous response (HazMat) teams, hospitals, and public health departments.", [["funds training", "TREATMENT", 51, 65]]], ["9 FEMA supports state emergency management agencies by providing grant assistance to sustain local-consequence management planning, training, and exercises for all disasters, including biological incidents.", [["local-consequence management planning", "TREATMENT", 93, 130]]], ["12 The goal of CSEPP is to improve preparedness in the event of an accident involving U.S. stockpiles of obsolete chemical munitions.", [["CSEPP", "TREATMENT", 15, 20]]], ["9 The core public health component will involve local public health departments, which have been described as \". . . the critical components of the public health system that directly deliver public health services to citizens.\" 13 A public health department is an administrative and/or service unit of local or state government that is staffed with a median of 20 people, varying between 1 and sometimes more than 20,000, with an average of 72 full-time workers.", [["people", "ORGANISM", 364, 370], ["people", "SPECIES", 364, 370]]], ["13 Local public health departments provide services ranging from immunizations to food and milk inspections.", [["milk", "ANATOMY", 91, 95], ["milk", "ORGANISM_SUBSTANCE", 91, 95], ["immunizations", "TREATMENT", 65, 78]]], ["13 Most departments conduct childhood and adult immunizations, communicable disease control practices, epidemiology and surveillance, community assessment, and sexually transmitted disease counseling.", [["sexually transmitted disease", "DISEASE", 160, 188], ["adult immunizations", "TREATMENT", 42, 61], ["community assessment", "TEST", 134, 154]]], ["13 Some others have injury control programs, solid waste management, and comprehensive primary care services.", [["injury control programs", "TREATMENT", 20, 43], ["solid waste management", "TREATMENT", 45, 67], ["injury", "OBSERVATION", 20, 26]]], ["9 For example, between August and September 2004, four hurricanes (Charley, Frances, Ivan, and Jeanne) ripped through Florida, ravaging hundreds of thousands of homes; displacing huge populations; and prompting the aid of 5000 FEMA workers in 15 states and 3800 National Guard members who provided security, directed traffic, and distributed supplies.", [["huge", "OBSERVATION_MODIFIER", 179, 183], ["populations", "OBSERVATION", 184, 195]]], ["14 Additionally, more than 140,000 volunteers spanning state and national volunteer organizations, such as the Red Cross and faith-based groups, arrived in Florida to lend help, ranging from preparing meals to removing trees.", [["volunteers", "ORGANISM", 35, 45]]], ["15 Further, the U.S. Public Health Services works alongside its other federal partners and state agencies, including the DHHS and its agencies, the CDC, and the FDA, as well as the USDA.They continue to be an active partner in the nationwide system of public health at the federal level in order to influence public health on a national scale.", [["a national scale", "TREATMENT", 326, 342], ["active", "OBSERVATION", 209, 215]]], ["The USPHS has until recently provided active support and direction to the National Disaster Medical System (now directly under FEMA) in the Department of Homeland Security.", [["active support", "TREATMENT", 38, 52]]], ["They continue to respond and sup-port operations as a partner of NDMS, providing expertise in several areas.Medical ServicesA biologic attack could result in the infection thousands of people without any indication in the first few hours of how many people are infected.", [["NDMS", "DISEASE", 65, 69], ["infection", "DISEASE", 162, 171], ["people", "ORGANISM", 185, 191], ["people", "ORGANISM", 250, 256], ["people", "SPECIES", 185, 191], ["people", "SPECIES", 250, 256], ["sup-port operations", "TREATMENT", 29, 48], ["NDMS", "PROBLEM", 65, 69], ["Medical ServicesA biologic attack", "PROBLEM", 108, 141], ["the infection", "PROBLEM", 158, 171], ["infection", "OBSERVATION", 162, 171], ["infected", "OBSERVATION", 261, 269]]], ["16 For example, one hypothetical scenario depicted a national and global spread of smallpox, resulting in 15,000 cases and 2000 deaths.", [["smallpox", "DISEASE", 83, 91], ["deaths", "DISEASE", 128, 134], ["global", "OBSERVATION_MODIFIER", 66, 72], ["spread", "OBSERVATION_MODIFIER", 73, 79]]], ["17 It is therefore recommended to provide mass prophylaxis to the population-the use of antibiotics being the primary key to survival for most people.", [["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["mass prophylaxis", "TREATMENT", 42, 58], ["antibiotics", "TREATMENT", 88, 99]]], ["16 Some believe that vaccines are not the first line of defense against biological threats but can be used for control of a smallpox epidemic, prophylaxis against anthrax in combination with antibiotics, control of global pandemic infections, and pre-exposure prophylaxis for high-risk workers in laboratory and health care environments.", [["smallpox", "DISEASE", 124, 132], ["anthrax", "DISEASE", 163, 170], ["infections", "DISEASE", 231, 241], ["anthrax", "SPECIES", 163, 170], ["vaccines", "TREATMENT", 21, 29], ["a smallpox epidemic", "PROBLEM", 122, 141], ["prophylaxis", "TREATMENT", 143, 154], ["anthrax", "PROBLEM", 163, 170], ["antibiotics", "TREATMENT", 191, 202], ["global pandemic infections", "PROBLEM", 215, 241], ["pre-exposure prophylaxis", "TREATMENT", 247, 271], ["global", "OBSERVATION_MODIFIER", 215, 221], ["pandemic", "OBSERVATION_MODIFIER", 222, 230], ["infections", "OBSERVATION", 231, 241]]], ["18 Because most public health departments, hospitals, and local institutions lack the amount of drugs needed for a national emergency, federal medical resources are available through the Strategic National Stockpile (SNS), formerly named the National Pharmaceutical Stockpile (NPS).", [["drugs", "TREATMENT", 96, 101], ["federal medical resources", "TREATMENT", 135, 160]]], ["After institution of the Homeland Security Act of 2002, the DHS and CDC began to jointly manage the SNS, with the DHS defining the goals and performance requirements of the program and being responsible for administering the actual deployment of the 12-hour push package.", [["the 12-hour push package", "TREATMENT", 246, 270]]], ["19 The cache of medical supplies includes antibiotics, chemical antidotes, antitoxins, life support medications, intravenous administration and airway maintenance supplies, and medical/surgical items that can be delivered in the event of a national emergency within 12 hours to strategically designated warehouses across the United States and its territories.", [["intravenous", "ANATOMY", 113, 124], ["airway", "ANATOMY", 144, 150], ["antitoxins", "SIMPLE_CHEMICAL", 75, 85], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["airway", "MULTI-TISSUE_STRUCTURE", 144, 150], ["medical supplies", "TREATMENT", 16, 32], ["antibiotics", "TREATMENT", 42, 53], ["chemical antidotes", "TREATMENT", 55, 73], ["antitoxins", "TREATMENT", 75, 85], ["life support medications", "TREATMENT", 87, 111], ["intravenous administration", "TREATMENT", 113, 139], ["airway maintenance supplies", "TREATMENT", 144, 171], ["medical/surgical items", "TREATMENT", 177, 199], ["airway", "ANATOMY", 144, 150]]], ["The SNS program conducts quarterly quality assurance checks, rotates materials, performs a full annual inventory of all package items, and regularly inspects environmental conditions, security, and overall package maintenance.", [["quarterly quality assurance checks", "TEST", 25, 59], ["overall package maintenance", "TREATMENT", 198, 225]]], ["19 Deployment of the SNS is made when the state governor's office directly requests assets from the CDC or DHS.", [["SNS", "ANATOMY", 21, 24]]], ["19 Once the SNS cache has been delivered, several key steps must be taken to effectively use it: officially receive the supplies and unload them; have adequate personnel for packaging, distributing, dispensing, tracking, and storing the supplies; have the local public health department assign dosages; and provide communication and security.", [["the SNS cache", "TREATMENT", 8, 21], ["packaging", "TREATMENT", 174, 183]]], ["16 There are additional public health issues beyond these logistics that should be taken into account when distributing mass prophylaxis to the public.", [["these logistics", "TREATMENT", 52, 67], ["distributing mass prophylaxis", "TREATMENT", 107, 136], ["mass", "OBSERVATION", 120, 124]]], ["They include dividing the population into groups who require medication first, a step that is politically sensitive and should be decided before a biologic attack happens.", [["medication", "TREATMENT", 61, 71], ["a biologic attack", "PROBLEM", 145, 162]]], ["16 Also, public health personnel should be ready to distribute clear agentspecific and drug information, to make available multilingual staff and handouts, to handle the needs of special populations, to provide personal protective equipment (PPE) for people at staffing and dispensing centers, and to provide security in case of crowd panic.", [["panic", "DISEASE", 335, 340], ["people", "ORGANISM", 251, 257], ["people", "SPECIES", 251, 257], ["crowd panic", "PROBLEM", 329, 340]]], ["16 Disasters cause various patterns of injury and disease, ranging from blast injuries by a terrorist bombing to ventilatory failure from the chemical release of a nerve agent.", [["nerve", "ANATOMY", 164, 169], ["blast injuries", "DISEASE", 72, 86], ["ventilatory failure", "DISEASE", 113, 132], ["injury", "PROBLEM", 39, 45], ["disease", "PROBLEM", 50, 57], ["blast injuries", "PROBLEM", 72, 86], ["ventilatory failure", "PROBLEM", 113, 132], ["a nerve agent", "TREATMENT", 162, 175], ["injury", "OBSERVATION", 39, 45], ["disease", "OBSERVATION", 50, 57], ["ventilatory failure", "OBSERVATION", 113, 132], ["nerve", "ANATOMY", 164, 169]]], ["As a result, responses significantly vary in terms of how widespread the response is (local to international), which personnel are used to respond, the duration of the response, and what medical management must be used to treat those affected or exposed.Medical ServicesFor example, some infectious diseases require a larger response, for which the help of national and sometimes international partners and resources is needed to identify the agent, conduct surveillance, report, and treat the range of people who may be infected.", [["infectious diseases", "DISEASE", 288, 307], ["people", "ORGANISM", 503, 509], ["people", "SPECIES", 503, 509], ["medical management", "TREATMENT", 187, 205], ["some infectious diseases", "PROBLEM", 283, 307], ["infectious", "OBSERVATION", 288, 298], ["infected", "OBSERVATION", 521, 529]]], ["Such responses may vary in location and size.", [["vary", "OBSERVATION_MODIFIER", 19, 23], ["size", "OBSERVATION_MODIFIER", 40, 44]]], ["For instance, injuries and deaths occur because victims fail to evacuate and take shelter, do not take precautions in securing property, and do not follow guidelines for food and water safety or injury prevention during the recovery phase.", [["injuries", "DISEASE", 14, 22], ["deaths", "DISEASE", 27, 33], ["injuries", "PROBLEM", 14, 22], ["deaths", "PROBLEM", 27, 33], ["injury prevention", "TREATMENT", 195, 212]]], ["20 Injuries from a hurricane can result from near-drowning; electrocution; lacerations from flying debris; blunt trauma or bone fractures from falling trees and other heavy objects; stress-related disorders; heart attacks; gastrointestinal, respiratory, vector-borne, and skin diseases; toxic poisoning; fires; bites from displaced wild animals, such as animals and snakes; and even improper use of mechanical equipment, such as chain saws and power tools.", [["bone", "ANATOMY", 123, 127], ["heart", "ANATOMY", 208, 213], ["gastrointestinal", "ANATOMY", 223, 239], ["respiratory", "ANATOMY", 241, 252], ["skin", "ANATOMY", 272, 276], ["Injuries", "DISEASE", 3, 11], ["hurricane", "DISEASE", 19, 28], ["drowning", "DISEASE", 50, 58], ["electrocution", "DISEASE", 60, 73], ["lacerations", "DISEASE", 75, 86], ["trauma", "DISEASE", 113, 119], ["bone fractures", "DISEASE", 123, 137], ["heart attacks", "DISEASE", 208, 221], ["gastrointestinal, respiratory, vector-borne", "DISEASE", 223, 266], ["skin diseases", "DISEASE", 272, 285], ["poisoning", "DISEASE", 293, 302], ["bone", "TISSUE", 123, 127], ["heart", "ORGAN", 208, 213], ["gastrointestinal", "ORGAN", 223, 239], ["skin", "ORGAN", 272, 276], ["electrocution", "PROBLEM", 60, 73], ["lacerations", "PROBLEM", 75, 86], ["flying debris", "PROBLEM", 92, 105], ["blunt trauma", "PROBLEM", 107, 119], ["bone fractures", "PROBLEM", 123, 137], ["falling trees", "PROBLEM", 143, 156], ["stress-related disorders", "PROBLEM", 182, 206], ["heart attacks", "PROBLEM", 208, 221], ["gastrointestinal, respiratory, vector-borne", "PROBLEM", 223, 266], ["skin diseases", "PROBLEM", 272, 285], ["toxic poisoning", "PROBLEM", 287, 302], ["displaced wild animals", "PROBLEM", 322, 344], ["mechanical equipment", "TREATMENT", 399, 419], ["lacerations", "OBSERVATION", 75, 86], ["debris", "OBSERVATION_MODIFIER", 99, 105], ["blunt trauma", "OBSERVATION", 107, 119], ["bone", "ANATOMY", 123, 127], ["fractures", "OBSERVATION", 128, 137], ["heart", "ANATOMY", 208, 213], ["attacks", "OBSERVATION", 214, 221], ["gastrointestinal", "ANATOMY", 223, 239], ["respiratory", "ANATOMY", 241, 252], ["skin", "ANATOMY", 272, 276], ["diseases", "OBSERVATION", 277, 285], ["toxic", "OBSERVATION_MODIFIER", 287, 292]]], ["20 Chemical and radiological incidents have more specific medical issues, including the recognition of patterns of injury, prophylaxis, and antidotes.", [["injury", "PROBLEM", 115, 121], ["prophylaxis", "TREATMENT", 123, 134], ["antidotes", "TREATMENT", 140, 149], ["injury", "OBSERVATION", 115, 121]]], ["Managing a volume of exposed patients in a limited healthcare environment can be challenging and can include issues of decontamination; on-site prehospital management; transportation; the use of PPE; and treatment of patterns of injury specifically associated with chemical and radiological sequelae, such as skin lesions, blisters and burns, nervous system disorders, inhalational injuries, and acute radiation syndrome.", [["skin lesions", "ANATOMY", 309, 321], ["blisters", "ANATOMY", 323, 331], ["nervous system", "ANATOMY", 343, 357], ["skin lesions", "DISEASE", 309, 321], ["blisters", "DISEASE", 323, 331], ["burns", "DISEASE", 336, 341], ["nervous system disorders", "DISEASE", 343, 367], ["inhalational injuries", "DISEASE", 369, 390], ["acute radiation syndrome", "DISEASE", 396, 420], ["patients", "ORGANISM", 29, 37], ["skin lesions", "PATHOLOGICAL_FORMATION", 309, 321], ["blisters", "PATHOLOGICAL_FORMATION", 323, 331], ["patients", "SPECIES", 29, 37], ["decontamination", "TREATMENT", 119, 134], ["site prehospital management", "TREATMENT", 139, 166], ["PPE", "TREATMENT", 195, 198], ["treatment", "TREATMENT", 204, 213], ["injury", "PROBLEM", 229, 235], ["chemical and radiological sequelae", "PROBLEM", 265, 299], ["skin lesions", "PROBLEM", 309, 321], ["blisters", "PROBLEM", 323, 331], ["burns", "PROBLEM", 336, 341], ["nervous system disorders", "PROBLEM", 343, 367], ["inhalational injuries", "PROBLEM", 369, 390], ["acute radiation syndrome", "PROBLEM", 396, 420], ["injury", "OBSERVATION", 229, 235], ["skin", "ANATOMY", 309, 313], ["lesions", "OBSERVATION", 314, 321], ["blisters", "OBSERVATION", 323, 331], ["burns", "OBSERVATION", 336, 341], ["nervous", "ANATOMY", 343, 350], ["acute", "OBSERVATION_MODIFIER", 396, 401], ["radiation syndrome", "OBSERVATION", 402, 420]]], ["Some disasters fall into less specific points for medical management due to the nature of the event.Medical ServicesConsider the blackout on Aug. 14, 2003, in the Northeastern United States and Southeastern Canada (Ottawa and Toronto) that affected 50 million people and a total of 240,00 square kilometers in areas including New York, New Jersey, Vermont, Michigan, Ohio, Pennsylvania, Connecticut, and Massachusetts.", [["people", "ORGANISM", 260, 266], ["people", "SPECIES", 260, 266], ["Some disasters fall", "PROBLEM", 0, 19], ["medical management", "TREATMENT", 50, 68], ["disasters", "OBSERVATION", 5, 14]]], ["22 The blackout affected all electrical functions, shutting down computers, trapping passengers in high-rise elevators, stalling subways, and disrupting airport control and landing procedures, hospital activities, food refrigeration, traffic operations, and most channels of communication.", [["landing procedures", "TREATMENT", 173, 191], ["traffic operations", "TREATMENT", 234, 252]]], ["Facilities with backup generators were able to continue operations, but only sparingly.", [["backup generators", "TREATMENT", 16, 33]]], ["In the United States, three people died as a result of the blackout and one firefighter was injured.", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34]]], ["In Ottawa, a teenager died from fire-related injuries and another person died after being hit by a car.", [["injuries", "DISEASE", 45, 53], ["person", "SPECIES", 66, 72]]], ["In New York during the 30-hour period of no electricity, 3000 fires were reported, mainly from people using candles, and EMS personnel responded to 80,000 calls to 911, double the average.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["New", "OBSERVATION_MODIFIER", 3, 6], ["no", "UNCERTAINTY", 41, 43]]], ["22 On the other hand, finite, sudden disasters causing immediate injury and mortality (such as terrorist bombings, transportation disasters, and building collapses) require a more robust response capacity at a local and perhaps regional level.This differs from the national and sometimes international assistance required after largescale natural disasters that affect vast regions of terrain, as was seen in the case of the 2004 tsunami disaster, as well as in several instances of floods, hurricanes, and even complex humanitarian emergencies overseas.", [["floods", "DISEASE", 483, 489], ["hurricanes", "DISEASE", 491, 501], ["sudden disasters", "PROBLEM", 30, 46], ["immediate injury", "PROBLEM", 55, 71], ["a more robust response capacity", "PROBLEM", 173, 204], ["injury", "OBSERVATION", 65, 71], ["terrain", "OBSERVATION_MODIFIER", 385, 392]]], ["In the case of an explosion, trauma systems must be equipped and ready to accept incoming patients, manage the bulk of patients with minor wounds who will flood the nearest hospital, and prepare for possibly unexpected rates of casualty flow.", [["wounds", "ANATOMY", 139, 145], ["trauma", "DISEASE", 29, 35], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 119, 127], ["wounds", "PATHOLOGICAL_FORMATION", 139, 145], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 119, 127], ["trauma systems", "TREATMENT", 29, 43], ["minor wounds", "PROBLEM", 133, 145]]], ["Physicians should be prepared to treat hundreds of trauma patients, which may be complicated by loss of utilities, difficulty in reaching hospitals, or possible damage to hospital facilities.", [["trauma", "DISEASE", 51, 57], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["trauma", "PROBLEM", 51, 57], ["loss of utilities", "PROBLEM", 96, 113]]], ["23 The physically injured from high-energy disasters, such as earthquakes, tornadoes, or explosions, will most likely be treated at regional trauma centers for severe injuries.", [["earthquakes", "DISEASE", 62, 73], ["trauma", "DISEASE", 141, 147], ["injuries", "DISEASE", 167, 175], ["earthquakes", "PROBLEM", 62, 73], ["tornadoes", "PROBLEM", 75, 84], ["explosions", "PROBLEM", 89, 99], ["severe injuries", "PROBLEM", 160, 175], ["physically", "OBSERVATION_MODIFIER", 7, 17], ["injured", "OBSERVATION", 18, 25], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["injuries", "OBSERVATION", 167, 175]]], ["In the United States, there are 600 regional trauma centers.", [["trauma", "DISEASE", 45, 51]]], ["24 They coordinate EMS, including paramedics and air medical transport.", [["air medical transport", "TREATMENT", 49, 70]]], ["A regional trauma center is composed of paramedics and emergency medical technicians (EMTs) who transport injured victims to trauma teams that include a trauma surgeon, emergency physician, several trauma nurses, and specialized personnel.", [["trauma", "DISEASE", 11, 17], ["trauma", "DISEASE", 125, 131], ["trauma", "DISEASE", 153, 159], ["trauma", "DISEASE", 198, 204]]], ["Up to 16 physicians in various specialties, from neurosurgery to obstetrics, comprise a trauma team ready to receive injured patients in the operating room and critical care unit.", [["trauma", "DISEASE", 88, 94], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133]]], ["24 For disease outbreaks, the provision of medical services and public health capabilities is considerably great and involves a large network of local to sometimes international response.", [["disease outbreaks", "PROBLEM", 7, 24], ["medical services", "TREATMENT", 43, 59], ["disease", "OBSERVATION", 7, 14]]], ["When severe acute respiratory syndrome (SARS) made its way onto the global front as a highly threatening disease in November 2002, it crippled the Asian healthcare system and brought to light serious questions about the U.S. public health system's ability to respond to a similar crisis at home.", [["acute respiratory syndrome", "DISEASE", 12, 38], ["SARS", "DISEASE", 40, 44], ["severe acute respiratory syndrome", "PROBLEM", 5, 38], ["SARS", "PROBLEM", 40, 44], ["a similar crisis", "PROBLEM", 270, 286], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["respiratory syndrome", "OBSERVATION", 18, 38]]], ["SARS had the greatest impact on Asian countries, with 7782 cases and 729 deaths, challenging Asian healthcare systems, adversely affecting Asian economies, and testing the effectiveness of international health codes.", [["SARS", "DISEASE", 0, 4], ["deaths", "DISEASE", 73, 79], ["greatest", "OBSERVATION_MODIFIER", 13, 21]]], ["25 SARS is part of the coronavirus family.", [["SARS", "DISEASE", 3, 7], ["coronavirus", "ORGANISM", 23, 34]]], ["Within 2 to 10 days after infection, the affected person can develop symptoms including cough, fever, and body aches that are indiscriminate from other respiratory illnesses, appearing as an atypical pneumonia.", [["body", "ANATOMY", 106, 110], ["respiratory", "ANATOMY", 152, 163], ["infection", "DISEASE", 26, 35], ["cough", "DISEASE", 88, 93], ["fever", "DISEASE", 95, 100], ["body aches", "DISEASE", 106, 116], ["respiratory illnesses", "DISEASE", 152, 173], ["pneumonia", "DISEASE", 200, 209], ["person", "ORGANISM", 50, 56], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["aches", "ORGANISM_SUBDIVISION", 111, 116], ["person", "SPECIES", 50, 56], ["infection", "PROBLEM", 26, 35], ["symptoms", "PROBLEM", 69, 77], ["cough", "PROBLEM", 88, 93], ["fever", "PROBLEM", 95, 100], ["body aches", "PROBLEM", 106, 116], ["other respiratory illnesses", "PROBLEM", 146, 173], ["an atypical pneumonia", "PROBLEM", 188, 209], ["infection", "OBSERVATION", 26, 35], ["respiratory", "ANATOMY", 152, 163], ["illnesses", "OBSERVATION", 164, 173], ["atypical", "OBSERVATION_MODIFIER", 191, 199], ["pneumonia", "OBSERVATION", 200, 209]]], ["25 The fatality rate from SARS is 11% and can be greater than 50% for people older than 65.", [["SARS", "DISEASE", 26, 30], ["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76], ["The fatality rate", "TEST", 3, 20], ["SARS", "TEST", 26, 30]]], ["25 SARS is a person-to-person transmitted disease that is acquired primarily through direct and indirect contact with respiratory secretions and/or contaminated objects.Medical ServicesAn international outbreak of SARS took place from February through deep into the spring of 2003.", [["respiratory secretions", "ANATOMY", 118, 140], ["SARS", "DISEASE", 3, 7], ["SARS", "DISEASE", 214, 218], ["person", "SPECIES", 13, 19], ["transmitted disease", "PROBLEM", 30, 49], ["respiratory secretions", "PROBLEM", 118, 140], ["SARS", "PROBLEM", 214, 218], ["disease", "OBSERVATION", 42, 49]]], ["When an infected physician who treated SARS patients in China stayed at a hotel in Hong Kong on travel, those who resided at the hotel acquired the disease and subsequently departed to Vietnam, Singapore, and Toronto, Canada, seeding secondary outbreaks.", [["SARS", "DISEASE", 39, 43], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["disease", "OBSERVATION", 148, 155]]], ["25 Cases spread from Asia to 26 countries, and at is peak in May 2003, hundreds of cases of SARS were being reported each week.Medical ServicesTo prevent and control the spread of SARS, public health efforts of case identification and contact tracing, transmission control, and exposure management were utilized.", [["SARS", "DISEASE", 92, 96], ["SARS", "DISEASE", 180, 184], ["SARS", "PROBLEM", 92, 96], ["Medical ServicesTo", "TREATMENT", 127, 145], ["SARS", "PROBLEM", 180, 184], ["contact tracing", "TEST", 235, 250], ["transmission control", "TREATMENT", 252, 272], ["exposure management", "TREATMENT", 278, 297]]], ["Case identification and contact tracing is \"defining what symptoms, laboratory results, and medical histories constitute a positive case in a patient and tracing and tracking individuals who may have been exposed to these patients.\" 25 Transmission control is \"controlling the transmission of disease-producing microorganisms through use of proper hand hygiene and personal protective equipment, such as masks, gowns, and gloves.\" 25 Exposure management separates those infected from noninfected individuals through the use of quarantine, which restricts movement of those who are not ill but were exposed to the disease agent and are potentially infectious.", [["hand", "ANATOMY", 348, 352], ["patient", "ORGANISM", 142, 149], ["individuals", "ORGANISM", 175, 186], ["patients", "ORGANISM", 222, 230], ["hand", "ORGANISM_SUBDIVISION", 348, 352], ["patient", "SPECIES", 142, 149], ["patients", "SPECIES", 222, 230], ["contact tracing", "TEST", 24, 39], ["what symptoms", "PROBLEM", 53, 66], ["tracing", "TEST", 154, 161], ["disease", "PROBLEM", 293, 300], ["proper hand hygiene", "TREATMENT", 341, 360], ["personal protective equipment", "TREATMENT", 365, 394], ["Exposure management", "TREATMENT", 434, 453], ["quarantine", "TREATMENT", 527, 537], ["infectious", "PROBLEM", 647, 657], ["disease", "OBSERVATION", 613, 620], ["potentially", "UNCERTAINTY", 635, 646], ["infectious", "OBSERVATION", 647, 657]]], ["Participants of a tabletop exercise are broad and may include government officials (mayors, city council members, risk manager), public works/utilities personnel (water superintendent, gas company representative), law enforcement (police chief, sheriff), community services (Red Cross representative), emergency management (emergency program manager, National Guard representative), fire department representatives (fire chief, dispatcher), emergency medical/health personnel (emergency medical coordinator, public health official), and public information officers.", [["Participants", "SPECIES", 0, 12]]], ["12 The tabletop exercise, which commonly includes senior-level officials, prompts participants to discuss how their respective agencies or units might react to a specific set of scenarios, emphasizing higherlevel policy and procedural issues.", [["participants", "SPECIES", 82, 94], ["The tabletop exercise", "TEST", 3, 24]]], ["12 Full-scale exercises engage tactics, techniques, and procedures that could be used in an actual incident and are designed to be realistic.", [["procedures", "TREATMENT", 56, 66]]], ["12 In May 2000, May 2003, and most recently May 2005, FEMA led three exercises called the Top Officials (TOPOFF1, TOPOFF2, and TOPOFF3), which were large-scale,\"no-notice\" field drills involving federal, state, and local agencies.", [["TOPOFF2", "TREATMENT", 114, 121]]], ["TOPOFF1 in 2000 was jointly led by FEMA and DOJ and was conducted in three cities: a biological weapons incident in Denver, Colo., a chemical incident in Portsmouth, N.H., and a mass casualty radiological incident in the Washington, D.C. region.", [["a mass casualty", "PROBLEM", 176, 191], ["mass", "OBSERVATION", 178, 182]]], ["12 In 2003, the TOPOFF2 4-day drill involved a Radiological Dispersal Device (RDD), or \"dirty bomb,\" release in Seattle, Washington, and a biologic incident involving Yersinia pestis, or Pneumonic Plague, in Chicago.", [["Yersinia pestis", "DISEASE", 167, 182], ["Pneumonic Plague", "DISEASE", 187, 203], ["Yersinia pestis", "ORGANISM", 167, 182], ["Yersinia pestis", "SPECIES", 167, 182], ["Yersinia pestis", "SPECIES", 167, 182], ["Yersinia pestis", "PROBLEM", 167, 182], ["Pneumonic Plague", "PROBLEM", 187, 203], ["Pneumonic", "OBSERVATION_MODIFIER", 187, 196], ["Plague", "OBSERVATION", 197, 203]]], ["The exercise simulated a chemical release attack in New London, Connecticut, and a biologic attack in New Jersey.EDUCATION, TRAINING, AND COMMUNICATIONSPhysicians and other healthcare providers are oftentimes on the front line when detecting a disease outbreak and play a primary role in early detection of the disease:EDUCATION, TRAINING, AND COMMUNICATIONS\"Health-care providers should be alert to illness patterns and diagnostic clues that might indicate an unusual infectious disease outbreak associated with intentional release of a biologic agent and should report any clusters or findings to their local or state health department. . . .\" 23, 27 Physicians and other healthcare providers are recommended to maintain a high level of suspicion for rare disease, ascertain thorough patient histories, and evaluate occupational and environmental exposures.", [["illness", "DISEASE", 400, 407], ["patient", "ORGANISM", 786, 793], ["patient", "SPECIES", 786, 793], ["a disease outbreak", "PROBLEM", 242, 260], ["an unusual infectious disease outbreak", "PROBLEM", 458, 496], ["a biologic agent", "TREATMENT", 536, 552], ["rare disease", "PROBLEM", 753, 765], ["New", "OBSERVATION_MODIFIER", 52, 55], ["biologic attack", "OBSERVATION", 83, 98], ["New", "OBSERVATION_MODIFIER", 102, 105]]], ["28 The CDC indicates the following three signs of a possible intentional biological release, emphasizing physicians should stay alert for the following 27 :EDUCATION, TRAINING, AND COMMUNICATIONS1.", [["The CDC", "TEST", 3, 10]]], ["An unusual temporal or geographic clustering of illness (e.g., persons who attended the same public event or gathering) or patients presenting with clinical signs and symptoms that suggest an infectious disease outbreak 2.", [["illness", "DISEASE", 48, 55], ["persons", "ORGANISM", 63, 70], ["patients", "ORGANISM", 123, 131], ["persons", "SPECIES", 63, 70], ["patients", "SPECIES", 123, 131], ["clinical signs and symptoms", "PROBLEM", 148, 175], ["an infectious disease outbreak", "PROBLEM", 189, 219], ["unusual", "OBSERVATION_MODIFIER", 3, 10], ["temporal", "OBSERVATION_MODIFIER", 11, 19], ["geographic", "OBSERVATION_MODIFIER", 23, 33], ["clustering", "OBSERVATION_MODIFIER", 34, 44], ["illness", "OBSERVATION", 48, 55], ["infectious", "OBSERVATION", 192, 202]]], ["An unusual age distribution for common diseases 3.", [["common diseases 3", "PROBLEM", 32, 49], ["common diseases", "OBSERVATION", 32, 47]]], ["A large number of cases of acute flaccid paralysis with prominent bulbar palsies, suggestive of a release of botulinum toxinEDUCATION, TRAINING, AND COMMUNICATIONSMost of the knowledge base and skills needed to treat patients after a terrorist or nonterrorist disaster involves an extension of everyday tools that physicians already possess.", [["bulbar", "ANATOMY", 66, 72], ["paralysis", "DISEASE", 41, 50], ["bulbar palsies", "DISEASE", 66, 80], ["bulbar", "ORGAN", 66, 72], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["acute flaccid paralysis", "PROBLEM", 27, 50], ["prominent bulbar palsies", "PROBLEM", 56, 80], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["flaccid", "OBSERVATION_MODIFIER", 33, 40], ["paralysis", "OBSERVATION", 41, 50], ["prominent", "OBSERVATION_MODIFIER", 56, 65], ["bulbar palsies", "OBSERVATION", 66, 80], ["suggestive of", "UNCERTAINTY", 82, 95]]], ["23 This may include symptoms to become familiar with for early recognition of an unusual infection, guidelines to manage chemical-and radiation-contaminated patients, and protocols to triage and treat acute trauma patients after an explosion.", [["infection", "DISEASE", 89, 98], ["trauma", "DISEASE", 207, 213], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 214, 222], ["symptoms", "PROBLEM", 20, 28], ["an unusual infection", "PROBLEM", 78, 98], ["radiation", "TREATMENT", 134, 143], ["acute trauma", "PROBLEM", 201, 213], ["infection", "OBSERVATION", 89, 98]]], ["20 Some likely public health information might include food and water safety, injury prevention measures, and warnings that, for example, increase timely evacuation from hurricanes and shelter against tornadoes.", [["injury prevention measures", "TREATMENT", 78, 104]]], ["20 Also, information should contain facts about the expected hazards (natural, man-made, or technological disaster), safety precautions, and requirements for evacuation or shelter-in-place.", [["safety precautions", "TREATMENT", 117, 135], ["evacuation", "TREATMENT", 158, 168]]], ["This has been documented to happen out of fear that panic will overwhelm the public and lead to more deaths and injuries than the actual disaster.", [["panic", "DISEASE", 52, 57], ["deaths", "DISEASE", 101, 107], ["injuries", "DISEASE", 112, 120], ["panic", "PROBLEM", 52, 57], ["injuries", "PROBLEM", 112, 120]]], ["20 Internally among public health systems and partners, secure and redundant lines of communication should be set up during a disaster.", [["redundant lines", "OBSERVATION", 67, 82]]], ["These include computers with a CD drive, e-mail capability, continuous online Internet access, and security software to protect sensitive data from intruders.", [["a CD drive", "TREATMENT", 29, 39], ["intruders", "PROBLEM", 148, 157]]], ["20 Communication equipment that has been used for public health response includes radio equipment, such as twoway radios, pagers, broadcast radios, televisions, and satellites; wire lines, such as telephones, facsimile machines, and computer modems; and a combination of both radio and wire lines, including cellular and satellite telephones.", [["cellular", "ANATOMY", 308, 316], ["wire lines", "CELL", 286, 296], ["cellular", "CELL", 308, 316], ["radio and wire lines", "CELL_LINE", 276, 296], ["Communication equipment", "TREATMENT", 3, 26], ["radio equipment", "TREATMENT", 82, 97], ["wire lines", "TREATMENT", 177, 187], ["facsimile machines", "TREATMENT", 209, 227], ["both radio and wire lines", "TREATMENT", 271, 296], ["wire lines", "OBSERVATION", 177, 187], ["wire lines", "OBSERVATION", 286, 296]]], ["Such was the case in the London Bombings on July 7, 2005, when private businesses found it nearly impossible to access e-mails or make mobile phone calls, as cellular networks were congested from a surge in traffic.ENVIRONMENTAL HEALTH AND PRECAUTIONSEnvironmental health precautions after a disaster will decrease illness, injury, and death.", [["cellular networks", "ANATOMY", 158, 175], ["illness", "DISEASE", 315, 322], ["injury", "DISEASE", 324, 330], ["death", "DISEASE", 336, 341], ["cellular networks", "MULTI-TISSUE_STRUCTURE", 158, 175], ["PRECAUTIONSEnvironmental health precautions", "TREATMENT", 240, 283], ["injury", "PROBLEM", 324, 330], ["death", "PROBLEM", 336, 341]]], ["The risks of infection increase in the days after a disaster due to disrupted water supplies and the problem of sanitation control.", [["infection", "DISEASE", 13, 22], ["infection", "PROBLEM", 13, 22], ["disrupted water supplies", "TREATMENT", 68, 92], ["sanitation control", "TREATMENT", 112, 130], ["infection", "OBSERVATION", 13, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31]]], ["These include maintaining water and food safety, proper sanitation and waste disposal, and the control of vector populations.", [["proper sanitation", "TREATMENT", 49, 66], ["waste disposal", "TREATMENT", 71, 85]]], ["Ensuring an adequate supply of safe drinking water 2.", [["adequate", "OBSERVATION_MODIFIER", 12, 20], ["supply", "OBSERVATION_MODIFIER", 21, 27]]], ["Providing food protection measures 3.", [["food protection measures", "TREATMENT", 10, 34]]], ["Measures of control that involve preventing the hazard in question from being released or occurring; controlling its transport; and keeping people from being exposed, such as cleaning, treating, and collecting clean water 2.", [["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["Measures of control", "TREATMENT", 0, 19]]], ["Establishing multiple barriers, meaning setting up redundant obstacles to separate unsanitary conditions from human contact that can sometimes be a matter of public works engineering 3.", [["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["multiple", "OBSERVATION_MODIFIER", 13, 21]]], ["Distance between hazards and populations Quantitative analyses must be used in a survey fashion to identify existing disposal facilities and procedures in a community; to determine how to deliver sanitation coverage; and to distribute safe drinking water and establish water consumption rates.", [["Quantitative analyses", "TEST", 41, 62], ["sanitation coverage", "TREATMENT", 196, 215]]], ["Consumption of and contact with contaminated water supplies from run-off sewage and disrupted sewage systems can lead to fecal-oral diseases such as cholera, typhoid fever, hepatitis A, and shigella.", [["oral", "ANATOMY", 127, 131], ["fecal-oral diseases", "DISEASE", 121, 140], ["cholera", "DISEASE", 149, 156], ["typhoid fever", "DISEASE", 158, 171], ["hepatitis A", "DISEASE", 173, 184], ["oral", "ORGANISM_SUBDIVISION", 127, 131], ["typhoid fever", "SPECIES", 158, 171], ["hepatitis A", "SPECIES", 173, 184], ["run-off sewage", "TREATMENT", 65, 79], ["disrupted sewage systems", "PROBLEM", 84, 108], ["fecal-oral diseases", "PROBLEM", 121, 140], ["cholera", "PROBLEM", 149, 156], ["typhoid fever", "PROBLEM", 158, 171], ["hepatitis A", "PROBLEM", 173, 184], ["shigella", "PROBLEM", 190, 198], ["fecal", "ANATOMY", 121, 126], ["oral", "ANATOMY", 127, 131], ["diseases", "OBSERVATION", 132, 140], ["hepatitis", "OBSERVATION", 173, 182]]], ["Improper food storage, for example, is often associated with Bacillus cereus, Clostridium perfringens, Salmonella, Staphylococcus aureus, and group A Streptococcus.", [["Clostridium perfringens", "DISEASE", 78, 101], ["Staphylococcus aureus", "DISEASE", 115, 136], ["Bacillus cereus", "ORGANISM", 61, 76], ["Clostridium perfringens", "ORGANISM", 78, 101], ["Salmonella, Staphylococcus aureus", "ORGANISM", 103, 136], ["group A Streptococcus", "ORGANISM", 142, 163], ["Bacillus cereus", "SPECIES", 61, 76], ["Clostridium perfringens", "SPECIES", 78, 101], ["Staphylococcus aureus", "SPECIES", 115, 136], ["Bacillus cereus", "SPECIES", 61, 76], ["Clostridium perfringens", "SPECIES", 78, 101], ["Staphylococcus aureus", "SPECIES", 115, 136], ["Improper food storage", "PROBLEM", 0, 21], ["Bacillus cereus", "PROBLEM", 61, 76], ["Clostridium perfringens", "PROBLEM", 78, 101], ["Salmonella", "PROBLEM", 103, 113], ["Staphylococcus aureus", "PROBLEM", 115, 136], ["group A Streptococcus", "PROBLEM", 142, 163], ["food storage", "OBSERVATION", 9, 21], ["Staphylococcus aureus", "OBSERVATION", 115, 136]]], ["Insufficient housing can expose people to environmental conditions that make them susceptible to frostbite, hypothermia, heat stroke, and dehydration.", [["frostbite", "DISEASE", 97, 106], ["hypothermia", "DISEASE", 108, 119], ["heat stroke", "DISEASE", 121, 132], ["dehydration", "DISEASE", 138, 149], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["frostbite", "PROBLEM", 97, 106], ["hypothermia", "PROBLEM", 108, 119], ["heat stroke", "PROBLEM", 121, 132], ["dehydration", "PROBLEM", 138, 149], ["hypothermia", "OBSERVATION", 108, 119], ["stroke", "OBSERVATION", 126, 132]]], ["20 Especially important to take into account are educational messages and warnings about carbon monoxide poisoning and untrained use of mechanical power generators.", [["carbon monoxide", "CHEMICAL", 89, 104], ["poisoning", "DISEASE", 105, 114], ["carbon monoxide", "CHEMICAL", 89, 104], ["carbon monoxide", "SIMPLE_CHEMICAL", 89, 104], ["carbon monoxide poisoning", "TREATMENT", 89, 114], ["mechanical power generators", "TREATMENT", 136, 163]]], ["Pest control to reduce infestation of rat and mosquito populations is also important.MENTAL HEALTHSeveral studies describe, characterize, and propose interventions for mental health issues encountered after a disaster.", [["rat", "ORGANISM", 38, 41], ["rat", "SPECIES", 38, 41], ["rat", "SPECIES", 38, 41], ["Pest control", "TREATMENT", 0, 12], ["infestation of rat and mosquito populations", "PROBLEM", 23, 66], ["MENTAL HEALTHSeveral studies", "TEST", 85, 113], ["mental health issues", "PROBLEM", 168, 188]]], ["Experts note the wide range of questionnaires, surveys, interviews, and psychiatric classification systems used to document postdisaster psychological sequelae and note the difficulty in cross-comparison and generalization of these findings toward many disasters.", [["psychiatric", "DISEASE", 72, 83], ["psychiatric classification systems", "TEST", 72, 106], ["postdisaster psychological sequelae", "PROBLEM", 124, 159]]], ["29 Although the disaster community agrees that effects of mental health require more investigation, they also agree that \"the worst scars in disasters are psychological and social scars.\" 30 Mental health issues stemming from disasters are becoming increasingly integrated into postdisaster assessment, with more emphasis on mental health being an urgent aspect of public health relief.MENTAL HEALTHThe mental health community stresses that providers and disaster relief personnel need to have a meaningful understanding of the psychological and social needs of victims in a disaster.", [["scars", "PATHOLOGICAL_FORMATION", 132, 137], ["postdisaster assessment", "TEST", 278, 301], ["public health relief", "TREATMENT", 365, 385]]], ["30 Disasters can provoke specific emotional reactions that take on a variety of different psychological responses, affecting primary victims (those directly involved in the disaster) and secondary victims (such as relatives, co-workers, and schoolmates).", [["specific emotional reactions", "PROBLEM", 25, 53]]], ["Other people who can experience mental health issues include onlookers, rescuers, body handlers, health personnel, evacuees, and refugees.", [["body", "ANATOMY", 82, 86], ["people", "ORGANISM", 6, 12], ["body", "ORGANISM_SUBDIVISION", 82, 86], ["people", "SPECIES", 6, 12], ["mental health issues", "PROBLEM", 32, 52]]], ["30 It is important to realize that most adults and children will experience normal stress reactions for several days after a disaster (Box 2-1).", [["adults", "ORGANISM", 40, 46], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["normal stress reactions", "PROBLEM", 76, 99]]], ["31 One should note that normal stress reactions can also spawn personal introspection, growth, and resilience.MENTAL HEALTHThe three forms of mental health problems that may follow a disaster are acute stress reactions, posttraumatic stress disorders (PTSDs), and adjustment disorders or enduring personality change.", [["posttraumatic stress disorders", "DISEASE", 220, 250], ["PTSDs", "DISEASE", 252, 257], ["normal stress reactions", "PROBLEM", 24, 47], ["mental health problems", "PROBLEM", 142, 164], ["acute stress reactions", "PROBLEM", 196, 218], ["posttraumatic stress disorders", "PROBLEM", 220, 250], ["adjustment disorders", "PROBLEM", 264, 284], ["enduring personality change", "PROBLEM", 288, 315], ["normal", "OBSERVATION", 24, 30]]], ["30 Acute reactions are characterized by absence of emotion; lack of response to external stimuli; total inhibition or outward activity and random movements; persons being stunned or shocked; and psychosomatic symptoms such as tremor, palpitations, hyperventilation, nausea, and vomiting.", [["psychosomatic symptoms", "DISEASE", 195, 217], ["tremor", "DISEASE", 226, 232], ["palpitations", "DISEASE", 234, 246], ["hyperventilation", "DISEASE", 248, 264], ["nausea", "DISEASE", 266, 272], ["vomiting", "DISEASE", 278, 286], ["persons", "SPECIES", 157, 164], ["Acute reactions", "PROBLEM", 3, 18], ["external stimuli", "TEST", 80, 96], ["total inhibition", "TREATMENT", 98, 114], ["outward activity", "PROBLEM", 118, 134], ["psychosomatic symptoms", "PROBLEM", 195, 217], ["tremor", "PROBLEM", 226, 232], ["palpitations", "PROBLEM", 234, 246], ["hyperventilation", "PROBLEM", 248, 264], ["nausea", "PROBLEM", 266, 272], ["vomiting", "PROBLEM", 278, 286], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["reactions", "OBSERVATION", 9, 18]]], ["30 PTSD is defined as 32 :MENTAL HEALTHAn anxiety disorder (and diagnostic construct used in the Diagnostic and Statistical Manual of Mental Disorders-IV ) that can develop after exposure to a terrifying event, or ordeal in which grave physical harm occurred or was threatened.", [["PTSD", "DISEASE", 3, 7], ["anxiety disorder", "DISEASE", 42, 58], ["MENTAL HEALTHAn anxiety disorder", "PROBLEM", 26, 58], ["Mental Disorders", "PROBLEM", 134, 150]]], ["The criteria for PTSD require:MENTAL HEALTHA.", [["PTSD", "DISEASE", 17, 21], ["PTSD", "PROBLEM", 17, 21]]], ["Exposure to a traumatic event B. Reexperiencing of the event C. Persistent avoidance of stimuli associated with the trauma D. Persistent increased arousal E. Duration of B, C, D of more than one month F. Clinically significant distress or impairment One of three survivors experiences severe stress that can lead to PTSD, anxiety disorders, or depression.", [["trauma", "DISEASE", 116, 122], ["impairment", "DISEASE", 239, 249], ["PTSD", "DISEASE", 316, 320], ["anxiety disorders", "DISEASE", 322, 339], ["depression", "DISEASE", 344, 354], ["a traumatic event", "PROBLEM", 12, 29], ["the trauma", "PROBLEM", 112, 122], ["Persistent increased arousal", "PROBLEM", 126, 154], ["significant distress", "PROBLEM", 215, 235], ["impairment", "PROBLEM", 239, 249], ["severe stress", "PROBLEM", 285, 298], ["PTSD", "PROBLEM", 316, 320], ["anxiety disorders", "PROBLEM", 322, 339], ["depression", "PROBLEM", 344, 354], ["significant", "OBSERVATION_MODIFIER", 215, 226], ["distress", "OBSERVATION", 227, 235], ["impairment", "OBSERVATION", 239, 249]]], ["Severe reactions possibly leading to PTSD include dissociation, intrusive reexperiencing (nightmares), extreme attempts to avoid disturbing memories (substance use), extreme emotional numbing, hyperarousal (panic attacks, rage), severe anxiety (extreme helplessness, compulsions, or obsessions), and severe depression.", [["PTSD", "DISEASE", 37, 41], ["emotional numbing", "DISEASE", 174, 191], ["hyperarousal", "DISEASE", 193, 205], ["panic attacks", "DISEASE", 207, 220], ["anxiety", "DISEASE", 236, 243], ["helplessness", "DISEASE", 253, 265], ["compulsions", "DISEASE", 267, 278], ["obsessions", "DISEASE", 283, 293], ["depression", "DISEASE", 307, 317], ["Severe reactions", "PROBLEM", 0, 16], ["PTSD", "PROBLEM", 37, 41], ["dissociation", "PROBLEM", 50, 62], ["intrusive reexperiencing (nightmares", "PROBLEM", 64, 100], ["extreme emotional numbing", "PROBLEM", 166, 191], ["hyperarousal (panic attacks", "PROBLEM", 193, 220], ["severe anxiety (extreme helplessness", "PROBLEM", 229, 265], ["compulsions", "PROBLEM", 267, 278], ["obsessions", "PROBLEM", 283, 293], ["severe depression", "PROBLEM", 300, 317], ["possibly leading to", "UNCERTAINTY", 17, 36], ["severe", "OBSERVATION_MODIFIER", 300, 306], ["depression", "OBSERVATION", 307, 317]]], ["Some examples include loss of loved ones; life-threatening danger or physical harm (especially to children); exposure to gruesome death, bodily injury, or dead and maimed bodies; extreme environmental or human violence and destruction; and loss of home.", [["loss of loved ones", "DISEASE", 22, 40], ["death", "DISEASE", 130, 135], ["bodily injury", "DISEASE", 137, 150], ["human violence and destruction", "DISEASE", 204, 234], ["children", "ORGANISM", 98, 106], ["human", "ORGANISM", 204, 209], ["children", "SPECIES", 98, 106], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["gruesome death", "PROBLEM", 121, 135], ["bodily injury", "PROBLEM", 137, 150], ["destruction", "PROBLEM", 223, 234]]], ["31 Inherently, specific individuals might have a typically higher risk of severe stress and lasting PTSD, such as those with a history of exposure to other traumas, chronic medical illness and psychological disorders, chronic poverty, and recent emotional strain.", [["PTSD", "DISEASE", 100, 104], ["traumas", "DISEASE", 156, 163], ["chronic medical illness", "DISEASE", 165, 188], ["psychological disorders", "DISEASE", 193, 216], ["chronic poverty", "DISEASE", 218, 233], ["individuals", "ORGANISM", 24, 35], ["severe stress and lasting PTSD", "PROBLEM", 74, 104], ["other traumas", "PROBLEM", 150, 163], ["chronic medical illness", "PROBLEM", 165, 188], ["psychological disorders", "PROBLEM", 193, 216], ["chronic poverty", "PROBLEM", 218, 233], ["recent emotional strain", "PROBLEM", 239, 262], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["stress", "OBSERVATION", 81, 87], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["emotional strain", "OBSERVATION", 246, 262]]], ["31 On the other hand, the National Center for PTSD states that some factors might be protective, including social support, higher income and education, successful mastery of past disasters and traumatic events, reduction of exposure to trauma, and provision of regular and factual information about the emergency.MENTAL HEALTHAt a recent national workshop on mental health and disasters, experts recommended some early intervention actions.", [["PTSD", "DISEASE", 46, 50], ["trauma", "DISEASE", 236, 242], ["PTSD", "PROBLEM", 46, 50], ["traumatic events", "PROBLEM", 193, 209], ["trauma", "PROBLEM", 236, 242], ["some early intervention actions", "TREATMENT", 408, 439]]], ["32 Early intervention is defined as 32BOX 2-1 NORMAL STRESS REACTIONS AFTER A DISASTERThe provision of psychological help to victims and survivors within the first month after a critical incident, traumatic event, emergency, or disaster aimed at reducing the severity or duration of eventrelated distress.", [["32BOX 2-1", "CHEMICAL", 36, 45], ["eventrelated distress", "PROBLEM", 283, 304]]], ["For mental health service providers, this may involve psychological first aid, needs assessment, consultation, fostering resilience and natural supports, and triage, as well as psychological and medical treatment.BOX 2-1 NORMAL STRESS REACTIONS AFTER A DISASTERInterventions include provision of the following: In regard to training, there are specific issues to consider when conducting mental health studies in foreign nations.", [["assessment", "TEST", 85, 95], ["psychological and medical treatment", "TREATMENT", 177, 212]]], ["34 These first responders are faced with dual functions: report the first observations about the environment and its risks and simultaneously carry out prehospital tasks.", [["prehospital tasks", "TEST", 152, 169]]], ["Because the disaster scene is dynamic, with active primary and secondary hazards, emergency responders must characterize the site, where oftentimes the evidence of the causative agent is not yet determined and therefore situational awareness is imperative.", [["active primary and secondary hazards", "PROBLEM", 44, 80], ["the causative agent", "PROBLEM", 164, 183]]], ["For example, the release or spillage of a chemical can cause toxic injury, whether it is by a physical asphyxiant (e.g., hypoxemia from inert gas in an enclosed space such as a silo), respiratory irritant (e.g., pulmonary damage and inflammatory response from chlorine or phosgene), or systemic toxicants (e.g., upper airway or alveolar injury or skin or neurological damage from organophosphates, volatile hydrocarbons, or hydrogen cyanide).WORKER SAFETY AND FIRST RESPONDERSEmergency first responders are also jeopardized by secondary risks on site.", [["respiratory", "ANATOMY", 184, 195], ["pulmonary", "ANATOMY", 212, 221], ["airway", "ANATOMY", 318, 324], ["alveolar", "ANATOMY", 328, 336], ["skin", "ANATOMY", 347, 351], ["neurological", "ANATOMY", 355, 367], ["hypoxemia", "DISEASE", 121, 130], ["pulmonary damage", "DISEASE", 212, 228], ["chlorine", "CHEMICAL", 260, 268], ["phosgene", "CHEMICAL", 272, 280], ["neurological damage", "DISEASE", 355, 374], ["organophosphates", "CHEMICAL", 380, 396], ["volatile hydrocarbons", "CHEMICAL", 398, 419], ["hydrogen cyanide", "CHEMICAL", 424, 440], ["chlorine", "CHEMICAL", 260, 268], ["phosgene", "CHEMICAL", 272, 280], ["organophosphates", "CHEMICAL", 380, 396], ["hydrocarbons", "CHEMICAL", 407, 419], ["hydrogen cyanide", "CHEMICAL", 424, 440], ["pulmonary", "ORGAN", 212, 221], ["chlorine", "SIMPLE_CHEMICAL", 260, 268], ["phosgene", "SIMPLE_CHEMICAL", 272, 280], ["upper", "ORGANISM_SUBDIVISION", 312, 317], ["airway", "MULTI-TISSUE_STRUCTURE", 318, 324], ["alveolar", "MULTI-TISSUE_STRUCTURE", 328, 336], ["skin", "ORGAN", 347, 351], ["volatile hydrocarbons", "SIMPLE_CHEMICAL", 398, 419], ["hydrogen cyanide", "SIMPLE_CHEMICAL", 424, 440], ["toxic injury", "PROBLEM", 61, 73], ["a physical asphyxiant", "PROBLEM", 92, 113], ["hypoxemia", "PROBLEM", 121, 130], ["inert gas", "PROBLEM", 136, 145], ["respiratory irritant (e.g., pulmonary damage", "PROBLEM", 184, 228], ["inflammatory response", "PROBLEM", 233, 254], ["chlorine", "TREATMENT", 260, 268], ["phosgene", "TREATMENT", 272, 280], ["systemic toxicants", "PROBLEM", 286, 304], ["upper airway or alveolar injury", "PROBLEM", 312, 343], ["skin or neurological damage", "PROBLEM", 347, 374], ["organophosphates", "TREATMENT", 380, 396], ["volatile hydrocarbons", "TREATMENT", 398, 419], ["hydrogen cyanide", "TREATMENT", 424, 440], ["secondary risks on site", "PROBLEM", 527, 550], ["toxic", "OBSERVATION_MODIFIER", 61, 66], ["injury", "OBSERVATION", 67, 73], ["hypoxemia", "OBSERVATION", 121, 130], ["inert gas", "OBSERVATION", 136, 145], ["respiratory", "ANATOMY", 184, 195], ["irritant", "OBSERVATION", 196, 204], ["pulmonary", "ANATOMY", 212, 221], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["upper", "ANATOMY_MODIFIER", 312, 317], ["airway", "ANATOMY", 318, 324], ["alveolar", "ANATOMY", 328, 336], ["injury", "OBSERVATION", 337, 343], ["skin", "ANATOMY", 347, 351]]], ["For example, rescue personnel can be in danger of confronting hazards from disasters such as riots, explosions and fires, road accidents, farm accidents, factory accidents, and railroad disasters.", [["explosions", "DISEASE", 100, 110], ["accidents", "DISEASE", 127, 136], ["accidents", "DISEASE", 143, 152], ["accidents", "DISEASE", 162, 171]]], ["35 Consider a scenario in which an overturned tanker truck has caused a major road accident; emergency personnel are likely to confront vehicle fires, fuel explosions, the instability of overturned vehicles and truck loads and cargo, the dangers of traffic control and safety, and exposure to release of toxic and dangerous chemicals.", [["traffic control", "TREATMENT", 249, 264], ["toxic and dangerous chemicals", "PROBLEM", 304, 333]]], ["Explosions present the first responder with the potential of building collapse, secondary explosions, and toxic smoke release hazards.WORKER SAFETY AND FIRST RESPONDERSFirst responders are trained to use PPE for a chemical, biological, or radiological event, either intentional or unintentional (as is the case with an industrial accident).", [["building collapse", "PROBLEM", 61, 78], ["secondary explosions", "PROBLEM", 80, 100], ["PPE", "TREATMENT", 204, 207], ["collapse", "OBSERVATION", 70, 78], ["secondary explosions", "OBSERVATION", 80, 100]]], ["The National Institute of Justice (NIJ) states:\"The purpose of personal protective clothing and equipment is to shield or isolate individuals from the chemical, physical, and biological hazards that may be encountered during hazardous materials operations.\" 36 PPE consists of a wardrobe of clothing and gear that allows the responder to confront and thwart exposure and to function normally.", [["personal protective clothing", "TREATMENT", 63, 91]]], ["NIJ categorizes PPE into the three following basic categories 36 :WORKER SAFETY AND FIRST RESPONDERS\u2022 Respiratory equipment (e.g., air purifying respirators and supplied air respirators) \u2022 Protective garments (e.g., encapsulated suits, coveralls, and overgarments) \u2022 Other protective apparel (e.g., protective hoods, boots, and gloves)WORKER SAFETY AND FIRST RESPONDERSThe NIJ Guide for the Selection of Personal Protective Equipment for Emergency First Responders is a good resource for more thorough and detailed information on PPE.", [["Respiratory equipment", "TREATMENT", 102, 123], ["air purifying respirators", "TREATMENT", 131, 156], ["Protective garments", "TREATMENT", 189, 208], ["protective hoods", "TREATMENT", 299, 315], ["boots", "TREATMENT", 317, 322], ["gloves", "TREATMENT", 328, 334], ["PPE", "TREATMENT", 530, 533], ["garments", "OBSERVATION", 200, 208]]], ["36 As the National Institute for Safety and Health points out, large incidents (such as the terrorist attack on the World Trade Center), unlike smaller-scale disasters (such as localized traffic accidents and explosions), pose serious challenges that make it more difficult to protect the responder from injury, illness, and death.", [["accidents", "DISEASE", 195, 204], ["explosions", "DISEASE", 209, 219], ["injury", "DISEASE", 304, 310], ["illness", "DISEASE", 312, 319], ["death", "DISEASE", 325, 330], ["injury", "PROBLEM", 304, 310], ["illness", "PROBLEM", 312, 319], ["death", "PROBLEM", 325, 330], ["large", "OBSERVATION_MODIFIER", 63, 68]]], ["Large-scale disasters can do the following 37 :WORKER SAFETY AND FIRST RESPONDERS\u2022 Affect, injure, or kill large numbers of people \u2022 Cover large geographical areas \u2022 Require prolonged response operations \u2022 Involve multiple, highly varied hazards \u2022 Require a wide range of capabilities and resources not routinely maintained by local response organizations \u2022 Attract a sizable influx of independent (\"convergent\") volunteers and supplies \u2022 Damage vital transportation, communications, and public works infrastructures \u2022 Directly affect the operational capacity of responder organizations Therefore, responder safety also requires human resource management, in which thoughtful planning can help one to operate in a chaotic, multiagency environment.", [["people", "ORGANISM", 124, 130], ["human", "ORGANISM", 629, 634], ["people", "SPECIES", 124, 130], ["human", "SPECIES", 629, 634], ["human", "SPECIES", 629, 634], ["Large-scale disasters", "PROBLEM", 0, 21], ["prolonged response operations", "TREATMENT", 174, 203], ["a wide range of capabilities", "TREATMENT", 256, 284], ["human resource management", "TREATMENT", 629, 654], ["-scale", "OBSERVATION_MODIFIER", 5, 11], ["injure", "OBSERVATION", 91, 97], ["large", "OBSERVATION_MODIFIER", 139, 144]]], ["This includes the delivery and sharing of critical information among multiple agencies of all types and levels in addition to making sense of overabundant information.", [["the delivery", "TREATMENT", 14, 26]]], ["38DATA COLLECTION AND ANALYSISPublic health detection and analysis follow key functional areas that involve the development and use of surveillance systems, analysis via algorithms and statistical methods, and investigation of disease and injury with great emphasis on critical agents.", [["ANALYSISPublic health detection", "TEST", 22, 53], ["analysis", "TEST", 58, 66], ["surveillance systems", "TEST", 135, 155], ["analysis", "TEST", 157, 165], ["algorithms", "TEST", 170, 180], ["statistical methods", "TEST", 185, 204], ["disease", "PROBLEM", 227, 234], ["injury", "PROBLEM", 239, 245], ["critical agents", "TREATMENT", 269, 284]]], ["5 Biological agents of highest concern, as categorized by the CDC, are B. anthracis (anthrax), Y. pestis (plague), variola major (smallpox), C. botulinum toxin (botulism), Francisella tularensis (tularemia), filoviruses (Ebola hemorrhagic fever, Marburg hemorrhagic fever), and arenaviruses (Lassa [Lassa fever], Junin [Argentine hemorrhagic fever], and related viruses).", [["anthrax", "DISEASE", 85, 92], ["Y. pestis", "DISEASE", 95, 104], ["variola major (smallpox", "DISEASE", 115, 138], ["botulism", "DISEASE", 161, 169], ["Francisella tularensis", "DISEASE", 172, 194], ["tularemia", "DISEASE", 196, 205], ["Ebola hemorrhagic fever", "DISEASE", 221, 244], ["Marburg hemorrhagic fever", "DISEASE", 246, 271], ["arenaviruses", "DISEASE", 278, 290], ["Lassa [Lassa fever", "DISEASE", 292, 310], ["Junin", "DISEASE", 313, 318], ["Argentine hemorrhagic fever", "DISEASE", 320, 347], ["B. anthracis", "ORGANISM", 71, 83], ["anthrax", "ORGANISM", 85, 92], ["Y. pestis", "ORGANISM", 95, 104], ["variola major", "ORGANISM", 115, 128], ["C. botulinum toxin", "ORGANISM", 141, 159], ["Francisella tularensis", "ORGANISM", 172, 194], ["filoviruses", "ORGANISM", 208, 219], ["Ebola hemorrhagic fever", "ORGANISM", 221, 244], ["Marburg hemorrhagic fever", "ORGANISM", 246, 271], ["Lassa [Lassa fever", "ORGANISM", 292, 310], ["Junin [Argentine hemorrhagic fever", "ORGANISM", 313, 347], ["B. anthracis", "SPECIES", 71, 83], ["Y. pestis", "SPECIES", 95, 104], ["variola major", "SPECIES", 115, 128], ["C. botulinum toxin", "SPECIES", 141, 159], ["Francisella tularensis", "SPECIES", 172, 194], ["Ebola hemorrhagic fever", "SPECIES", 221, 244], ["Marburg hemorrhagic fever", "SPECIES", 246, 271], ["arenaviruses", "SPECIES", 278, 290], ["Lassa", "SPECIES", 292, 297], ["Lassa fever", "SPECIES", 299, 310], ["Argentine hemorrhagic fever", "SPECIES", 320, 347], ["B. anthracis", "SPECIES", 71, 83], ["Y. pestis", "SPECIES", 95, 104], ["C. botulinum toxin", "SPECIES", 141, 159], ["Francisella tularensis", "SPECIES", 172, 194], ["Marburg hemorrhagic fever)", "SPECIES", 246, 272], ["variola major (smallpox", "TREATMENT", 115, 138], ["C. botulinum toxin", "PROBLEM", 141, 159], ["botulism", "PROBLEM", 161, 169], ["Francisella tularensis (tularemia)", "PROBLEM", 172, 206], ["filoviruses (Ebola hemorrhagic fever", "PROBLEM", 208, 244], ["Marburg hemorrhagic fever)", "PROBLEM", 246, 272], ["arenaviruses (Lassa [Lassa fever", "PROBLEM", 278, 310], ["Junin", "PROBLEM", 313, 318], ["Argentine hemorrhagic fever", "PROBLEM", 320, 347], ["related viruses", "PROBLEM", 354, 369], ["viruses", "OBSERVATION", 362, 369]]], ["27 Epidemiology in bioterrorist incidents is not too different from standard epidemiological investigations.", [["standard epidemiological investigations", "TEST", 68, 107], ["too different", "OBSERVATION_MODIFIER", 49, 62]]], ["39 First, laboratory and clinical findings are used to confirm that an outbreak has occurred, using case definitions to determine the number of cases and attack rate.", [["clinical findings", "TEST", 25, 42], ["attack rate", "TEST", 154, 165]]], ["To characterize unusual levels of activity, the attack rate for the disease in question is compared against that of previous years to measure deviation from the norm.", [["the disease", "PROBLEM", 64, 75], ["activity", "OBSERVATION_MODIFIER", 34, 42], ["disease", "OBSERVATION", 68, 75]]], ["The outbreak can then be characterized in terms of time, place, and person, lending crucial data to determine the origin of the disease.", [["person", "SPECIES", 68, 74], ["the disease", "PROBLEM", 124, 135], ["disease", "OBSERVATION", 128, 135]]], ["39 By analyzing data of cases over time, an epidemic curve can be calculated that will allow for differentiation between an outbreak and normal pattern of disease.", [["an epidemic curve", "PROBLEM", 41, 58], ["an outbreak", "PROBLEM", 121, 132], ["disease", "PROBLEM", 155, 162], ["normal", "OBSERVATION", 137, 143], ["disease", "OBSERVATION", 155, 162]]], ["Therefore, the development of surveillance systems, including syndromic surveillance systems and real-time computer models, are being developed.", [["surveillance systems", "TEST", 30, 50], ["syndromic surveillance systems", "TEST", 62, 92]]], ["Surveillance \"concentrates on the incidence, prevalence, and severity of illness or injury due to ecological changes, changes in endemic levels of disease, population displacement, loss of usual source of health care, overcrowding, breakdowns in sanitation, disruption of public utilities, monitors increases in communicable diseases, including vector-borne, waterborne, and person-to-person transmission\" and ultimately helps one to determine an association between exposure and outcome, whether that outcome includes specific injuries, illnesses, or death.", [["illness", "DISEASE", 73, 80], ["communicable diseases", "DISEASE", 312, 333], ["injuries", "DISEASE", 528, 536], ["death", "DISEASE", 552, 557], ["person", "SPECIES", 375, 381], ["person", "SPECIES", 385, 391], ["illness", "PROBLEM", 73, 80], ["injury", "PROBLEM", 84, 90], ["ecological changes", "PROBLEM", 98, 116], ["disease", "PROBLEM", 147, 154], ["population displacement", "PROBLEM", 156, 179], ["health care", "TREATMENT", 205, 216], ["breakdowns", "PROBLEM", 232, 242], ["communicable diseases", "PROBLEM", 312, 333], ["specific injuries", "PROBLEM", 519, 536], ["illnesses", "PROBLEM", 538, 547], ["death", "PROBLEM", 552, 557]]], ["20 In setting up a surveillance system, managers should consider using existing systems, such as those used to track reportable diseases, or developing temporary systems to track specific injuries and illnesses before, during, or after the disaster.", [["injuries", "DISEASE", 188, 196], ["existing systems", "TREATMENT", 71, 87], ["temporary systems", "PROBLEM", 152, 169], ["illnesses", "PROBLEM", 201, 210]]], ["20 Primary and secondary sources of data need to be identified and can vary from patient medical records (primary) to victim surveys and interviews (secondary).", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88]]], ["20 Increasingly, nontraditional data sources such as worker sick days from employer records are being used to screen for disease outbreaks.", [["disease outbreaks", "PROBLEM", 121, 138]]], ["Finally, appropriate analytical methods should be used and can include descriptive measures, geographical analysis of spread, rates of disease or death, or an analysis over time measuring total numbers of cases and rates of appearance.", [["death", "DISEASE", 146, 151], ["appropriate analytical methods", "TREATMENT", 9, 39], ["descriptive measures", "TEST", 71, 91], ["geographical analysis", "TEST", 93, 114], ["disease", "PROBLEM", 135, 142], ["death", "PROBLEM", 146, 151], ["an analysis", "TEST", 156, 167]]], ["As a result, disaster situations invoke the use of \"quick and dirty\" data collection, \"quick\" being simple and flexible and \"dirty\" being that some quantitative data are rough estimates gathered to answer immediate questions.", [["\"quick and dirty\" data collection", "PROBLEM", 51, 84]]], ["Syndromic surveillance is \"an investigational approach where health department staff, assisted by automated data acquisition and generation of statistical alarms, monitor disease indicators continually (real-time) or at least daily (near real-time) to detect outbreaks of diseases earlier and more completely than would otherwise be possible with traditional public health methods (e.g., by reportable disease surveillance or telephone consultation).\"", [["statistical alarms", "TEST", 143, 161], ["diseases", "PROBLEM", 272, 280], ["diseases", "OBSERVATION", 272, 280]]], ["Syndromic surveillance uses nontraditional data sources, or those other than laboratory data.These data reflect events \"that precede clinical diagnosis, such as emergency department chief complaints, clinical impressions on ambulance run sheets, prescriptions filled, retail drug and product purchases, school or work absenteeism, and constellations of medical signs and symptoms in persons seen in various clinical settings.\" 40CONCLUSIONHistorically, promoting and managing the health of a society have shown to increase the welfare of the community.", [["persons", "SPECIES", 383, 390], ["Syndromic surveillance", "TEST", 0, 22], ["laboratory data", "TEST", 77, 92], ["medical signs", "PROBLEM", 353, 366], ["symptoms", "PROBLEM", 371, 379]]], ["Collectively, these groups respond to disasters to study, reduce, and develop ways to mitigate adverse health effects in the future.", [["study", "TEST", 51, 56]]], ["Additionally, we have reviewed components of public health infrastructure, provision of medical services, education and communications in disasters, mental health issues, worker safety, and finally the value and techniques of data collection and analysis.CONCLUSIONIt is recommended that the newcomer to public health and disaster medicine review the many references in this chapter and refer to resources on the Internet.", [["data collection", "TEST", 226, 241], ["analysis", "TEST", 246, 254]]], ["Between Sept. 13 and Oct. 12, 68,546 emergency department visits were recorded, with trauma as the highest syndrome-to-none-ratio (SNR) found (18.6%), followed by exacerbation of a chronic respiratory condition (7.6%).", [["respiratory", "ANATOMY", 189, 200], ["trauma", "DISEASE", 85, 91], ["chronic respiratory condition", "DISEASE", 181, 210], ["trauma", "PROBLEM", 85, 91], ["the highest syndrome", "PROBLEM", 95, 115], ["SNR", "TEST", 131, 134], ["a chronic respiratory condition", "PROBLEM", 179, 210], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["respiratory condition", "OBSERVATION", 189, 210]]], ["Diarrhea/gastroenteritis (4.4%) and upper and lower respiratory infections (4.2%) were also reported.", [["respiratory", "ANATOMY", 52, 63], ["Diarrhea", "DISEASE", 0, 8], ["gastroenteritis", "DISEASE", 9, 24], ["upper and lower respiratory infections", "DISEASE", 36, 74], ["upper", "ORGANISM_SUBDIVISION", 36, 41], ["Diarrhea", "PROBLEM", 0, 8], ["gastroenteritis", "PROBLEM", 9, 24], ["upper and lower respiratory infections", "PROBLEM", 36, 74], ["gastroenteritis", "OBSERVATION", 9, 24], ["4.4%", "OBSERVATION_MODIFIER", 26, 30], ["upper", "ANATOMY_MODIFIER", 36, 41], ["lower", "ANATOMY_MODIFIER", 46, 51], ["respiratory", "ANATOMY", 52, 63], ["infections", "OBSERVATION", 64, 74]]], ["Children younger than 15 years presented most often with respiratory syndrome complaints (67%) and rash syndromes (59%).", [["respiratory", "ANATOMY", 57, 68], ["respiratory syndrome complaints", "DISEASE", 57, 88], ["rash", "DISEASE", 99, 103], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["respiratory syndrome complaints", "PROBLEM", 57, 88], ["rash syndromes", "PROBLEM", 99, 113]]], ["Those between 25 and 64 years old made up 80% of inhalational visits and 75% of anxiety visits.", [["anxiety", "DISEASE", 80, 87]]], ["Analyses were also specifically conducted for home postal codes within a two-mile radius of the World Trade Center and revealed that persons in the two-mile radius were no more likely to have a syndrome of bioterrorism interest than those who were outside of that proximity.", [["persons", "ORGANISM", 133, 140], ["persons", "SPECIES", 133, 140], ["no more likely", "UNCERTAINTY", 169, 183], ["syndrome", "OBSERVATION", 194, 202]]], ["However, the study found that people in close proximity to the towers on Sept. 11 were 61.5 times more likely to visit the emergency department for smoke/dust inhalation complaints than people from other areas.", [["smoke", "CHEMICAL", 148, 153], ["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["people", "SPECIES", 186, 192], ["the study", "TEST", 9, 18], ["dust inhalation complaints", "PROBLEM", 154, 180]]], ["Overall, no health data to support a bioterrorist release were found.", [["a bioterrorist release", "TREATMENT", 35, 57], ["no", "UNCERTAINTY", 9, 11]]]], "9d7910f5a5115b8f611d961343d29ac9f7a9fb60": [["The number of older people, including those living with dementia, is rising, as younger age mortality declines.", [["dementia", "DISEASE", 56, 64], ["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["dementia", "PROBLEM", 56, 64], ["dementia", "OBSERVATION", 56, 64]]], ["However, the age-specific incidence of dementia has fallen in many countries, probably because of improvements in education, nutrition, health care, and lifestyle changes.", [["dementia", "DISEASE", 39, 47], ["dementia", "PROBLEM", 39, 47], ["dementia", "OBSERVATION", 39, 47]]], ["Overall, a growing body of evidence supports the nine potentially modifiable risk factors for dementia modelled by the 2017 Lancet Commission on dementia prevention, intervention, and care: less education, hypertension, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and low social contact.", [["dementia", "DISEASE", 94, 102], ["dementia", "DISEASE", 145, 153], ["hypertension", "DISEASE", 206, 218], ["hearing impairment", "DISEASE", 220, 238], ["smoking", "CHEMICAL", 240, 247], ["obesity", "DISEASE", 249, 256], ["depression", "DISEASE", 258, 268], ["physical inactivity", "DISEASE", 270, 289], ["diabetes", "DISEASE", 291, 299], ["low social contact", "DISEASE", 305, 323], ["dementia", "PROBLEM", 94, 102], ["dementia prevention", "TREATMENT", 145, 164], ["intervention", "TREATMENT", 166, 178], ["hypertension", "PROBLEM", 206, 218], ["hearing impairment", "PROBLEM", 220, 238], ["obesity", "PROBLEM", 249, 256], ["depression", "PROBLEM", 258, 268], ["physical inactivity", "PROBLEM", 270, 289], ["diabetes", "PROBLEM", 291, 299], ["hypertension", "OBSERVATION", 206, 218], ["obesity", "OBSERVATION", 249, 256]]], ["We now add three more risk factors for dementia with newer, convincing evidence.", [["dementia", "DISEASE", 39, 47], ["dementia", "PROBLEM", 39, 47]]], ["These factors are excessive alcohol consumption, traumatic brain injury, and air pollution.", [["brain", "ANATOMY", 59, 64], ["alcohol", "CHEMICAL", 28, 35], ["traumatic brain injury", "DISEASE", 49, 71], ["alcohol", "CHEMICAL", 28, 35], ["alcohol", "SIMPLE_CHEMICAL", 28, 35], ["brain", "ORGAN", 59, 64], ["traumatic brain injury", "PROBLEM", 49, 71], ["air pollution", "PROBLEM", 77, 90], ["excessive", "OBSERVATION_MODIFIER", 18, 27], ["alcohol consumption", "OBSERVATION", 28, 47], ["traumatic", "OBSERVATION_MODIFIER", 49, 58], ["brain", "ANATOMY", 59, 64], ["injury", "OBSERVATION", 65, 71], ["air pollution", "OBSERVATION", 77, 90]]], ["We have completed new reviews and meta-analyses and incorporated these into an updated 12 risk factor life-course model of dementia prevention.", [["dementia", "DISEASE", 123, 131], ["dementia prevention", "TREATMENT", 123, 142], ["dementia", "OBSERVATION", 123, 131]]], ["Together the 12 modifiable risk factors account for around 40% of worldwide dementias, which consequently could theo retically be prevented or delayed.", [["dementias", "DISEASE", 76, 85], ["the 12 modifiable risk factors", "PROBLEM", 9, 39], ["worldwide dementias", "PROBLEM", 66, 85]]], ["The potential for prevention is high and might be higher in low-income and middle-income countries (LMIC) where more dementias occur.", [["dementias", "DISEASE", 117, 126], ["dementias", "PROBLEM", 117, 126], ["high", "OBSERVATION", 32, 36], ["higher", "OBSERVATION_MODIFIER", 50, 56]]]], "7fa2f5a443163614e02fa7b7d7c89fa535dc7b23": [["(Continued from previous page)Abbreviations: Ab, Antibody; AP-1, Activating protein 1; BBB, Blood-brain barrier; C/EBP, CCAAT/enhancer-binding protein; CCR, CC chemokine receptor; CNS, Central nervous system; CRE, cAMP response element; CREB, cAMP response element-binding protein; CSF, Cerebrospinal fluid; CXCL10, C-X-C motif chemokine 10; CXCL11, C-X-C motif chemokine 11; ELISA, Enzyme-linked immunosorbent assay; HE, Hematoxylin-eosin; HIV-1, Human immunodeficiency virus type 1; HSV-1, Herpes simplex virus-1; IkB\u03b1, Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; IKK\u03b5, Inhibitor-kB kinase epsilon; IRF-3, Interferon regulatory factor 3; ISRE, Interferon-stimulated response element; JEV, Japanese encephalitis virus; MAVS, Mitochondrial antiviral signaling protein; MCP-1, Monocyte chemoattractant protein-1; MDA5, Melanoma differentiation-associated protein 5; MHV, Mouse hepatitis virus; MOI, Multiplicity of infection; NF-IL6, Nuclear factor for interleukin 6; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; PBS, Phosphate-buffered saline; PFA, Paraformaldehyde; PMA, Phorbol 12-myristate 13-acetate; PRR, Pattern recognition receptors; RABV, Rabies virus; RANTES, Regulated upon activation, normal T cell expressed, and presumably secreted; RIG-I, Retinoic acid-inducible gene 1; RSV, Respiratory syncytial virus; RT, Room temperature; SCID, Severe combined immunodeficiency; TBK1, TANK-binding kinase 1; TCID 50 , Median tissue culture infective dose; TNF, Tumor necrosis factor; TBEV, Tick-borne encephalitis virus Background Tick-borne encephalitis (TBE), an endemic in many regions of Europe and Asia, is an important emerging infectious disease that targets the central nervous system (CNS) caused by the TBE virus (TBEV; family Flaviviridae, genus Flavivirus).", [["CNS", "ANATOMY", 180, 183], ["B cells", "ANATOMY", 581, 588], ["B cells", "ANATOMY", 1070, 1077], ["T cell", "ANATOMY", 1270, 1276], ["tissue", "ANATOMY", 1494, 1500], ["central nervous system", "ANATOMY", 1739, 1761], ["CNS", "ANATOMY", 1763, 1766], ["Human immunodeficiency virus", "DISEASE", 448, 476], ["Japanese encephalitis", "DISEASE", 732, 753], ["Mouse hepatitis virus", "DISEASE", 911, 932], ["infection", "DISEASE", 955, 964], ["Paraformaldehyde", "CHEMICAL", 1116, 1132], ["PMA", "CHEMICAL", 1134, 1137], ["Phorbol 12-myristate 13-acetate", "CHEMICAL", 1139, 1170], ["Respiratory syncytial virus", "DISEASE", 1357, 1384], ["SCID", "DISEASE", 1408, 1412], ["immunodeficiency", "DISEASE", 1430, 1446], ["Tumor necrosis", "DISEASE", 1530, 1544], ["Tick-borne encephalitis", "DISEASE", 1559, 1582], ["Tick-borne encephalitis", "DISEASE", 1600, 1623], ["TBE", "DISEASE", 1625, 1628], ["infectious disease", "DISEASE", 1703, 1721], ["cAMP", "CHEMICAL", 214, 218], ["cAMP", "CHEMICAL", 243, 247], ["Phosphate", "CHEMICAL", 1084, 1093], ["PFA", "CHEMICAL", 1111, 1114], ["Paraformaldehyde", "CHEMICAL", 1116, 1132], ["PMA", "CHEMICAL", 1134, 1137], ["Phorbol 12-myristate 13-acetate", "CHEMICAL", 1139, 1170], ["AP-1", "GENE_OR_GENE_PRODUCT", 59, 63], ["Activating protein 1", "GENE_OR_GENE_PRODUCT", 65, 85], ["BBB", "MULTI-TISSUE_STRUCTURE", 87, 90], ["brain", "ORGAN", 98, 103], ["C/EBP", "GENE_OR_GENE_PRODUCT", 113, 118], ["CCAAT/enhancer-binding protein", "GENE_OR_GENE_PRODUCT", 120, 150], ["CCR", "GENE_OR_GENE_PRODUCT", 152, 155], ["CC chemokine receptor", "GENE_OR_GENE_PRODUCT", 157, 178], ["CNS", "ANATOMICAL_SYSTEM", 180, 183], ["nervous system", "ANATOMICAL_SYSTEM", 193, 207], ["CRE", "GENE_OR_GENE_PRODUCT", 209, 212], ["cAMP", "SIMPLE_CHEMICAL", 214, 218], ["CREB", "GENE_OR_GENE_PRODUCT", 237, 241], ["cAMP response element-binding protein", "GENE_OR_GENE_PRODUCT", 243, 280], ["CSF", "GENE_OR_GENE_PRODUCT", 282, 285], ["CXCL10", "GENE_OR_GENE_PRODUCT", 308, 314], ["C-X-C motif chemokine 10", "GENE_OR_GENE_PRODUCT", 316, 340], ["CXCL11", "GENE_OR_GENE_PRODUCT", 342, 348], ["C-X-C motif chemokine 11", "GENE_OR_GENE_PRODUCT", 350, 374], ["Hematoxylin-eosin", "SIMPLE_CHEMICAL", 422, 439], ["HIV-1", "ORGANISM", 441, 446], ["Human immunodeficiency virus type 1", "ORGANISM", 448, 483], ["HSV-1", "ORGANISM", 485, 490], ["Herpes simplex virus-1", "ORGANISM", 492, 514], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 516, 520], ["Nuclear factor of kappa light polypeptide", "GENE_OR_GENE_PRODUCT", 522, 563], ["B cells", "CELL", 581, 588], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 607, 611], ["Inhibitor-kB kinase epsilon", "GENE_OR_GENE_PRODUCT", 613, 640], ["IRF-3", "GENE_OR_GENE_PRODUCT", 642, 647], ["Interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 649, 679], ["ISRE", "GENE_OR_GENE_PRODUCT", 681, 685], ["Interferon-stimulated response element", "GENE_OR_GENE_PRODUCT", 687, 725], ["JEV", "ORGANISM", 727, 730], ["Japanese encephalitis virus", "ORGANISM", 732, 759], ["MAVS", "GENE_OR_GENE_PRODUCT", 761, 765], ["Mitochondrial antiviral signaling protein", "GENE_OR_GENE_PRODUCT", 767, 808], ["MCP-1", "GENE_OR_GENE_PRODUCT", 810, 815], ["Monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 817, 851], ["MDA5", "GENE_OR_GENE_PRODUCT", 853, 857], ["Melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 859, 904], ["MHV", "ORGANISM", 906, 909], ["Mouse hepatitis virus", "ORGANISM", 911, 932], ["NF-IL6", "GENE_OR_GENE_PRODUCT", 966, 972], ["Nuclear factor", "GENE_OR_GENE_PRODUCT", 974, 988], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 993, 1006], ["NF-kB", "GENE_OR_GENE_PRODUCT", 1008, 1013], ["B cells", "CELL", 1070, 1077], ["PBS", "SIMPLE_CHEMICAL", 1079, 1082], ["Phosphate-buffered saline", "SIMPLE_CHEMICAL", 1084, 1109], ["PFA", "SIMPLE_CHEMICAL", 1111, 1114], ["Paraformaldehyde", "SIMPLE_CHEMICAL", 1116, 1132], ["PMA", "SIMPLE_CHEMICAL", 1134, 1137], ["Phorbol 12-myristate 13-acetate", "SIMPLE_CHEMICAL", 1139, 1170], ["PRR", "SIMPLE_CHEMICAL", 1172, 1175], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 1177, 1206], ["RABV", "ORGANISM", 1208, 1212], ["Rabies virus", "ORGANISM", 1214, 1226], ["RANTES", "GENE_OR_GENE_PRODUCT", 1228, 1234], ["T cell", "CELL", 1270, 1276], ["RIG-I", "GENE_OR_GENE_PRODUCT", 1313, 1318], ["Retinoic acid-inducible gene 1", "GENE_OR_GENE_PRODUCT", 1320, 1350], ["RSV", "ORGANISM", 1352, 1355], ["Respiratory syncytial virus", "ORGANISM", 1357, 1384], ["TBK1", "GENE_OR_GENE_PRODUCT", 1448, 1452], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 1454, 1475], ["tissue", "TISSUE", 1494, 1500], ["TNF", "GENE_OR_GENE_PRODUCT", 1525, 1528], ["Tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 1530, 1551], ["TBEV", "ORGANISM", 1553, 1557], ["Tick-borne encephalitis virus Background", "ORGANISM", 1559, 1599], ["Tick-borne encephalitis", "ORGANISM", 1600, 1623], ["central nervous system", "ANATOMICAL_SYSTEM", 1739, 1761], ["CNS", "ANATOMICAL_SYSTEM", 1763, 1766], ["TBE virus", "ORGANISM", 1782, 1791], ["Antibody", "PROTEIN", 49, 57], ["AP", "PROTEIN", 59, 61], ["Activating protein 1", "PROTEIN", 65, 85], ["BBB", "PROTEIN", 87, 90], ["EBP", "PROTEIN", 115, 118], ["CCAAT/enhancer-binding protein", "PROTEIN", 120, 150], ["CCR", "PROTEIN", 152, 155], ["CC chemokine receptor", "PROTEIN", 157, 178], ["CRE, cAMP response element", "DNA", 209, 235], ["CREB", "PROTEIN", 237, 241], ["cAMP response element-binding protein", "PROTEIN", 243, 280], ["CSF", "PROTEIN", 282, 285], ["CXCL10", "PROTEIN", 308, 314], ["C-X-C motif chemokine 10", "PROTEIN", 316, 340], ["CXCL11", "PROTEIN", 342, 348], ["C-X-C motif chemokine 11", "PROTEIN", 350, 374], ["Nuclear factor of kappa light polypeptide gene enhancer", "DNA", 522, 577], ["B cells", "CELL_TYPE", 581, 588], ["alpha; IKK\u03b5, Inhibitor-kB kinase epsilon; IRF-3", "DNA", 600, 647], ["Interferon regulatory factor 3", "PROTEIN", 649, 679], ["ISRE, Interferon-stimulated response element", "DNA", 681, 725], ["MAVS", "PROTEIN", 761, 765], ["Mitochondrial antiviral signaling protein", "PROTEIN", 767, 808], ["MCP-1", "PROTEIN", 810, 815], ["Monocyte chemoattractant protein-1", "PROTEIN", 817, 851], ["MDA5", "PROTEIN", 853, 857], ["Melanoma differentiation-associated protein 5", "PROTEIN", 859, 904], ["MHV", "PROTEIN", 906, 909], ["NF", "PROTEIN", 966, 968], ["IL6", "PROTEIN", 969, 972], ["Nuclear factor", "PROTEIN", 974, 988], ["interleukin 6", "PROTEIN", 993, 1006], ["NF-kB", "PROTEIN", 1008, 1013], ["Nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 1015, 1077], ["PRR", "PROTEIN", 1172, 1175], ["Pattern recognition receptors", "PROTEIN", 1177, 1206], ["RABV", "PROTEIN", 1208, 1212], ["RANTES", "PROTEIN", 1228, 1234], ["normal T cell", "CELL_TYPE", 1263, 1276], ["RIG-I", "PROTEIN", 1313, 1318], ["TBK1", "PROTEIN", 1448, 1452], ["TANK-binding kinase 1", "PROTEIN", 1454, 1475], ["TCID 50", "PROTEIN", 1477, 1484], ["TNF", "PROTEIN", 1525, 1528], ["Tumor necrosis factor", "PROTEIN", 1530, 1551], ["HIV-1", "SPECIES", 441, 446], ["Human immunodeficiency virus", "SPECIES", 448, 476], ["HSV-1", "SPECIES", 485, 490], ["Herpes simplex virus", "SPECIES", 492, 512], ["-1", "SPECIES", 512, 514], ["Japanese encephalitis virus", "SPECIES", 732, 759], ["Mouse hepatitis virus", "SPECIES", 911, 932], ["Rabies virus", "SPECIES", 1214, 1226], ["Tick-borne encephalitis virus", "SPECIES", 1559, 1588], ["Tick-borne encephalitis", "SPECIES", 1600, 1623], ["HIV-1", "SPECIES", 441, 446], ["Human immunodeficiency virus type 1", "SPECIES", 448, 483], ["HSV-1", "SPECIES", 485, 490], ["Herpes simplex virus-1", "SPECIES", 492, 514], ["Japanese encephalitis virus", "SPECIES", 732, 759], ["MHV", "SPECIES", 906, 909], ["Mouse hepatitis virus", "SPECIES", 911, 932], ["Rabies virus", "SPECIES", 1214, 1226], ["RSV", "SPECIES", 1352, 1355], ["Respiratory syncytial virus", "SPECIES", 1357, 1384], ["TBEV", "SPECIES", 1553, 1557], ["Tick-borne encephalitis virus", "SPECIES", 1559, 1588], ["Tick-borne encephalitis (", "SPECIES", 1600, 1625], ["TBE", "SPECIES", 1625, 1628], ["TBE virus", "SPECIES", 1782, 1791], ["TBEV", "SPECIES", 1793, 1797], ["Ab, Antibody", "TEST", 45, 57], ["AP", "TEST", 59, 61], ["Activating protein", "TEST", 65, 83], ["BBB", "TEST", 87, 90], ["Blood", "TEST", 92, 97], ["brain barrier", "TEST", 98, 111], ["C/EBP", "TEST", 113, 118], ["CCAAT/enhancer", "TEST", 120, 134], ["binding protein", "TEST", 135, 150], ["CCR", "TEST", 152, 155], ["CC chemokine receptor", "TEST", 157, 178], ["CRE", "TEST", 209, 212], ["cAMP response element", "TEST", 214, 235], ["CREB", "TEST", 237, 241], ["cAMP response element", "TEST", 243, 264], ["binding protein", "TEST", 265, 280], ["CSF", "TEST", 282, 285], ["Cerebrospinal fluid", "TEST", 287, 306], ["CXCL10", "TEST", 308, 314], ["C", "TEST", 316, 317], ["motif chemokine", "TEST", 322, 337], ["CXCL11", "TEST", 342, 348], ["C", "TEST", 350, 351], ["motif chemokine", "TEST", 356, 371], ["ELISA", "TEST", 376, 381], ["Enzyme", "TEST", 383, 389], ["immunosorbent assay", "TEST", 397, 416], ["HE", "TEST", 418, 420], ["Hematoxylin", "TEST", 422, 433], ["eosin", "TEST", 434, 439], ["HIV", "TEST", 441, 444], ["Human immunodeficiency virus type", "TEST", 448, 481], ["HSV", "TEST", 485, 488], ["Herpes simplex virus", "TEST", 492, 512], ["IkB\u03b1", "TEST", 516, 520], ["kappa light polypeptide gene enhancer in B cells inhibitor", "TREATMENT", 540, 598], ["alpha", "TEST", 600, 605], ["IKK\u03b5", "TEST", 607, 611], ["Inhibitor", "TREATMENT", 613, 622], ["kB kinase epsilon", "TEST", 623, 640], ["IRF", "TEST", 642, 645], ["Interferon regulatory factor", "TREATMENT", 649, 677], ["ISRE, Interferon-stimulated response element", "TREATMENT", 681, 725], ["JEV", "PROBLEM", 727, 730], ["Japanese encephalitis virus", "PROBLEM", 732, 759], ["MAVS", "PROBLEM", 761, 765], ["Mitochondrial antiviral signaling protein", "TEST", 767, 808], ["MCP", "TEST", 810, 813], ["Monocyte chemoattractant protein", "TEST", 817, 849], ["MDA5", "PROBLEM", 853, 857], ["Melanoma differentiation", "PROBLEM", 859, 883], ["associated protein 5", "PROBLEM", 884, 904], ["MHV", "PROBLEM", 906, 909], ["Mouse hepatitis virus", "PROBLEM", 911, 932], ["MOI", "PROBLEM", 934, 937], ["infection", "PROBLEM", 955, 964], ["NF", "PROBLEM", 966, 968], ["IL6", "PROBLEM", 969, 972], ["Nuclear factor", "TEST", 974, 988], ["interleukin", "TEST", 993, 1004], ["NF", "TEST", 1008, 1010], ["Nuclear factor kappa-light", "TEST", 1015, 1041], ["activated B cells", "TREATMENT", 1060, 1077], ["PBS", "TEST", 1079, 1082], ["Phosphate", "TEST", 1084, 1093], ["buffered saline", "TREATMENT", 1094, 1109], ["PFA", "TREATMENT", 1111, 1114], ["Paraformaldehyde", "TREATMENT", 1116, 1132], ["PMA", "TEST", 1134, 1137], ["Phorbol", "TEST", 1139, 1146], ["myristate", "TREATMENT", 1150, 1159], ["acetate", "TREATMENT", 1163, 1170], ["PRR", "TREATMENT", 1172, 1175], ["RABV", "PROBLEM", 1208, 1212], ["Rabies virus", "PROBLEM", 1214, 1226], ["RIG-I, Retinoic acid-inducible gene", "TEST", 1313, 1348], ["RSV", "PROBLEM", 1352, 1355], ["Respiratory syncytial virus", "PROBLEM", 1357, 1384], ["Room temperature", "TEST", 1390, 1406], ["SCID", "PROBLEM", 1408, 1412], ["Severe combined immunodeficiency", "PROBLEM", 1414, 1446], ["TBK1", "TEST", 1448, 1452], ["TANK-binding kinase", "TEST", 1454, 1473], ["TCID", "TEST", 1477, 1481], ["Median tissue culture", "TEST", 1487, 1508], ["TNF", "PROBLEM", 1525, 1528], ["Tumor necrosis factor", "PROBLEM", 1530, 1551], ["TBEV", "PROBLEM", 1553, 1557], ["Tick-borne encephalitis virus", "PROBLEM", 1559, 1588], ["Background Tick-borne encephalitis", "PROBLEM", 1589, 1623], ["an important emerging infectious disease", "PROBLEM", 1681, 1721], ["the TBE virus", "PROBLEM", 1778, 1791], ["brain", "ANATOMY", 98, 103], ["Central nervous", "ANATOMY", 185, 200], ["Cerebrospinal fluid", "ANATOMY", 287, 306], ["Melanoma", "OBSERVATION", 859, 867], ["hepatitis virus", "OBSERVATION", 917, 932], ["infection", "OBSERVATION", 955, 964], ["Respiratory syncytial", "ANATOMY", 1357, 1378], ["Tumor necrosis", "OBSERVATION", 1530, 1544], ["endemic", "OBSERVATION_MODIFIER", 1634, 1641], ["infectious", "OBSERVATION", 1703, 1713], ["central", "ANATOMY_MODIFIER", 1739, 1746], ["nervous system", "ANATOMY", 1747, 1761]]], ["TBEV consists of three subtypes: the European subtype (TBEV-Eu) in most parts of Europe; Siberian subtype in eastern Europe, Russia, and northern Asia; and Far Eastern subtype (TBEV-FE) in eastern Russia and some parts of China and Japan.", [["TBEV", "DISEASE", 0, 4], ["TBEV", "ORGANISM", 0, 4], ["TBEV-Eu", "ORGANISM", 55, 62], ["TBEV", "SPECIES", 0, 4], ["TBEV", "SPECIES", 177, 181], ["TBEV", "TEST", 55, 59], ["three subtypes", "OBSERVATION_MODIFIER", 17, 31], ["Siberian subtype", "OBSERVATION", 89, 105]]], ["TBEV-Eu is mainly transmitted by Ixodes ricinus and the other two subtypes by Ixodes persulcatus [1] .", [["TBEV-Eu", "CHEMICAL", 0, 7], ["TBEV-Eu", "ORGANISM", 0, 7], ["Ixodes ricinus", "ORGANISM", 33, 47], ["Ixodes persulcatus", "ORGANISM", 78, 96], ["Ixodes ricinus", "SPECIES", 33, 47], ["Ixodes persulcatus", "SPECIES", 78, 96], ["TBEV-Eu", "SPECIES", 0, 7], ["Ixodes ricinus", "SPECIES", 33, 47], ["Ixodes persulcatus", "SPECIES", 78, 96], ["TBEV", "TEST", 0, 4]]], ["In humans, TBEV causes a variety of clinical manifestations, ranging from flu-like febrile disease to encephalitis of differing severity levels [2] .", [["TBEV", "DISEASE", 11, 15], ["flu-like febrile disease", "DISEASE", 74, 98], ["encephalitis", "DISEASE", 102, 114], ["humans", "ORGANISM", 3, 9], ["TBEV", "ORGANISM", 11, 15], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["TBEV", "SPECIES", 11, 15], ["clinical manifestations", "PROBLEM", 36, 59], ["flu", "PROBLEM", 74, 77], ["febrile disease", "PROBLEM", 83, 98], ["encephalitis", "PROBLEM", 102, 114], ["differing severity levels", "PROBLEM", 118, 143], ["TBEV", "OBSERVATION", 11, 15], ["encephalitis", "OBSERVATION", 102, 114]]], ["The clinical outcome may in part depend upon the subtype of TBEV infection.", [["TBEV infection", "DISEASE", 60, 74], ["TBEV", "ORGANISM", 60, 64], ["TBEV", "SPECIES", 60, 64], ["TBEV infection", "PROBLEM", 60, 74], ["TBEV infection", "OBSERVATION", 60, 74]]], ["TBEV-Eu and TBEV-Sib subtypes are usually associated with milder disease, with mortality rates of 0.5-2 %.", [["TBEV-Eu", "ORGANISM", 0, 7], ["TBEV-Sib", "ORGANISM", 12, 20], ["TBEV", "SPECIES", 0, 4], ["TBEV-Sib", "SPECIES", 12, 20], ["TBEV", "TEST", 0, 4], ["TBEV", "TEST", 12, 16], ["milder disease", "PROBLEM", 58, 72], ["mortality rates", "TEST", 79, 94], ["milder", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 65, 72]]], ["In contrast, infection with the TBEV-FE subtype results in the most severe CNS disorder, with mortality rates of up to 40 % and higher rates of severe neurologic sequelae [3, 4] .(Continued from previous page)The first TBEV replication usually occurs in dendritic cells of the skin following tick bites, later in regional lymph nodes, and then virus can be detected in plasma [5, 6] .", [["CNS", "ANATOMY", 75, 78], ["neurologic", "ANATOMY", 151, 161], ["dendritic cells", "ANATOMY", 254, 269], ["skin", "ANATOMY", 277, 281], ["lymph nodes", "ANATOMY", 322, 333], ["plasma", "ANATOMY", 369, 375], ["infection", "DISEASE", 13, 22], ["CNS disorder", "DISEASE", 75, 87], ["neurologic sequelae", "DISEASE", 151, 170], ["tick bites", "DISEASE", 292, 302], ["TBEV-FE", "ORGANISM", 32, 39], ["CNS", "ANATOMICAL_SYSTEM", 75, 78], ["TBEV", "ORGANISM", 219, 223], ["dendritic cells", "CELL", 254, 269], ["skin", "ORGAN", 277, 281], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 322, 333], ["plasma", "ORGANISM_SUBSTANCE", 369, 375], ["dendritic cells", "CELL_TYPE", 254, 269], ["TBEV", "SPECIES", 219, 223], ["infection", "PROBLEM", 13, 22], ["the TBEV", "TEST", 28, 36], ["the most severe CNS disorder", "PROBLEM", 59, 87], ["mortality rates", "TEST", 94, 109], ["severe neurologic sequelae", "PROBLEM", 144, 170], ["The first TBEV replication", "PROBLEM", 209, 235], ["tick bites", "PROBLEM", 292, 302], ["infection", "OBSERVATION", 13, 22], ["most severe", "OBSERVATION_MODIFIER", 63, 74], ["CNS", "ANATOMY", 75, 78], ["disorder", "OBSERVATION", 79, 87], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["TBEV replication", "OBSERVATION", 219, 235], ["dendritic cells", "OBSERVATION", 254, 269], ["skin", "ANATOMY", 277, 281], ["regional", "ANATOMY", 313, 321], ["lymph nodes", "OBSERVATION", 322, 333]]], ["During the stage of active viremia, virus may cross the blood-brain barrier (BBB) and invade the CNS where it causes profound destruction of nerve cells [2] .", [["blood-brain barrier", "ANATOMY", 56, 75], ["BBB", "ANATOMY", 77, 80], ["CNS", "ANATOMY", 97, 100], ["nerve cells", "ANATOMY", 141, 152], ["viremia", "DISEASE", 27, 34], ["blood-", "MULTI-TISSUE_STRUCTURE", 56, 62], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 62, 75], ["BBB", "MULTI-TISSUE_STRUCTURE", 77, 80], ["CNS", "ANATOMICAL_SYSTEM", 97, 100], ["nerve cells", "CELL", 141, 152], ["nerve cells", "CELL_TYPE", 141, 152], ["active viremia", "PROBLEM", 20, 34], ["virus", "PROBLEM", 36, 41], ["profound destruction of nerve cells", "PROBLEM", 117, 152], ["active", "OBSERVATION_MODIFIER", 20, 26], ["viremia", "OBSERVATION", 27, 34], ["brain", "ANATOMY", 62, 67], ["CNS", "ANATOMY", 97, 100], ["profound", "OBSERVATION_MODIFIER", 117, 125], ["destruction", "OBSERVATION", 126, 137], ["nerve cells", "OBSERVATION", 141, 152]]], ["The most severe forms of TBE may be characterized by major damage to neurons in different parts of the brain and spinal cord [4] .", [["neurons", "ANATOMY", 69, 76], ["brain", "ANATOMY", 103, 108], ["spinal cord", "ANATOMY", 113, 124], ["TBE", "DISEASE", 25, 28], ["neurons", "CELL", 69, 76], ["brain", "ORGAN", 103, 108], ["spinal cord", "ORGAN", 113, 124], ["TBE", "SPECIES", 25, 28], ["The most severe forms of TBE", "PROBLEM", 0, 28], ["major damage to neurons", "PROBLEM", 53, 76], ["most severe", "OBSERVATION_MODIFIER", 4, 15], ["TBE", "OBSERVATION", 25, 28], ["major", "OBSERVATION_MODIFIER", 53, 58], ["damage", "OBSERVATION", 59, 65], ["neurons", "ANATOMY_MODIFIER", 69, 76], ["different", "ANATOMY_MODIFIER", 80, 89], ["parts", "ANATOMY_MODIFIER", 90, 95], ["brain", "ANATOMY", 103, 108], ["spinal cord", "ANATOMY", 113, 124]]], ["Generally, CNS pathology is the consequence of viral infection of corresponding cells and the resulting neuroinflammatory responses.", [["CNS", "ANATOMY", 11, 14], ["cells", "ANATOMY", 80, 85], ["infection", "DISEASE", 53, 62], ["CNS", "ANATOMICAL_SYSTEM", 11, 14], ["cells", "CELL", 80, 85], ["CNS pathology", "TEST", 11, 24], ["viral infection of corresponding cells", "PROBLEM", 47, 85], ["CNS", "ANATOMY", 11, 14], ["pathology", "OBSERVATION", 15, 24], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62], ["neuroinflammatory responses", "OBSERVATION", 104, 131]]], ["In clinical studies, common findings include immunohistochemical staining of TBEV antigen in large neurons of human brains of fatal cases with relatively short natural clinical course.", [["neurons", "ANATOMY", 99, 106], ["brains", "ANATOMY", 116, 122], ["TBEV antigen", "GENE_OR_GENE_PRODUCT", 77, 89], ["neurons", "CELL", 99, 106], ["human", "ORGANISM", 110, 115], ["TBEV antigen", "PROTEIN", 77, 89], ["human", "SPECIES", 110, 115], ["TBEV", "SPECIES", 77, 81], ["human", "SPECIES", 110, 115], ["clinical studies", "TEST", 3, 19], ["immunohistochemical staining", "TEST", 45, 73], ["TBEV antigen", "TEST", 77, 89]]], ["However, topographical correlation between inflammatory changes and distribution of viral antigens is poor, since affected regions with prominent inflammatory infiltrates and marked neuronal damage contained only few immunolabeled structures [7] .", [["neuronal", "ANATOMY", 182, 190], ["neuronal damage", "DISEASE", 182, 197], ["neuronal", "CELL", 182, 190], ["viral antigens", "PROTEIN", 84, 98], ["inflammatory changes", "PROBLEM", 43, 63], ["viral antigens", "PROBLEM", 84, 98], ["prominent inflammatory infiltrates", "PROBLEM", 136, 170], ["marked neuronal damage", "PROBLEM", 175, 197], ["inflammatory", "OBSERVATION", 43, 55], ["distribution", "OBSERVATION_MODIFIER", 68, 80], ["viral antigens", "OBSERVATION", 84, 98], ["prominent", "OBSERVATION_MODIFIER", 136, 145], ["inflammatory", "OBSERVATION_MODIFIER", 146, 158], ["infiltrates", "OBSERVATION", 159, 170], ["marked", "OBSERVATION_MODIFIER", 175, 181], ["neuronal damage", "OBSERVATION", 182, 197], ["few", "OBSERVATION_MODIFIER", 213, 216]]], ["Furthermore, it was found that granzyme B-releasing cytotoxic T cells contribute significantly to neuronal damage in human TBE [8] , supporting the notion that liberation of inflammatory mediators and recruitment of cytotoxic T cells may contribute to nerve cell dysfunction in human TBEV infection.", [["cytotoxic T cells", "ANATOMY", 52, 69], ["neuronal", "ANATOMY", 98, 106], ["cytotoxic T cells", "ANATOMY", 216, 233], ["nerve cell", "ANATOMY", 252, 262], ["neuronal damage", "DISEASE", 98, 113], ["nerve cell dysfunction", "DISEASE", 252, 274], ["TBEV infection", "DISEASE", 284, 298], ["granzyme B", "GENE_OR_GENE_PRODUCT", 31, 41], ["cytotoxic T cells", "CELL", 52, 69], ["neuronal", "CELL", 98, 106], ["human", "ORGANISM", 117, 122], ["cytotoxic T cells", "CELL", 216, 233], ["nerve cell", "CELL", 252, 262], ["human", "ORGANISM", 278, 283], ["TBEV", "ORGANISM", 284, 288], ["granzyme B", "PROTEIN", 31, 41], ["cytotoxic T cells", "CELL_TYPE", 52, 69], ["inflammatory mediators", "PROTEIN", 174, 196], ["cytotoxic T cells", "CELL_TYPE", 216, 233], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 278, 283], ["TBEV", "SPECIES", 284, 288], ["granzyme B-releasing cytotoxic T cells", "PROBLEM", 31, 69], ["neuronal damage in human TBE", "PROBLEM", 98, 126], ["inflammatory mediators", "PROBLEM", 174, 196], ["cytotoxic T cells", "PROBLEM", 216, 233], ["nerve cell dysfunction", "PROBLEM", 252, 274], ["human TBEV infection", "PROBLEM", 278, 298], ["inflammatory", "OBSERVATION_MODIFIER", 174, 186], ["cytotoxic T cells", "OBSERVATION", 216, 233], ["nerve cell dysfunction", "OBSERVATION", 252, 274], ["TBEV infection", "OBSERVATION", 284, 298]]], ["In a TBEV-infected mouse model, CD8 + T cells was also shown to play a pivotal role in the immunopathology of TBE as evidenced by prolonged survival of severe combined immunodeficiency (SCID) or CD8 \u2212/\u2212 mice following infection, compared with immunocompetent mice or mice with adoptively transferred CD8 + T cells [9] .(Continued from previous page)These results imply that immunopathological effects significantly contribute to the onset of TBE.", [["CD8 + T cells", "ANATOMY", 32, 45], ["CD8 + T cells", "ANATOMY", 300, 313], ["TBEV-infected", "DISEASE", 5, 18], ["TBE", "DISEASE", 110, 113], ["immunodeficiency", "DISEASE", 168, 184], ["SCID", "DISEASE", 186, 190], ["infection", "DISEASE", 218, 227], ["TBE", "DISEASE", 442, 445], ["mouse", "ORGANISM", 19, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 195, 198], ["mice", "ORGANISM", 259, 263], ["mice", "ORGANISM", 267, 271], ["CD8", "GENE_OR_GENE_PRODUCT", 300, 303], ["CD8 + T cells", "CELL_TYPE", 32, 45], ["CD8 + T cells", "CELL_TYPE", 300, 313], ["mouse", "SPECIES", 19, 24], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 267, 271], ["TBEV", "SPECIES", 5, 9], ["mouse", "SPECIES", 19, 24], ["TBE", "SPECIES", 110, 113], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 267, 271], ["TBE", "SPECIES", 442, 445], ["a TBEV", "TEST", 3, 9], ["CD8 + T cells", "PROBLEM", 32, 45], ["TBE", "PROBLEM", 110, 113], ["severe combined immunodeficiency (SCID)", "PROBLEM", 152, 191], ["CD8", "PROBLEM", 195, 198], ["infection", "PROBLEM", 218, 227], ["immunopathological effects", "PROBLEM", 374, 400], ["TBE", "PROBLEM", 442, 445], ["TBEV", "OBSERVATION", 5, 9], ["infected mouse model", "OBSERVATION", 10, 30], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["infection", "OBSERVATION", 218, 227], ["TBE", "OBSERVATION", 442, 445]]], ["However, the exact mechanisms of proinflammatory effects responsible for immune-mediated neuronal injury are still unclear with limited data available on the role of chemoattractant cytokines (chemokines) during TBEV infection.", [["neuronal", "ANATOMY", 89, 97], ["neuronal injury", "DISEASE", 89, 104], ["TBEV infection", "DISEASE", 212, 226], ["neuronal", "CELL", 89, 97], ["TBEV", "ORGANISM", 212, 216], ["chemoattractant cytokines", "PROTEIN", 166, 191], ["chemokines", "PROTEIN", 193, 203], ["TBEV", "SPECIES", 212, 216], ["proinflammatory effects", "PROBLEM", 33, 56], ["immune-mediated neuronal injury", "PROBLEM", 73, 104], ["chemoattractant cytokines (chemokines", "TREATMENT", 166, 203], ["TBEV infection", "PROBLEM", 212, 226], ["proinflammatory", "OBSERVATION", 33, 48], ["neuronal", "ANATOMY", 89, 97], ["injury", "OBSERVATION", 98, 104]]], ["Although proinflammatory chemokines C-X-C motif chemokine 10 (CXCL10), C-X-C motif chemokine 11 (CXCL11), monocyte chemoattractant protein-1 (MCP-1), and regulated upon activation, normal T cell expressed, and presumably secreted (RANTES) have been detected in the cerebrospinal fluid (CSF) samples of TBE patients [10] [11] [12] [13] [14] , the specific impact on inflammatory responses and the molecular mechanisms that regulate chemokine expression remain to be further addressed.(Continued from previous page)Chemokines constitute a family of small, secreted proteins that orchestrate leukocyte migration to sites of inflammation, playing a crucial role in the regulations of homeostasis by trafficking specific cells under physiologic conditions [15, 16] .", [["T cell", "ANATOMY", 188, 194], ["cerebrospinal fluid", "ANATOMY", 265, 284], ["CSF) samples", "ANATOMY", 286, 298], ["leukocyte", "ANATOMY", 589, 598], ["sites", "ANATOMY", 612, 617], ["cells", "ANATOMY", 716, 721], ["inflammation", "DISEASE", 621, 633], ["C-X-C motif chemokine 10", "GENE_OR_GENE_PRODUCT", 36, 60], ["CXCL10", "GENE_OR_GENE_PRODUCT", 62, 68], ["C-X-C motif chemokine 11", "GENE_OR_GENE_PRODUCT", 71, 95], ["CXCL11", "GENE_OR_GENE_PRODUCT", 97, 103], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 106, 140], ["MCP-1", "GENE_OR_GENE_PRODUCT", 142, 147], ["T cell", "CELL", 188, 194], ["RANTES", "GENE_OR_GENE_PRODUCT", 231, 237], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 265, 284], ["CSF", "ORGANISM_SUBSTANCE", 286, 289], ["patients", "ORGANISM", 306, 314], ["leukocyte", "CELL", 589, 598], ["cells", "CELL", 716, 721], ["proinflammatory chemokines", "PROTEIN", 9, 35], ["C-X-C motif chemokine 10", "PROTEIN", 36, 60], ["CXCL10", "PROTEIN", 62, 68], ["CXCL11", "PROTEIN", 97, 103], ["monocyte chemoattractant protein-1", "PROTEIN", 106, 140], ["MCP", "PROTEIN", 142, 145], ["RANTES", "PROTEIN", 231, 237], ["chemokine", "PROTEIN", 431, 440], ["Chemokines", "PROTEIN", 513, 523], ["secreted proteins", "PROTEIN", 554, 571], ["patients", "SPECIES", 306, 314], ["TBE", "SPECIES", 302, 305], ["proinflammatory chemokines", "TEST", 9, 35], ["C", "TEST", 36, 37], ["motif chemokine", "TEST", 42, 57], ["CXCL10", "TEST", 62, 68], ["C", "TEST", 71, 72], ["motif chemokine", "TEST", 77, 92], ["CXCL11", "TEST", 97, 103], ["monocyte chemoattractant protein", "TEST", 106, 138], ["MCP", "TEST", 142, 145], ["the cerebrospinal fluid", "TEST", 261, 284], ["TBE patients", "TEST", 302, 314], ["inflammatory responses", "PROBLEM", 365, 387], ["small, secreted proteins", "PROBLEM", 547, 571], ["leukocyte migration", "PROBLEM", 589, 608], ["inflammation", "PROBLEM", 621, 633], ["cerebrospinal fluid", "ANATOMY", 265, 284], ["inflammatory", "OBSERVATION", 365, 377], ["leukocyte migration", "OBSERVATION", 589, 608], ["inflammation", "OBSERVATION", 621, 633]]], ["However, overproduction of chemokines in response to immunologic, inflammatory, infectious signals may elicit deleterious effects, especially in the largely non-self-renewing brain tissues [17] .", [["brain tissues", "ANATOMY", 175, 188], ["brain tissues", "TISSUE", 175, 188], ["chemokines", "PROTEIN", 27, 37], ["chemokines", "PROBLEM", 27, 37], ["inflammatory, infectious signals", "PROBLEM", 66, 98], ["deleterious effects", "PROBLEM", 110, 129], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78], ["infectious", "OBSERVATION", 80, 90], ["brain tissues", "ANATOMY", 175, 188]]], ["Therefore, a clearer understanding of how chemokines impact the inflammatory response to viral infections within the CNS is important for identifying targets that can potentially be manipulated for the development of host defense with minimal negative effects.", [["CNS", "ANATOMY", 117, 120], ["infections", "DISEASE", 95, 105], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["chemokines", "PROTEIN", 42, 52], ["the inflammatory response", "PROBLEM", 60, 85], ["viral infections", "PROBLEM", 89, 105], ["inflammatory", "OBSERVATION_MODIFIER", 64, 76], ["viral infections", "OBSERVATION", 89, 105]]], ["To date, there is limited information concerning specific chemokines responsible for cell recruitment and their potential impact on disease progression during TBEV infection.(Continued from previous page)In the present study, we have evaluated chemokine expression profiles within CNS after TBEV infection using mouse as a model.", [["cell", "ANATOMY", 85, 89], ["CNS", "ANATOMY", 281, 284], ["TBEV infection", "DISEASE", 159, 173], ["TBEV infection", "DISEASE", 291, 305], ["cell", "CELL", 85, 89], ["TBEV", "ORGANISM", 159, 163], ["CNS", "ANATOMICAL_SYSTEM", 281, 284], ["TBEV", "ORGANISM", 291, 295], ["mouse", "ORGANISM", 312, 317], ["chemokines", "PROTEIN", 58, 68], ["chemokine", "PROTEIN", 244, 253], ["mouse", "SPECIES", 312, 317], ["TBEV", "SPECIES", 159, 163], ["TBEV", "SPECIES", 291, 295], ["mouse", "SPECIES", 312, 317], ["cell recruitment", "TREATMENT", 85, 101], ["disease progression", "PROBLEM", 132, 151], ["TBEV infection", "PROBLEM", 159, 173], ["the present study", "TEST", 207, 224], ["chemokine expression profiles", "PROBLEM", 244, 273], ["TBEV infection", "PROBLEM", 291, 305], ["TBEV infection", "OBSERVATION", 159, 173]]], ["We demonstrate that TBEV induces marked inflammatory cell infiltrates in the brain.", [["inflammatory cell", "ANATOMY", 40, 57], ["brain", "ANATOMY", 77, 82], ["TBEV", "DISEASE", 20, 24], ["TBEV", "ORGANISM", 20, 24], ["inflammatory cell", "CELL", 40, 57], ["brain", "ORGAN", 77, 82], ["TBEV", "SPECIES", 20, 24], ["TBEV", "PROBLEM", 20, 24], ["marked inflammatory cell infiltrates in the brain", "PROBLEM", 33, 82], ["TBEV", "OBSERVATION", 20, 24], ["marked", "OBSERVATION_MODIFIER", 33, 39], ["inflammatory cell infiltrates", "OBSERVATION", 40, 69], ["brain", "ANATOMY", 77, 82]]], ["RANTES has been shown to be one of the main chemokines induced within CNS during primary TBEV infection [12, 14] .", [["CNS", "ANATOMY", 70, 73], ["TBEV infection", "DISEASE", 89, 103], ["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["TBEV", "ORGANISM", 89, 93], ["RANTES", "PROTEIN", 0, 6], ["chemokines", "PROTEIN", 44, 54], ["TBEV", "SPECIES", 89, 93], ["primary TBEV infection", "PROBLEM", 81, 103], ["main", "OBSERVATION_MODIFIER", 39, 43], ["chemokines", "OBSERVATION", 44, 54], ["CNS", "ANATOMY", 70, 73]]], ["Blockade of RANTES reduces the accumulation of infiltrating cells and extends the survival of mice after TBEV infection.", [["infiltrating cells", "ANATOMY", 47, 65], ["TBEV infection", "DISEASE", 105, 119], ["RANTES", "GENE_OR_GENE_PRODUCT", 12, 18], ["cells", "CELL", 60, 65], ["mice", "ORGANISM", 94, 98], ["TBEV", "ORGANISM", 105, 109], ["RANTES", "PROTEIN", 12, 18], ["infiltrating cells", "CELL_TYPE", 47, 65], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["TBEV", "SPECIES", 105, 109], ["Blockade of RANTES", "TREATMENT", 0, 18], ["infiltrating cells", "PROBLEM", 47, 65], ["TBEV infection", "PROBLEM", 105, 119], ["RANTES", "OBSERVATION", 12, 18], ["accumulation", "OBSERVATION_MODIFIER", 31, 43], ["infiltrating cells", "OBSERVATION", 47, 65], ["survival", "OBSERVATION_MODIFIER", 82, 90], ["TBEV", "OBSERVATION_MODIFIER", 105, 109], ["infection", "OBSERVATION", 110, 119]]], ["Furthermore, our data indicate that stimulation of interferon regulatory factor 3 (IRF-3) pathway leads to RANTES secretion by TBEV-infected human brain-derived cells.", [["brain-derived cells", "ANATOMY", 147, 166], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 51, 81], ["IRF-3", "GENE_OR_GENE_PRODUCT", 83, 88], ["RANTES", "GENE_OR_GENE_PRODUCT", 107, 113], ["TBEV", "ORGANISM", 127, 131], ["human", "ORGANISM", 141, 146], ["brain-derived cells", "CELL", 147, 166], ["interferon regulatory factor 3 (IRF-3", "PROTEIN", 51, 88], ["RANTES", "PROTEIN", 107, 113], ["human brain-derived cells", "CELL_TYPE", 141, 166], ["human", "SPECIES", 141, 146], ["TBEV", "SPECIES", 127, 131], ["human", "SPECIES", 141, 146], ["our data", "TEST", 13, 21], ["stimulation of interferon regulatory factor", "TREATMENT", 36, 79], ["RANTES secretion", "PROBLEM", 107, 123], ["TBEV", "TEST", 127, 131], ["infected human brain", "PROBLEM", 132, 152]]], ["Together, our results identify RANTES as a potential mediator of the neuroinflammatory responses seen in TBEV infection, providing basic insights into the molecular mechanism underlying TBEV-induced RANTES production.Ethics statementAll experimental procedures were conducted according to the guidance of the Institutional Animal Care and Use Committee of Wuhan Institute of Virology, Chinese Academy of Sciences.", [["TBEV infection", "DISEASE", 105, 119], ["TBEV", "DISEASE", 186, 190], ["RANTES", "GENE_OR_GENE_PRODUCT", 31, 37], ["TBEV", "ORGANISM", 105, 109], ["TBEV", "ORGANISM", 186, 190], ["RANTES", "GENE_OR_GENE_PRODUCT", 199, 205], ["RANTES", "PROTEIN", 31, 37], ["RANTES", "PROTEIN", 199, 205], ["TBEV", "SPECIES", 105, 109], ["TBEV", "SPECIES", 186, 190], ["the neuroinflammatory responses", "PROBLEM", 65, 96], ["TBEV infection", "PROBLEM", 105, 119], ["induced RANTES production", "PROBLEM", 191, 216], ["All experimental procedures", "TREATMENT", 233, 260], ["neuroinflammatory", "OBSERVATION", 69, 86], ["TBEV infection", "OBSERVATION", 105, 119], ["TBEV", "OBSERVATION", 186, 190]]], ["All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering as well as the number of animals used.Viruses and cell culturesWH2012, a Far Eastern strain of TBEV, was isolated from tick (I. persulcatus) samples and characterized as previously described [18] .", [["cell", "ANATOMY", 166, 170], ["samples", "ANATOMY", 257, 264], ["sodium pentobarbital", "CHEMICAL", 35, 55], ["sodium pentobarbital", "CHEMICAL", 35, 55], ["sodium pentobarbital", "SIMPLE_CHEMICAL", 35, 55], ["cell culturesWH2012", "CELL", 166, 185], ["TBEV", "ORGANISM", 211, 215], ["I. persulcatus", "ORGANISM", 241, 255], ["I. persulcatus", "SPECIES", 241, 255], ["TBEV", "SPECIES", 211, 215], ["I. persulcatus", "SPECIES", 241, 255], ["All surgeries", "TREATMENT", 0, 13], ["sodium pentobarbital anesthesia", "TREATMENT", 35, 66], ["Viruses", "PROBLEM", 154, 161], ["cell culturesWH2012", "TEST", 166, 185], ["TBEV", "PROBLEM", 211, 215], ["TBEV", "OBSERVATION", 211, 215]]], ["The nucleotide acid sequence of WH2012 strain was deposited in the GenBank database (accession number KJ755186).", [["nucleotide acid", "CHEMICAL", 4, 19], ["nucleotide acid", "CHEMICAL", 4, 19], ["nucleotide acid", "SIMPLE_CHEMICAL", 4, 19], ["The nucleotide acid sequence", "TEST", 0, 28], ["WH2012 strain", "PROBLEM", 32, 45]]], ["Working stocks of TBEV were routinely propagated on Vero cells.", [["Vero cells", "ANATOMY", 52, 62], ["TBEV", "ORGANISM", 18, 22], ["Vero cells", "CELL", 52, 62], ["Vero cells", "CELL_LINE", 52, 62], ["TBEV", "SPECIES", 18, 22], ["TBEV", "PROBLEM", 18, 22]]], ["All procedures with infectious materials were performed under biosafety level-3 (BSL-3) conditions.", [["All procedures", "TREATMENT", 0, 14], ["infectious materials", "TREATMENT", 20, 40]]], ["BHK-21, Vero, SK-N-SH (a human neuroblastoma cell line; ATCC HTB-11), and T98G (a human glioblastoma cell line; ATCC CRL-1690) cells were cultured in Minimum Essential Medium (MEM).", [["BHK-21", "ANATOMY", 0, 6], ["Vero", "ANATOMY", 8, 12], ["SK-N-SH", "ANATOMY", 14, 21], ["neuroblastoma cell line", "ANATOMY", 31, 54], ["ATCC HTB-11", "ANATOMY", 56, 67], ["T98G", "ANATOMY", 74, 78], ["glioblastoma cell line", "ANATOMY", 88, 110], ["ATCC CRL-1690) cells", "ANATOMY", 112, 132], ["glioblastoma", "DISEASE", 88, 100], ["BHK-21", "CELL", 0, 6], ["Vero", "CELL", 8, 12], ["SK-N-SH", "CELL", 14, 21], ["human", "ORGANISM", 25, 30], ["neuroblastoma cell line", "CELL", 31, 54], ["ATCC HTB-11", "CELL", 56, 67], ["T98G", "CELL", 74, 78], ["human", "ORGANISM", 82, 87], ["glioblastoma cell line", "CELL", 88, 110], ["ATCC CRL-1690) cells", "CELL", 112, 132], ["BHK-21", "CELL_LINE", 0, 6], ["SK-N-SH", "CELL_LINE", 14, 21], ["human neuroblastoma cell line", "CELL_LINE", 25, 54], ["ATCC HTB-11", "CELL_LINE", 56, 67], ["T98G", "CELL_LINE", 74, 78], ["human glioblastoma cell line", "CELL_LINE", 82, 110], ["ATCC CRL-1690) cells", "CELL_LINE", 112, 132], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 25, 30], ["ATCC HTB-11", "SPECIES", 56, 67], ["human", "SPECIES", 82, 87], ["ATCC CRL-1690", "SPECIES", 112, 125], ["BHK", "TEST", 0, 3], ["Vero", "TEST", 8, 12], ["SK", "TEST", 14, 16], ["SH", "PROBLEM", 19, 21], ["a human neuroblastoma cell line", "TREATMENT", 23, 54], ["ATCC HTB", "TEST", 56, 64], ["T98G", "TEST", 74, 78], ["a human glioblastoma cell line", "TREATMENT", 80, 110], ["ATCC CRL", "TEST", 112, 120], ["neuroblastoma cell line", "OBSERVATION", 31, 54]]], ["CCF-STTG1 (a human astrocytoma cell line; ATCC CRL-1718) and THP-1 (a human monocytic cell line; ATCC TIB-202) were grown in RPMI 1640 medium.", [["astrocytoma cell line", "ANATOMY", 19, 40], ["ATCC CRL-1718", "ANATOMY", 42, 55], ["THP-1", "ANATOMY", 61, 66], ["monocytic cell line", "ANATOMY", 76, 95], ["ATCC TIB-202", "ANATOMY", 97, 109], ["astrocytoma", "DISEASE", 19, 30], ["CCF-STTG1", "CELL", 0, 9], ["human", "ORGANISM", 13, 18], ["astrocytoma cell line", "CELL", 19, 40], ["ATCC CRL-1718", "CELL", 42, 55], ["THP-1", "CELL", 61, 66], ["human", "ORGANISM", 70, 75], ["monocytic cell line", "CELL", 76, 95], ["ATCC TIB-202", "CELL", 97, 109], ["CCF", "CELL_LINE", 0, 3], ["STTG1", "CELL_LINE", 4, 9], ["human astrocytoma cell line", "CELL_LINE", 13, 40], ["ATCC CRL-1718", "CELL_LINE", 42, 55], ["THP-1", "CELL_LINE", 61, 66], ["human monocytic cell line", "CELL_LINE", 70, 95], ["ATCC TIB-202", "CELL_LINE", 97, 109], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 13, 18], ["ATCC CRL-1718", "SPECIES", 42, 55], ["human", "SPECIES", 70, 75], ["ATCC TIB-202", "SPECIES", 97, 109], ["CCF", "TEST", 0, 3], ["STTG1", "PROBLEM", 4, 9], ["a human astrocytoma cell line", "PROBLEM", 11, 40], ["ATCC CRL", "TEST", 42, 50], ["THP", "TEST", 61, 64], ["a human monocytic cell line", "TREATMENT", 68, 95], ["ATCC TIB", "TEST", 97, 105]]], ["A549 (a human alveolar epithelial cell line, ATCC CCL-185) cells were cultured in F-12K medium.", [["A549", "ANATOMY", 0, 4], ["alveolar epithelial cell line", "ANATOMY", 14, 43], ["ATCC CCL-185) cells", "ANATOMY", 45, 64], ["A549", "CELL", 0, 4], ["human", "ORGANISM", 8, 13], ["alveolar epithelial cell line", "CELL", 14, 43], ["ATCC CCL-185) cells", "CELL", 45, 64], ["F-12K", "CELL", 82, 87], ["A549", "CELL_LINE", 0, 4], ["human alveolar epithelial cell line", "CELL_LINE", 8, 43], ["ATCC CCL-185) cells", "CELL_LINE", 45, 64], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["ATCC CCL-185", "SPECIES", 45, 57], ["A549", "TEST", 0, 4], ["a human alveolar epithelial cell line", "TREATMENT", 6, 43], ["ATCC CCL", "TEST", 45, 53], ["cells", "TEST", 59, 64], ["alveolar epithelial", "ANATOMY", 14, 33], ["cell line", "OBSERVATION", 34, 43]]], ["All media were supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U ml \u22121 penicillin and 100 mg ml \u22121 streptomycin (Life Technologies, NY).", [["fetal bovine serum", "ANATOMY", 38, 56], ["L-glutamine", "CHEMICAL", 63, 74], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 116, 128], ["L-glutamine", "CHEMICAL", 63, 74], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 116, 128], ["bovine", "ORGANISM", 44, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["L-glutamine", "SIMPLE_CHEMICAL", 63, 74], ["penicillin", "SIMPLE_CHEMICAL", 88, 98], ["streptomycin", "SIMPLE_CHEMICAL", 116, 128], ["bovine", "SPECIES", 44, 50], ["bovine", "SPECIES", 44, 50], ["All media", "TREATMENT", 0, 9], ["10 % fetal bovine serum", "TREATMENT", 33, 56], ["2 mM L-glutamine", "TREATMENT", 58, 74], ["penicillin", "TREATMENT", 88, 98], ["streptomycin", "TREATMENT", 116, 128]]], ["Human progenitorderived astrocytes (HPDAs) were generated from neural progenitor cells and cultured as previously described [19, 20] .", [["progenitorderived astrocytes", "ANATOMY", 6, 34], ["HPDAs", "ANATOMY", 36, 41], ["neural progenitor cells", "ANATOMY", 63, 86], ["Human", "ORGANISM", 0, 5], ["progenitorderived astrocytes", "CELL", 6, 34], ["HPDAs", "CELL", 36, 41], ["neural progenitor cells", "CELL", 63, 86], ["Human progenitorderived astrocytes", "CELL_TYPE", 0, 34], ["HPDAs", "CELL_TYPE", 36, 41], ["neural progenitor cells", "CELL_TYPE", 63, 86], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human progenitorderived astrocytes (HPDAs)", "PROBLEM", 0, 42], ["neural progenitor cells", "TREATMENT", 63, 86], ["progenitor cells", "OBSERVATION", 70, 86]]], ["Differentiation of THP-1 (2 \u00d7 10 5 cells/ml) monocytes into macrophage-like cells was achieved using 200 nM phorbol 12-myristate 13-acetate (PMA; Sigma, NY) for 3 days as previously described [21] .Mice infection and monitoringGroups of 1-week-old BALB/c mice of either sex were challenged with TBEV WH2012 by intraperitoneal (ip) or intracerebral (ic) inoculation route with a volume of 20 \u03bcl of virus suspensions at various concentrations, using Hamilton syringe (Hamilton Co., Switzerland).", [["cells", "ANATOMY", 35, 40], ["monocytes", "ANATOMY", 45, 54], ["macrophage-like cells", "ANATOMY", 60, 81], ["intraperitoneal", "ANATOMY", 310, 325], ["intracerebral", "ANATOMY", 334, 347], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 108, 139], ["PMA", "CHEMICAL", 141, 144], ["infection", "DISEASE", 203, 212], ["WH2012", "CHEMICAL", 300, 306], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 108, 139], ["PMA", "CHEMICAL", 141, 144], ["THP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["cells", "CELL", 35, 40], ["monocytes", "CELL", 45, 54], ["macrophage-like cells", "CELL", 60, 81], ["phorbol 12-myristate 13-acetate", "SIMPLE_CHEMICAL", 108, 139], ["PMA", "SIMPLE_CHEMICAL", 141, 144], ["Mice", "ORGANISM", 198, 202], ["BALB/c mice", "ORGANISM", 248, 259], ["TBEV", "ORGANISM", 295, 299], ["WH2012", "SIMPLE_CHEMICAL", 300, 306], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 310, 325], ["monocytes", "CELL_TYPE", 45, 54], ["macrophage-like cells", "CELL_TYPE", 60, 81], ["Mice", "SPECIES", 198, 202], ["mice", "SPECIES", 255, 259], ["mice", "SPECIES", 255, 259], ["TBEV", "SPECIES", 295, 299], ["THP", "TEST", 19, 22], ["monocytes", "TEST", 45, 54], ["macrophage", "TEST", 60, 70], ["like cells", "PROBLEM", 71, 81], ["200 nM phorbol", "TREATMENT", 101, 115], ["myristate", "TREATMENT", 119, 128], ["Mice infection", "PROBLEM", 198, 212], ["intracerebral (ic) inoculation route", "TREATMENT", 334, 370], ["virus suspensions", "TREATMENT", 397, 414], ["infection", "OBSERVATION", 203, 212]]], ["Mock-infected animals were inoculated with 20 \u03bcl of diluent (serum-free DMEM).", [["serum", "ANATOMY", 61, 66], ["animals", "ORGANISM", 14, 21], ["serum", "ORGANISM_SUBSTANCE", 61, 66]]], ["Groups of female mice aged 7-8 weeks were infected intracerebrally with 10 3 median tissue culture infective dose (TCID 50 )s of TBEV WH2012.", [["tissue", "ANATOMY", 84, 90], ["WH2012", "CHEMICAL", 134, 140], ["mice", "ORGANISM", 17, 21], ["tissue", "TISSUE", 84, 90], ["TBEV", "ORGANISM", 129, 133], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["TBEV", "SPECIES", 129, 133], ["TBEV", "PROBLEM", 129, 133]]], ["Mice were then monitored daily for signs of neurological disease and survival over a period of 12 to 25 days.", [["neurological", "ANATOMY", 44, 56], ["neurological disease", "DISEASE", 44, 64], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["neurological disease", "PROBLEM", 44, 64], ["neurological disease", "OBSERVATION", 44, 64]]], ["Mortality rate was assessed at the time points indicated below.Tissue isolation and preparationCohorts of virus-infected mice were sacrificed after ic inoculation with a virus dose containing 10 3 TCID 50 s for the time points indicated below.", [["Tissue", "ANATOMY", 63, 69], ["Tissue", "TISSUE", 63, 69], ["mice", "ORGANISM", 121, 125], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["Mortality rate", "TEST", 0, 14], ["Tissue isolation", "TREATMENT", 63, 79], ["virus", "PROBLEM", 106, 111], ["infected mice", "PROBLEM", 112, 125], ["ic inoculation", "TREATMENT", 148, 162], ["a virus dose", "TREATMENT", 168, 180]]], ["Whole blood was obtained by cardiac puncture, and sera were separated by centrifugation.", [["Whole blood", "ANATOMY", 0, 11], ["cardiac", "ANATOMY", 28, 35], ["sera", "ANATOMY", 50, 54], ["Whole", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 28, 44], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["Whole blood", "TEST", 0, 11], ["cardiac puncture", "TEST", 28, 44], ["cardiac", "ANATOMY", 28, 35], ["puncture", "OBSERVATION", 36, 44]]], ["Following perfusion with ice-cold phosphate-buffered saline (PBS), the small intestine, hind limb muscle, heart, lung, spleen, liver, and brain were collected, homogenized, and cleared by low-speed centrifugation.", [["small intestine", "ANATOMY", 71, 86], ["hind limb muscle", "ANATOMY", 88, 104], ["heart", "ANATOMY", 106, 111], ["lung", "ANATOMY", 113, 117], ["spleen", "ANATOMY", 119, 125], ["liver", "ANATOMY", 127, 132], ["brain", "ANATOMY", 138, 143], ["phosphate", "CHEMICAL", 34, 43], ["phosphate", "CHEMICAL", 34, 43], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 34, 59], ["small intestine", "ORGAN", 71, 86], ["hind limb muscle", "TISSUE", 88, 104], ["heart", "ORGAN", 106, 111], ["lung", "ORGAN", 113, 117], ["spleen", "ORGAN", 119, 125], ["liver", "ORGAN", 127, 132], ["brain", "ORGAN", 138, 143], ["perfusion", "TEST", 10, 19], ["ice-cold phosphate", "TEST", 25, 43], ["buffered saline (PBS", "TREATMENT", 44, 64], ["small intestine", "ANATOMY", 71, 86], ["hind", "ANATOMY_MODIFIER", 88, 92], ["limb muscle", "ANATOMY", 93, 104], ["heart", "ANATOMY", 106, 111], ["lung", "ANATOMY", 113, 117], ["spleen", "ANATOMY", 119, 125], ["liver", "ANATOMY", 127, 132], ["brain", "ANATOMY", 138, 143]]], ["Then, sera and tissue samples were immediately stored at \u221280\u00b0C for further analysis.Virus titrationVirus infectivity was determined by estimation of the TCID 50 using standard cell culture conditions.", [["sera", "ANATOMY", 6, 10], ["tissue samples", "ANATOMY", 15, 29], ["cell", "ANATOMY", 176, 180], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["tissue samples", "CANCER", 15, 29], ["C", "GENE_OR_GENE_PRODUCT", 61, 62], ["Virus", "ORGANISM", 84, 89], ["cell", "CELL", 176, 180], ["TCID 50", "PROTEIN", 153, 160], ["sera and tissue samples", "TEST", 6, 29], ["further analysis", "TEST", 67, 83], ["Virus titrationVirus infectivity", "PROBLEM", 84, 116], ["standard cell culture conditions", "TEST", 167, 199]]], ["Briefly, BHK-21 cells were seeded in 96-well plates.", [["BHK-21 cells", "ANATOMY", 9, 21], ["BHK-21 cells", "CELL", 9, 21], ["BHK-21 cells", "CELL_LINE", 9, 21], ["BHK", "TEST", 9, 12]]], ["When the cells reach 80 % confluence, they were infected with 150 \u03bcl of serial decimal dilutions of each sample for 4 days.", [["cells", "ANATOMY", 9, 14], ["sample", "ANATOMY", 105, 111], ["cells", "CELL", 9, 14], ["serial decimal dilutions", "TREATMENT", 72, 96]]], ["The cytopathic effect was thereby monitored by microscopic examination, and the infectivity titer was expressed as TCID 50 /g tissue using the Reed-Muench formula.HistologyAfter anesthesia with sodium pentobarbital (60 mg kg \u22121 ), mice were transcardially perfused with ice-cold PBS followed by 4 % (w/v) paraformaldehyde (PFA) in PBS.", [["tissue", "ANATOMY", 126, 132], ["sodium pentobarbital", "CHEMICAL", 194, 214], ["sodium pentobarbital", "CHEMICAL", 194, 214], ["paraformaldehyde", "CHEMICAL", 305, 321], ["PFA", "CHEMICAL", 323, 326], ["tissue", "TISSUE", 126, 132], ["sodium pentobarbital", "SIMPLE_CHEMICAL", 194, 214], ["mice", "ORGANISM", 231, 235], ["/v) paraformaldehyde", "SIMPLE_CHEMICAL", 301, 321], ["PFA", "SIMPLE_CHEMICAL", 323, 326], ["mice", "SPECIES", 231, 235], ["mice", "SPECIES", 231, 235], ["The cytopathic effect", "PROBLEM", 0, 21], ["microscopic examination", "TEST", 47, 70], ["the infectivity titer", "PROBLEM", 76, 97], ["the Reed-Muench formula", "TREATMENT", 139, 162], ["HistologyAfter anesthesia", "TREATMENT", 163, 188], ["sodium pentobarbital", "TREATMENT", 194, 214], ["ice-cold PBS", "TREATMENT", 270, 282], ["w/v) paraformaldehyde (PFA) in PBS", "TREATMENT", 300, 334], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21]]], ["The brains were dissected and post-fixed overnight, then trimmed, and routinely paraffin wax embedded.", [["brains", "ANATOMY", 4, 10], ["paraffin", "CHEMICAL", 80, 88], ["brains", "ORGAN", 4, 10], ["brains", "ANATOMY", 4, 10]]], ["Serial 3-5-\u03bcm-thick sections were stained with hematoxylin-eosin (HE) for histological analysis under a light microscopy.Protein array analysisBrains of mice were screened for 40 inflammatory factors using a commercialized mouse inflammation antibody (Ab) array C1 Kit according to the manufacturer's instructions (RayBiotech, Inc., Norcross, GA).", [["sections", "ANATOMY", 20, 28], ["hematoxylin-eosin", "CHEMICAL", 47, 64], ["hematoxylin", "CHEMICAL", 47, 58], ["eosin", "CHEMICAL", 59, 64], ["sections", "MULTI-TISSUE_STRUCTURE", 20, 28], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 47, 64], ["mice", "ORGANISM", 153, 157], ["mouse", "ORGANISM", 223, 228], ["inflammatory factors", "PROTEIN", 179, 199], ["commercialized mouse inflammation antibody (Ab) array C1", "PROTEIN", 208, 264], ["mice", "SPECIES", 153, 157], ["mouse", "SPECIES", 223, 228], ["mice", "SPECIES", 153, 157], ["mouse", "SPECIES", 223, 228], ["hematoxylin", "TEST", 47, 58], ["histological analysis", "TEST", 74, 95], ["a light microscopy", "TEST", 102, 120], ["Protein array analysisBrains", "TEST", 121, 149], ["40 inflammatory factors", "PROBLEM", 176, 199], ["a commercialized mouse inflammation antibody", "TREATMENT", 206, 250]]], ["Briefly, brain sections were pooled (n = 4/group), homogenized in lysis buffer (kit component), and then centrifuged at 12,000 rpm for 15 min at 4\u00b0C. The membranes were incubated with the supernatants at a final concentration of 1 \u03bcg/\u03bcl.", [["brain sections", "ANATOMY", 9, 23], ["membranes", "ANATOMY", 154, 163], ["supernatants", "ANATOMY", 188, 200], ["brain sections", "MULTI-TISSUE_STRUCTURE", 9, 23], ["membranes", "CELLULAR_COMPONENT", 154, 163], ["brain sections", "TEST", 9, 23], ["lysis buffer", "TREATMENT", 66, 78]]], ["Chemiluminescent blot documentation was performed with a FluorChem HD2 imaging system.In vitro TBEV infectionT98G, CCF-STTG1, SK-N-SH, HPDAs, A549, and differentiated THP-1 cells were infected with TBEV WH2012 at a multiplicity of infection (MOI) of 1.", [["T98G", "ANATOMY", 109, 113], ["CCF-STTG1", "ANATOMY", 115, 124], ["SK-N-SH", "ANATOMY", 126, 133], ["HPDAs", "ANATOMY", 135, 140], ["A549", "ANATOMY", 142, 146], ["THP-1 cells", "ANATOMY", 167, 178], ["TBEV infection", "DISEASE", 95, 109], ["WH2012", "CHEMICAL", 203, 209], ["multiplicity of infection", "DISEASE", 215, 240], ["TBEV", "ORGANISM", 95, 99], ["T98G", "CELL", 109, 113], ["CCF-STTG1", "CELL", 115, 124], ["SK-N-SH", "CELL", 126, 133], ["HPDAs", "CELL", 135, 140], ["A549", "CELL", 142, 146], ["THP-1 cells", "CELL", 167, 178], ["TBEV", "ORGANISM", 198, 202], ["HD2", "PROTEIN", 67, 70], ["CCF-STTG1, SK-N-SH", "CELL_LINE", 115, 133], ["HPDAs", "CELL_LINE", 135, 140], ["A549", "CELL_LINE", 142, 146], ["differentiated THP-1 cells", "CELL_LINE", 152, 178], ["TBEV", "SPECIES", 95, 99], ["TBEV", "SPECIES", 198, 202], ["Chemiluminescent blot documentation", "TEST", 0, 35], ["a FluorChem HD2 imaging system", "TEST", 55, 85], ["vitro TBEV infection", "PROBLEM", 89, 109], ["T98G", "TEST", 109, 113], ["CCF", "TEST", 115, 118], ["STTG1", "TEST", 119, 124], ["SK", "TEST", 126, 128], ["HPDAs", "TEST", 135, 140], ["A549", "TEST", 142, 146], ["differentiated THP-1 cells", "PROBLEM", 152, 178], ["TBEV", "PROBLEM", 198, 202], ["infection", "PROBLEM", 231, 240], ["TBEV infection", "OBSERVATION", 95, 109], ["A549", "ANATOMY", 142, 146], ["infection", "OBSERVATION", 231, 240]]], ["To assess the requirement for viral replication in the generation of RANTES, cells were treated with UV-inactivated preparations of TBEV.", [["cells", "ANATOMY", 77, 82], ["TBEV", "DISEASE", 132, 136], ["RANTES", "GENE_OR_GENE_PRODUCT", 69, 75], ["cells", "CELL", 77, 82], ["TBEV", "ORGANISM", 132, 136], ["RANTES", "PROTEIN", 69, 75], ["TBEV", "SPECIES", 132, 136], ["viral replication", "TREATMENT", 30, 47], ["UV", "TREATMENT", 101, 103], ["TBEV", "TREATMENT", 132, 136]]], ["At the indicated time points, culture supernatants and cell monolayers were harvested for further analysis.RANTES mRNA quantificationTotal RNA was extracted from cell monolayers using Omega HP total RNA Isolation kit (Omega Bio-Tek, Inc., GA).", [["supernatants", "ANATOMY", 38, 50], ["cell monolayers", "ANATOMY", 55, 70], ["cell monolayers", "ANATOMY", 162, 177], ["cell monolayers", "CELL", 55, 70], ["RANTES", "GENE_OR_GENE_PRODUCT", 107, 113], ["cell monolayers", "CELL", 162, 177], ["RANTES mRNA", "RNA", 107, 118], ["quantificationTotal RNA", "RNA", 119, 142], ["culture supernatants", "TEST", 30, 50], ["cell monolayers", "TEST", 55, 70], ["further analysis", "TEST", 90, 106], ["RANTES mRNA quantificationTotal RNA", "TREATMENT", 107, 142], ["cell monolayers", "TREATMENT", 162, 177], ["Omega HP total RNA Isolation kit (Omega Bio", "TREATMENT", 184, 227], ["cell monolayers", "OBSERVATION", 55, 70], ["cell monolayers", "OBSERVATION", 162, 177]]], ["To remove residual genomic DNA, RNA samples were pretreated with RQ1 RNase-free DNase (Promega, WI).", [["samples", "ANATOMY", 36, 43], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["RNase", "GENE_OR_GENE_PRODUCT", 69, 74], ["DNase", "GENE_OR_GENE_PRODUCT", 80, 85], ["genomic DNA", "DNA", 19, 30], ["RNase", "PROTEIN", 69, 74], ["DNase", "PROTEIN", 80, 85], ["residual genomic DNA", "PROBLEM", 10, 30], ["RNA samples", "TEST", 32, 43], ["RQ1 RNase", "TREATMENT", 65, 74], ["residual", "OBSERVATION_MODIFIER", 10, 18], ["genomic DNA", "OBSERVATION", 19, 30]]], ["Then, RNA was converted to cDNA using M-MLV Reverse Transcriptase (Promega).", [["Promega", "GENE_OR_GENE_PRODUCT", 67, 74], ["cDNA", "DNA", 27, 31], ["MLV Reverse Transcriptase (Promega)", "TREATMENT", 40, 75]]], ["Real-time PCR was carried out using primers specific for human RANTES (sense 5\u2032-ACCACACCCTGCTGCTTTGC-3\u2032, antisense 5\u2032-CCGAACCCATTTCTTCTCTGG-3\u2032) and TransStart Eco Green qPCR SuperMix kit (TransGen, Beijing, China) on the Bio-Rad CFX96 Real-Time PCR System (Bio-Rad Laboratories, Inc., CA).", [["human", "ORGANISM", 57, 62], ["RANTES", "GENE_OR_GENE_PRODUCT", 63, 69], ["human RANTES", "PROTEIN", 57, 69], ["antisense 5", "DNA", 105, 116], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["Real-time PCR", "TEST", 0, 13], ["human RANTES", "TEST", 57, 69], ["sense", "TEST", 71, 76], ["ACCACACCCTGCTGCTTTGC", "TEST", 80, 100], ["CCGAACCCATTTCTTCTCTGG", "TEST", 118, 139]]], ["The data acquisition and analysis were carried out with CFX Manager Software (version 2.1; Bio-Rad).", [["The data acquisition", "TEST", 0, 20], ["analysis", "TEST", 25, 33]]], ["Relative expression of RANTES was calculated using the 2 \u2212\u0394\u0394Ct method [22] after normalization with endogenous control \u03b2-actin (sense 5\u2032-CGGGAAATCGTGCGTGACAT-3\u2032, antisense 5\u2032-GAACTTTGGGGGATGCTCGC-3\u2032).", [["RANTES", "GENE_OR_GENE_PRODUCT", 23, 29], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 119, 126], ["RANTES", "PROTEIN", 23, 29], ["\u03b2-actin", "PROTEIN", 119, 126], ["antisense 5", "DNA", 162, 173], ["RANTES", "TEST", 23, 29], ["the 2 \u2212\u0394\u0394Ct method", "TREATMENT", 51, 69], ["endogenous control \u03b2-actin (sense", "TREATMENT", 100, 133], ["CGGGAAATCGTGCGTGACAT", "TEST", 137, 157]]], ["Results are expressed as the relative fold increase of the stimulated over the mock control group.RANTES ELISAThe mouse tissue homogenates and cell culture supernatants were assessed for RANTES protein levels using RANTES-specific enzyme-linked immunosorbent assay (ELISA) kit (Boster, Wuhan, China), according to the manufacturer's instructions.", [["tissue homogenates", "ANATOMY", 120, 138], ["cell culture supernatants", "ANATOMY", 143, 168], ["mouse", "ORGANISM", 114, 119], ["tissue homogenates", "ORGANISM_SUBSTANCE", 120, 138], ["cell", "CELL", 143, 147], ["RANTES", "GENE_OR_GENE_PRODUCT", 187, 193], ["RANTES", "GENE_OR_GENE_PRODUCT", 215, 221], ["RANTES", "PROTEIN", 98, 104], ["RANTES", "PROTEIN", 187, 193], ["RANTES", "PROTEIN", 215, 221], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 114, 119], ["mouse tissue homogenates", "TEST", 114, 138], ["cell culture supernatants", "TEST", 143, 168], ["RANTES protein levels", "TEST", 187, 208], ["RANTES", "TEST", 215, 221], ["specific enzyme", "TEST", 222, 237], ["immunosorbent assay", "TEST", 245, 264], ["fold", "OBSERVATION_MODIFIER", 38, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51]]], ["The analytical procedure has been described previously [20] .ChemotaxisCell chemotaxis assay was performed as previously described [23, 24] .", [["The analytical procedure", "TREATMENT", 0, 24], ["ChemotaxisCell chemotaxis assay", "TEST", 61, 92]]], ["Briefly, THP-1 cells (5 \u00d7 10 5 cells/ 100 \u03bcl) were added to the upper chamber of Transwell insert (5-\u03bcm polycarbonate filter; Corning, NY).", [["THP-1 cells", "ANATOMY", 9, 20], ["cells", "ANATOMY", 31, 36], ["\u03bcl", "ANATOMY", 42, 44], ["polycarbonate", "CHEMICAL", 104, 117], ["THP-1 cells", "CELL", 9, 20], ["cells", "CELL", 31, 36], ["THP-1 cells", "CELL_LINE", 9, 20], ["Transwell insert (5-\u03bcm polycarbonate filter", "TREATMENT", 81, 124], ["upper", "ANATOMY_MODIFIER", 64, 69], ["chamber", "ANATOMY_MODIFIER", 70, 77], ["Transwell insert", "OBSERVATION", 81, 97]]], ["A total of 1-ml culture supernatant from TBEV-infected T98G (MOI = 5) for 72 h was added to the lower chamber of Transwell insert.", [["supernatant", "ANATOMY", 24, 35], ["T98G", "ANATOMY", 55, 59], ["TBEV-infected", "DISEASE", 41, 54], ["TBEV", "ORGANISM", 41, 45], ["T98G", "CELL", 55, 59], ["TBEV", "SPECIES", 41, 45], ["ml culture", "TEST", 13, 23], ["TBEV", "TEST", 41, 45], ["MOI", "TEST", 61, 64], ["Transwell insert", "TREATMENT", 113, 129], ["lower", "ANATOMY_MODIFIER", 96, 101], ["chamber", "ANATOMY_MODIFIER", 102, 109], ["Transwell insert", "OBSERVATION", 113, 129]]], ["For the neutralizing experiment, anti-hRANTES Ab (0.5 \u03bcg/ml; R&D Systems, Minneapolis, MN) or control normal goat IgG was added to the conditioned media in the lower chamber.", [["anti-hRANTES Ab", "GENE_OR_GENE_PRODUCT", 33, 48], ["goat", "ORGANISM", 109, 113], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["anti-hRANTES Ab", "PROTEIN", 33, 48], ["normal goat IgG", "PROTEIN", 102, 117], ["goat", "SPECIES", 109, 113], ["goat", "SPECIES", 109, 113], ["the neutralizing experiment", "TREATMENT", 4, 31], ["anti-hRANTES Ab", "TREATMENT", 33, 48], ["Minneapolis, MN)", "TREATMENT", 74, 90], ["control normal goat IgG", "TREATMENT", 94, 117], ["lower", "ANATOMY_MODIFIER", 160, 165], ["chamber", "ANATOMY_MODIFIER", 166, 173]]], ["Plates were incubated for 4 h at 37\u00b0C and 5 % CO2.", [["CO2", "CHEMICAL", 46, 49], ["CO2", "CHEMICAL", 46, 49], ["CO2", "SIMPLE_CHEMICAL", 46, 49]]], ["Transwell inserts were then removed, and the number of cells migrated to the lower chamber was determined with a TC20 Automated Cell Counter (Bio-Rad).", [["cells", "ANATOMY", 55, 60], ["Cell", "ANATOMY", 128, 132], ["cells", "CELL", 55, 60], ["TC20", "PROTEIN", 113, 117], ["Transwell inserts", "TREATMENT", 0, 17], ["a TC20 Automated Cell Counter", "TREATMENT", 111, 140], ["lower chamber", "ANATOMY", 77, 90]]], ["Data are expressed as percentage of the migrated cells in total number of input cells.Anti-RANTES treatmentCohorts of mice were treated via ic injection with Met-RANTES (1 \u03bcg/mouse; Bachem, Basel, Switzerland), vehicle, anti-RANTES mAb (MAB478), or an IgG2a isotype-matched control mAb (10 \u03bcg/mouse; R&D Systems) on days 2 to 8 after ic infection with TBEV WH2012 (10 3 TCID 50 s).", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 80, 85], ["Anti-RANTES", "CHEMICAL", 86, 97], ["Met-RANTES", "CHEMICAL", 158, 168], ["MAB478", "CHEMICAL", 237, 243], ["infection", "DISEASE", 337, 346], ["WH2012", "CHEMICAL", 357, 363], ["Met-RANTES", "CHEMICAL", 158, 168], ["cells", "CELL", 49, 54], ["cells", "CELL", 80, 85], ["Anti-RANTES", "SIMPLE_CHEMICAL", 86, 97], ["mice", "ORGANISM", 118, 122], ["Met-RANTES", "SIMPLE_CHEMICAL", 158, 168], ["mouse", "ORGANISM", 175, 180], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 220, 235], ["MAB478", "SIMPLE_CHEMICAL", 237, 243], ["mouse", "ORGANISM", 293, 298], ["TBEV", "ORGANISM", 352, 356], ["migrated cells", "CELL_TYPE", 40, 54], ["input cells", "CELL_TYPE", 74, 85], ["Anti-RANTES", "PROTEIN", 86, 97], ["anti-RANTES mAb", "PROTEIN", 220, 235], ["IgG2a isotype-matched control mAb", "PROTEIN", 252, 285], ["mice", "SPECIES", 118, 122], ["mouse", "SPECIES", 175, 180], ["mouse", "SPECIES", 293, 298], ["mice", "SPECIES", 118, 122], ["mouse", "SPECIES", 175, 180], ["mouse", "SPECIES", 293, 298], ["TBEV", "SPECIES", 352, 356], ["the migrated cells", "PROBLEM", 36, 54], ["Anti-RANTES treatment", "TREATMENT", 86, 107], ["Met-RANTES", "TREATMENT", 158, 168], ["vehicle", "TREATMENT", 211, 218], ["anti-RANTES mAb", "TREATMENT", 220, 235], ["an IgG2a isotype", "TREATMENT", 249, 265], ["ic infection", "PROBLEM", 334, 346], ["TBEV", "TEST", 352, 356], ["migrated cells", "OBSERVATION", 40, 54], ["total", "OBSERVATION_MODIFIER", 58, 63], ["IgG2a isotype", "OBSERVATION", 252, 265], ["infection", "OBSERVATION", 337, 346]]], ["Met-RANTES is a recombinant RANTES analog, in which the initiating methionine residue is retained after expression in Escherichia coli cells, resulting in a potent antagonist of the murine RANTES receptors CC chemokine receptor (CCR)5 and CCR1 [25, 26] .", [["cells", "ANATOMY", 135, 140], ["methionine", "CHEMICAL", 67, 77], ["CC", "CHEMICAL", 206, 208], ["methionine", "CHEMICAL", 67, 77], ["Met-RANTES", "SIMPLE_CHEMICAL", 0, 10], ["RANTES", "GENE_OR_GENE_PRODUCT", 28, 34], ["methionine", "SIMPLE_CHEMICAL", 67, 77], ["Escherichia coli cells", "CELL", 118, 140], ["murine", "ORGANISM", 182, 188], ["RANTES receptors CC chemokine receptor", "GENE_OR_GENE_PRODUCT", 189, 227], ["CCR)5", "GENE_OR_GENE_PRODUCT", 229, 234], ["CCR1", "GENE_OR_GENE_PRODUCT", 239, 243], ["Met-RANTES", "PROTEIN", 0, 10], ["RANTES", "PROTEIN", 28, 34], ["Escherichia coli cells", "CELL_LINE", 118, 140], ["murine RANTES receptors", "PROTEIN", 182, 205], ["CC chemokine receptor (CCR)5", "PROTEIN", 206, 234], ["CCR1", "PROTEIN", 239, 243], ["Escherichia coli", "SPECIES", 118, 134], ["murine", "SPECIES", 182, 188], ["Escherichia coli", "SPECIES", 118, 134], ["a recombinant RANTES analog", "TREATMENT", 14, 41], ["methionine residue", "TREATMENT", 67, 85], ["Escherichia coli cells", "PROBLEM", 118, 140], ["a potent antagonist of the murine RANTES receptors", "TREATMENT", 155, 205], ["chemokine receptor", "TEST", 209, 227], ["CCR", "TEST", 229, 232], ["CCR1", "TEST", 239, 243], ["Escherichia coli cells", "OBSERVATION", 118, 140]]], ["The chosen RANTES-neutralizing mAb reacts with murine and human RANTES and no other identified cytokine or chemokine [27, 28] .", [["RANTES", "GENE_OR_GENE_PRODUCT", 11, 17], ["murine", "ORGANISM", 47, 53], ["human", "ORGANISM", 58, 63], ["RANTES", "GENE_OR_GENE_PRODUCT", 64, 70], ["RANTES", "PROTEIN", 11, 17], ["neutralizing mAb", "PROTEIN", 18, 34], ["murine and human RANTES", "PROTEIN", 47, 70], ["cytokine", "PROTEIN", 95, 103], ["chemokine", "PROTEIN", 107, 116], ["murine", "SPECIES", 47, 53], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["The chosen RANTES", "TEST", 0, 17], ["neutralizing mAb", "TREATMENT", 18, 34], ["human RANTES", "TEST", 58, 70]]], ["Mice were monitored daily for signs of neurological disease and survival over a period of 14 days.", [["neurological", "ANATOMY", 39, 51], ["neurological disease", "DISEASE", 39, 59], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["neurological disease", "PROBLEM", 39, 59], ["neurological disease", "OBSERVATION", 39, 59]]], ["The survival curves were compared using Kaplan-Meier tests.", [["The survival curves", "TEST", 0, 19], ["Meier tests", "TEST", 47, 58]]], ["Both brain virus titers and mice survival rates were estimated at the time points indicated below.", [["brain", "ANATOMY", 5, 10], ["brain virus", "ORGANISM", 5, 16], ["mice", "ORGANISM", 28, 32], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["Both brain virus titers", "TREATMENT", 0, 23], ["mice survival rates", "TREATMENT", 28, 47], ["brain", "ANATOMY", 5, 10], ["virus titers", "OBSERVATION", 11, 23]]], ["The severity of inflammation was determined by staining sections of paraffin-embedded brain tissue with HE by day 8 post infection (p.i.), as after this time, the efficacy of this treatment may decline due to the decay of corresponding molecules within the mouse brain.Plasmids and cell transfectionThe RANTES promoter reporter construct (pGL2-220) and site-mutated plasmids for cAMP response element (CRE) (CRE Mut), interferon-stimulated response element (ISRE) (ISRE Mut), nuclear factor for interleukin 6 (NF-IL6) (NF-IL6 Mut), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB1) (NF-kB1 Mut), and NF-kB2 (NF-kB2 Mut) were kindly given by Dr. Casola (University of Texas Medical Branch, USA) [29] .", [["sections", "ANATOMY", 56, 64], ["brain tissue", "ANATOMY", 86, 98], ["brain", "ANATOMY", 263, 268], ["cell", "ANATOMY", 282, 286], ["plasmids", "ANATOMY", 366, 374], ["B cells", "ANATOMY", 587, 594], ["inflammation", "DISEASE", 16, 28], ["cAMP", "CHEMICAL", 379, 383], ["paraffin", "CHEMICAL", 68, 76], ["cAMP", "CHEMICAL", 379, 383], ["brain tissue", "TISSUE", 86, 98], ["mouse", "ORGANISM", 257, 262], ["brain", "ORGAN", 263, 268], ["cell", "CELL", 282, 286], ["RANTES", "GENE_OR_GENE_PRODUCT", 303, 309], ["pGL2-220", "GENE_OR_GENE_PRODUCT", 339, 347], ["cAMP response element (CRE)", "GENE_OR_GENE_PRODUCT", 379, 406], ["CRE Mut", "GENE_OR_GENE_PRODUCT", 408, 415], ["interferon-stimulated response element", "GENE_OR_GENE_PRODUCT", 418, 456], ["ISRE", "GENE_OR_GENE_PRODUCT", 458, 462], ["ISRE Mut", "GENE_OR_GENE_PRODUCT", 465, 473], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 495, 508], ["NF-IL6", "GENE_OR_GENE_PRODUCT", 510, 516], ["NF-IL6 Mut", "GENE_OR_GENE_PRODUCT", 519, 529], ["kappa-light-chain-enhancer of activated B cells", "GENE_OR_GENE_PRODUCT", 547, 594], ["NF-kB1", "GENE_OR_GENE_PRODUCT", 596, 602], ["NF-kB1 Mut", "GENE_OR_GENE_PRODUCT", 605, 615], ["NF-kB2", "GENE_OR_GENE_PRODUCT", 622, 628], ["NF-kB2", "GENE_OR_GENE_PRODUCT", 630, 636], ["RANTES promoter reporter construct", "DNA", 303, 337], ["pGL2-220", "DNA", 339, 347], ["mutated plasmids", "DNA", 358, 374], ["cAMP response element", "DNA", 379, 400], ["CRE", "DNA", 402, 405], ["CRE Mut", "DNA", 408, 415], ["interferon-stimulated response element", "DNA", 418, 456], ["ISRE", "DNA", 458, 462], ["ISRE Mut", "DNA", 465, 473], ["interleukin 6", "PROTEIN", 495, 508], ["NF", "PROTEIN", 510, 512], ["IL6", "PROTEIN", 513, 516], ["NF-IL6 Mut", "PROTEIN", 519, 529], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 532, 594], ["NF", "PROTEIN", 596, 598], ["kB1", "PROTEIN", 599, 602], ["NF-kB1 Mut", "PROTEIN", 605, 615], ["NF-kB2", "DNA", 622, 628], ["NF-kB2 Mut", "DNA", 630, 640], ["mouse", "SPECIES", 257, 262], ["mouse", "SPECIES", 257, 262], ["inflammation", "PROBLEM", 16, 28], ["staining sections", "TEST", 47, 64], ["paraffin-embedded brain tissue", "PROBLEM", 68, 98], ["infection", "PROBLEM", 121, 130], ["this treatment", "TREATMENT", 175, 189], ["corresponding molecules within the mouse brain", "PROBLEM", 222, 268], ["Plasmids", "TREATMENT", 269, 277], ["cell transfectionThe RANTES promoter reporter construct", "TREATMENT", 282, 337], ["pGL2", "TEST", 339, 343], ["mutated plasmids", "TREATMENT", 358, 374], ["cAMP response element", "TEST", 379, 400], ["CRE", "TEST", 402, 405], ["CRE Mut", "TEST", 408, 415], ["interferon-stimulated response element (ISRE) (ISRE Mut", "TEST", 418, 473], ["nuclear factor", "TEST", 476, 490], ["interleukin", "TEST", 495, 506], ["nuclear factor kappa-light", "TEST", 532, 558], ["activated B cells", "PROBLEM", 577, 594], ["NF", "TEST", 596, 598], ["NF", "TEST", 605, 607], ["NF", "TEST", 622, 624], ["NF", "TEST", 630, 632], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["inflammation", "OBSERVATION", 16, 28], ["brain tissue", "ANATOMY", 86, 98], ["infection", "OBSERVATION", 121, 130], ["mouse", "ANATOMY_MODIFIER", 257, 262], ["brain", "ANATOMY", 263, 268], ["cell transfection", "OBSERVATION", 282, 299]]], ["The dominant-negative mutants of IkB kinase alpha (mIkB\u03b1), IRF-3\u0394N, and IRF-7\u0394N were kind gifts of Prof. S. B. Xiao (Huazhong Agricultural University, China).", [["IkB kinase alpha", "GENE_OR_GENE_PRODUCT", 33, 49], ["mIkB\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["IRF-3\u0394N", "GENE_OR_GENE_PRODUCT", 59, 66], ["IRF-7\u0394N", "GENE_OR_GENE_PRODUCT", 72, 79], ["dominant-negative mutants", "PROTEIN", 4, 29], ["IkB kinase alpha", "PROTEIN", 33, 49], ["mIkB\u03b1", "PROTEIN", 51, 56], ["IRF", "PROTEIN", 59, 62], ["3\u0394N", "PROTEIN", 63, 66], ["IRF", "PROTEIN", 72, 75], ["7\u0394N", "PROTEIN", 76, 79], ["S. B.", "SPECIES", 105, 110], ["IkB kinase alpha", "TEST", 33, 49], ["IkB", "TEST", 52, 55], ["IRF", "TEST", 59, 62], ["IRF", "TEST", 72, 75], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["negative mutants", "OBSERVATION", 13, 29]]], ["All plasmids for transfection were prepared with Endo-free Plasmid Midi Kit (Omega Bio-Tek, Inc., GA).", [["plasmids", "ANATOMY", 4, 12], ["plasmids", "DNA", 4, 12], ["All plasmids", "TREATMENT", 0, 12], ["transfection", "TREATMENT", 17, 29], ["Endo", "TEST", 49, 53]]], ["Exponentially growing T98G cells in 24-well plates were transfected with 0.1 \u03bcg of pRL-TK reporter (Renilla luciferase for internal control) and 0.5 \u03bcg of RANTES-pGL2 plasmids (Firefly luciferase, experimental reporter) using the X-tremeGENE HP reagent (Roche, Mannheim, Germany).", [["Exponentially", "ANATOMY", 0, 13], ["T98G cells", "ANATOMY", 22, 32], ["T98G cells", "CELL", 22, 32], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 83, 89], ["luciferase", "GENE_OR_GENE_PRODUCT", 108, 118], ["RANTES", "GENE_OR_GENE_PRODUCT", 155, 161], ["pGL2", "GENE_OR_GENE_PRODUCT", 162, 166], ["luciferase", "GENE_OR_GENE_PRODUCT", 185, 195], ["T98G cells", "CELL_LINE", 22, 32], ["pRL-TK reporter", "DNA", 83, 98], ["Renilla luciferase", "DNA", 100, 118], ["RANTES", "PROTEIN", 155, 161], ["pGL2 plasmids", "DNA", 162, 175], ["Firefly luciferase", "DNA", 177, 195], ["T98G cells", "TEST", 22, 32], ["pRL", "TEST", 83, 86], ["Renilla luciferase", "TEST", 100, 118], ["internal control", "TREATMENT", 123, 139], ["RANTES-pGL2 plasmids", "TREATMENT", 155, 175], ["the X-tremeGENE HP reagent", "TREATMENT", 226, 252], ["T98G cells", "OBSERVATION", 22, 32]]], ["For coexpression experiments, 0.5 \u03bcg of each indicated expression plasmid was added to the reporter vectors.", [["plasmid", "ANATOMY", 66, 73], ["expression plasmid", "DNA", 55, 73], ["reporter vectors", "DNA", 91, 107], ["coexpression experiments", "TREATMENT", 4, 28], ["expression plasmid", "TREATMENT", 55, 73]]], ["Twenty-four hours after transfection, cells were inoculated with TBEV and harvested at the indicated time interval.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["TBEV", "ORGANISM", 65, 69], ["TBEV", "SPECIES", 65, 69], ["TBEV", "PROBLEM", 65, 69]]], ["Reporter gene activity was measured using a dual-luciferase assay system (Promega, Madison, WI), according to the manufacturer's instructions.Western blot analysisT98G cells were washed with PBS and lysed with RIPA lysis buffer (Beyotime, Nantong, China) containing protease inhibitor (cOmplete Protease Inhibitor Cocktail Tablets; Roche).", [["T98G cells", "ANATOMY", 163, 173], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["T98G cells", "CELL", 163, 173], ["T98G cells", "CELL_LINE", 163, 173], ["T98G cells", "TREATMENT", 163, 173], ["PBS", "TREATMENT", 191, 194], ["RIPA lysis buffer (Beyotime, Nantong, China)", "TREATMENT", 210, 254], ["protease inhibitor", "TREATMENT", 266, 284], ["cOmplete Protease Inhibitor Cocktail Tablets", "TREATMENT", 286, 330], ["activity", "OBSERVATION_MODIFIER", 14, 22]]], ["Equal amounts of protein were separated on 12 % SDS-PAGE and transferred onto an Immobilon-P PVDF membrane (Millipore, MA).", [["SDS", "CHEMICAL", 48, 51], ["PVDF", "CHEMICAL", 93, 97], ["an Immobilon-P PVDF membrane", "TREATMENT", 78, 106], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["The blots were blocked for 1 h with 2 % bovine serum albumin in Tris-buffered saline (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl) containing 0.1 % Tween 20 (TBST) at room temperature (RT) and reacted overnight at 4\u00b0C with the primary antibodies.", [["serum", "ANATOMY", 47, 52], ["Tris-HCl", "CHEMICAL", 92, 100], ["NaCl", "CHEMICAL", 117, 121], ["Tris", "CHEMICAL", 64, 68], ["Tris-HCl", "CHEMICAL", 92, 100], ["NaCl", "CHEMICAL", 117, 121], ["Tween 20", "CHEMICAL", 140, 148], ["bovine", "ORGANISM", 40, 46], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["albumin", "SIMPLE_CHEMICAL", 53, 60], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 64, 84], ["Tris-HCl", "SIMPLE_CHEMICAL", 92, 100], ["Tween 20", "SIMPLE_CHEMICAL", 140, 148], ["primary antibodies", "PROTEIN", 219, 237], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 40, 46], ["2 % bovine serum albumin in Tris", "TREATMENT", 36, 68], ["buffered saline", "TREATMENT", 69, 84], ["pH", "TEST", 102, 104], ["0.15 M NaCl)", "TREATMENT", 110, 122]]], ["The membranes were washed four times with TBST and then incubated with the secondary Ab for 1 h at RT.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["secondary Ab", "PROTEIN", 75, 87], ["TBST", "TREATMENT", 42, 46], ["the secondary Ab", "TREATMENT", 71, 87]]], ["Horseradish peroxidase-conjugated goat anti-rabbit IgG (#31460) or goat anti-mouse IgG (#31430) secondary antibodies were used (Thermo Scientific Pierce, IL).", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["goat", "ORGANISM", 67, 71], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["conjugated goat anti-rabbit IgG", "PROTEIN", 23, 54], ["#31460", "PROTEIN", 56, 62], ["goat anti-mouse IgG", "PROTEIN", 67, 86], ["#31430", "PROTEIN", 88, 94], ["secondary antibodies", "PROTEIN", 96, 116], ["Horseradish", "SPECIES", 0, 11], ["goat", "SPECIES", 34, 38], ["anti-rabbit", "SPECIES", 39, 50], ["goat", "SPECIES", 67, 71], ["anti-mouse", "SPECIES", 72, 82], ["goat", "SPECIES", 34, 38], ["goat", "SPECIES", 67, 71], ["Horseradish peroxidase", "TEST", 0, 22], ["conjugated goat anti-rabbit IgG", "TREATMENT", 23, 54], ["goat anti-mouse IgG", "TREATMENT", 67, 86], ["secondary antibodies", "PROBLEM", 96, 116]]], ["The membranes were washed and visualized with BeyoECL Plus Chemiluminescent Substrate (Beyotime) for signal detection.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["BeyoECL Plus Chemiluminescent Substrate (Beyotime)", "TREATMENT", 46, 96], ["signal detection", "TEST", 101, 117]]], ["Primary antibodies directed against p-IRF-3 (Ser396, 4D4G, #4947), p-TANK-binding kinase 1 (TBK1) (Ser172, D52C2, #5483), retinoic acid-inducible gene 1 (RIG-I) (D14G6, #3743), melanoma differentiation-associated protein 5 (MDA5) (D74E4, #5321), IkB\u03b1 (#9242), and TBK1 (#3013) were obtained from Cell Signaling Technologies (Beverly, MA).", [["melanoma", "ANATOMY", 177, 185], ["Cell", "ANATOMY", 296, 300], ["p-IRF-3", "GENE_OR_GENE_PRODUCT", 36, 43], ["Ser396", "GENE_OR_GENE_PRODUCT", 45, 51], ["p-TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 67, 90], ["TBK1", "GENE_OR_GENE_PRODUCT", 92, 96], ["Ser172", "GENE_OR_GENE_PRODUCT", 99, 105], ["retinoic acid-inducible gene 1", "GENE_OR_GENE_PRODUCT", 122, 152], ["RIG-I", "GENE_OR_GENE_PRODUCT", 154, 159], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 177, 222], ["MDA5", "GENE_OR_GENE_PRODUCT", 224, 228], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 246, 250], ["TBK1", "GENE_OR_GENE_PRODUCT", 264, 268], ["Cell", "CELL", 296, 300], ["IRF-3", "PROTEIN", 38, 43], ["TANK-binding kinase 1", "PROTEIN", 69, 90], ["TBK1", "PROTEIN", 92, 96], ["Ser172", "PROTEIN", 99, 105], ["D52C2", "PROTEIN", 107, 112], ["retinoic acid-inducible gene 1", "DNA", 122, 152], ["RIG-I", "DNA", 154, 159], ["D14G6", "DNA", 162, 167], ["melanoma differentiation-associated protein 5", "PROTEIN", 177, 222], ["MDA5", "PROTEIN", 224, 228], ["D74E4", "PROTEIN", 231, 236], ["IkB\u03b1", "PROTEIN", 246, 250], ["#9242", "DNA", 252, 257], ["TBK1", "PROTEIN", 264, 268], ["#3013", "DNA", 270, 275], ["Primary antibodies", "TEST", 0, 18], ["IRF", "TEST", 38, 41], ["p-TANK-binding kinase", "TEST", 67, 88], ["TBK1", "TEST", 92, 96], ["D52C2", "TEST", 107, 112], ["retinoic acid-inducible gene", "TEST", 122, 150], ["melanoma differentiation", "PROBLEM", 177, 201], ["protein", "TEST", 213, 220], ["IkB\u03b1", "TEST", 246, 250], ["TBK1", "TEST", 264, 268], ["melanoma", "OBSERVATION", 177, 185]]], ["IRF-3 (#11312-1-AP) and \u03b2-actin (#60008-1-Ig) antibodies were purchased from Proteintech Group, Inc. (Chicago, IL).RNA interferenceT98G cells were transfected with small interfering RNA (siRNA) duplexes using HiPerFect transfection reagent (Qiagen, Hilden, Germany) according to the manufacturer's protocols. siRNA oligonucleotides were synthesized (RiboBio, Guangzhou, China) with the following sequences (sense strands): RIG-I, 5\u2032-GGAAGAGGUG-CAGUAUAUU-3\u2032; MDA5, 5\u2032-GGUGAAGGAGCAGAU UCAG-3\u2032 [30] .", [["T98G cells", "ANATOMY", 131, 141], ["IRF-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["#11312-1-AP", "GENE_OR_GENE_PRODUCT", 7, 18], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 24, 31], ["#60008-1-Ig", "GENE_OR_GENE_PRODUCT", 33, 44], ["T98G cells", "CELL", 131, 141], ["HiPerFect", "SIMPLE_CHEMICAL", 209, 218], ["RIG-I", "GENE_OR_GENE_PRODUCT", 423, 428], ["MDA5", "GENE_OR_GENE_PRODUCT", 458, 462], ["IRF-3 (#11312-1-AP", "PROTEIN", 0, 18], ["\u03b2-actin", "PROTEIN", 24, 31], ["#60008-1-Ig) antibodies", "PROTEIN", 33, 56], ["T98G cells", "CELL_LINE", 131, 141], ["RIG-I", "DNA", 423, 428], ["GGAAGAGGUG", "DNA", 433, 443], ["CAGUAUAUU", "DNA", 444, 453], ["MDA5", "DNA", 458, 462], ["IRF", "TEST", 0, 3], ["\u03b2-actin", "TEST", 24, 31], ["RNA interferenceT98G cells", "PROBLEM", 115, 141], ["small interfering RNA (siRNA) duplexes", "TREATMENT", 164, 202], ["HiPerFect transfection reagent", "TREATMENT", 209, 239], ["the manufacturer's protocols", "TREATMENT", 279, 307], ["siRNA oligonucleotides", "TREATMENT", 309, 331], ["the following sequences", "TEST", 382, 405], ["RIG", "TEST", 423, 426], ["GGAAGAGGUG", "TEST", 433, 443], ["CAGUAUAUU", "TEST", 444, 453], ["MDA5", "TEST", 458, 462], ["\u2032", "TEST", 465, 466], ["GGUGAAGGAGCAGAU", "TEST", 467, 482], ["UCAG", "TEST", 483, 487], ["T98G cells", "OBSERVATION", 131, 141], ["small", "OBSERVATION_MODIFIER", 164, 169], ["interfering RNA", "OBSERVATION", 170, 185], ["MDA5", "ANATOMY", 458, 462]]], ["Nonsilencing siRNA with a scrambled sequence were used as a negative control (control siRNA (Ctrl siRNA)).", [["scrambled sequence", "DNA", 26, 44], ["Nonsilencing siRNA", "TREATMENT", 0, 18], ["a scrambled sequence", "TREATMENT", 24, 44]]], ["After cultured for 16 h, the medium with transfection reagent was removed.", [["transfection reagent", "TREATMENT", 41, 61]]], ["Cells were either mock treated or infected with TBEV at an MOI of 1 for 24 h.", [["Cells", "ANATOMY", 0, 5], ["TBEV", "DISEASE", 48, 52], ["Cells", "CELL", 0, 5], ["TBEV", "ORGANISM", 48, 52], ["TBEV", "SPECIES", 48, 52], ["TBEV", "TREATMENT", 48, 52]]], ["Culture supernatants and cell monolayers were harvested for further analysis.Inhibition of cellular signaling pathwayInhibition of IRF-3 and NF-kB signaling in T98G and CCF-STTG1 cells was performed with BX795 (InvivoGen, CA) and MG132 (Millipore), respectively, as described previously [31, 32] .", [["supernatants", "ANATOMY", 8, 20], ["cell monolayers", "ANATOMY", 25, 40], ["cellular", "ANATOMY", 91, 99], ["T98G", "ANATOMY", 160, 164], ["CCF-STTG1 cells", "ANATOMY", 169, 184], ["BX795", "CHEMICAL", 204, 209], ["MG132", "CHEMICAL", 230, 235], ["BX795", "CHEMICAL", 204, 209], ["MG132", "CHEMICAL", 230, 235], ["cell monolayers", "CELL", 25, 40], ["cellular", "CELL", 91, 99], ["IRF-3", "GENE_OR_GENE_PRODUCT", 131, 136], ["NF-kB", "GENE_OR_GENE_PRODUCT", 141, 146], ["T98G", "CELL", 160, 164], ["CCF-STTG1 cells", "CELL", 169, 184], ["BX795", "SIMPLE_CHEMICAL", 204, 209], ["CA", "GENE_OR_GENE_PRODUCT", 222, 224], ["MG132", "SIMPLE_CHEMICAL", 230, 235], ["IRF-3", "PROTEIN", 131, 136], ["NF-kB", "PROTEIN", 141, 146], ["T98G", "CELL_LINE", 160, 164], ["CCF-STTG1 cells", "CELL_LINE", 169, 184], ["Culture supernatants", "TEST", 0, 20], ["cell monolayers", "TEST", 25, 40], ["further analysis", "TEST", 60, 76], ["IRF", "TEST", 131, 134], ["NF", "TEST", 141, 143], ["kB signaling", "TEST", 144, 156], ["T98G", "TEST", 160, 164], ["CCF", "TEST", 169, 172], ["STTG1 cells", "PROBLEM", 173, 184], ["CA", "TEST", 222, 224], ["MG132", "TEST", 230, 235], ["cell monolayers", "OBSERVATION", 25, 40], ["cellular signaling", "OBSERVATION", 91, 109], ["IRF", "OBSERVATION", 131, 134]]], ["Briefly, virus inoculation were carried out as mentioned above, followed by treatment with BX795 (2 \u03bcM), MG132 (3 \u03bcM), or DMSO vehicle in the absence of serum for 36 h, and the levels of RANTES released in culture supernatants were determined by ELISA.", [["serum", "ANATOMY", 153, 158], ["supernatants", "ANATOMY", 214, 226], ["BX795", "CHEMICAL", 91, 96], ["MG132", "CHEMICAL", 105, 110], ["DMSO", "CHEMICAL", 122, 126], ["BX795", "CHEMICAL", 91, 96], ["MG132", "CHEMICAL", 105, 110], ["DMSO", "CHEMICAL", 122, 126], ["BX795", "SIMPLE_CHEMICAL", 91, 96], ["MG132", "SIMPLE_CHEMICAL", 105, 110], ["DMSO", "SIMPLE_CHEMICAL", 122, 126], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["RANTES", "GENE_OR_GENE_PRODUCT", 187, 193], ["RANTES", "PROTEIN", 187, 193], ["virus inoculation", "PROBLEM", 9, 26], ["MG132", "TREATMENT", 105, 110], ["DMSO vehicle", "TREATMENT", 122, 134], ["the levels", "TEST", 173, 183], ["RANTES", "TEST", 187, 193], ["culture supernatants", "TEST", 206, 226]]], ["IRF-3 and p-IRF-3 were detected by Western blot analysis.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["p-IRF-3", "GENE_OR_GENE_PRODUCT", 10, 17], ["IRF-3", "PROTEIN", 0, 5], ["IRF-3", "PROTEIN", 12, 17], ["IRF", "TEST", 0, 3], ["blot analysis", "TEST", 43, 56]]], ["Virus infectivity was determined by TCID 50 assay as described above.Statistical analysesData were expressed as means \u00b1 SD.", [["Virus", "ORGANISM", 0, 5], ["Virus infectivity", "PROBLEM", 0, 17]]], ["All statistical analyses were carried out using SigmaPlot\u00ae10.0 software (Stystat Software, CA), with a P value of <0.05 considered statistically significant.Virulence studiesAfter ic inoculation of 1-week-old mice with TBEV (10 3 TCID 50 s), most animals developed neurological symptoms, such as hunched posture, loss of balance, hind limb paralysis, and convulsions in the final stage of the disease prior to death (data not shown).", [["neurological", "ANATOMY", 265, 277], ["hind limb", "ANATOMY", 330, 339], ["TBEV", "DISEASE", 219, 223], ["neurological symptoms", "DISEASE", 265, 286], ["loss of balance", "DISEASE", 313, 328], ["paralysis", "DISEASE", 340, 349], ["convulsions", "DISEASE", 355, 366], ["death", "DISEASE", 410, 415], ["mice", "ORGANISM", 209, 213], ["TBEV", "ORGANISM", 219, 223], ["hind limb", "ORGANISM_SUBDIVISION", 330, 339], ["mice", "SPECIES", 209, 213], ["mice", "SPECIES", 209, 213], ["TBEV", "SPECIES", 219, 223], ["All statistical analyses", "TEST", 0, 24], ["SigmaPlot", "TEST", 48, 57], ["a P value", "TEST", 101, 110], ["Virulence studies", "TEST", 157, 174], ["TBEV", "TREATMENT", 219, 223], ["neurological symptoms", "PROBLEM", 265, 286], ["hunched posture", "PROBLEM", 296, 311], ["loss of balance", "PROBLEM", 313, 328], ["hind limb paralysis", "PROBLEM", 330, 349], ["convulsions", "PROBLEM", 355, 366], ["the disease", "PROBLEM", 389, 400], ["death", "PROBLEM", 410, 415], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["hind limb", "ANATOMY", 330, 339], ["paralysis", "OBSERVATION", 340, 349], ["convulsions", "OBSERVATION", 355, 366], ["disease", "OBSERVATION", 393, 400]]], ["Major organs were harvested at various time points to determine virus titers in mice infected with TBEV.", [["organs", "ANATOMY", 6, 12], ["TBEV", "DISEASE", 99, 103], ["organs", "ORGAN", 6, 12], ["mice", "ORGANISM", 80, 84], ["TBEV", "ORGANISM", 99, 103], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["TBEV", "SPECIES", 99, 103], ["virus titers", "PROBLEM", 64, 76], ["harvested", "OBSERVATION", 18, 27]]], ["Virus was initially detected between 2 and 5 days p.i., with virus titers peaking on day 8 p.i. except for small intestine and heart.", [["small intestine", "ANATOMY", 107, 122], ["heart", "ANATOMY", 127, 132], ["Virus", "ORGANISM", 0, 5], ["intestine", "ORGAN", 113, 122], ["heart", "ORGAN", 127, 132], ["Virus", "PROBLEM", 0, 5], ["virus titers", "TEST", 61, 73], ["small intestine and heart", "PROBLEM", 107, 132], ["small intestine", "ANATOMY", 107, 122], ["heart", "ANATOMY", 127, 132]]], ["With respect to viral distribution, significantly higher virus titers were recovered from the brain, but relatively mediocre levels of viruses were also detected in peripheral tissues (Fig. 1a) .", [["brain", "ANATOMY", 94, 99], ["peripheral tissues", "ANATOMY", 165, 183], ["brain", "ORGAN", 94, 99], ["peripheral tissues", "TISSUE", 165, 183], ["viral distribution", "PROBLEM", 16, 34], ["significantly higher virus titers", "PROBLEM", 36, 69], ["viruses", "PROBLEM", 135, 142], ["viral distribution", "OBSERVATION", 16, 34], ["significantly", "OBSERVATION_MODIFIER", 36, 49], ["higher", "OBSERVATION_MODIFIER", 50, 56], ["virus titers", "OBSERVATION", 57, 69], ["brain", "ANATOMY", 94, 99], ["relatively", "OBSERVATION_MODIFIER", 105, 115], ["mediocre", "OBSERVATION_MODIFIER", 116, 124], ["viruses", "OBSERVATION", 135, 142], ["peripheral", "ANATOMY_MODIFIER", 165, 175], ["tissues", "ANATOMY", 176, 183]]], ["Following ic infection of mice with sequentially increasing doses, all tested groups exhibited fatal outcomes, with no significant differences in the mean survival times between the challenge doses (Fig. 1b) .", [["infection", "DISEASE", 13, 22], ["mice", "ORGANISM", 26, 30], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["sequentially increasing doses", "TREATMENT", 36, 65], ["infection", "OBSERVATION", 13, 22]]], ["However, following ip (Fig. 1c) , subcutaneous (sc) [18] or intramuscular (im) (data not shown) infection of groups of mice with sequentially increasing doses, 100 % mortality was not observed even with the highest tested virus challenge dose.", [["subcutaneous", "ANATOMY", 34, 46], ["infection", "DISEASE", 96, 105], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["mice", "ORGANISM", 119, 123], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["ip (Fig. 1c)", "TREATMENT", 19, 31], ["subcutaneous (sc)", "TREATMENT", 34, 51], ["infection", "PROBLEM", 96, 105], ["sequentially increasing doses", "TREATMENT", 129, 158], ["subcutaneous", "ANATOMY", 34, 46], ["infection", "OBSERVATION", 96, 105]]], ["These observations indicate that direct CNS infection induces early death in mice even after low-dose challenge.TBEV induces RANTES within host CNSTo gain insight into the neuroinflammatory responses elicited specifically in the CNS compartment, TBEV WH2012 strain was inoculated by the ic route.", [["CNS", "ANATOMY", 40, 43], ["CNS compartment", "ANATOMY", 229, 244], ["infection", "DISEASE", 44, 53], ["death", "DISEASE", 68, 73], ["TBEV", "DISEASE", 112, 116], ["CNS", "ANATOMICAL_SYSTEM", 40, 43], ["mice", "ORGANISM", 77, 81], ["TBEV", "ORGANISM", 112, 116], ["RANTES", "GENE_OR_GENE_PRODUCT", 125, 131], ["CNSTo", "GENE_OR_GENE_PRODUCT", 144, 149], ["CNS compartment", "MULTI-TISSUE_STRUCTURE", 229, 244], ["TBEV WH2012 strain", "ORGANISM", 246, 264], ["RANTES", "PROTEIN", 125, 131], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["TBEV", "SPECIES", 112, 116], ["TBEV", "SPECIES", 246, 250], ["direct CNS infection", "PROBLEM", 33, 53], ["low-dose challenge", "TREATMENT", 93, 111], ["the neuroinflammatory responses", "TEST", 168, 199], ["CNS", "ANATOMY", 40, 43], ["infection", "OBSERVATION", 44, 53], ["CNS", "ANATOMY", 229, 232], ["compartment", "ANATOMY_MODIFIER", 233, 244]]], ["Time course of acute brain injury was assessed histologically.", [["brain", "ANATOMY", 21, 26], ["brain injury", "DISEASE", 21, 33], ["brain", "ORGAN", 21, 26], ["acute brain injury", "PROBLEM", 15, 33], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["brain", "ANATOMY", 21, 26], ["injury", "OBSERVATION", 27, 33]]], ["As depicted in Fig. 2 , the HE-stained brain sections of the cerebral cortex obtained from virus-infected group indicate inflammatory cell infiltrates appeared as early as 3 days post challenge.", [["brain sections", "ANATOMY", 39, 53], ["cerebral cortex", "ANATOMY", 61, 76], ["inflammatory cell", "ANATOMY", 121, 138], ["HE", "GENE_OR_GENE_PRODUCT", 28, 30], ["brain sections", "MULTI-TISSUE_STRUCTURE", 39, 53], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 61, 76], ["inflammatory cell", "CELL", 121, 138], ["virus", "PROBLEM", 91, 96], ["inflammatory cell infiltrates", "PROBLEM", 121, 150], ["cerebral cortex", "ANATOMY", 61, 76], ["inflammatory cell infiltrates", "OBSERVATION", 121, 150]]], ["By day 4 p.i., the inflammatory reaction increased.", [["the inflammatory reaction", "PROBLEM", 15, 40], ["inflammatory", "OBSERVATION_MODIFIER", 19, 31], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["Marked inflammatory cell infiltrates were observed on day 8 p.i. when nearly all infected mice succumbed to infection.TBEV induces RANTES within host CNSCNS infiltration of peripheral immune cells requires antecedent local expression of cytokines, chemokines, and cell adhesion molecules [33] .", [["inflammatory cell", "ANATOMY", 7, 24], ["CNSCNS", "ANATOMY", 150, 156], ["peripheral immune cells", "ANATOMY", 173, 196], ["cell", "ANATOMY", 264, 268], ["infection", "DISEASE", 108, 117], ["TBEV", "DISEASE", 118, 122], ["inflammatory cell", "CELL", 7, 24], ["mice", "ORGANISM", 90, 94], ["TBEV", "ORGANISM", 118, 122], ["RANTES", "GENE_OR_GENE_PRODUCT", 131, 137], ["CNSCNS", "CELL", 150, 156], ["peripheral immune cells", "CELL", 173, 196], ["cell", "CELL", 264, 268], ["RANTES", "PROTEIN", 131, 137], ["peripheral immune cells", "CELL_TYPE", 173, 196], ["cytokines", "PROTEIN", 237, 246], ["chemokines", "PROTEIN", 248, 258], ["cell adhesion molecules", "PROTEIN", 264, 287], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["TBEV", "SPECIES", 118, 122], ["Marked inflammatory cell infiltrates", "PROBLEM", 0, 36], ["infection", "PROBLEM", 108, 117], ["TBEV", "PROBLEM", 118, 122], ["peripheral immune cells", "TREATMENT", 173, 196], ["antecedent local expression of cytokines", "TREATMENT", 206, 246], ["chemokines", "TREATMENT", 248, 258], ["cell adhesion molecules", "TREATMENT", 264, 287], ["inflammatory cell", "OBSERVATION", 7, 24], ["infiltrates", "OBSERVATION", 25, 36], ["infected", "OBSERVATION", 81, 89], ["infection", "OBSERVATION", 108, 117], ["peripheral immune cells", "OBSERVATION", 173, 196]]], ["To identify the key immune factors induced by TBEV in CNS, brains of virus-infected mice were harvested on days 2, 5, and 8 p.i., and the expression of 40 inflammatory factors was profiled by a mouse-specific protein array.", [["CNS", "ANATOMY", 54, 57], ["brains", "ANATOMY", 59, 65], ["TBEV", "ORGANISM", 46, 50], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["brains", "ORGAN", 59, 65], ["mice", "ORGANISM", 84, 88], ["mouse", "ORGANISM", 194, 199], ["immune factors", "PROTEIN", 20, 34], ["40 inflammatory factors", "PROTEIN", 152, 175], ["mice", "SPECIES", 84, 88], ["mouse", "SPECIES", 194, 199], ["TBEV", "SPECIES", 46, 50], ["mice", "SPECIES", 84, 88], ["mouse", "SPECIES", 194, 199], ["TBEV", "PROBLEM", 46, 50], ["brains of virus", "PROBLEM", 59, 74], ["infected mice", "PROBLEM", 75, 88], ["40 inflammatory factors", "PROBLEM", 152, 175], ["TBEV", "OBSERVATION", 46, 50]]], ["Compared with baseline expression in uninfected controls, the secretion of a panel of immune factors was increased in mouse brains after virus inoculation.", [["brains", "ANATOMY", 124, 130], ["mouse", "ORGANISM", 118, 123], ["brains", "DEVELOPING_ANATOMICAL_STRUCTURE", 124, 130], ["immune factors", "PROTEIN", 86, 100], ["mouse", "SPECIES", 118, 123], ["mouse", "SPECIES", 118, 123], ["uninfected controls", "TREATMENT", 37, 56], ["immune factors", "PROBLEM", 86, 100], ["virus inoculation", "TREATMENT", 137, 154], ["uninfected controls", "OBSERVATION", 37, 56]]], ["Among them, the CC-chemokine RANTES was induced within 5 days after TBEV infection, and the expression levels also remained elevated until the moribund state (Fig. 3a) .", [["CC", "CHEMICAL", 16, 18], ["TBEV infection", "DISEASE", 68, 82], ["RANTES", "GENE_OR_GENE_PRODUCT", 29, 35], ["TBEV", "ORGANISM", 68, 72], ["CC", "PROTEIN", 16, 18], ["chemokine", "PROTEIN", 19, 28], ["RANTES", "PROTEIN", 29, 35], ["TBEV", "SPECIES", 68, 72], ["TBEV infection", "PROBLEM", 68, 82], ["the expression levels", "TEST", 88, 109], ["elevated", "PROBLEM", 124, 132], ["infection", "OBSERVATION", 73, 82]]], ["Below, the expression of RANTES upon TBEV infection is characterized.TBEV induces RANTES within host CNSTo confirm the protein array data, induction of RANTES was examined by ELISA.", [["TBEV infection", "DISEASE", 37, 51], ["TBEV", "DISEASE", 69, 73], ["RANTES", "GENE_OR_GENE_PRODUCT", 25, 31], ["TBEV", "ORGANISM", 37, 41], ["TBEV", "ORGANISM", 69, 73], ["RANTES", "GENE_OR_GENE_PRODUCT", 82, 88], ["RANTES", "GENE_OR_GENE_PRODUCT", 152, 158], ["RANTES", "PROTEIN", 25, 31], ["RANTES", "PROTEIN", 82, 88], ["RANTES", "PROTEIN", 152, 158], ["TBEV", "SPECIES", 37, 41], ["TBEV", "SPECIES", 69, 73], ["RANTES upon TBEV infection", "PROBLEM", 25, 51], ["the protein array data", "TEST", 115, 137], ["RANTES", "TEST", 152, 158], ["infection", "OBSERVATION", 42, 51]]], ["Mediocre induction of RANTES in response to TBEV infection was found as early as 3 days post challenge (13.9 \u00b1 0.6-fold increase).", [["TBEV infection", "DISEASE", 44, 58], ["RANTES", "GENE_OR_GENE_PRODUCT", 22, 28], ["TBEV", "ORGANISM", 44, 48], ["RANTES", "PROTEIN", 22, 28], ["TBEV", "SPECIES", 44, 48], ["RANTES", "PROBLEM", 22, 28], ["TBEV infection", "PROBLEM", 44, 58], ["challenge", "TEST", 93, 102], ["TBEV infection", "OBSERVATION", 44, 58]]], ["Then, sustained up-regulation of RANTES in CNS was observed from day 4 to day 8 after infection.", [["CNS", "ANATOMY", 43, 46], ["infection", "DISEASE", 86, 95], ["RANTES", "GENE_OR_GENE_PRODUCT", 33, 39], ["CNS", "ANATOMICAL_SYSTEM", 43, 46], ["RANTES", "PROTEIN", 33, 39], ["sustained up-regulation of RANTES in CNS", "PROBLEM", 6, 46], ["infection", "PROBLEM", 86, 95], ["up-regulation", "OBSERVATION_MODIFIER", 16, 29], ["RANTES", "OBSERVATION", 33, 39], ["CNS", "ANATOMY", 43, 46], ["infection", "OBSERVATION", 86, 95]]], ["Closely mimicking the results from the protein array analysis, a robust increase in RANTES protein expression was observed on day 5 (226.6 \u00b1 11.7-fold increase) and persisted up to day 8 (258.8 \u00b1 10.5-fold increase) p.i. within the brain tissue.", [["brain tissue", "ANATOMY", 232, 244], ["RANTES", "GENE_OR_GENE_PRODUCT", 84, 90], ["brain tissue", "TISSUE", 232, 244], ["RANTES", "PROTEIN", 84, 90], ["the protein array analysis", "TEST", 35, 61], ["RANTES protein expression", "TEST", 84, 109], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["brain tissue", "ANATOMY", 232, 244]]], ["Interestingly, the induction pattern of RANTES expression appeared to be coincided with the dynamics of immune cell infiltration in the CNS.", [["immune cell", "ANATOMY", 104, 115], ["CNS", "ANATOMY", 136, 139], ["RANTES", "GENE_OR_GENE_PRODUCT", 40, 46], ["immune cell", "CELL", 104, 115], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["RANTES", "PROTEIN", 40, 46], ["RANTES expression", "PROBLEM", 40, 57], ["immune cell infiltration", "PROBLEM", 104, 128], ["immune cell infiltration", "OBSERVATION", 104, 128], ["CNS", "ANATOMY", 136, 139]]], ["It is noteworthy that no concomitant increase of RANTES expression was recorded in tested peripheral tissues and sera (Fig. 3b) .", [["peripheral tissues", "ANATOMY", 90, 108], ["sera", "ANATOMY", 113, 117], ["RANTES", "GENE_OR_GENE_PRODUCT", 49, 55], ["peripheral tissues", "TISSUE", 90, 108], ["sera", "ORGANISM_SUBSTANCE", 113, 117], ["RANTES", "PROTEIN", 49, 55], ["concomitant increase of RANTES expression", "PROBLEM", 25, 66], ["no", "UNCERTAINTY", 22, 24], ["concomitant", "OBSERVATION_MODIFIER", 25, 36], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["RANTES expression", "OBSERVATION", 49, 66], ["peripheral tissues", "ANATOMY", 90, 108]]], ["Besides, the protein abundance for RANTES (in pg/ml) in the brain was also greater than those observed in tested peripheral tissues and sera following ic TBEV infection (data not shown).", [["brain", "ANATOMY", 60, 65], ["peripheral tissues", "ANATOMY", 113, 131], ["sera", "ANATOMY", 136, 140], ["TBEV infection", "DISEASE", 154, 168], ["RANTES", "GENE_OR_GENE_PRODUCT", 35, 41], ["brain", "ORGAN", 60, 65], ["peripheral tissues", "TISSUE", 113, 131], ["sera", "ORGANISM_SUBSTANCE", 136, 140], ["ic TBEV", "ORGANISM", 151, 158], ["RANTES", "PROTEIN", 35, 41], ["TBEV", "SPECIES", 154, 158], ["RANTES", "TEST", 35, 41], ["sera", "TEST", 136, 140], ["ic TBEV infection", "PROBLEM", 151, 168], ["brain", "ANATOMY", 60, 65], ["greater", "OBSERVATION_MODIFIER", 75, 82], ["peripheral tissues", "ANATOMY", 113, 131]]], ["To strengthen that the results obtained from 1-week-old mice are also valid in adult mice, RANTES protein levels in the brain and serum were also measured in mice aged 7-8 weeks after ic infection with TBEV.", [["brain", "ANATOMY", 120, 125], ["serum", "ANATOMY", 130, 135], ["infection", "DISEASE", 187, 196], ["TBEV", "DISEASE", 202, 206], ["mice", "ORGANISM", 56, 60], ["mice", "ORGANISM", 85, 89], ["RANTES", "GENE_OR_GENE_PRODUCT", 91, 97], ["brain", "ORGAN", 120, 125], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["mice", "ORGANISM", 158, 162], ["TBEV", "ORGANISM", 202, 206], ["RANTES", "PROTEIN", 91, 97], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 158, 162], ["TBEV", "SPECIES", 202, 206], ["RANTES protein levels", "TEST", 91, 112], ["ic infection", "PROBLEM", 184, 196], ["TBEV", "PROBLEM", 202, 206], ["brain", "ANATOMY", 120, 125], ["infection", "OBSERVATION", 187, 196]]], ["By day 5 p.i., a slight increase in RANTES expression occurred in the brain of adult mice (2.9 \u00b1 0.5-fold increase).", [["brain", "ANATOMY", 70, 75], ["RANTES", "GENE_OR_GENE_PRODUCT", 36, 42], ["brain", "ORGAN", 70, 75], ["mice", "ORGANISM", 85, 89], ["RANTES", "PROTEIN", 36, 42], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["a slight increase in RANTES expression", "PROBLEM", 15, 53], ["slight", "OBSERVATION_MODIFIER", 17, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["RANTES expression", "OBSERVATION", 36, 53], ["brain", "ANATOMY", 70, 75]]], ["TBEV infection caused a dramatic increase in the level of brain RANTES on days 8 (36.4 \u00b1 4.5-fold increase) or 11 (31.3 \u00b1 4.6-fold increase) p.i. compared to mock controls (Fig. 3c) .", [["brain", "ANATOMY", 58, 63], ["TBEV infection", "DISEASE", 0, 14], ["TBEV", "ORGANISM", 0, 4], ["brain", "ORGAN", 58, 63], ["RANTES", "GENE_OR_GENE_PRODUCT", 64, 70], ["RANTES", "PROTEIN", 64, 70], ["TBEV", "SPECIES", 0, 4], ["TBEV infection", "PROBLEM", 0, 14], ["a dramatic increase", "PROBLEM", 22, 41], ["infection", "OBSERVATION", 5, 14], ["dramatic", "OBSERVATION_MODIFIER", 24, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["brain", "ANATOMY", 58, 63], ["RANTES", "OBSERVATION", 64, 70]]], ["There was no obvious induction of RANTES production in the serum, and RANTES level in the brain of TBEV-infected adult mice was also significantly higher when compared to that in the serum (data not shown).", [["serum", "ANATOMY", 59, 64], ["brain", "ANATOMY", 90, 95], ["serum", "ANATOMY", 183, 188], ["RANTES", "GENE_OR_GENE_PRODUCT", 34, 40], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["RANTES", "GENE_OR_GENE_PRODUCT", 70, 76], ["brain", "ORGAN", 90, 95], ["TBEV", "ORGANISM", 99, 103], ["mice", "ORGANISM", 119, 123], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["RANTES", "PROTEIN", 34, 40], ["RANTES", "PROTEIN", 70, 76], ["mice", "SPECIES", 119, 123], ["TBEV", "SPECIES", 99, 103], ["mice", "SPECIES", 119, 123], ["RANTES production", "PROBLEM", 34, 51], ["the serum", "TEST", 55, 64], ["RANTES level", "TEST", 70, 82], ["TBEV", "TEST", 99, 103], ["the serum", "TEST", 179, 188], ["no obvious", "UNCERTAINTY", 10, 20], ["RANTES", "OBSERVATION", 34, 40], ["brain", "ANATOMY", 90, 95], ["TBEV", "OBSERVATION", 99, 103], ["infected", "OBSERVATION_MODIFIER", 104, 112], ["significantly", "OBSERVATION_MODIFIER", 133, 146], ["higher", "OBSERVATION_MODIFIER", 147, 153]]], ["This higher RANTES concentration in the brain of virus-infected adult mice as compared to that in the serum suggest potential localized Histopathological analyses for the TBEV-infected mice brain.", [["brain", "ANATOMY", 40, 45], ["serum", "ANATOMY", 102, 107], ["brain", "ANATOMY", 190, 195], ["TBEV-infected", "DISEASE", 171, 184], ["RANTES", "GENE_OR_GENE_PRODUCT", 12, 18], ["brain", "ORGAN", 40, 45], ["adult mice", "ORGANISM", 64, 74], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["TBEV", "ORGANISM", 171, 175], ["mice", "ORGANISM", 185, 189], ["brain", "ORGAN", 190, 195], ["RANTES", "PROTEIN", 12, 18], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 70, 74], ["TBEV", "SPECIES", 171, 175], ["mice", "SPECIES", 185, 189], ["This higher RANTES concentration", "PROBLEM", 0, 32], ["Histopathological analyses", "TEST", 136, 162], ["the TBEV", "TEST", 167, 175], ["infected mice brain", "PROBLEM", 176, 195], ["brain", "ANATOMY", 40, 45], ["virus", "OBSERVATION", 49, 54], ["infected", "OBSERVATION_MODIFIER", 55, 63], ["adult mice", "OBSERVATION_MODIFIER", 64, 74], ["infected", "OBSERVATION", 176, 184], ["brain", "ANATOMY", 190, 195]]], ["The histopathological changes of PFA-fixed sections in cerebral cortex were examined by HE staining at the denoted time points after TBEV or mock infection.", [["sections", "ANATOMY", 43, 51], ["cerebral cortex", "ANATOMY", 55, 70], ["infection", "DISEASE", 146, 155], ["PFA", "CHEMICAL", 33, 36], ["PFA", "SIMPLE_CHEMICAL", 33, 36], ["sections", "MULTI-TISSUE_STRUCTURE", 43, 51], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 55, 70], ["TBEV", "ORGANISM", 133, 137], ["TBEV", "SPECIES", 133, 137], ["PFA", "TEST", 33, 36], ["fixed sections in cerebral cortex", "PROBLEM", 37, 70], ["TBEV", "PROBLEM", 133, 137], ["mock infection", "PROBLEM", 141, 155], ["PFA", "OBSERVATION_MODIFIER", 33, 36], ["fixed sections", "OBSERVATION", 37, 51], ["cerebral cortex", "ANATOMY", 55, 70], ["infection", "OBSERVATION", 146, 155]]], ["Black arrows identify leukocytes infiltrating into the brain tissues.", [["leukocytes", "ANATOMY", 22, 32], ["brain tissues", "ANATOMY", 55, 68], ["leukocytes", "CELL", 22, 32], ["brain tissues", "TISSUE", 55, 68], ["leukocytes", "CELL_TYPE", 22, 32], ["Black arrows", "PROBLEM", 0, 12], ["leukocytes infiltrating into the brain tissues", "PROBLEM", 22, 68], ["leukocytes infiltrating", "OBSERVATION", 22, 45], ["brain tissues", "ANATOMY", 55, 68]]], ["The photomicrographs demonstrate representative images obtained from three independent experiments (n = 4 mice per group).", [["mice", "ORGANISM", 106, 110], ["mice", "SPECIES", 106, 110], ["The photomicrographs", "TEST", 0, 20], ["representative images", "TEST", 33, 54]]], ["Bars, 100 \u03bcm inflammatory responses.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["Taken together, these observations suggest that TBEV induces a significant increase of RANTES production within CNS, which is likely related to the progression of neuroinflammatory responses.Antagonizing RANTES slows down CNS disease progression in TBEV-infected micePrevious studies have demonstrated that TBEV induced significant alterations in brain physiology that appeared to closely parallel the pattern of RANTES expression.", [["CNS", "ANATOMY", 112, 115], ["CNS", "ANATOMY", 222, 225], ["brain", "ANATOMY", 347, 352], ["TBEV", "DISEASE", 48, 52], ["TBEV", "DISEASE", 307, 311], ["TBEV", "ORGANISM", 48, 52], ["RANTES", "GENE_OR_GENE_PRODUCT", 87, 93], ["CNS", "ANATOMICAL_SYSTEM", 112, 115], ["RANTES", "GENE_OR_GENE_PRODUCT", 204, 210], ["CNS", "ANATOMICAL_SYSTEM", 222, 225], ["TBEV", "ORGANISM", 249, 253], ["TBEV", "ORGANISM", 307, 311], ["brain", "ORGAN", 347, 352], ["RANTES", "GENE_OR_GENE_PRODUCT", 413, 419], ["RANTES", "PROTEIN", 87, 93], ["RANTES", "PROTEIN", 204, 210], ["RANTES", "PROTEIN", 413, 419], ["TBEV", "SPECIES", 48, 52], ["TBEV", "SPECIES", 249, 253], ["TBEV", "SPECIES", 307, 311], ["TBEV", "PROBLEM", 48, 52], ["a significant increase of RANTES production within CNS", "PROBLEM", 61, 115], ["the progression of neuroinflammatory responses", "PROBLEM", 144, 190], ["Antagonizing RANTES slows", "PROBLEM", 191, 216], ["CNS disease progression", "PROBLEM", 222, 245], ["TBEV", "PROBLEM", 249, 253], ["infected micePrevious studies", "TEST", 254, 283], ["TBEV", "PROBLEM", 307, 311], ["significant alterations in brain physiology", "PROBLEM", 320, 363], ["TBEV", "OBSERVATION", 48, 52], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["RANTES production", "OBSERVATION", 87, 104], ["likely related to", "UNCERTAINTY", 126, 143], ["progression", "OBSERVATION_MODIFIER", 148, 159], ["neuroinflammatory responses", "OBSERVATION", 163, 190], ["CNS", "ANATOMY", 222, 225], ["TBEV", "OBSERVATION", 307, 311], ["significant", "OBSERVATION_MODIFIER", 320, 331], ["alterations", "OBSERVATION", 332, 343], ["brain", "ANATOMY", 347, 352], ["RANTES expression", "OBSERVATION", 413, 430]]], ["To determine whether antagonizing the activity of this chemokine within CNS would affect disease progression, virus-infected mice were treated with either Met-RANTES or anti-RANTES mAb.", [["CNS", "ANATOMY", 72, 75], ["CNS", "ANATOMICAL_SYSTEM", 72, 75], ["mice", "ORGANISM", 125, 129], ["Met-RANTES", "SIMPLE_CHEMICAL", 155, 165], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 169, 184], ["chemokine", "PROTEIN", 55, 64], ["Met-RANTES", "PROTEIN", 155, 165], ["anti-RANTES mAb", "PROTEIN", 169, 184], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 125, 129], ["this chemokine", "TREATMENT", 50, 64], ["disease progression", "PROBLEM", 89, 108], ["virus", "PROBLEM", 110, 115], ["infected mice", "PROBLEM", 116, 129], ["anti-RANTES mAb", "TREATMENT", 169, 184]]], ["As shown in Fig. 4a , b, all infected vehicle, Met-RANTES, isotype control mAb, and anti-RANTES mAb-treated mice eventually succumbed to TBEV infection.", [["TBEV infection", "DISEASE", 137, 151], ["Met-RANTES", "SIMPLE_CHEMICAL", 47, 57], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 84, 99], ["mice", "ORGANISM", 108, 112], ["TBEV", "ORGANISM", 137, 141], ["Met-RANTES", "PROTEIN", 47, 57], ["isotype control mAb", "PROTEIN", 59, 78], ["anti-RANTES mAb", "PROTEIN", 84, 99], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["TBEV", "SPECIES", 137, 141], ["isotype control mAb", "TREATMENT", 59, 78], ["anti-RANTES mAb", "TREATMENT", 84, 99], ["TBEV infection", "PROBLEM", 137, 151], ["infected", "OBSERVATION", 29, 37], ["TBEV infection", "OBSERVATION", 137, 151]]], ["However, both Met-RANTES and anti-RANTES mAb-treated mice showed a significant delay in mean time to death after infection, compared with corresponding control groups.", [["death", "DISEASE", 101, 106], ["infection", "DISEASE", 113, 122], ["Met-RANTES", "SIMPLE_CHEMICAL", 14, 24], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 29, 44], ["mice", "ORGANISM", 53, 57], ["Met-RANTES", "PROTEIN", 14, 24], ["anti-RANTES mAb", "PROTEIN", 29, 44], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["anti-RANTES mAb", "TREATMENT", 29, 44], ["a significant delay", "PROBLEM", 65, 84], ["infection", "PROBLEM", 113, 122], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["delay", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 113, 122]]], ["The mean survival time for isotype control mAb-treated infected mice was approximately 7.1 days, while anti-RANTES mAb-treated mice succumbed to mortality later after infection (mean days until death, 10.0 days).", [["infection", "DISEASE", 167, 176], ["death", "DISEASE", 194, 199], ["mice", "ORGANISM", 64, 68], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 103, 118], ["mice", "ORGANISM", 127, 131], ["isotype control mAb", "PROTEIN", 27, 46], ["anti-RANTES mAb", "PROTEIN", 103, 118], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 127, 131], ["The mean survival time", "TREATMENT", 0, 22], ["isotype control mAb", "TREATMENT", 27, 46], ["anti-RANTES mAb", "TREATMENT", 103, 118], ["infection", "PROBLEM", 167, 176]]], ["TBEV-infected Met-RANTEStreated mice lived an average of approximately 4 days longer (mean days until death, 11.3), compared with virus- Fig. 3 TBEV infection induces RANTES production within the brain of mice. a Expression of 40 inflammatory factors in the mice brain detected by an inflammation Ab array assay.", [["brain", "ANATOMY", 196, 201], ["brain", "ANATOMY", 263, 268], ["death", "DISEASE", 102, 107], ["TBEV infection", "DISEASE", 144, 158], ["TBEV", "ORGANISM", 0, 4], ["Met-RANTEStreated mice", "ORGANISM", 14, 36], ["3 TBEV", "ORGANISM", 142, 148], ["RANTES", "GENE_OR_GENE_PRODUCT", 167, 173], ["brain", "ORGAN", 196, 201], ["mice", "ORGANISM", 205, 209], ["mice", "ORGANISM", 258, 262], ["brain", "ORGAN", 263, 268], ["RANTES", "PROTEIN", 167, 173], ["40 inflammatory factors", "PROTEIN", 227, 250], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 258, 262], ["TBEV", "SPECIES", 0, 4], ["mice", "SPECIES", 32, 36], ["TBEV", "SPECIES", 144, 148], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 258, 262], ["TBEV", "PROBLEM", 0, 4], ["death", "PROBLEM", 102, 107], ["TBEV infection", "PROBLEM", 144, 158], ["RANTES production", "PROBLEM", 167, 184], ["40 inflammatory factors in the mice brain", "PROBLEM", 227, 268], ["an inflammation Ab array assay", "TEST", 281, 311], ["infected", "OBSERVATION_MODIFIER", 5, 13], ["infection", "OBSERVATION", 149, 158], ["brain", "ANATOMY", 196, 201], ["inflammatory", "OBSERVATION_MODIFIER", 230, 242], ["mice brain", "ANATOMY", 258, 268], ["inflammation", "OBSERVATION", 284, 296]]], ["Representative photomicrographs demonstrate that TBEV infection stimulated RANTES (indicated by arrows) expression.", [["TBEV infection", "DISEASE", 49, 63], ["TBEV", "ORGANISM", 49, 53], ["RANTES", "GENE_OR_GENE_PRODUCT", 75, 81], ["RANTES", "PROTEIN", 75, 81], ["TBEV", "SPECIES", 49, 53], ["Representative photomicrographs", "TEST", 0, 31], ["TBEV infection stimulated RANTES", "PROBLEM", 49, 81], ["TBEV", "OBSERVATION_MODIFIER", 49, 53], ["infection", "OBSERVATION", 54, 63]]], ["Data shown are pooled from three independent experiments (n = 4 mice per group). b Time course of TBEV-induced stimulation of RANTES protein expression in different tissues.", [["tissues", "ANATOMY", 165, 172], ["mice", "ORGANISM", 64, 68], ["TBEV", "ORGANISM", 98, 102], ["RANTES", "GENE_OR_GENE_PRODUCT", 126, 132], ["tissues", "TISSUE", 165, 172], ["RANTES", "PROTEIN", 126, 132], ["mice", "SPECIES", 64, 68], ["TBEV", "SPECIES", 98, 102], ["TBEV-induced stimulation of RANTES protein expression", "TREATMENT", 98, 151], ["different tissues", "OBSERVATION_MODIFIER", 155, 172]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments (n = 4 mice per group).", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 91, 95]]], ["The fold changes in expression of RANTES in the brain of TBEV-infected mice were significantly higher when compared to those of the peripheral tissues and sera on days 3, 4, 5, and 8 p.i. ( * P < 0.05). c Fold changes of RANTES protein levels in the brain and serum of TBEV-infected adult mice.", [["brain", "ANATOMY", 48, 53], ["peripheral tissues", "ANATOMY", 132, 150], ["sera", "ANATOMY", 155, 159], ["brain", "ANATOMY", 250, 255], ["serum", "ANATOMY", 260, 265], ["RANTES", "GENE_OR_GENE_PRODUCT", 34, 40], ["brain", "ORGAN", 48, 53], ["TBEV", "ORGANISM", 57, 61], ["mice", "ORGANISM", 71, 75], ["peripheral tissues", "TISSUE", 132, 150], ["sera", "ORGANISM_SUBSTANCE", 155, 159], ["RANTES", "GENE_OR_GENE_PRODUCT", 221, 227], ["brain", "ORGAN", 250, 255], ["serum", "ORGANISM_SUBSTANCE", 260, 265], ["TBEV-infected adult mice", "ORGANISM", 269, 293], ["RANTES", "PROTEIN", 34, 40], ["RANTES", "PROTEIN", 221, 227], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 289, 293], ["TBEV", "SPECIES", 57, 61], ["mice", "SPECIES", 71, 75], ["TBEV", "SPECIES", 269, 273], ["mice", "SPECIES", 289, 293], ["The fold changes", "PROBLEM", 0, 16], ["TBEV", "PROBLEM", 57, 61], ["infected mice", "PROBLEM", 62, 75], ["sera", "TEST", 155, 159], ["RANTES protein levels", "TEST", 221, 242], ["TBEV", "TEST", 269, 273], ["fold", "OBSERVATION_MODIFIER", 4, 8], ["RANTES", "OBSERVATION", 34, 40], ["brain", "ANATOMY", 48, 53], ["TBEV", "OBSERVATION", 57, 61], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["mice", "OBSERVATION_MODIFIER", 71, 75], ["significantly", "OBSERVATION_MODIFIER", 81, 94], ["higher", "OBSERVATION_MODIFIER", 95, 101], ["peripheral tissues", "ANATOMY", 132, 150], ["RANTES", "OBSERVATION", 221, 227], ["brain", "ANATOMY", 250, 255]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments (n = 4 mice per group).", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 91, 95]]], ["The fold changes in expression of RANTES in the brain of TBEV-infected mice were significantly higher when compared to that of the sera on days 5, 8, and 11 p.i. ( * P < 0.05) infected vehicle-treated mice (mean days until death, 7.2).", [["brain", "ANATOMY", 48, 53], ["sera", "ANATOMY", 131, 135], ["death", "DISEASE", 223, 228], ["RANTES", "GENE_OR_GENE_PRODUCT", 34, 40], ["brain", "ORGAN", 48, 53], ["TBEV", "ORGANISM", 57, 61], ["mice", "ORGANISM", 71, 75], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["vehicle", "SIMPLE_CHEMICAL", 185, 192], ["mice", "ORGANISM", 201, 205], ["RANTES", "PROTEIN", 34, 40], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 201, 205], ["TBEV", "SPECIES", 57, 61], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 201, 205], ["The fold changes", "PROBLEM", 0, 16], ["TBEV", "PROBLEM", 57, 61], ["infected mice", "PROBLEM", 62, 75], ["death", "PROBLEM", 223, 228], ["fold", "OBSERVATION_MODIFIER", 4, 8], ["RANTES", "OBSERVATION", 34, 40], ["brain", "ANATOMY", 48, 53], ["TBEV", "OBSERVATION", 57, 61], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["significantly", "OBSERVATION_MODIFIER", 81, 94], ["higher", "OBSERVATION_MODIFIER", 95, 101]]], ["Moreover, TBEV-infected mice treated with Met-RANTES (Fig. 4c) or anti-RANTES mAb (Fig. 4d) exhibited delayed growth retardation, compared with virus-infected vehicleor isotype Ab-treated animals, respectively.", [["TBEV-infected", "DISEASE", 10, 23], ["growth retardation", "DISEASE", 110, 128], ["TBEV", "ORGANISM", 10, 14], ["mice", "ORGANISM", 24, 28], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 66, 81], ["vehicleor", "ORGANISM", 159, 168], ["Ab", "GENE_OR_GENE_PRODUCT", 177, 179], ["Met-RANTES", "PROTEIN", 42, 52], ["anti-RANTES mAb", "PROTEIN", 66, 81], ["vehicleor isotype Ab", "PROTEIN", 159, 179], ["mice", "SPECIES", 24, 28], ["TBEV", "SPECIES", 10, 14], ["mice", "SPECIES", 24, 28], ["TBEV", "TEST", 10, 14], ["Met-RANTES (Fig. 4c", "TREATMENT", 42, 61], ["anti-RANTES mAb", "TREATMENT", 66, 81], ["delayed growth retardation", "PROBLEM", 102, 128], ["virus", "PROBLEM", 144, 149], ["infected vehicleor isotype Ab", "TREATMENT", 150, 179], ["growth retardation", "OBSERVATION", 110, 128]]], ["The intensity of symptoms increased gradually up to a moribund state, at a much slower rate for TBEV-infected mice treated with Met-RANTES or anti-RANTES mAb, compared with vehicle-or isotype Ab-injected animals, respectively (data not shown).", [["TBEV-infected", "DISEASE", 96, 109], ["Met-RANTES", "CHEMICAL", 128, 138], ["TBEV", "ORGANISM", 96, 100], ["mice", "ORGANISM", 110, 114], ["Met-RANTES", "SIMPLE_CHEMICAL", 128, 138], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 142, 157], ["Ab", "GENE_OR_GENE_PRODUCT", 192, 194], ["Met-RANTES", "PROTEIN", 128, 138], ["anti-RANTES mAb", "PROTEIN", 142, 157], ["isotype Ab", "PROTEIN", 184, 194], ["mice", "SPECIES", 110, 114], ["TBEV", "SPECIES", 96, 100], ["mice", "SPECIES", 110, 114], ["symptoms", "PROBLEM", 17, 25], ["TBEV", "PROBLEM", 96, 100], ["Met-RANTES", "TREATMENT", 128, 138], ["anti-RANTES mAb", "TREATMENT", 142, 157], ["isotype Ab", "TEST", 184, 194], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["gradually", "OBSERVATION_MODIFIER", 36, 45]]], ["These results suggest that antagonizing RANTES within CNS affects disease progression following lethal ic challenge with TBEV.Antagonizing RANTES slows down CNS disease progression in TBEV-infected miceIn an effort to identify the potential contributing factors to the enhanced survival of anti-RANTES-treated mice, we assess virus replication in the brain of infected mice.", [["CNS", "ANATOMY", 54, 57], ["CNS", "ANATOMY", 157, 160], ["brain", "ANATOMY", 351, 356], ["TBEV", "DISEASE", 121, 125], ["TBEV-infected", "DISEASE", 184, 197], ["anti-RANTES", "CHEMICAL", 290, 301], ["RANTES", "GENE_OR_GENE_PRODUCT", 40, 46], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["TBEV", "ORGANISM", 121, 125], ["RANTES", "GENE_OR_GENE_PRODUCT", 139, 145], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["TBEV", "ORGANISM", 184, 188], ["anti-RANTES", "SIMPLE_CHEMICAL", 290, 301], ["mice", "ORGANISM", 310, 314], ["brain", "ORGAN", 351, 356], ["mice", "ORGANISM", 369, 373], ["RANTES", "PROTEIN", 40, 46], ["RANTES", "PROTEIN", 139, 145], ["anti-RANTES", "PROTEIN", 290, 301], ["mice", "SPECIES", 310, 314], ["mice", "SPECIES", 369, 373], ["TBEV", "SPECIES", 121, 125], ["TBEV", "SPECIES", 184, 188], ["mice", "SPECIES", 310, 314], ["mice", "SPECIES", 369, 373], ["antagonizing RANTES", "PROBLEM", 27, 46], ["disease progression", "PROBLEM", 66, 85], ["lethal ic challenge", "TREATMENT", 96, 115], ["Antagonizing RANTES", "PROBLEM", 126, 145], ["CNS disease progression", "PROBLEM", 157, 180], ["TBEV", "PROBLEM", 184, 188], ["anti-RANTES", "TREATMENT", 290, 301], ["virus replication", "TREATMENT", 326, 343], ["CNS", "ANATOMY", 157, 160], ["disease", "OBSERVATION", 161, 168], ["brain", "ANATOMY", 351, 356], ["infected mice", "OBSERVATION", 360, 373]]], ["As shown in Fig. 4e , no significant difference was observed in TBEV titer recovered from the brain of Met-RANTES-treated mice compared with that in vehicle- Fig. 4 Antagonizing RANTES within CNS extends the survival of mice after TBEV infection.", [["brain", "ANATOMY", 94, 99], ["CNS", "ANATOMY", 192, 195], ["Met-RANTES", "CHEMICAL", 103, 113], ["TBEV infection", "DISEASE", 231, 245], ["TBEV", "ORGANISM", 64, 68], ["brain", "ORGAN", 94, 99], ["Met-RANTES", "SIMPLE_CHEMICAL", 103, 113], ["mice", "ORGANISM", 122, 126], ["RANTES", "GENE_OR_GENE_PRODUCT", 178, 184], ["CNS", "ANATOMICAL_SYSTEM", 192, 195], ["mice", "ORGANISM", 220, 224], ["TBEV", "ORGANISM", 231, 235], ["RANTES", "PROTEIN", 178, 184], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 220, 224], ["TBEV", "SPECIES", 64, 68], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 220, 224], ["TBEV", "SPECIES", 231, 235], ["significant difference", "PROBLEM", 25, 47], ["TBEV titer", "TEST", 64, 74], ["TBEV infection", "PROBLEM", 231, 245], ["brain", "ANATOMY", 94, 99], ["infection", "OBSERVATION", 236, 245]]], ["Mice were treated with Met-RANTES, vehicle, anti-RANTES mAb, or isotype-matched control Ab daily from day 2 to 8 after a primary TBEV infection. a Met-RANTES-treated mice exhibited a delay in mortality following lethal TBEV challenge.", [["Met-RANTES", "CHEMICAL", 23, 33], ["TBEV infection", "DISEASE", 129, 143], ["Met-RANTES", "CHEMICAL", 147, 157], ["TBEV", "DISEASE", 219, 223], ["Met-RANTES", "CHEMICAL", 23, 33], ["Mice", "ORGANISM", 0, 4], ["Met-RANTES", "SIMPLE_CHEMICAL", 23, 33], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 44, 59], ["TBEV", "ORGANISM", 129, 133], ["Met-RANTES", "SIMPLE_CHEMICAL", 147, 157], ["mice", "ORGANISM", 166, 170], ["anti-RANTES mAb", "PROTEIN", 44, 59], ["isotype", "PROTEIN", 64, 71], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 166, 170], ["TBEV", "SPECIES", 129, 133], ["mice", "SPECIES", 166, 170], ["TBEV", "SPECIES", 219, 223], ["Met-RANTES", "TREATMENT", 23, 33], ["vehicle", "TREATMENT", 35, 42], ["anti-RANTES mAb", "TREATMENT", 44, 59], ["isotype-matched control", "TREATMENT", 64, 87], ["a primary TBEV infection", "PROBLEM", 119, 143], ["a delay in mortality", "PROBLEM", 181, 201], ["lethal TBEV challenge", "TREATMENT", 212, 233], ["infection", "OBSERVATION", 134, 143]]], ["Data were pooled from three independent experiments (total of approximately 18 mice per group).", [["mice", "ORGANISM", 79, 83], ["mice", "SPECIES", 79, 83]]], ["Statistical differences were evaluated using the Kaplan-Meier test for mortality.", [["Meier test", "TEST", 56, 66]]], ["P < 0.05, compared to isotype Ab-treated mice. c, d Body weight changes of mice were monitored daily.", [["Ab", "GENE_OR_GENE_PRODUCT", 30, 32], ["mice", "ORGANISM", 41, 45], ["c", "GENE_OR_GENE_PRODUCT", 47, 48], ["mice", "ORGANISM", 75, 79], ["isotype Ab", "PROTEIN", 22, 32], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 75, 79], ["P", "TEST", 0, 1], ["isotype Ab", "TEST", 22, 32], ["d Body weight changes", "TEST", 50, 71], ["Body", "ANATOMY_MODIFIER", 52, 56]]], ["For each time point, the measured values are the average of the surviving mice.", [["mice", "ORGANISM", 74, 78], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments (total of approximately 18 mice per group). e Infectious virus in brain tissues.", [["brain tissues", "ANATOMY", 150, 163], ["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 111, 115], ["brain tissues", "TISSUE", 150, 163], ["mice", "SPECIES", 111, 115], ["Infectious virus", "SPECIES", 130, 146], ["e Infectious virus in brain tissues", "PROBLEM", 128, 163], ["Infectious", "OBSERVATION_MODIFIER", 130, 140], ["virus", "OBSERVATION", 141, 146], ["brain tissues", "ANATOMY", 150, 163]]], ["No significant difference in virus titers was observed at day 2, 5, or 8 between Met-RANTES-treated mice and vehicleinjected mice or anti-RANTES mAb-treated and isotype Ab-injected mice.", [["Met-RANTES", "CHEMICAL", 81, 91], ["anti-RANTES", "CHEMICAL", 133, 144], ["Met-RANTES", "SIMPLE_CHEMICAL", 81, 91], ["mice", "ORGANISM", 100, 104], ["mice", "ORGANISM", 125, 129], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 133, 148], ["Ab", "GENE_OR_GENE_PRODUCT", 169, 171], ["mice", "ORGANISM", 181, 185], ["anti-RANTES mAb", "PROTEIN", 133, 148], ["isotype Ab", "PROTEIN", 161, 171], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 181, 185], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 181, 185], ["significant difference in virus titers", "PROBLEM", 3, 41], ["Met-RANTES", "TEST", 81, 91], ["vehicleinjected mice", "TREATMENT", 109, 129], ["anti-RANTES mAb", "TREATMENT", 133, 148], ["isotype Ab", "TREATMENT", 161, 171], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["virus titers", "OBSERVATION", 29, 41]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments (n = 4 mice per group).", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 91, 95]]], ["NS not significant. f Met-RANTES or anti-RANTES mAb treatment reduced inflammatory cell accumulation (indicated by black arrows) in cerebral cortex sections, compared to results for vehicle-or isotype Ab-treated mice, respectively.", [["inflammatory cell", "ANATOMY", 70, 87], ["cerebral cortex sections", "ANATOMY", 132, 156], ["f Met-RANTES", "SIMPLE_CHEMICAL", 20, 32], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 36, 51], ["inflammatory cell", "CELL", 70, 87], ["cerebral cortex sections", "MULTI-TISSUE_STRUCTURE", 132, 156], ["vehicle", "SIMPLE_CHEMICAL", 182, 189], ["Ab", "GENE_OR_GENE_PRODUCT", 201, 203], ["mice", "ORGANISM", 212, 216], ["anti-RANTES mAb", "PROTEIN", 36, 51], ["isotype Ab", "PROTEIN", 193, 203], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["NS", "TREATMENT", 0, 2], ["Met-RANTES", "TREATMENT", 22, 32], ["anti-RANTES mAb treatment", "TREATMENT", 36, 61], ["inflammatory cell accumulation", "PROBLEM", 70, 100], ["black arrows) in cerebral cortex sections", "PROBLEM", 115, 156], ["vehicle", "TEST", 182, 189], ["isotype Ab", "TREATMENT", 193, 203], ["not", "UNCERTAINTY", 3, 6], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["inflammatory cell accumulation", "OBSERVATION", 70, 100], ["cerebral cortex", "ANATOMY", 132, 147]]], ["The histopathological changes of PFA-fixed sections in cerebral cortex were examined by HE staining on day 8 p.i.", [["sections", "ANATOMY", 43, 51], ["cerebral cortex", "ANATOMY", 55, 70], ["PFA", "CHEMICAL", 33, 36], ["PFA", "SIMPLE_CHEMICAL", 33, 36], ["sections", "MULTI-TISSUE_STRUCTURE", 43, 51], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 55, 70], ["The histopathological changes", "PROBLEM", 0, 29], ["PFA", "TEST", 33, 36], ["fixed sections in cerebral cortex", "PROBLEM", 37, 70], ["PFA", "OBSERVATION_MODIFIER", 33, 36], ["fixed sections", "OBSERVATION", 37, 51], ["cerebral cortex", "ANATOMY", 55, 70]]], ["The photomicrographs demonstrate representative images obtained from three independent experiments (n = 4 mice per group).", [["mice", "ORGANISM", 106, 110], ["mice", "SPECIES", 106, 110], ["The photomicrographs", "TEST", 0, 20], ["representative images", "TEST", 33, 54]]], ["Bars, 100 \u03bcm injected mice.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 22, 26], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26]]], ["On day 2, 5, and 8 p.i., virus titers in brain tissue were also similar between the infected anti-RANTES mAb-treated and isotype Ab-treated groups.", [["brain tissue", "ANATOMY", 41, 53], ["anti-RANTES", "CHEMICAL", 93, 104], ["brain tissue", "TISSUE", 41, 53], ["mAb", "GENE_OR_GENE_PRODUCT", 105, 108], ["anti-RANTES mAb", "PROTEIN", 93, 108], ["isotype Ab", "PROTEIN", 121, 131], ["virus titers in brain tissue", "PROBLEM", 25, 53], ["the infected anti-RANTES mAb", "TREATMENT", 80, 108], ["isotype Ab", "TREATMENT", 121, 131], ["brain tissue", "ANATOMY", 41, 53], ["infected", "OBSERVATION_MODIFIER", 84, 92]]], ["Morphologically, treatment of TBEV-infected mice with either RANTES receptor antagonist Met-RANTES or anti-RANTES mAb resulted in a significant decrease in local infiltration of inflammatory cells.", [["inflammatory cells", "ANATOMY", 178, 196], ["TBEV-infected", "DISEASE", 30, 43], ["Met-RANTES", "CHEMICAL", 88, 98], ["TBEV", "ORGANISM", 30, 34], ["mice", "ORGANISM", 44, 48], ["RANTES", "GENE_OR_GENE_PRODUCT", 61, 67], ["Met-RANTES", "SIMPLE_CHEMICAL", 88, 98], ["anti-RANTES mAb", "SIMPLE_CHEMICAL", 102, 117], ["cells", "CELL", 191, 196], ["RANTES receptor", "PROTEIN", 61, 76], ["anti-RANTES mAb", "PROTEIN", 102, 117], ["inflammatory cells", "CELL_TYPE", 178, 196], ["mice", "SPECIES", 44, 48], ["TBEV", "SPECIES", 30, 34], ["mice", "SPECIES", 44, 48], ["TBEV", "PROBLEM", 30, 34], ["infected mice", "TREATMENT", 35, 48], ["RANTES receptor antagonist Met-RANTES", "TREATMENT", 61, 98], ["anti-RANTES mAb", "TREATMENT", 102, 117], ["a significant decrease in local infiltration of inflammatory cells", "PROBLEM", 130, 196], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["decrease", "OBSERVATION_MODIFIER", 144, 152], ["local", "OBSERVATION_MODIFIER", 156, 161], ["infiltration", "OBSERVATION", 162, 174], ["inflammatory cells", "OBSERVATION", 178, 196]]], ["In addition, less severe perivascular cuffing and hemorrhage within brains after Met-RANTES or anti-RANTES mAb administration, compared to the pathological manifestations present within the cerebral cortex of vehicle or isotype Ab-treated mice was found (Fig. 4f) .", [["perivascular", "ANATOMY", 25, 37], ["brains", "ANATOMY", 68, 74], ["cerebral cortex", "ANATOMY", 190, 205], ["hemorrhage", "DISEASE", 50, 60], ["Met-RANTES", "CHEMICAL", 81, 91], ["perivascular cuffing", "PATHOLOGICAL_FORMATION", 25, 45], ["brains", "ORGAN", 68, 74], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 95, 110], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 190, 205], ["Ab", "GENE_OR_GENE_PRODUCT", 228, 230], ["mice", "ORGANISM", 239, 243], ["anti-RANTES mAb", "PROTEIN", 95, 110], ["isotype Ab", "PROTEIN", 220, 230], ["mice", "SPECIES", 239, 243], ["mice", "SPECIES", 239, 243], ["less severe perivascular cuffing", "PROBLEM", 13, 45], ["hemorrhage within brains", "PROBLEM", 50, 74], ["Met-RANTES", "TREATMENT", 81, 91], ["anti-RANTES mAb administration", "TREATMENT", 95, 125], ["the pathological manifestations", "PROBLEM", 139, 170], ["less", "OBSERVATION_MODIFIER", 13, 17], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["perivascular", "ANATOMY_MODIFIER", 25, 37], ["cuffing", "OBSERVATION", 38, 45], ["hemorrhage", "OBSERVATION", 50, 60], ["brains", "ANATOMY", 68, 74], ["cerebral cortex", "ANATOMY", 190, 205]]], ["Therefore, it is likely that blockade of RANTES within CNS reduced accumulation of infiltrating cells and extended the survival of mice after TBEV infection.", [["CNS", "ANATOMY", 55, 58], ["infiltrating cells", "ANATOMY", 83, 101], ["TBEV infection", "DISEASE", 142, 156], ["RANTES", "GENE_OR_GENE_PRODUCT", 41, 47], ["CNS", "ANATOMICAL_SYSTEM", 55, 58], ["cells", "CELL", 96, 101], ["mice", "ORGANISM", 131, 135], ["TBEV", "ORGANISM", 142, 146], ["RANTES", "PROTEIN", 41, 47], ["infiltrating cells", "CELL_TYPE", 83, 101], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["TBEV", "SPECIES", 142, 146], ["blockade of RANTES", "PROBLEM", 29, 47], ["infiltrating cells", "PROBLEM", 83, 101], ["TBEV infection", "PROBLEM", 142, 156], ["is likely", "UNCERTAINTY", 14, 23], ["RANTES", "OBSERVATION", 41, 47], ["infiltrating cells", "OBSERVATION", 83, 101], ["infection", "OBSERVATION", 147, 156]]], ["Overall, our data highlight a potential role for RANTES within CNS in affecting neuroinflammation during TBEV infection.TBEV up-regulates RANTES production in human brain-derived cellsThe primary target of TBEV is the brain.", [["CNS", "ANATOMY", 63, 66], ["brain-derived cells", "ANATOMY", 165, 184], ["brain", "ANATOMY", 218, 223], ["neuroinflammation", "DISEASE", 80, 97], ["TBEV infection", "DISEASE", 105, 119], ["RANTES", "GENE_OR_GENE_PRODUCT", 49, 55], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["TBEV", "ORGANISM", 105, 109], ["TBEV", "ORGANISM", 120, 124], ["RANTES", "GENE_OR_GENE_PRODUCT", 138, 144], ["human", "ORGANISM", 159, 164], ["brain-derived cells", "CELL", 165, 184], ["TBEV", "ORGANISM", 206, 210], ["brain", "ORGAN", 218, 223], ["RANTES", "PROTEIN", 49, 55], ["RANTES", "PROTEIN", 138, 144], ["human brain-derived cells", "CELL_TYPE", 159, 184], ["human", "SPECIES", 159, 164], ["TBEV", "SPECIES", 105, 109], ["TBEV", "SPECIES", 120, 124], ["human", "SPECIES", 159, 164], ["TBEV", "SPECIES", 206, 210], ["our data", "TEST", 9, 17], ["RANTES within CNS", "PROBLEM", 49, 66], ["neuroinflammation", "PROBLEM", 80, 97], ["TBEV infection", "PROBLEM", 105, 119], ["TBEV", "TEST", 120, 124], ["RANTES production in human brain", "PROBLEM", 138, 170], ["TBEV infection", "OBSERVATION", 105, 119], ["brain", "ANATOMY", 165, 170], ["TBEV", "OBSERVATION", 206, 210], ["brain", "ANATOMY", 218, 223]]], ["To investigate the mechanism by which TBEV induces RANTES in the CNS, the ability of TBEV infection to trigger RANTES expression in human brain-derived cell lines was assessed.", [["CNS", "ANATOMY", 65, 68], ["brain-derived cell lines", "ANATOMY", 138, 162], ["TBEV infection", "DISEASE", 85, 99], ["TBEV", "ORGANISM", 38, 42], ["RANTES", "GENE_OR_GENE_PRODUCT", 51, 57], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["TBEV", "ORGANISM", 85, 89], ["RANTES", "GENE_OR_GENE_PRODUCT", 111, 117], ["human", "ORGANISM", 132, 137], ["brain-derived cell lines", "CELL", 138, 162], ["RANTES", "PROTEIN", 51, 57], ["RANTES", "PROTEIN", 111, 117], ["human brain-derived cell lines", "CELL_LINE", 132, 162], ["human", "SPECIES", 132, 137], ["TBEV", "SPECIES", 38, 42], ["TBEV", "SPECIES", 85, 89], ["human", "SPECIES", 132, 137], ["TBEV infection", "PROBLEM", 85, 99], ["RANTES expression in human brain", "PROBLEM", 111, 143], ["derived cell lines", "TREATMENT", 144, 162], ["CNS", "ANATOMY", 65, 68], ["cell lines", "OBSERVATION", 152, 162]]], ["TBEV significantly induced RANTES production both at the messenger RNA (mRNA) and protein levels in human glioblastoma cells T98G at 24 h p.i. and reached a high level at 72 h p.i. compared with mock-infected controls (Fig. 5a, b) .", [["glioblastoma cells T98G", "ANATOMY", 106, 129], ["glioblastoma", "DISEASE", 106, 118], ["TBEV", "ORGANISM", 0, 4], ["RANTES", "GENE_OR_GENE_PRODUCT", 27, 33], ["human", "ORGANISM", 100, 105], ["glioblastoma cells T98G", "CELL", 106, 129], ["RANTES", "PROTEIN", 27, 33], ["messenger RNA", "RNA", 57, 70], ["mRNA", "RNA", 72, 76], ["human glioblastoma cells T98G", "CELL_LINE", 100, 129], ["human", "SPECIES", 100, 105], ["TBEV", "SPECIES", 0, 4], ["human", "SPECIES", 100, 105], ["TBEV significantly induced RANTES production", "PROBLEM", 0, 44], ["protein levels", "TEST", 82, 96], ["human glioblastoma cells T98G", "TREATMENT", 100, 129], ["RANTES production", "OBSERVATION", 27, 44], ["glioblastoma cells", "OBSERVATION", 106, 124], ["infected", "OBSERVATION", 200, 208]]], ["Human astrocytoma cells CCF-STTG1 and neuroblastoma cells SK-N-SH were also capable of significantly expressing RANTES in response to TBEV infection, but the level of RANTES expression was generally much lower than that in T98G cells (Fig. 5c-f ).", [["astrocytoma cells CCF-STTG1", "ANATOMY", 6, 33], ["neuroblastoma cells", "ANATOMY", 38, 57], ["T98G cells", "ANATOMY", 223, 233], ["astrocytoma", "DISEASE", 6, 17], ["TBEV infection", "DISEASE", 134, 148], ["Human", "ORGANISM", 0, 5], ["astrocytoma cells", "CELL", 6, 23], ["CCF-STTG1", "CELL", 24, 33], ["neuroblastoma cells SK-N-SH", "CELL", 38, 65], ["RANTES", "GENE_OR_GENE_PRODUCT", 112, 118], ["TBEV", "ORGANISM", 134, 138], ["RANTES", "GENE_OR_GENE_PRODUCT", 167, 173], ["T98G cells", "CELL", 223, 233], ["Human astrocytoma cells CCF", "CELL_LINE", 0, 27], ["STTG1", "CELL_LINE", 28, 33], ["neuroblastoma cells", "CELL_LINE", 38, 57], ["SK-N-SH", "CELL_LINE", 58, 65], ["RANTES", "PROTEIN", 112, 118], ["RANTES", "PROTEIN", 167, 173], ["T98G cells", "CELL_LINE", 223, 233], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["TBEV", "SPECIES", 134, 138], ["Human astrocytoma cells", "PROBLEM", 0, 23], ["CCF", "TEST", 24, 27], ["STTG1", "PROBLEM", 28, 33], ["neuroblastoma cells", "PROBLEM", 38, 57], ["SK", "TEST", 58, 60], ["TBEV infection", "PROBLEM", 134, 148], ["RANTES expression", "TEST", 167, 184], ["astrocytoma cells", "OBSERVATION", 6, 23], ["neuroblastoma cells", "OBSERVATION", 38, 57], ["TBEV infection", "OBSERVATION", 134, 148]]], ["To examine whether TBEV infection induces RANTES expression in primary CNS cells, further experiments were conducted using HPDAs as a model.", [["primary CNS cells", "ANATOMY", 63, 80], ["TBEV infection", "DISEASE", 19, 33], ["TBEV", "ORGANISM", 19, 23], ["RANTES", "GENE_OR_GENE_PRODUCT", 42, 48], ["CNS cells", "CELL", 71, 80], ["HPDAs", "SIMPLE_CHEMICAL", 123, 128], ["RANTES", "PROTEIN", 42, 48], ["primary CNS cells", "CELL_TYPE", 63, 80], ["TBEV", "SPECIES", 19, 23], ["TBEV infection", "PROBLEM", 19, 33], ["RANTES expression in primary CNS cells", "PROBLEM", 42, 80], ["further experiments", "TEST", 82, 101]]], ["RANTES transcription was induced by TBEV infection, with the increase started at 24 h p.i. and peaked at 72 h p.i.", [["TBEV infection", "DISEASE", 36, 50], ["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["TBEV", "ORGANISM", 36, 40], ["RANTES", "PROTEIN", 0, 6], ["TBEV", "SPECIES", 36, 40], ["RANTES transcription", "TREATMENT", 0, 20], ["TBEV infection", "PROBLEM", 36, 50], ["TBEV infection", "OBSERVATION", 36, 50]]], ["The protein levels of RANTES reached the peak at 72 h p.i., and the pattern was similar to that of the three cell lines described above (Fig. 5h) .", [["cell lines", "ANATOMY", 109, 119], ["RANTES", "GENE_OR_GENE_PRODUCT", 22, 28], ["cell lines", "CELL", 109, 119], ["RANTES", "PROTEIN", 22, 28], ["cell lines", "CELL_LINE", 109, 119], ["The protein levels", "TEST", 0, 18], ["RANTES", "TEST", 22, 28], ["the three cell lines", "TREATMENT", 99, 119], ["three cell lines", "OBSERVATION", 103, 119]]], ["In tested virus-infected brain cells, the upregulation of RANTES gene expression by TBEV was likely replication dependent, since UV inactivation dramatically impaired the ability of TBEV to induce RANTES mRNA expression and protein secretion.", [["brain cells", "ANATOMY", 25, 36], ["brain cells", "CELL", 25, 36], ["RANTES", "GENE_OR_GENE_PRODUCT", 58, 64], ["TBEV", "ORGANISM", 84, 88], ["TBEV", "ORGANISM", 182, 186], ["RANTES", "GENE_OR_GENE_PRODUCT", 197, 203], ["infected brain cells", "CELL_TYPE", 16, 36], ["RANTES gene", "DNA", 58, 69], ["RANTES mRNA", "RNA", 197, 208], ["TBEV", "SPECIES", 84, 88], ["TBEV", "SPECIES", 182, 186], ["infected brain cells", "PROBLEM", 16, 36], ["RANTES gene expression", "TREATMENT", 58, 80], ["TBEV", "PROBLEM", 84, 88], ["replication dependent", "PROBLEM", 100, 121], ["UV inactivation", "PROBLEM", 129, 144], ["RANTES mRNA expression and protein secretion", "PROBLEM", 197, 241], ["virus", "OBSERVATION", 10, 15], ["infected brain cells", "OBSERVATION", 16, 36], ["protein secretion", "OBSERVATION", 224, 241]]], ["To reveal the kinetics of virus replication, virus titers were measured for the indicated time points by TCID 50 assay.", [["virus replication", "TREATMENT", 26, 43], ["virus titers", "TEST", 45, 57], ["virus replication", "OBSERVATION", 26, 43]]], ["As shown in Fig. 5i , TBEV replicated efficiently in all cell lines tested.", [["cell lines", "ANATOMY", 57, 67], ["TBEV", "ORGANISM", 22, 26], ["cell lines", "CELL", 57, 67], ["cell lines", "CELL_LINE", 57, 67], ["TBEV", "SPECIES", 22, 26], ["TBEV", "PROBLEM", 22, 26], ["all cell lines", "TREATMENT", 53, 67], ["cell lines", "OBSERVATION", 57, 67]]], ["Increasing titers of infectious virus were observed after 24 h p.i., and the maximum titer of virus was attained after 72 h p.i.", [["Increasing titers of infectious virus", "PROBLEM", 0, 37], ["virus", "PROBLEM", 94, 99], ["titers", "OBSERVATION_MODIFIER", 11, 17], ["infectious virus", "OBSERVATION", 21, 37]]], ["Given the above-described RANTES expression profile, its production appeared to be significantly induced at time points that coincided with significant virus replication in human brain-derived cells.", [["brain-derived cells", "ANATOMY", 179, 198], ["RANTES", "GENE_OR_GENE_PRODUCT", 26, 32], ["human", "ORGANISM", 173, 178], ["brain-derived cells", "CELL", 179, 198], ["RANTES", "PROTEIN", 26, 32], ["human brain-derived cells", "CELL_TYPE", 173, 198], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["significant virus replication in human brain", "PROBLEM", 140, 184], ["significant", "OBSERVATION_MODIFIER", 140, 151], ["virus", "OBSERVATION", 152, 157]]], ["It was also found that viral replication was coupled to RANTES upregulation in alveolar epithelial A549 cells (Additional file 1: Figure S1A -C).", [["alveolar epithelial A549 cells", "ANATOMY", 79, 109], ["RANTES", "GENE_OR_GENE_PRODUCT", 56, 62], ["alveolar epithelial A549 cells", "CELL", 79, 109], ["RANTES", "PROTEIN", 56, 62], ["alveolar epithelial A549 cells", "CELL_LINE", 79, 109], ["viral replication", "PROBLEM", 23, 40], ["RANTES upregulation", "TEST", 56, 75], ["alveolar epithelial A549 cells", "PROBLEM", 79, 109], ["viral replication", "OBSERVATION", 23, 40], ["alveolar", "ANATOMY_MODIFIER", 79, 87], ["epithelial", "ANATOMY_MODIFIER", 88, 98], ["A549 cells", "OBSERVATION", 99, 109]]], ["However, though TBEV could replicate in human monocytic cell line THP-1, RANTES production was not significantly induced after infection of this cell line, demonstrating a cell type-specific pattern of RANTES production (Additional file 1: Figure S1D -F).", [["monocytic cell line", "ANATOMY", 46, 65], ["cell line", "ANATOMY", 145, 154], ["cell", "ANATOMY", 172, 176], ["TBEV", "ORGANISM", 16, 20], ["human", "ORGANISM", 40, 45], ["monocytic cell line THP-1", "CELL", 46, 71], ["RANTES", "GENE_OR_GENE_PRODUCT", 73, 79], ["cell line", "CELL", 145, 154], ["cell", "CELL", 172, 176], ["RANTES", "GENE_OR_GENE_PRODUCT", 202, 208], ["human monocytic cell line THP-1", "CELL_LINE", 40, 71], ["RANTES", "PROTEIN", 73, 79], ["RANTES", "PROTEIN", 202, 208], ["human", "SPECIES", 40, 45], ["TBEV", "SPECIES", 16, 20], ["human", "SPECIES", 40, 45], ["TBEV", "PROBLEM", 16, 20], ["THP", "TEST", 66, 69], ["RANTES production", "PROBLEM", 73, 90], ["infection of this cell line", "PROBLEM", 127, 154], ["RANTES production", "PROBLEM", 202, 219], ["TBEV", "OBSERVATION", 16, 20], ["monocytic cell line", "OBSERVATION", 46, 65], ["cell line", "OBSERVATION", 145, 154], ["RANTES", "OBSERVATION", 202, 208]]], ["To conclude, the human brain cells are capable of significantly producing RANTES upon TBEV infection, although the level of induced RANTES may vary depending on the cell type.TBEV up-regulates RANTES production in human brain-derived cellsWe further determined the chemotactic activity of the secreted RANTES from TBEV-infected T98G cells using a transwell migration assay.", [["brain cells", "ANATOMY", 23, 34], ["cell", "ANATOMY", 165, 169], ["brain-derived cells", "ANATOMY", 220, 239], ["T98G cells", "ANATOMY", 328, 338], ["TBEV infection", "DISEASE", 86, 100], ["human", "ORGANISM", 17, 22], ["brain cells", "CELL", 23, 34], ["RANTES", "GENE_OR_GENE_PRODUCT", 74, 80], ["TBEV", "ORGANISM", 86, 90], ["RANTES", "GENE_OR_GENE_PRODUCT", 132, 138], ["cell type", "CELL", 165, 174], ["TBEV", "ORGANISM", 175, 179], ["RANTES", "GENE_OR_GENE_PRODUCT", 193, 199], ["human", "ORGANISM", 214, 219], ["brain-derived cells", "CELL", 220, 239], ["RANTES", "GENE_OR_GENE_PRODUCT", 302, 308], ["TBEV", "ORGANISM", 314, 318], ["T98G cells", "CELL", 328, 338], ["human brain cells", "CELL_TYPE", 17, 34], ["RANTES", "PROTEIN", 74, 80], ["RANTES", "PROTEIN", 132, 138], ["RANTES", "PROTEIN", 193, 199], ["human brain-derived cells", "CELL_TYPE", 214, 239], ["RANTES", "PROTEIN", 302, 308], ["TBEV-infected T98G cells", "CELL_LINE", 314, 338], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 17, 22], ["TBEV", "SPECIES", 86, 90], ["TBEV", "SPECIES", 175, 179], ["human", "SPECIES", 214, 219], ["TBEV", "SPECIES", 314, 318], ["TBEV infection", "PROBLEM", 86, 100], ["induced RANTES", "PROBLEM", 124, 138], ["TBEV", "TEST", 175, 179], ["RANTES production in human brain", "PROBLEM", 193, 225], ["TBEV", "PROBLEM", 314, 318], ["infected T98G cells", "TREATMENT", 319, 338], ["a transwell migration assay", "TEST", 345, 372], ["TBEV infection", "OBSERVATION", 86, 100], ["cell type", "OBSERVATION", 165, 174], ["brain", "ANATOMY", 220, 225], ["chemotactic activity", "OBSERVATION_MODIFIER", 265, 285], ["T98G cells", "OBSERVATION", 328, 338], ["transwell migration", "OBSERVATION", 347, 366]]], ["Supernatants from these cultures were more potent in chemoattracting THP-1 cells, compared with those from uninfected control cells.", [["Supernatants", "ANATOMY", 0, 12], ["cultures", "ANATOMY", 24, 32], ["THP-1 cells", "ANATOMY", 69, 80], ["cells", "ANATOMY", 126, 131], ["Supernatants", "CELL", 0, 12], ["THP-1 cells", "CELL", 69, 80], ["cells", "CELL", 126, 131], ["chemoattracting THP-1 cells", "CELL_LINE", 53, 80], ["uninfected control cells", "CELL_TYPE", 107, 131], ["these cultures", "TEST", 18, 32]]], ["Notably, the chemoattractant activities of these conditioned medium were largely reduced when incubated with anti-hRANTES Ab, suggesting that RANTES is a functionally active chemotactic component secreted by TBEV-infected T98G cells (Fig. 5j) .TBEV-induced RANTES expression is mediated through transactivation of RANTES promoterTo determine whether TBEV infection transactivates the RANTES promoter, a reporter plasmid pGL-220 which contains the sequence from nucleotides \u2212220 to \u221255 (relative to the mRNA start site) was co-transfected with pRL-TK into T98G cells, followed by TBEV infection.", [["T98G cells", "ANATOMY", 222, 232], ["T98G cells", "ANATOMY", 555, 565], ["TBEV", "DISEASE", 244, 248], ["TBEV infection", "DISEASE", 350, 364], ["pGL-220", "CHEMICAL", 420, 427], ["TBEV infection", "DISEASE", 579, 593], ["nucleotides", "CHEMICAL", 461, 472], ["Ab", "GENE_OR_GENE_PRODUCT", 122, 124], ["RANTES", "GENE_OR_GENE_PRODUCT", 142, 148], ["TBEV", "ORGANISM", 208, 212], ["T98G cells", "CELL", 222, 232], ["TBEV", "ORGANISM", 244, 248], ["RANTES", "GENE_OR_GENE_PRODUCT", 257, 263], ["RANTES", "GENE_OR_GENE_PRODUCT", 314, 320], ["TBEV", "ORGANISM", 350, 354], ["RANTES", "GENE_OR_GENE_PRODUCT", 384, 390], ["pGL-220", "GENE_OR_GENE_PRODUCT", 420, 427], ["\u221255", "GENE_OR_GENE_PRODUCT", 481, 484], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 543, 549], ["T98G cells", "CELL", 555, 565], ["TBEV", "ORGANISM", 579, 583], ["RANTES", "PROTEIN", 142, 148], ["chemotactic component", "PROTEIN", 174, 195], ["TBEV-infected T98G cells", "CELL_LINE", 208, 232], ["RANTES", "PROTEIN", 257, 263], ["RANTES promoter", "DNA", 314, 329], ["RANTES promoter", "DNA", 384, 399], ["reporter plasmid pGL-220", "DNA", 403, 427], ["nucleotides \u2212220 to \u221255", "DNA", 461, 484], ["mRNA start site", "DNA", 502, 517], ["pRL", "PROTEIN", 543, 546], ["T98G cells", "CELL_LINE", 555, 565], ["TBEV", "SPECIES", 208, 212], ["TBEV", "SPECIES", 244, 248], ["TBEV", "SPECIES", 350, 354], ["TBEV", "SPECIES", 579, 583], ["a functionally active chemotactic component", "PROBLEM", 152, 195], ["infected T98G cells", "TREATMENT", 213, 232], ["TBEV", "PROBLEM", 244, 248], ["transactivation of RANTES promoter", "TREATMENT", 295, 329], ["TBEV infection", "PROBLEM", 350, 364], ["a reporter plasmid pGL", "TEST", 401, 423], ["nucleotides", "TEST", 461, 472], ["pRL-TK into T98G cells", "TREATMENT", 543, 565], ["TBEV infection", "PROBLEM", 579, 593], ["RANTES", "OBSERVATION", 142, 148], ["active", "OBSERVATION_MODIFIER", 167, 173], ["chemotactic", "OBSERVATION_MODIFIER", 174, 185], ["T98G cells", "OBSERVATION", 222, 232], ["T98G cells", "OBSERVATION", 555, 565], ["TBEV infection", "OBSERVATION", 579, 593]]], ["T98G was chosen as a cell model due to its relatively high transfection efficiency and the ability of the cells to produce high levels of RANTES transcripts upon TBEV infection.", [["T98G", "ANATOMY", 0, 4], ["cell", "ANATOMY", 21, 25], ["cells", "ANATOMY", 106, 111], ["T98G", "CHEMICAL", 0, 4], ["TBEV infection", "DISEASE", 162, 176], ["T98G", "CELL", 0, 4], ["cell", "CELL", 21, 25], ["cells", "CELL", 106, 111], ["RANTES", "GENE_OR_GENE_PRODUCT", 138, 144], ["TBEV", "ORGANISM", 162, 166], ["T98G", "CELL_LINE", 0, 4], ["RANTES transcripts", "RNA", 138, 156], ["TBEV", "SPECIES", 162, 166], ["T98G", "PROBLEM", 0, 4], ["a cell model", "TEST", 19, 31], ["its relatively high transfection efficiency", "PROBLEM", 39, 82], ["the cells", "PROBLEM", 102, 111], ["high levels of RANTES transcripts", "PROBLEM", 123, 156], ["TBEV infection", "PROBLEM", 162, 176], ["transfection efficiency", "OBSERVATION", 59, 82], ["TBEV infection", "OBSERVATION", 162, 176]]], ["As shown in Fig. 6a , TBEV infection of transfected T98G cells induced a dose-dependent increase of luciferase activity, with the maximal stimulation detected at an MOI of 5.", [["T98G cells", "ANATOMY", 52, 62], ["infection", "DISEASE", 27, 36], ["TBEV", "ORGANISM", 22, 26], ["T98G cells", "CELL", 52, 62], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["transfected T98G cells", "CELL_LINE", 40, 62], ["luciferase", "PROTEIN", 100, 110], ["TBEV", "SPECIES", 22, 26], ["TBEV infection", "PROBLEM", 22, 36], ["transfected T98G cells", "PROBLEM", 40, 62], ["luciferase activity", "PROBLEM", 100, 119], ["the maximal stimulation", "TEST", 126, 149], ["T98G cells", "OBSERVATION", 52, 62], ["dependent", "OBSERVATION_MODIFIER", 78, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["luciferase activity", "OBSERVATION", 100, 119]]], ["UV-inactivated virus was not capable of inducing RANTES transcription, confirming our previous observation that RANTES induction requires productive TBEV infection.", [["TBEV infection", "DISEASE", 149, 163], ["RANTES", "GENE_OR_GENE_PRODUCT", 49, 55], ["RANTES", "GENE_OR_GENE_PRODUCT", 112, 118], ["TBEV", "ORGANISM", 149, 153], ["RANTES", "PROTEIN", 49, 55], ["RANTES", "PROTEIN", 112, 118], ["TBEV", "SPECIES", 149, 153], ["UV", "TREATMENT", 0, 2], ["inactivated virus", "PROBLEM", 3, 20], ["RANTES induction", "TREATMENT", 112, 128], ["productive TBEV infection", "PROBLEM", 138, 163], ["productive", "OBSERVATION_MODIFIER", 138, 148], ["TBEV infection", "OBSERVATION", 149, 163]]], ["The TBEV-induced promoter activation was also time-dependent, with the increase of luciferase activity started at 24 h and reached the highest levels at 48 h p.i.", [["TBEV", "DISEASE", 4, 8], ["TBEV", "ORGANISM", 4, 8], ["luciferase", "GENE_OR_GENE_PRODUCT", 83, 93], ["luciferase", "PROTEIN", 83, 93], ["TBEV", "SPECIES", 4, 8], ["The TBEV-induced promoter activation", "TREATMENT", 0, 36], ["luciferase activity", "TREATMENT", 83, 102]]], ["(Fig. 6b) .TBEV-induced RANTES expression is mediated through transactivation of RANTES promoterThe RANTES promoter comprises five pivotal binding sites for the transcription factors CRE, ISRE, NF-IL-6, NF-kB1, and NF-kB2 (Fig. 6c) [29] .", [["TBEV", "DISEASE", 11, 15], ["TBEV", "ORGANISM", 11, 15], ["RANTES", "GENE_OR_GENE_PRODUCT", 24, 30], ["RANTES", "GENE_OR_GENE_PRODUCT", 81, 87], ["RANTES", "GENE_OR_GENE_PRODUCT", 100, 106], ["CRE", "GENE_OR_GENE_PRODUCT", 183, 186], ["ISRE", "GENE_OR_GENE_PRODUCT", 188, 192], ["NF-IL-6", "GENE_OR_GENE_PRODUCT", 194, 201], ["NF-kB1", "GENE_OR_GENE_PRODUCT", 203, 209], ["NF-kB2", "GENE_OR_GENE_PRODUCT", 215, 221], ["RANTES", "PROTEIN", 24, 30], ["RANTES promoter", "DNA", 81, 96], ["RANTES promoter", "DNA", 100, 115], ["binding sites", "DNA", 139, 152], ["transcription factors", "PROTEIN", 161, 182], ["CRE", "PROTEIN", 183, 186], ["ISRE", "DNA", 188, 192], ["NF-IL-6", "PROTEIN", 194, 201], ["NF-kB1", "DNA", 203, 209], ["NF-kB2", "DNA", 215, 221], ["TBEV", "SPECIES", 11, 15], ["TBEV", "PROBLEM", 11, 15], ["transactivation of RANTES promoter", "TREATMENT", 62, 96], ["The RANTES promoter", "TREATMENT", 96, 115], ["the transcription factors CRE", "TEST", 157, 186], ["ISRE", "TEST", 188, 192], ["NF", "TEST", 194, 196], ["IL", "TEST", 197, 199], ["NF", "TEST", 203, 205], ["NF", "TREATMENT", 215, 217]]], ["To determine the contributions of individual cis regulatory elements in conferring responsiveness to TBEV infection, we tested the impact of mutations at these sites on TBEV-induced RANTES production.", [["TBEV infection", "DISEASE", 101, 115], ["TBEV", "ORGANISM", 101, 105], ["TBEV", "ORGANISM", 169, 173], ["RANTES", "GENE_OR_GENE_PRODUCT", 182, 188], ["cis regulatory elements", "DNA", 45, 68], ["RANTES", "PROTEIN", 182, 188], ["TBEV", "SPECIES", 101, 105], ["TBEV", "SPECIES", 169, 173], ["individual cis regulatory elements", "PROBLEM", 34, 68], ["TBEV infection", "PROBLEM", 101, 115], ["mutations at these sites", "PROBLEM", 141, 165], ["TBEV", "PROBLEM", 169, 173], ["induced RANTES production", "PROBLEM", 174, 199]]], ["As shown in Fig. 6d , mutation of the ISRE site not only affected the promoter basal activity but also nearly completely abolished TBEV-induced RANTES promoter activation.", [["ISRE", "GENE_OR_GENE_PRODUCT", 38, 42], ["RANTES", "GENE_OR_GENE_PRODUCT", 144, 150], ["ISRE site", "DNA", 38, 47], ["RANTES promoter", "DNA", 144, 159], ["TBEV", "SPECIES", 131, 135], ["mutation of the ISRE site", "PROBLEM", 22, 47]]], ["Mutation of the NF-kB1 or NF-kB2 site also reduced the basal activity, with the latter decreasing the TBEV-induced luciferase activity, although were inoculated with medium alone, TBEV, or UV-inactivated TBEV at an MOI of 1.", [["UV", "CHEMICAL", 189, 191], ["NF-kB1", "GENE_OR_GENE_PRODUCT", 16, 22], ["NF-kB2", "GENE_OR_GENE_PRODUCT", 26, 32], ["luciferase", "GENE_OR_GENE_PRODUCT", 115, 125], ["TBEV", "ORGANISM", 204, 208], ["NF-kB1 or NF-kB2 site", "DNA", 16, 37], ["luciferase", "PROTEIN", 115, 125], ["TBEV", "SPECIES", 102, 106], ["TBEV", "SPECIES", 180, 184], ["TBEV", "SPECIES", 204, 208], ["the NF", "TEST", 12, 18], ["NF", "PROBLEM", 26, 28], ["the TBEV", "PROBLEM", 98, 106], ["TBEV", "PROBLEM", 180, 184], ["UV", "PROBLEM", 189, 191], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["basal activity", "OBSERVATION", 55, 69], ["TBEV", "OBSERVATION", 102, 106], ["luciferase activity", "OBSERVATION", 115, 134]]], ["Total RNA was extracted from cell lysates at 6, 24, 48, and 72 h post inoculation.", [["cell lysates", "ANATOMY", 29, 41], ["cell lysates", "ORGANISM_SUBSTANCE", 29, 41], ["Total RNA", "PROBLEM", 0, 9], ["cell lysates", "TEST", 29, 41], ["inoculation", "PROBLEM", 70, 81], ["cell lysates", "OBSERVATION", 29, 41]]], ["RANTES mRNA was quantified by real-time PCR (a, c, e, and g), and results were normalized to GAPDH and expressed as fold induction over medium alone at 6 h post inoculation.", [["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["GAPDH", "GENE_OR_GENE_PRODUCT", 93, 98], ["RANTES mRNA", "RNA", 0, 11], ["GAPDH", "PROTEIN", 93, 98], ["RANTES mRNA", "TEST", 0, 11], ["real-time PCR", "TEST", 30, 43]]], ["Supernatants were harvested at 6, 24, 48, and 72 h post inoculation, and levels of RANTES (pg/mL) released were determined by ELISA (b, d, f, and h) .", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["RANTES", "GENE_OR_GENE_PRODUCT", 83, 89], ["RANTES", "PROTEIN", 83, 89], ["inoculation", "TEST", 56, 67], ["RANTES", "TEST", 83, 89], ["ELISA", "TEST", 126, 131], ["harvested", "OBSERVATION", 18, 27]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["P < 0.05 versus control; # P < 0.05 versus TBEV-infected alone.", [["TBEV-infected", "DISEASE", 43, 56], ["TBEV", "ORGANISM", 43, 47], ["TBEV", "SPECIES", 43, 47], ["TBEV", "PROBLEM", 43, 47], ["infected", "OBSERVATION", 48, 56]]], ["Statistical analysis was performed by Student's t test to a much lesser extent.", [["Statistical analysis", "TEST", 0, 20], ["Student's t test", "TEST", 38, 54]]], ["Taken together, these data indicate that ISRE element of RANTES promoter is possibly mainly responsible for TBEV-induced RANTES expression.TBEV-induced RANTES expression is mediated by activation of IRF-3 signaling pathwayTo clarify the essential role of ISRE, the effects of ISREbinding IRF-3 and IRF-7 transcription factors lacking their DNA-binding domains (mutants IRF-3\u0394N and IRF-7\u0394N, respectively) on TBEV-induced RANTES expression were determined.", [["TBEV", "DISEASE", 139, 143], ["RANTES", "GENE_OR_GENE_PRODUCT", 57, 63], ["TBEV", "ORGANISM", 108, 112], ["RANTES", "GENE_OR_GENE_PRODUCT", 121, 127], ["TBEV", "ORGANISM", 139, 143], ["RANTES", "GENE_OR_GENE_PRODUCT", 152, 158], ["IRF-3", "GENE_OR_GENE_PRODUCT", 199, 204], ["ISRE", "GENE_OR_GENE_PRODUCT", 255, 259], ["IRF-3", "GENE_OR_GENE_PRODUCT", 288, 293], ["IRF-7", "GENE_OR_GENE_PRODUCT", 298, 303], ["DNA", "CELLULAR_COMPONENT", 340, 343], ["IRF-3\u0394N", "GENE_OR_GENE_PRODUCT", 369, 376], ["IRF-7\u0394N", "GENE_OR_GENE_PRODUCT", 381, 388], ["TBEV", "ORGANISM", 407, 411], ["RANTES", "GENE_OR_GENE_PRODUCT", 420, 426], ["ISRE element", "DNA", 41, 53], ["RANTES promoter", "DNA", 57, 72], ["RANTES", "PROTEIN", 121, 127], ["RANTES", "PROTEIN", 152, 158], ["IRF-3", "PROTEIN", 199, 204], ["ISRE", "PROTEIN", 255, 259], ["ISREbinding IRF-3", "PROTEIN", 276, 293], ["IRF-7", "PROTEIN", 298, 303], ["transcription factors", "PROTEIN", 304, 325], ["DNA-binding domains", "PROTEIN", 340, 359], ["IRF", "PROTEIN", 369, 372], ["3\u0394N", "PROTEIN", 373, 376], ["IRF", "PROTEIN", 381, 384], ["7\u0394N", "PROTEIN", 385, 388], ["RANTES", "PROTEIN", 420, 426], ["TBEV", "SPECIES", 108, 112], ["TBEV", "SPECIES", 139, 143], ["TBEV", "SPECIES", 407, 411], ["these data", "TEST", 16, 26], ["ISRE element of RANTES promoter", "PROBLEM", 41, 72], ["TBEV", "PROBLEM", 108, 112], ["TBEV", "PROBLEM", 139, 143], ["ISREbinding IRF", "PROBLEM", 276, 291], ["IRF", "PROBLEM", 298, 301], ["transcription factors", "PROBLEM", 304, 325], ["mutants IRF", "TEST", 361, 372], ["IRF", "TEST", 381, 384], ["TBEV", "TREATMENT", 407, 411], ["possibly mainly responsible", "UNCERTAINTY", 76, 103]]], ["In reporter gene assays, compared with corresponding controls, over-expression of IRF-3\u0394N dramatically inhibited the ability of TBEV in activating RANTES gene transcription, whereas cotransfection with IRF-7\u0394N in TBEV-infected T98G cells did not have such impact (Fig. 6a) .", [["T98G cells", "ANATOMY", 227, 237], ["IRF-3\u0394N", "GENE_OR_GENE_PRODUCT", 82, 89], ["TBEV", "ORGANISM", 128, 132], ["RANTES", "GENE_OR_GENE_PRODUCT", 147, 153], ["IRF-7\u0394N", "GENE_OR_GENE_PRODUCT", 202, 209], ["TBEV", "ORGANISM", 213, 217], ["T98G cells", "CELL", 227, 237], ["IRF", "PROTEIN", 82, 85], ["3\u0394N", "PROTEIN", 86, 89], ["RANTES gene", "DNA", 147, 158], ["IRF", "PROTEIN", 202, 205], ["7\u0394N", "PROTEIN", 206, 209], ["TBEV-infected T98G cells", "CELL_LINE", 213, 237], ["TBEV", "SPECIES", 128, 132], ["TBEV", "SPECIES", 213, 217], ["reporter gene assays", "TEST", 3, 23], ["IRF", "PROBLEM", 82, 85], ["TBEV in activating RANTES gene transcription", "TREATMENT", 128, 172], ["IRF", "TEST", 202, 205], ["TBEV", "PROBLEM", 213, 217], ["infected T98G cells", "PROBLEM", 218, 237], ["T98G cells", "OBSERVATION", 227, 237]]], ["Moreover, overexpression of a nondegradable IkB\u03b1 mutant (mIkB\u03b1) had no effect on activation of the RANTES promoter (Fig. 6b) .TBEV-induced RANTES expression is mediated by activation of IRF-3 signaling pathwayTo determine whether TBEV trigger RANTES expression by directly inducing activation of known IRF-3 pathway component, we performed Western blot analysis to detect the levels of endogenous RIG-I, MDA5, TLR3, p-TBK-1, p-inhibitor-kB kinase epsilon (IKK\u03b5), and p-IRF-3 following infection of T98G cells with TBEV.", [["T98G cells", "ANATOMY", 498, 508], ["TBEV", "DISEASE", 126, 130], ["infection", "DISEASE", 485, 494], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 44, 48], ["mIkB\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["RANTES", "GENE_OR_GENE_PRODUCT", 99, 105], ["TBEV", "ORGANISM", 126, 130], ["RANTES", "GENE_OR_GENE_PRODUCT", 139, 145], ["IRF-3", "GENE_OR_GENE_PRODUCT", 186, 191], ["TBEV", "ORGANISM", 230, 234], ["RANTES", "GENE_OR_GENE_PRODUCT", 243, 249], ["IRF-3", "GENE_OR_GENE_PRODUCT", 302, 307], ["RIG-I", "GENE_OR_GENE_PRODUCT", 397, 402], ["MDA5", "GENE_OR_GENE_PRODUCT", 404, 408], ["TLR3", "GENE_OR_GENE_PRODUCT", 410, 414], ["p-TBK-1", "GENE_OR_GENE_PRODUCT", 416, 423], ["p-inhibitor-kB kinase epsilon", "GENE_OR_GENE_PRODUCT", 425, 454], ["IKK", "GENE_OR_GENE_PRODUCT", 456, 459], ["\u03b5", "GENE_OR_GENE_PRODUCT", 459, 460], ["p-IRF-3", "GENE_OR_GENE_PRODUCT", 467, 474], ["T98G cells", "CELL", 498, 508], ["TBEV", "ORGANISM", 514, 518], ["IkB\u03b1 mutant", "PROTEIN", 44, 55], ["IkB\u03b1", "PROTEIN", 58, 62], ["RANTES promoter", "DNA", 99, 114], ["RANTES", "PROTEIN", 139, 145], ["IRF-3", "PROTEIN", 186, 191], ["RANTES", "PROTEIN", 243, 249], ["IRF-3", "PROTEIN", 302, 307], ["endogenous RIG-I", "PROTEIN", 386, 402], ["MDA5", "PROTEIN", 404, 408], ["TLR3", "PROTEIN", 410, 414], ["TBK", "PROTEIN", 418, 421], ["p-inhibitor-kB kinase epsilon", "PROTEIN", 425, 454], ["IKK\u03b5", "PROTEIN", 456, 460], ["IRF-3", "DNA", 469, 474], ["T98G cells", "CELL_LINE", 498, 508], ["TBEV", "SPECIES", 126, 130], ["TBEV", "SPECIES", 230, 234], ["TBEV", "SPECIES", 514, 518], ["a nondegradable IkB\u03b1 mutant", "PROBLEM", 28, 55], ["the RANTES promoter", "TREATMENT", 95, 114], ["TBEV", "PROBLEM", 126, 130], ["known IRF", "PROBLEM", 296, 305], ["blot analysis", "TEST", 348, 361], ["the levels", "TEST", 372, 382], ["endogenous RIG", "TEST", 386, 400], ["MDA5", "TEST", 404, 408], ["TLR3", "TEST", 410, 414], ["TBK", "TEST", 418, 421], ["p-inhibitor", "TEST", 425, 436], ["kB kinase epsilon", "TEST", 437, 454], ["IKK", "TEST", 456, 459], ["infection of T98G cells", "PROBLEM", 485, 508], ["TBEV", "PROBLEM", 514, 518]]], ["As depicted in Fig. 6c , TBEV induced upregulation of RIG-I and MDA5 as early as by 24 h p.i., whereas no detectable TLR3 and p-IKK\u03b5 were seen during the process of infection in T98G cells (data not shown).", [["T98G cells", "ANATOMY", 178, 188], ["infection", "DISEASE", 165, 174], ["TBEV", "ORGANISM", 25, 29], ["RIG-I", "GENE_OR_GENE_PRODUCT", 54, 59], ["MDA5", "GENE_OR_GENE_PRODUCT", 64, 68], ["TLR3", "GENE_OR_GENE_PRODUCT", 117, 121], ["p-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 126, 132], ["T98G cells", "CELL", 178, 188], ["RIG-I", "PROTEIN", 54, 59], ["MDA5", "PROTEIN", 64, 68], ["TLR3", "PROTEIN", 117, 121], ["IKK\u03b5", "PROTEIN", 128, 132], ["T98G cells", "CELL_LINE", 178, 188], ["TBEV", "SPECIES", 25, 29], ["infection in T98G cells", "PROBLEM", 165, 188], ["infection", "OBSERVATION", 165, 174], ["T98G cells", "OBSERVATION", 178, 188]]], ["Concomitantly, virus replication also activates specific virus-induced kinase TBK-1, which regulates the phosphorylation and thus the activation of IRF-3 [34] .", [["TBK-1", "GENE_OR_GENE_PRODUCT", 78, 83], ["IRF-3", "GENE_OR_GENE_PRODUCT", 148, 153], ["TBK-1", "PROTEIN", 78, 83], ["IRF", "PROTEIN", 148, 151], ["virus replication", "TREATMENT", 15, 32], ["kinase TBK", "TEST", 71, 81], ["IRF", "TEST", 148, 151], ["virus replication", "OBSERVATION", 15, 32]]], ["Indeed, phosphorylated forms of IRF-3 (p-IRF-3) were clearly detectable by 24 h p.i.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 32, 37], ["p-IRF-3", "GENE_OR_GENE_PRODUCT", 39, 46], ["IRF-3", "PROTEIN", 32, 37], ["IRF-3", "PROTEIN", 41, 46], ["IRF", "TEST", 32, 35], ["IRF", "TEST", 41, 44], ["IRF", "OBSERVATION", 32, 35]]], ["However, we failed to detect a significant decrease in the level of endogenous IkB\u03b1, which is a hallmark of IkB\u03b1 degradation and NF-kB activation.TBEV-induced RANTES expression is mediated by activation of IRF-3 signaling pathwayThe abovementioned results indicate that the expression of both RIG-I and MDA5 is greatly enhanced in response to TBEV infection.", [["TBEV", "DISEASE", 146, 150], ["TBEV infection", "DISEASE", 343, 357], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 79, 83], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 108, 112], ["NF-kB", "GENE_OR_GENE_PRODUCT", 129, 134], ["TBEV", "ORGANISM", 146, 150], ["RANTES", "GENE_OR_GENE_PRODUCT", 159, 165], ["IRF-3", "GENE_OR_GENE_PRODUCT", 206, 211], ["RIG-I", "GENE_OR_GENE_PRODUCT", 293, 298], ["MDA5", "GENE_OR_GENE_PRODUCT", 303, 307], ["TBEV", "ORGANISM", 343, 347], ["IkB\u03b1", "PROTEIN", 79, 83], ["IkB\u03b1", "PROTEIN", 108, 112], ["NF-kB", "PROTEIN", 129, 134], ["RANTES", "PROTEIN", 159, 165], ["IRF-3", "PROTEIN", 206, 211], ["RIG-I", "PROTEIN", 293, 298], ["MDA5", "PROTEIN", 303, 307], ["TBEV", "SPECIES", 146, 150], ["TBEV", "SPECIES", 343, 347], ["a significant decrease", "PROBLEM", 29, 51], ["IkB\u03b1 degradation", "PROBLEM", 108, 124], ["TBEV", "PROBLEM", 146, 150], ["TBEV infection", "PROBLEM", 343, 357], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["endogenous IkB\u03b1", "OBSERVATION", 68, 83], ["MDA5", "ANATOMY", 303, 307], ["greatly", "OBSERVATION_MODIFIER", 311, 318], ["enhanced", "OBSERVATION", 319, 327], ["TBEV infection", "OBSERVATION", 343, 357]]], ["To explore the role of these proteins in modulation of virus-induced RANTES production, we performed knockdown of RIG-I and MDA5 using siRNA.", [["RANTES", "GENE_OR_GENE_PRODUCT", 69, 75], ["RIG-I", "GENE_OR_GENE_PRODUCT", 114, 119], ["MDA5", "GENE_OR_GENE_PRODUCT", 124, 128], ["RANTES", "PROTEIN", 69, 75], ["RIG-I", "PROTEIN", 114, 119], ["MDA5", "PROTEIN", 124, 128], ["these proteins", "TREATMENT", 23, 37], ["virus-induced RANTES production", "TREATMENT", 55, 86], ["MDA5 using siRNA", "TREATMENT", 124, 140]]], ["As shown in Fig. 7d , Ctrl siRNA did not affect the virus-induced activation.", [["Ctrl siRNA", "TREATMENT", 22, 32], ["the virus", "PROBLEM", 48, 57]]], ["Knockdown of either RIG-I or MDA5 led to a significant decrease in the amount of RANTES chemokine production under the experimental conditions.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 20, 25], ["MDA5", "GENE_OR_GENE_PRODUCT", 29, 33], ["RANTES chemokine", "GENE_OR_GENE_PRODUCT", 81, 97], ["RIG-I", "PROTEIN", 20, 25], ["MDA5", "PROTEIN", 29, 33], ["RANTES", "PROTEIN", 81, 87], ["chemokine", "PROTEIN", 88, 97], ["MDA5", "PROBLEM", 29, 33], ["RANTES chemokine production", "TREATMENT", 81, 108], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["decrease", "OBSERVATION_MODIFIER", 55, 63], ["amount", "OBSERVATION_MODIFIER", 71, 77], ["RANTES chemokine", "OBSERVATION", 81, 97]]], ["These results indicate the Fig. 6 TBEV infection results in the induction of RANTES promoter activity. a T98G cells were co-transfected with pGL2-220 and pRL-TK, followed by UV-inactivated TBEV or TBEV infection at different MOIs; 24 h p.i. cells were harvested to measure luciferase activity.", [["T98G cells", "ANATOMY", 105, 115], ["cells", "ANATOMY", 241, 246], ["TBEV infection", "DISEASE", 34, 48], ["TBEV infection", "DISEASE", 197, 211], ["TBEV", "ORGANISM", 34, 38], ["RANTES", "GENE_OR_GENE_PRODUCT", 77, 83], ["T98G cells", "CELL", 105, 115], ["pGL2-220", "GENE_OR_GENE_PRODUCT", 141, 149], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 154, 160], ["TBEV", "ORGANISM", 189, 193], ["TBEV", "ORGANISM", 197, 201], ["cells", "CELL", 241, 246], ["luciferase", "GENE_OR_GENE_PRODUCT", 273, 283], ["RANTES promoter", "DNA", 77, 92], ["T98G cells", "CELL_LINE", 105, 115], ["pGL2-220 and pRL-TK", "DNA", 141, 160], ["luciferase", "PROTEIN", 273, 283], ["TBEV", "SPECIES", 34, 38], ["TBEV", "SPECIES", 189, 193], ["TBEV", "SPECIES", 197, 201], ["6 TBEV infection", "PROBLEM", 32, 48], ["RANTES promoter activity", "TREATMENT", 77, 101], ["a T98G cells", "TEST", 103, 115], ["pGL2", "TEST", 141, 145], ["pRL", "TEST", 154, 157], ["UV", "TEST", 174, 176], ["TBEV", "PROBLEM", 189, 193], ["TBEV infection", "PROBLEM", 197, 211], ["Fig", "OBSERVATION", 27, 30], ["TBEV", "OBSERVATION_MODIFIER", 34, 38], ["infection", "OBSERVATION", 39, 48], ["T98G cells", "OBSERVATION", 105, 115], ["TBEV", "OBSERVATION", 189, 193], ["TBEV infection", "OBSERVATION", 197, 211]]], ["The results are expressed as fold induction of RANTES promoter activity relative to the basal level.", [["RANTES", "GENE_OR_GENE_PRODUCT", 47, 53], ["RANTES promoter", "DNA", 47, 62], ["fold induction of RANTES promoter activity", "TREATMENT", 29, 71], ["basal", "ANATOMY_MODIFIER", 88, 93]]], ["P < 0.05 versus mock control. c Schematic representation of the RANTES promoter constructs [29] .", [["RANTES", "GENE_OR_GENE_PRODUCT", 64, 70], ["RANTES promoter constructs", "DNA", 64, 90], ["mock control", "TREATMENT", 16, 28], ["the RANTES promoter constructs", "TREATMENT", 60, 90]]], ["Locations of the putative binding sites for CRE, ISRE, NF-IL-6, and NF-kB are illustrated.", [["CRE", "GENE_OR_GENE_PRODUCT", 44, 47], ["ISRE", "GENE_OR_GENE_PRODUCT", 49, 53], ["NF-IL-6", "GENE_OR_GENE_PRODUCT", 55, 62], ["NF-kB", "GENE_OR_GENE_PRODUCT", 68, 73], ["putative binding sites", "DNA", 17, 39], ["CRE, ISRE, NF-IL-6", "DNA", 44, 62], ["NF-kB", "DNA", 68, 73], ["CRE", "TEST", 44, 47], ["ISRE", "TEST", 49, 53], ["NF", "TEST", 55, 57]]], ["Numbering is relative to the transcription initiation site. d Effect of site mutations in the RANTES promoter sequence on TBEV-inducible activity.", [["RANTES", "GENE_OR_GENE_PRODUCT", 94, 100], ["TBEV", "ORGANISM", 122, 126], ["transcription initiation site", "DNA", 29, 58], ["RANTES promoter sequence", "DNA", 94, 118], ["TBEV", "SPECIES", 122, 126], ["site mutations", "PROBLEM", 72, 86], ["site mutations", "OBSERVATION", 72, 86]]], ["T98G cells were transiently transfected with site-mutated (Mut) plasmids of the pGL2-220 RANTES promoter and infected with TBEV for 36 h.", [["T98G cells", "ANATOMY", 0, 10], ["plasmids", "ANATOMY", 64, 72], ["T98G cells", "CELL", 0, 10], ["pGL2-220 RANTES", "GENE_OR_GENE_PRODUCT", 80, 95], ["T98G cells", "CELL_LINE", 0, 10], ["site-mutated (Mut) plasmids", "DNA", 45, 72], ["pGL2-220 RANTES promoter", "DNA", 80, 104], ["TBEV", "SPECIES", 123, 127], ["T98G cells", "PROBLEM", 0, 10], ["RANTES promoter", "TREATMENT", 89, 104], ["TBEV", "TREATMENT", 123, 127]]], ["The results are expressed as fold induction of RANTES promoter activity relative to the basal level.", [["RANTES", "GENE_OR_GENE_PRODUCT", 47, 53], ["RANTES promoter", "DNA", 47, 62], ["fold induction of RANTES promoter activity", "TREATMENT", 29, 71], ["basal", "ANATOMY_MODIFIER", 88, 93]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["P < 0.05 indicates significant difference between groups tested.", [["significant difference between groups tested", "PROBLEM", 19, 63], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["NS not significant on aspects of extracerebral infection and neuroinvasion, we challenged mice with TBEV via ic route.", [["extracerebral", "ANATOMY", 33, 46], ["extracerebral infection", "DISEASE", 33, 56], ["neuroinvasion", "DISEASE", 61, 74], ["TBEV", "DISEASE", 100, 104], ["extracerebral", "ANATOMICAL_SYSTEM", 33, 46], ["mice", "ORGANISM", 90, 94], ["TBEV", "ORGANISM", 100, 104], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["TBEV", "SPECIES", 100, 104], ["NS", "TREATMENT", 0, 2], ["extracerebral infection", "PROBLEM", 33, 56], ["neuroinvasion", "PROBLEM", 61, 74], ["TBEV via ic route", "TREATMENT", 100, 117], ["not", "UNCERTAINTY", 3, 6], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["extracerebral", "ANATOMY", 33, 46], ["infection", "OBSERVATION", 47, 56], ["neuroinvasion", "OBSERVATION", 61, 74]]], ["Pathological analysis of CNS tissues from moribund mice demonstrated marked leukocytes infiltration, which is consistent with autopsy studies on human patients infected with TBEV [7, 8] .", [["CNS tissues", "ANATOMY", 25, 36], ["leukocytes", "ANATOMY", 76, 86], ["TBEV", "DISEASE", 174, 178], ["CNS tissues", "TISSUE", 25, 36], ["mice", "ORGANISM", 51, 55], ["leukocytes", "CELL", 76, 86], ["human", "ORGANISM", 145, 150], ["patients", "ORGANISM", 151, 159], ["leukocytes", "CELL_TYPE", 76, 86], ["mice", "SPECIES", 51, 55], ["human", "SPECIES", 145, 150], ["patients", "SPECIES", 151, 159], ["mice", "SPECIES", 51, 55], ["human", "SPECIES", 145, 150], ["TBEV", "SPECIES", 174, 178], ["Pathological analysis", "TEST", 0, 21], ["CNS tissues", "PROBLEM", 25, 36], ["moribund mice", "TEST", 42, 55], ["marked leukocytes infiltration", "PROBLEM", 69, 99], ["autopsy studies", "TEST", 126, 141], ["CNS tissues", "ANATOMY", 25, 36], ["marked", "OBSERVATION_MODIFIER", 69, 75], ["leukocytes infiltration", "OBSERVATION", 76, 99], ["consistent with", "UNCERTAINTY", 110, 125]]], ["Once in the CNS, there are three possible mechanisms by which flaviviruses induce brain tissue destruction leading to the clinical manifestations of disease.", [["CNS", "ANATOMY", 12, 15], ["brain tissue", "ANATOMY", 82, 94], ["flaviviruses", "DISEASE", 62, 74], ["tissue destruction", "DISEASE", 88, 106], ["CNS", "ANATOMICAL_SYSTEM", 12, 15], ["flaviviruses", "ORGANISM", 62, 74], ["brain tissue", "TISSUE", 82, 94], ["flaviviruses", "PROBLEM", 62, 74], ["brain tissue destruction", "PROBLEM", 82, 106], ["disease", "PROBLEM", 149, 156], ["CNS", "ANATOMY", 12, 15], ["brain tissue", "ANATOMY", 82, 94], ["destruction", "OBSERVATION", 95, 106]]], ["Virus infection may directly lead to neuronal cell injury and virus-induced neuroinflammatory responses may cause neuronal death, or both [9, 35] .", [["neuronal cell", "ANATOMY", 37, 50], ["neuronal", "ANATOMY", 114, 122], ["Virus infection", "DISEASE", 0, 15], ["neuronal death", "DISEASE", 114, 128], ["Virus", "ORGANISM", 0, 5], ["neuronal cell", "CELL", 37, 50], ["neuronal", "CELL", 114, 122], ["Virus infection", "PROBLEM", 0, 15], ["neuronal cell injury", "PROBLEM", 37, 57], ["virus", "PROBLEM", 62, 67], ["neuronal death", "PROBLEM", 114, 128], ["infection", "OBSERVATION", 6, 15], ["may directly lead to", "UNCERTAINTY", 16, 36], ["neuronal cell injury", "OBSERVATION", 37, 57]]], ["CNS pathology of TBEV is considered to be, at least in part, due to viral infection of corresponding cells, since virus induces both apoptosis and necrosis in human neural cells and also in mouse and monkey brain neurons [36] [37] [38] [39] .", [["CNS", "ANATOMY", 0, 3], ["cells", "ANATOMY", 101, 106], ["neural cells", "ANATOMY", 165, 177], ["brain neurons", "ANATOMY", 207, 220], ["TBEV", "DISEASE", 17, 21], ["infection", "DISEASE", 74, 83], ["necrosis", "DISEASE", 147, 155], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["TBEV", "ORGANISM", 17, 21], ["cells", "CELL", 101, 106], ["human", "ORGANISM", 159, 164], ["neural cells", "CELL", 165, 177], ["mouse", "ORGANISM", 190, 195], ["monkey", "ORGANISM", 200, 206], ["brain", "ORGAN", 207, 212], ["human neural cells", "CELL_TYPE", 159, 177], ["human", "SPECIES", 159, 164], ["mouse", "SPECIES", 190, 195], ["monkey", "SPECIES", 200, 206], ["TBEV", "SPECIES", 17, 21], ["human", "SPECIES", 159, 164], ["mouse", "SPECIES", 190, 195], ["CNS pathology", "TEST", 0, 13], ["TBEV", "PROBLEM", 17, 21], ["viral infection of corresponding cells", "PROBLEM", 68, 106], ["virus", "PROBLEM", 114, 119], ["both apoptosis", "PROBLEM", 128, 142], ["necrosis in human neural cells", "PROBLEM", 147, 177], ["TBEV", "OBSERVATION", 17, 21], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infection", "OBSERVATION", 74, 83], ["apoptosis", "OBSERVATION_MODIFIER", 133, 142], ["necrosis", "OBSERVATION", 147, 155], ["human neural cells", "OBSERVATION", 159, 177]]], ["However, there is a growing body of evidence indicating that abnormal immune response is one major cause of tissue damage and fatal encephalitis [40] .", [["tissue", "ANATOMY", 108, 114], ["tissue damage", "DISEASE", 108, 121], ["encephalitis", "DISEASE", 132, 144], ["tissue", "TISSUE", 108, 114], ["abnormal immune response", "PROBLEM", 61, 85], ["tissue damage", "PROBLEM", 108, 121], ["fatal encephalitis", "PROBLEM", 126, 144], ["evidence indicating", "UNCERTAINTY", 36, 55], ["abnormal", "OBSERVATION_MODIFIER", 61, 69], ["immune response", "OBSERVATION", 70, 85], ["tissue", "ANATOMY", 108, 114], ["damage", "OBSERVATION", 115, 121], ["fatal", "OBSERVATION_MODIFIER", 126, 131], ["encephalitis", "OBSERVATION", 132, 144]]], ["TBEV infection of the CNS has been shown to result in markedly enhanced leukocyte migration into the brain tissue and immune-mediated BBB breakdown, both of which corresponded with excessive expression of chemokines and cytokines in the brain parenchyma [41] .", [["CNS", "ANATOMY", 22, 25], ["leukocyte", "ANATOMY", 72, 81], ["brain tissue", "ANATOMY", 101, 113], ["BBB", "ANATOMY", 134, 137], ["brain parenchyma", "ANATOMY", 237, 253], ["TBEV infection", "DISEASE", 0, 14], ["TBEV", "ORGANISM", 0, 4], ["CNS", "ANATOMICAL_SYSTEM", 22, 25], ["leukocyte", "CELL", 72, 81], ["brain tissue", "TISSUE", 101, 113], ["BBB", "MULTI-TISSUE_STRUCTURE", 134, 137], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 237, 253], ["chemokines", "PROTEIN", 205, 215], ["cytokines", "PROTEIN", 220, 229], ["TBEV", "SPECIES", 0, 4], ["TBEV infection of the CNS", "PROBLEM", 0, 25], ["markedly enhanced leukocyte migration into the brain tissue", "PROBLEM", 54, 113], ["immune-mediated BBB breakdown", "PROBLEM", 118, 147], ["excessive expression of chemokines and cytokines in the brain parenchyma", "PROBLEM", 181, 253], ["infection", "OBSERVATION", 5, 14], ["CNS", "ANATOMY", 22, 25], ["markedly", "OBSERVATION_MODIFIER", 54, 62], ["enhanced leukocyte migration", "OBSERVATION", 63, 91], ["brain tissue", "ANATOMY", 101, 113], ["BBB", "OBSERVATION_MODIFIER", 134, 137], ["breakdown", "OBSERVATION", 138, 147], ["excessive", "OBSERVATION_MODIFIER", 181, 190], ["expression", "OBSERVATION_MODIFIER", 191, 201], ["chemokines", "OBSERVATION", 205, 215], ["brain", "ANATOMY", 237, 242], ["parenchyma", "ANATOMY_MODIFIER", 243, 253]]], ["Using an Ab array that detects 40 immune factors, we observed that TBEV infection stimulated several inflammatory mediators, including chemokine RANTES and MCP-1 and cytokines IL-12p40p70, IL-12p70, and IL-4.", [["TBEV infection", "DISEASE", 67, 81], ["TBEV", "ORGANISM", 67, 71], ["RANTES", "GENE_OR_GENE_PRODUCT", 145, 151], ["MCP-1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IL-12p40p70", "GENE_OR_GENE_PRODUCT", 176, 187], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 189, 197], ["IL-4", "GENE_OR_GENE_PRODUCT", 203, 207], ["40 immune factors", "PROTEIN", 31, 48], ["inflammatory mediators", "PROTEIN", 101, 123], ["chemokine", "PROTEIN", 135, 144], ["RANTES", "PROTEIN", 145, 151], ["MCP-1", "PROTEIN", 156, 161], ["cytokines", "PROTEIN", 166, 175], ["IL-12p70", "PROTEIN", 189, 197], ["IL-4", "PROTEIN", 203, 207], ["TBEV", "SPECIES", 67, 71], ["an Ab array", "TEST", 6, 17], ["40 immune factors", "PROBLEM", 31, 48], ["TBEV infection", "PROBLEM", 67, 81], ["chemokine RANTES", "TEST", 135, 151], ["MCP", "TEST", 156, 159], ["cytokines IL", "TEST", 166, 178], ["IL", "TEST", 189, 191]]], ["Our findings are in line with previous studies on chemokine and cytokine profiles of mouse CNS infected with the Neudoerfl strain of TBEV-Eu subtype or the Sofjin strain of TBEV-FE subtype, demonstrating a common induction pattern of these immune mediators among TBEV infection [41, 42] .", [["CNS", "ANATOMY", 91, 94], ["TBEV infection", "DISEASE", 263, 277], ["mouse", "ORGANISM", 85, 90], ["CNS", "ANATOMICAL_SYSTEM", 91, 94], ["Neudoerfl strain", "ORGANISM", 113, 129], ["TBEV-Eu subtype", "ORGANISM", 133, 148], ["Sofjin strain", "ORGANISM", 156, 169], ["TBEV-FE subtype", "ORGANISM", 173, 188], ["TBEV", "ORGANISM", 263, 267], ["chemokine", "PROTEIN", 50, 59], ["cytokine", "PROTEIN", 64, 72], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["TBEV", "SPECIES", 133, 137], ["TBEV", "SPECIES", 173, 177], ["TBEV", "SPECIES", 263, 267], ["previous studies", "TEST", 30, 46], ["chemokine", "TREATMENT", 50, 59], ["TBEV", "PROBLEM", 133, 137], ["the Sofjin strain of TBEV-FE subtype", "PROBLEM", 152, 188], ["these immune mediators", "TREATMENT", 234, 256], ["TBEV infection", "PROBLEM", 263, 277]]], ["It is noteworthy that we did not observe a significant increase of certain proinflammatory cytokines including tumor necrosis factor (TNF)-\u03b1 and IL-6.", [["tumor", "DISEASE", 111, 116], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 111, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["proinflammatory cytokines", "PROTEIN", 75, 100], ["tumor necrosis factor (TNF)-\u03b1 and IL-6", "PROTEIN", 111, 149], ["certain proinflammatory cytokines", "PROBLEM", 67, 100], ["tumor necrosis factor", "PROBLEM", 111, 132], ["TNF", "TEST", 134, 137], ["IL", "TEST", 145, 147], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["proinflammatory cytokines", "OBSERVATION", 75, 100], ["tumor", "OBSERVATION_MODIFIER", 111, 116], ["necrosis", "OBSERVATION", 117, 125]]], ["This could be due to the sensitivity of the protein array adopted, various immune responses of distinct mouse models, or the difference in inducing specific cytokines by different TBEV strains.", [["mouse", "ORGANISM", 104, 109], ["TBEV strains", "ORGANISM", 180, 192], ["cytokines", "PROTEIN", 157, 166], ["mouse", "SPECIES", 104, 109], ["mouse", "SPECIES", 104, 109], ["TBEV", "SPECIES", 180, 184], ["the protein array", "TEST", 40, 57], ["distinct mouse models", "PROBLEM", 95, 116], ["different TBEV strains", "PROBLEM", 170, 192], ["could be due to", "UNCERTAINTY", 5, 20], ["distinct mouse models", "OBSERVATION", 95, 116], ["TBEV strains", "OBSERVATION", 180, 192]]], ["These need to be clarified in future studies.DiscussionDuring TBEV infection, the expression of proinflammatory molecules may contribute to the influx of peripheral lymphocytes in the brain as well as to the severity of the encephalitis [7, 8, 14] .", [["peripheral lymphocytes", "ANATOMY", 154, 176], ["brain", "ANATOMY", 184, 189], ["TBEV infection", "DISEASE", 62, 76], ["encephalitis", "DISEASE", 224, 236], ["peripheral lymphocytes", "CELL", 154, 176], ["brain", "ORGAN", 184, 189], ["proinflammatory molecules", "PROTEIN", 96, 121], ["peripheral lymphocytes", "CELL_TYPE", 154, 176], ["TBEV", "SPECIES", 62, 66], ["future studies", "TEST", 30, 44], ["TBEV infection", "PROBLEM", 62, 76], ["proinflammatory molecules", "PROBLEM", 96, 121], ["the influx of peripheral lymphocytes in the brain", "PROBLEM", 140, 189], ["the encephalitis", "PROBLEM", 220, 236], ["infection", "OBSERVATION", 67, 76], ["proinflammatory molecules", "OBSERVATION", 96, 121], ["peripheral lymphocytes", "OBSERVATION", 154, 176], ["brain", "ANATOMY", 184, 189], ["encephalitis", "OBSERVATION", 224, 236]]], ["In this report, we found that CC chemokine RANTES was one of the most rapidly and rigorously induced molecule in the CNS during TBEV infection.", [["CNS", "ANATOMY", 117, 120], ["CC", "CHEMICAL", 30, 32], ["TBEV infection", "DISEASE", 128, 142], ["RANTES", "GENE_OR_GENE_PRODUCT", 43, 49], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["TBEV", "ORGANISM", 128, 132], ["CC chemokine", "PROTEIN", 30, 42], ["RANTES", "PROTEIN", 43, 49], ["TBEV", "SPECIES", 128, 132], ["CC chemokine RANTES", "TEST", 30, 49], ["TBEV infection", "PROBLEM", 128, 142], ["CNS", "ANATOMY", 117, 120], ["TBEV infection", "OBSERVATION", 128, 142]]], ["The increasing level of RANTES expression between 3 and 8 days p.i. was shown to be consistent with increasing immune cell infiltrates and neuroinflammation in virus-infected 1-week-old mice.", [["immune cell", "ANATOMY", 111, 122], ["neuroinflammation", "DISEASE", 139, 156], ["RANTES", "GENE_OR_GENE_PRODUCT", 24, 30], ["immune cell", "CELL", 111, 122], ["mice", "ORGANISM", 186, 190], ["RANTES", "PROTEIN", 24, 30], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["increasing immune cell infiltrates", "PROBLEM", 100, 134], ["neuroinflammation in virus", "PROBLEM", 139, 165], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["consistent with", "UNCERTAINTY", 84, 99], ["increasing", "OBSERVATION_MODIFIER", 100, 110], ["immune cell infiltrates", "OBSERVATION", 111, 134], ["neuroinflammation", "OBSERVATION_MODIFIER", 139, 156], ["infected", "OBSERVATION_MODIFIER", 166, 174]]], ["Besides, ic infection of TBEV in adult mice also induced a significant increase in the level of RANTES within CNS, but not in sera.", [["CNS", "ANATOMY", 110, 113], ["sera", "ANATOMY", 126, 130], ["infection", "DISEASE", 12, 21], ["TBEV", "DISEASE", 25, 29], ["TBEV", "ORGANISM", 25, 29], ["mice", "ORGANISM", 39, 43], ["RANTES", "GENE_OR_GENE_PRODUCT", 96, 102], ["CNS", "ANATOMICAL_SYSTEM", 110, 113], ["sera", "ORGANISM_SUBSTANCE", 126, 130], ["RANTES", "PROTEIN", 96, 102], ["mice", "SPECIES", 39, 43], ["TBEV", "SPECIES", 25, 29], ["mice", "SPECIES", 39, 43], ["ic infection of TBEV", "PROBLEM", 9, 29], ["ic", "OBSERVATION_MODIFIER", 9, 11], ["infection", "OBSERVATION", 12, 21], ["TBEV", "OBSERVATION", 25, 29], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["increase", "OBSERVATION_MODIFIER", 71, 79]]], ["These findings suggest that the capability of inducing RANTES expression by TBEV infection seems not to depend on age of the mouse.", [["TBEV infection", "DISEASE", 76, 90], ["RANTES", "GENE_OR_GENE_PRODUCT", 55, 61], ["TBEV", "ORGANISM", 76, 80], ["mouse", "ORGANISM", 125, 130], ["RANTES", "PROTEIN", 55, 61], ["mouse", "SPECIES", 125, 130], ["TBEV", "SPECIES", 76, 80], ["mouse", "SPECIES", 125, 130], ["inducing RANTES expression", "TREATMENT", 46, 72], ["TBEV infection", "PROBLEM", 76, 90]]], ["Even though the neonatal immune system is somewhat less mature than those of adult, neonates are not immune privileged, especially under high inflammatory conditions.", [["neonates", "ORGANISM", 84, 92], ["high inflammatory conditions", "PROBLEM", 137, 165], ["less mature", "OBSERVATION_MODIFIER", 51, 62]]], ["A large body of evidence indicated that the mouse neonatal immune system is capable of mounting virus-specific T cell-based immune responses, as well as protective memory and Ab responses [43] [44] [45] .", [["T cell", "ANATOMY", 111, 117], ["mouse", "ORGANISM", 44, 49], ["immune system", "ANATOMICAL_SYSTEM", 59, 72], ["T cell", "CELL", 111, 117], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 44, 49], ["the mouse neonatal immune system", "PROBLEM", 40, 72], ["mounting virus", "PROBLEM", 87, 101], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["In other studies, increased expression of RANTES was found in neonatal mice after infection with viruses such as coxsackievirus B3 [46] and influenza virus [47] or protozoan parasite such as Cryptosporidium parvum [48] .", [["infection", "DISEASE", 82, 91], ["influenza virus", "DISEASE", 140, 155], ["protozoan parasite", "DISEASE", 164, 182], ["Cryptosporidium parvum", "DISEASE", 191, 213], ["RANTES", "GENE_OR_GENE_PRODUCT", 42, 48], ["mice", "ORGANISM", 71, 75], ["coxsackievirus B3 [46]", "ORGANISM", 113, 135], ["influenza virus", "ORGANISM", 140, 155], ["Cryptosporidium parvum", "ORGANISM", 191, 213], ["RANTES", "PROTEIN", 42, 48], ["mice", "SPECIES", 71, 75], ["coxsackievirus B3", "SPECIES", 113, 130], ["influenza virus", "SPECIES", 140, 155], ["Cryptosporidium parvum", "SPECIES", 191, 213], ["mice", "SPECIES", 71, 75], ["coxsackievirus B3", "SPECIES", 113, 130], ["Cryptosporidium parvum", "SPECIES", 191, 213], ["other studies", "TEST", 3, 16], ["increased expression of RANTES", "PROBLEM", 18, 48], ["infection", "PROBLEM", 82, 91], ["viruses", "PROBLEM", 97, 104], ["coxsackievirus B3", "PROBLEM", 113, 130], ["influenza virus", "PROBLEM", 140, 155], ["protozoan parasite", "PROBLEM", 164, 182], ["Cryptosporidium parvum", "PROBLEM", 191, 213], ["infection", "OBSERVATION", 82, 91]]], ["It should be noted that though neonatal mice are a relatively highsensitive model for the study of flavivirus infections, peripheral administration of WH2012 strain via either ip, sc [18] , or im (data not shown) route did not lead to 100 % lethality.", [["flavivirus infections", "DISEASE", 99, 120], ["WH2012", "CHEMICAL", 151, 157], ["mice", "ORGANISM", 40, 44], ["flavivirus", "ORGANISM", 99, 109], ["ip", "SIMPLE_CHEMICAL", 176, 178], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["flavivirus", "SPECIES", 99, 109], ["the study", "TEST", 86, 95], ["flavivirus infections", "PROBLEM", 99, 120], ["peripheral administration", "TREATMENT", 122, 147]]], ["These data indicate that WH2012 strain used in this study is less pathogenic, as compared with some highly virulent TBEV isolates, such as strain Hypr [49] and strain Sofjin [50] .DiscussionRANTES is usually significantly induced following viral infection, and its production represents a characteristic of neuroinflammation [51] .", [["WH2012", "CHEMICAL", 25, 31], ["viral infection", "DISEASE", 240, 255], ["neuroinflammation", "DISEASE", 307, 324], ["WH2012 strain", "ORGANISM", 25, 38], ["TBEV isolates", "ORGANISM", 116, 129], ["TBEV", "SPECIES", 116, 120], ["These data", "TEST", 0, 10], ["WH2012 strain", "PROBLEM", 25, 38], ["this study", "TEST", 47, 57], ["some highly virulent TBEV isolates", "PROBLEM", 95, 129], ["strain Hypr", "TEST", 139, 150], ["viral infection", "PROBLEM", 240, 255], ["neuroinflammation", "PROBLEM", 307, 324], ["less", "OBSERVATION_MODIFIER", 61, 65], ["pathogenic", "OBSERVATION", 66, 76], ["viral", "OBSERVATION_MODIFIER", 240, 245], ["infection", "OBSERVATION", 246, 255], ["neuroinflammation", "OBSERVATION", 307, 324]]], ["It has been reported that several viruses including human immunodeficiency virus type 1 (HIV-1), herpes simplex virus-1 (HSV-1), Japanese encephalitis virus (JEV), mouse hepatitis virus (MHV), and rabies virus (RABV) can up-regulate RANTES production within CNS [52] [53] [54] [55] [56] .", [["human immunodeficiency virus", "DISEASE", 52, 80], ["herpes simplex virus", "DISEASE", 97, 117], ["Japanese encephalitis", "DISEASE", 129, 150], ["JEV", "DISEASE", 158, 161], ["mouse hepatitis virus", "DISEASE", 164, 185], ["human immunodeficiency virus type 1", "ORGANISM", 52, 87], ["HIV-1", "ORGANISM", 89, 94], ["herpes simplex virus-1", "ORGANISM", 97, 119], ["HSV-1", "ORGANISM", 121, 126], ["Japanese encephalitis virus", "ORGANISM", 129, 156], ["JEV", "ORGANISM", 158, 161], ["mouse hepatitis virus", "ORGANISM", 164, 185], ["MHV", "ORGANISM", 187, 190], ["rabies virus", "ORGANISM", 197, 209], ["RABV", "ORGANISM", 211, 215], ["RANTES", "GENE_OR_GENE_PRODUCT", 233, 239], ["CNS [52] [53] [54] [55", "SIMPLE_CHEMICAL", 258, 280], ["RANTES", "PROTEIN", 233, 239], ["human immunodeficiency virus type 1", "SPECIES", 52, 87], ["HIV-1", "SPECIES", 89, 94], ["herpes simplex virus-1", "SPECIES", 97, 119], ["HSV-1", "SPECIES", 121, 126], ["Japanese encephalitis virus", "SPECIES", 129, 156], ["mouse", "SPECIES", 164, 169], ["hepatitis virus", "SPECIES", 170, 185], ["rabies virus", "SPECIES", 197, 209], ["human immunodeficiency virus type 1", "SPECIES", 52, 87], ["HIV-1", "SPECIES", 89, 94], ["herpes simplex virus-1", "SPECIES", 97, 119], ["HSV-1", "SPECIES", 121, 126], ["Japanese encephalitis virus", "SPECIES", 129, 156], ["JEV", "SPECIES", 158, 161], ["mouse hepatitis virus", "SPECIES", 164, 185], ["MHV", "SPECIES", 187, 190], ["rabies virus", "SPECIES", 197, 209], ["RABV", "SPECIES", 211, 215], ["several viruses", "PROBLEM", 26, 41], ["human immunodeficiency virus type", "TEST", 52, 85], ["HIV", "TEST", 89, 92], ["herpes simplex virus", "TEST", 97, 117], ["HSV", "TEST", 121, 124], ["Japanese encephalitis virus (JEV)", "PROBLEM", 129, 162], ["mouse hepatitis virus (MHV)", "PROBLEM", 164, 191], ["rabies virus", "PROBLEM", 197, 209], ["several", "OBSERVATION_MODIFIER", 26, 33], ["viruses", "OBSERVATION", 34, 41]]], ["Moreover, we demonstrated a TBEV-induced robust expression of RANTES in human brain-derived cell cultures that recapitulated the cell types normally found in the brain including neurons, astrocytes, and microglia.", [["brain", "ANATOMY", 78, 83], ["cell cultures", "ANATOMY", 92, 105], ["cell", "ANATOMY", 129, 133], ["brain", "ANATOMY", 162, 167], ["neurons", "ANATOMY", 178, 185], ["astrocytes", "ANATOMY", 187, 197], ["microglia", "ANATOMY", 203, 212], ["TBEV", "DISEASE", 28, 32], ["TBEV", "ORGANISM", 28, 32], ["RANTES", "GENE_OR_GENE_PRODUCT", 62, 68], ["human", "ORGANISM", 72, 77], ["brain-derived cell cultures", "CELL", 78, 105], ["cell", "CELL", 129, 133], ["brain", "ORGAN", 162, 167], ["neurons", "CELL", 178, 185], ["astrocytes", "CELL", 187, 197], ["microglia", "CELL", 203, 212], ["RANTES", "PROTEIN", 62, 68], ["human brain-derived cell cultures", "CELL_LINE", 72, 105], ["neurons", "CELL_TYPE", 178, 185], ["astrocytes", "CELL_TYPE", 187, 197], ["microglia", "CELL_TYPE", 203, 212], ["human", "SPECIES", 72, 77], ["TBEV", "SPECIES", 28, 32], ["human", "SPECIES", 72, 77], ["a TBEV", "PROBLEM", 26, 32], ["RANTES in human brain", "PROBLEM", 62, 83], ["derived cell cultures", "TEST", 84, 105], ["the cell types", "TEST", 125, 139], ["microglia", "PROBLEM", 203, 212], ["TBEV", "OBSERVATION", 28, 32], ["cell types", "OBSERVATION", 129, 139], ["brain", "ANATOMY", 162, 167], ["neurons", "ANATOMY", 178, 185], ["astrocytes", "ANATOMY", 187, 197], ["microglia", "ANATOMY", 203, 212]]], ["It is worth noting that RANTES was dramatically increased neither in tested peripheral tissues nor in sera.", [["peripheral tissues", "ANATOMY", 76, 94], ["sera", "ANATOMY", 102, 106], ["RANTES", "GENE_OR_GENE_PRODUCT", 24, 30], ["peripheral tissues", "TISSUE", 76, 94], ["sera", "ORGANISM_SUBSTANCE", 102, 106], ["RANTES", "PROTEIN", 24, 30], ["RANTES", "OBSERVATION", 24, 30], ["dramatically", "OBSERVATION_MODIFIER", 35, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["peripheral tissues", "ANATOMY", 76, 94]]], ["Similar findings were previously reported in human cases of TBE, showing that RANTES was significantly increased in CSF, but not in sera [12, 14] .", [["CSF", "ANATOMY", 116, 119], ["sera", "ANATOMY", 132, 136], ["TBE", "DISEASE", 60, 63], ["human", "ORGANISM", 45, 50], ["RANTES", "GENE_OR_GENE_PRODUCT", 78, 84], ["CSF", "ORGANISM_SUBSTANCE", 116, 119], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["RANTES", "PROTEIN", 78, 84], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["TBE", "SPECIES", 60, 63], ["TBE", "PROBLEM", 60, 63], ["RANTES", "TEST", 78, 84], ["RANTES", "OBSERVATION", 78, 84], ["significantly", "OBSERVATION_MODIFIER", 89, 102], ["increased", "OBSERVATION_MODIFIER", 103, 112]]], ["Furthermore, our in vitro culture systems showed that TBEV induces the production of RANTES which is functionally active in recruiting human monocytic cells.", [["monocytic cells", "ANATOMY", 141, 156], ["TBEV", "ORGANISM", 54, 58], ["RANTES", "GENE_OR_GENE_PRODUCT", 85, 91], ["human", "ORGANISM", 135, 140], ["monocytic cells", "CELL", 141, 156], ["RANTES", "PROTEIN", 85, 91], ["human monocytic cells", "CELL_TYPE", 135, 156], ["human", "SPECIES", 135, 140], ["TBEV", "SPECIES", 54, 58], ["human", "SPECIES", 135, 140], ["our in vitro culture systems", "TEST", 13, 41], ["TBEV", "PROBLEM", 54, 58], ["the production of RANTES", "PROBLEM", 67, 91], ["TBEV", "OBSERVATION", 54, 58], ["active", "OBSERVATION_MODIFIER", 114, 120], ["human monocytic cells", "OBSERVATION", 135, 156]]], ["Therefore, the strikingly high expression of RANTES within CNS is likely to be one of the mediators that form a concentration gradient in the brain during TBEV infection.", [["CNS", "ANATOMY", 59, 62], ["brain", "ANATOMY", 142, 147], ["TBEV infection", "DISEASE", 155, 169], ["RANTES", "GENE_OR_GENE_PRODUCT", 45, 51], ["CNS", "ANATOMICAL_SYSTEM", 59, 62], ["brain", "ORGAN", 142, 147], ["TBEV", "ORGANISM", 155, 159], ["RANTES", "PROTEIN", 45, 51], ["TBEV", "SPECIES", 155, 159], ["a concentration gradient in the brain", "PROBLEM", 110, 147], ["TBEV infection", "PROBLEM", 155, 169], ["high", "OBSERVATION_MODIFIER", 26, 30], ["RANTES", "OBSERVATION", 45, 51], ["concentration gradient", "OBSERVATION", 112, 134], ["brain", "ANATOMY", 142, 147], ["TBEV infection", "OBSERVATION", 155, 169]]], ["For describing a specific involvement of RANTES in experimental TBE, future research should define the activated cell types which will be recruited into CNS after RANTES production upon TBEV infection.DiscussionIn this work, we observed that treatment of mice with Met-RANTES or anti-RANTES mAb prolonged survival and decreased cellular infiltrates in the brain.", [["cell", "ANATOMY", 113, 117], ["CNS", "ANATOMY", 153, 156], ["cellular", "ANATOMY", 328, 336], ["brain", "ANATOMY", 356, 361], ["TBE", "DISEASE", 64, 67], ["TBEV infection", "DISEASE", 186, 200], ["Met-RANTES", "CHEMICAL", 265, 275], ["Met-RANTES", "CHEMICAL", 265, 275], ["RANTES", "GENE_OR_GENE_PRODUCT", 41, 47], ["cell", "CELL", 113, 117], ["CNS", "ANATOMICAL_SYSTEM", 153, 156], ["RANTES", "GENE_OR_GENE_PRODUCT", 163, 169], ["TBEV", "ORGANISM", 186, 190], ["mice", "ORGANISM", 255, 259], ["Met-RANTES", "SIMPLE_CHEMICAL", 265, 275], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 279, 294], ["cellular", "CELL", 328, 336], ["brain", "ORGAN", 356, 361], ["RANTES", "PROTEIN", 41, 47], ["RANTES", "PROTEIN", 163, 169], ["Met-RANTES", "PROTEIN", 265, 275], ["anti-RANTES mAb", "PROTEIN", 279, 294], ["mice", "SPECIES", 255, 259], ["TBE", "SPECIES", 64, 67], ["TBEV", "SPECIES", 186, 190], ["mice", "SPECIES", 255, 259], ["RANTES in experimental TBE", "PROBLEM", 41, 67], ["the activated cell types", "PROBLEM", 99, 123], ["TBEV infection", "PROBLEM", 186, 200], ["treatment of mice with Met-RANTES", "TREATMENT", 242, 275], ["anti-RANTES mAb", "TREATMENT", 279, 294], ["decreased cellular infiltrates in the brain", "PROBLEM", 318, 361], ["decreased", "OBSERVATION_MODIFIER", 318, 327], ["cellular", "OBSERVATION_MODIFIER", 328, 336], ["infiltrates", "OBSERVATION", 337, 348], ["brain", "ANATOMY", 356, 361]]], ["In agreement with our study, a previous report showed that, in a severe herpes simplex encephalitis mouse model, treatment with either Met-RANTES or anti-RANTES mAb decreased leukocyte recruitment into the brain of HSV-1infected mice [54] .", [["leukocyte", "ANATOMY", 175, 184], ["brain", "ANATOMY", 206, 211], ["herpes simplex encephalitis", "DISEASE", 72, 99], ["Met-RANTES", "CHEMICAL", 135, 145], ["herpes simplex encephalitis mouse", "ORGANISM", 72, 105], ["Met-RANTES", "SIMPLE_CHEMICAL", 135, 145], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 149, 164], ["leukocyte", "CELL", 175, 184], ["brain", "ORGAN", 206, 211], ["HSV-1infected", "ORGANISM", 215, 228], ["mice", "ORGANISM", 229, 233], ["Met-RANTES", "PROTEIN", 135, 145], ["anti-RANTES mAb", "PROTEIN", 149, 164], ["herpes simplex encephalitis", "SPECIES", 72, 99], ["mouse", "SPECIES", 100, 105], ["mice", "SPECIES", 229, 233], ["mouse", "SPECIES", 100, 105], ["HSV-1infected mice", "SPECIES", 215, 233], ["our study", "TEST", 18, 27], ["a severe herpes simplex encephalitis mouse model", "PROBLEM", 63, 111], ["Met-RANTES", "TREATMENT", 135, 145], ["anti-RANTES mAb", "TREATMENT", 149, 164], ["leukocyte recruitment", "TREATMENT", 175, 196], ["HSV", "TEST", 215, 218], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["brain", "ANATOMY", 206, 211]]], ["Moreover, Met-RANTES treatment significantly reduced proinflammatory chemokine or cytokine production in the CNS and prolonged survival time of the mice after RABV infection [56] .", [["CNS", "ANATOMY", 109, 112], ["Met-RANTES", "CHEMICAL", 10, 20], ["RABV infection", "DISEASE", 159, 173], ["Met-RANTES", "CHEMICAL", 10, 20], ["Met-RANTES", "SIMPLE_CHEMICAL", 10, 20], ["CNS", "ANATOMICAL_SYSTEM", 109, 112], ["mice", "ORGANISM", 148, 152], ["RABV", "ORGANISM", 159, 163], ["proinflammatory chemokine", "PROTEIN", 53, 78], ["cytokine", "PROTEIN", 82, 90], ["mice", "SPECIES", 148, 152], ["mice", "SPECIES", 148, 152], ["RABV", "SPECIES", 159, 163], ["Met-RANTES treatment", "TREATMENT", 10, 30], ["reduced proinflammatory chemokine", "PROBLEM", 45, 78], ["cytokine production", "PROBLEM", 82, 101], ["RABV infection", "PROBLEM", 159, 173], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["proinflammatory chemokine", "OBSERVATION", 53, 78], ["cytokine production", "OBSERVATION", 82, 101], ["CNS", "ANATOMY", 109, 112]]], ["Considering the important role of RANTES in exerting a potent chemotactic effect on both monocytes and T cells, our data suggest that both immune cells infiltrate reduction and survival extension in treated TBEVinfected mice was, at least in part, correlated with the blockade of RANTES alone.", [["monocytes", "ANATOMY", 89, 98], ["T cells", "ANATOMY", 103, 110], ["immune cells", "ANATOMY", 139, 151], ["RANTES", "GENE_OR_GENE_PRODUCT", 34, 40], ["monocytes", "CELL", 89, 98], ["T cells", "CELL", 103, 110], ["immune cells", "CELL", 139, 151], ["mice", "ORGANISM", 220, 224], ["RANTES", "GENE_OR_GENE_PRODUCT", 280, 286], ["RANTES", "PROTEIN", 34, 40], ["monocytes", "CELL_TYPE", 89, 98], ["T cells", "CELL_TYPE", 103, 110], ["immune cells", "CELL_TYPE", 139, 151], ["RANTES", "PROTEIN", 280, 286], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 220, 224], ["a potent chemotactic effect", "TREATMENT", 53, 80], ["our data", "TEST", 112, 120], ["immune cells infiltrate reduction", "TREATMENT", 139, 172], ["survival extension", "PROBLEM", 177, 195], ["the blockade of RANTES alone", "TREATMENT", 264, 292], ["immune cells", "OBSERVATION", 139, 151]]], ["Early studies demonstrated the importance of CCR5, which is one of the receptors of RANTES, as a protective factor in the context of flaviviral infections.", [["flaviviral infections", "DISEASE", 133, 154], ["CCR5", "GENE_OR_GENE_PRODUCT", 45, 49], ["RANTES", "GENE_OR_GENE_PRODUCT", 84, 90], ["CCR5", "PROTEIN", 45, 49], ["RANTES", "PROTEIN", 84, 90], ["Early studies", "TEST", 0, 13], ["CCR5", "TREATMENT", 45, 49], ["a protective factor", "PROBLEM", 95, 114], ["flaviviral infections", "PROBLEM", 133, 154], ["infections", "OBSERVATION", 144, 154]]], ["With the use of knockout mice, it was demonstrated that CCR5 deficiency reduced immune cell infiltration of the CNS and increased mortality after peripheral inoculation of WNV [57] or JEV [58] .", [["immune cell", "ANATOMY", 80, 91], ["CNS", "ANATOMY", 112, 115], ["mice", "ORGANISM", 25, 29], ["CCR5", "GENE_OR_GENE_PRODUCT", 56, 60], ["immune cell", "CELL", 80, 91], ["CNS", "ANATOMICAL_SYSTEM", 112, 115], ["WNV", "ORGANISM", 172, 175], ["JEV", "ORGANISM", 184, 187], ["CCR5", "PROTEIN", 56, 60], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["WNV", "SPECIES", 172, 175], ["JEV", "SPECIES", 184, 187], ["knockout mice", "TREATMENT", 16, 29], ["CCR5 deficiency", "PROBLEM", 56, 71], ["immune cell infiltration", "PROBLEM", 80, 104], ["the CNS", "PROBLEM", 108, 115], ["increased mortality", "PROBLEM", 120, 139], ["peripheral inoculation of WNV", "PROBLEM", 146, 175], ["JEV", "PROBLEM", 184, 187], ["immune cell infiltration", "OBSERVATION", 80, 104], ["CNS", "ANATOMY", 112, 115], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["mortality", "OBSERVATION_MODIFIER", 130, 139]]], ["In humans, homozygosity for the CCR5\u039432 allele is associated with the predisposition to the clinical TBE in Lithuanian people [59, 60] , but not Russian people [61] .", [["TBE", "DISEASE", 101, 104], ["humans", "ORGANISM", 3, 9], ["CCR5\u039432", "GENE_OR_GENE_PRODUCT", 32, 39], ["people", "ORGANISM", 119, 125], ["people", "ORGANISM", 153, 159], ["CCR5\u039432 allele", "DNA", 32, 46], ["humans", "SPECIES", 3, 9], ["people", "SPECIES", 119, 125], ["people", "SPECIES", 153, 159], ["humans", "SPECIES", 3, 9]]], ["These findings suggest that CCR5 deficiency is probably relevant to a weakened immune defense against evading flaviviruses.", [["flaviviruses", "DISEASE", 110, 122], ["CCR5", "GENE_OR_GENE_PRODUCT", 28, 32], ["CCR5", "PROTEIN", 28, 32], ["CCR5 deficiency", "PROBLEM", 28, 43], ["a weakened immune defense", "PROBLEM", 68, 93], ["evading flaviviruses", "PROBLEM", 102, 122], ["CCR5 deficiency", "OBSERVATION", 28, 43]]], ["However, it can be speculated that direct administration of a receptor antagonist to the brain is clearly different to a systemic loss of the receptor, which may be ascribes to significant difference between the immune response elicited in the CNS and the response in the periphery.", [["brain", "ANATOMY", 89, 94], ["CNS", "ANATOMY", 244, 247], ["brain", "ORGAN", 89, 94], ["CNS", "ANATOMICAL_SYSTEM", 244, 247], ["a receptor antagonist", "TREATMENT", 60, 81], ["a systemic loss of the receptor", "PROBLEM", 119, 150], ["the immune response", "TEST", 208, 227], ["brain", "ANATOMY", 89, 94], ["systemic", "OBSERVATION_MODIFIER", 121, 129], ["loss", "OBSERVATION", 130, 134], ["may be", "UNCERTAINTY", 158, 164], ["immune response", "OBSERVATION", 212, 227], ["CNS", "ANATOMY", 244, 247], ["periphery", "ANATOMY_MODIFIER", 272, 281]]], ["Moreover, it would be expected that antagonizing RANTES alone may differ from blockade of CCR5, in which both binding of a number of chemokines and recruitment of main immune cell types may be affected.", [["immune cell", "ANATOMY", 168, 179], ["RANTES", "GENE_OR_GENE_PRODUCT", 49, 55], ["CCR5", "GENE_OR_GENE_PRODUCT", 90, 94], ["immune cell", "CELL", 168, 179], ["RANTES", "PROTEIN", 49, 55], ["CCR5", "PROTEIN", 90, 94], ["chemokines", "PROTEIN", 133, 143], ["antagonizing RANTES alone", "TREATMENT", 36, 61], ["blockade of CCR5", "TREATMENT", 78, 94], ["chemokines", "TREATMENT", 133, 143], ["main immune cell types", "OBSERVATION", 163, 185]]], ["In this study, we were not able to draw any conclusions on relationships between disease severities of TBE and a functional RANTES-CCR5 axis.", [["TBE", "DISEASE", 103, 106], ["RANTES", "GENE_OR_GENE_PRODUCT", 124, 130], ["CCR5", "GENE_OR_GENE_PRODUCT", 131, 135], ["RANTES", "PROTEIN", 124, 130], ["CCR5", "PROTEIN", 131, 135], ["this study", "TEST", 3, 13], ["disease severities of TBE", "PROBLEM", 81, 106], ["a functional RANTES", "TEST", 111, 130]]], ["Future studies with conditional RANTES and CCR5 knockout mouse models may help delineating the pathogenic mechanisms of the disease.DiscussionIt is worth noting that despite remarkable prolongation of survival times of infected mice after Met-RANTES and anti-RANTES mAb treatments, both strategies led to no change in viral burdens following a high inoculum of TBEV injection in the brain.", [["brain", "ANATOMY", 383, 388], ["Met-RANTES", "CHEMICAL", 239, 249], ["RANTES", "GENE_OR_GENE_PRODUCT", 32, 38], ["CCR5", "GENE_OR_GENE_PRODUCT", 43, 47], ["mouse", "ORGANISM", 57, 62], ["mice", "ORGANISM", 228, 232], ["Met-RANTES", "SIMPLE_CHEMICAL", 239, 249], ["anti-RANTES mAb", "GENE_OR_GENE_PRODUCT", 254, 269], ["TBEV", "ORGANISM", 361, 365], ["brain", "ORGAN", 383, 388], ["RANTES", "PROTEIN", 32, 38], ["CCR5", "PROTEIN", 43, 47], ["anti-RANTES mAb", "PROTEIN", 254, 269], ["mouse", "SPECIES", 57, 62], ["mice", "SPECIES", 228, 232], ["mouse", "SPECIES", 57, 62], ["mice", "SPECIES", 228, 232], ["TBEV", "SPECIES", 361, 365], ["Future studies", "TEST", 0, 14], ["conditional RANTES", "TREATMENT", 20, 38], ["CCR5 knockout mouse models", "TREATMENT", 43, 69], ["the disease", "PROBLEM", 120, 131], ["Met-RANTES", "TREATMENT", 239, 249], ["anti-RANTES mAb treatments", "TREATMENT", 254, 280], ["change in viral burdens", "PROBLEM", 308, 331], ["a high inoculum of TBEV injection", "TREATMENT", 342, 375], ["disease", "OBSERVATION", 124, 131], ["viral burdens", "OBSERVATION", 318, 331], ["brain", "ANATOMY", 383, 388]]], ["Therefore, it seems that blockade of RANTES within CNS appears to result in alteration of the immune/inflammatory response, rather than a simple modulation of increase or decrease in the level of TBEV infection.", [["CNS", "ANATOMY", 51, 54], ["TBEV infection", "DISEASE", 196, 210], ["RANTES", "GENE_OR_GENE_PRODUCT", 37, 43], ["CNS", "ANATOMICAL_SYSTEM", 51, 54], ["TBEV", "ORGANISM", 196, 200], ["RANTES", "PROTEIN", 37, 43], ["TBEV", "SPECIES", 196, 200], ["blockade of RANTES within CNS", "PROBLEM", 25, 54], ["the immune/inflammatory response", "PROBLEM", 90, 122], ["TBEV infection", "PROBLEM", 196, 210], ["RANTES", "OBSERVATION", 37, 43], ["inflammatory", "OBSERVATION_MODIFIER", 101, 113], ["simple", "OBSERVATION_MODIFIER", 138, 144], ["modulation", "OBSERVATION_MODIFIER", 145, 155], ["increase", "OBSERVATION_MODIFIER", 159, 167], ["decrease", "OBSERVATION_MODIFIER", 171, 179], ["TBEV infection", "OBSERVATION", 196, 210]]], ["Since both viral infection and host immune responses likely contribute to the pathogenesis of TBE, enhancement of the antiviral activity against TBEV and amelioration of the neuroinflammatory response may theoretically help in reducing the severity of the disease.", [["viral infection", "DISEASE", 11, 26], ["TBE", "DISEASE", 94, 97], ["TBEV", "DISEASE", 145, 149], ["TBEV", "ORGANISM", 145, 149], ["TBE", "SPECIES", 94, 97], ["TBEV", "SPECIES", 145, 149], ["both viral infection", "PROBLEM", 6, 26], ["the pathogenesis of TBE", "PROBLEM", 74, 97], ["the antiviral activity", "PROBLEM", 114, 136], ["TBEV", "PROBLEM", 145, 149], ["the neuroinflammatory response", "PROBLEM", 170, 200], ["the disease", "PROBLEM", 252, 263], ["viral", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26], ["TBE", "OBSERVATION", 94, 97], ["antiviral activity", "OBSERVATION", 118, 136], ["neuroinflammatory response", "OBSERVATION", 174, 200], ["disease", "OBSERVATION", 256, 263]]], ["Further studies are needed to determine whether concomitant administration of antivirus drugs together with antiinflammatory agents could offer an additive beneficial effect on TBE.", [["TBE", "SPECIES", 177, 180], ["Further studies", "TEST", 0, 15], ["antivirus drugs", "TREATMENT", 78, 93], ["antiinflammatory agents", "TREATMENT", 108, 131]]], ["With respect to other chemokines induced by TBEV, antagonizing MCP-1 within CNS did not significantly ameliorate TBEV infection (data not shown).", [["CNS", "ANATOMY", 76, 79], ["TBEV infection", "DISEASE", 113, 127], ["TBEV", "ORGANISM", 44, 48], ["MCP-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["CNS", "ANATOMICAL_SYSTEM", 76, 79], ["TBEV", "ORGANISM", 113, 117], ["chemokines", "PROTEIN", 22, 32], ["MCP", "PROTEIN", 63, 66], ["TBEV", "SPECIES", 44, 48], ["TBEV", "SPECIES", 113, 117], ["TBEV", "PROBLEM", 44, 48], ["antagonizing MCP", "TEST", 50, 66], ["TBEV infection", "PROBLEM", 113, 127], ["infection", "OBSERVATION", 118, 127]]], ["However, future research is warranted to explore whether some of the detected or as yet unidentified immune mediators contribute individually and synergistically to neuroinflammatory responses in the process of TBEV infection.DiscussionIn this study, we found that TBEV infection could induce RANTES production in human brain-derived cell lines and primary progenitor-derived astrocytes in vitro.", [["brain-derived cell lines", "ANATOMY", 320, 344], ["primary progenitor-derived astrocytes", "ANATOMY", 349, 386], ["TBEV infection", "DISEASE", 211, 225], ["TBEV infection", "DISEASE", 265, 279], ["TBEV", "ORGANISM", 211, 215], ["TBEV", "ORGANISM", 265, 269], ["RANTES", "GENE_OR_GENE_PRODUCT", 293, 299], ["human", "ORGANISM", 314, 319], ["brain-derived cell lines", "CELL", 320, 344], ["primary progenitor-derived astrocytes", "CELL", 349, 386], ["RANTES", "PROTEIN", 293, 299], ["human brain-derived cell lines", "CELL_LINE", 314, 344], ["primary progenitor-derived astrocytes", "CELL_TYPE", 349, 386], ["human", "SPECIES", 314, 319], ["TBEV", "SPECIES", 211, 215], ["TBEV", "SPECIES", 265, 269], ["human", "SPECIES", 314, 319], ["TBEV infection", "PROBLEM", 211, 225], ["this study", "TEST", 239, 249], ["TBEV infection", "PROBLEM", 265, 279], ["RANTES production in human brain", "PROBLEM", 293, 325], ["derived cell lines", "TREATMENT", 326, 344], ["primary progenitor", "TREATMENT", 349, 367], ["TBEV infection", "OBSERVATION", 211, 225], ["TBEV", "OBSERVATION", 265, 269], ["cell lines", "OBSERVATION", 334, 344]]], ["This up-regulation was not detectable as early as 6 h p.i., and measurable RANTES mRNA expression and protein release only occurred between 24 and 48 h p.i.", [["RANTES", "GENE_OR_GENE_PRODUCT", 75, 81], ["RANTES mRNA", "RNA", 75, 86], ["protein release", "TEST", 102, 117]]], ["The results observed here are reminiscent of some previous studies on delay of IFN induction upon TBEV infection.", [["IFN", "CHEMICAL", 79, 82], ["TBEV infection", "DISEASE", 98, 112], ["IFN", "GENE_OR_GENE_PRODUCT", 79, 82], ["TBEV", "ORGANISM", 98, 102], ["IFN", "PROTEIN", 79, 82], ["TBEV", "SPECIES", 98, 102], ["IFN induction", "TREATMENT", 79, 92], ["TBEV infection", "PROBLEM", 98, 112]]], ["At early stages of infection, viral double-stranded RNA (dsRNA) was mainly found within ER-derived vesicles, thus to be largely unavailable for cytoplasmic pattern recognition receptors (PRR) [62, 63] .", [["ER-derived vesicles", "ANATOMY", 88, 107], ["cytoplasmic", "ANATOMY", 144, 155], ["infection", "DISEASE", 19, 28], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["vesicles", "CELLULAR_COMPONENT", 99, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 144, 155], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 156, 185], ["PRR", "GENE_OR_GENE_PRODUCT", 187, 190], ["viral double-stranded RNA", "RNA", 30, 55], ["ER", "PROTEIN", 88, 90], ["cytoplasmic pattern recognition receptors", "PROTEIN", 144, 185], ["PRR", "PROTEIN", 187, 190], ["infection", "PROBLEM", 19, 28], ["viral double-stranded RNA (dsRNA", "PROBLEM", 30, 62], ["infection", "OBSERVATION", 19, 28], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["double", "OBSERVATION_MODIFIER", 36, 42], ["stranded RNA", "OBSERVATION_MODIFIER", 43, 55]]], ["Similarly, the mechanism behind the delay of RANTES production might also be that TBEV induces replication vesicles, thereby delaying the detection of viral dsRNA by PRR sensors.", [["vesicles", "ANATOMY", 107, 115], ["RANTES", "GENE_OR_GENE_PRODUCT", 45, 51], ["TBEV", "ORGANISM", 82, 86], ["vesicles", "CELLULAR_COMPONENT", 107, 115], ["PRR", "GENE_OR_GENE_PRODUCT", 166, 169], ["RANTES", "PROTEIN", 45, 51], ["viral dsRNA", "RNA", 151, 162], ["PRR", "PROTEIN", 166, 169], ["TBEV", "SPECIES", 82, 86], ["the delay of RANTES production", "PROBLEM", 32, 62], ["TBEV", "PROBLEM", 82, 86], ["replication vesicles", "PROBLEM", 95, 115], ["viral dsRNA", "PROBLEM", 151, 162], ["TBEV", "OBSERVATION", 82, 86], ["viral dsRNA", "OBSERVATION", 151, 162]]], ["Although it is known that TBEV infection can induce RANTES production in vivo and in vitro, the underlying mechanism contributing to the induction of RANTES after TBEV infection has not been explored.", [["TBEV infection", "DISEASE", 26, 40], ["TBEV infection", "DISEASE", 163, 177], ["TBEV", "ORGANISM", 26, 30], ["RANTES", "GENE_OR_GENE_PRODUCT", 52, 58], ["RANTES", "GENE_OR_GENE_PRODUCT", 150, 156], ["TBEV", "ORGANISM", 163, 167], ["RANTES", "PROTEIN", 52, 58], ["RANTES", "PROTEIN", 150, 156], ["TBEV", "SPECIES", 26, 30], ["TBEV", "SPECIES", 163, 167], ["TBEV infection", "PROBLEM", 26, 40], ["the induction of RANTES", "TREATMENT", 133, 156], ["TBEV infection", "PROBLEM", 163, 177], ["TBEV", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 31, 40]]], ["Using brain-derived cells as a model, we demonstrated that TBEV infection activated the RANTES promoter in both time-and dose-dependent manners.", [["brain-derived cells", "ANATOMY", 6, 25], ["TBEV infection", "DISEASE", 59, 73], ["brain-derived cells", "CELL", 6, 25], ["TBEV", "ORGANISM", 59, 63], ["RANTES", "GENE_OR_GENE_PRODUCT", 88, 94], ["brain-derived cells", "CELL_TYPE", 6, 25], ["RANTES promoter", "DNA", 88, 103], ["TBEV", "SPECIES", 59, 63], ["TBEV infection", "PROBLEM", 59, 73], ["the RANTES promoter", "TREATMENT", 84, 103], ["TBEV infection", "OBSERVATION", 59, 73]]], ["It is generally believed that expression of many of the chemokine genes is regulated primarily at the level of transcription, and their promoter regions contain recognition sites for virus-activated transcription factors [64] .", [["chemokine genes", "DNA", 56, 71], ["promoter regions", "DNA", 136, 152], ["recognition sites", "DNA", 161, 178], ["virus-activated transcription factors", "PROTEIN", 183, 220], ["the chemokine genes", "PROBLEM", 52, 71], ["virus", "PROBLEM", 183, 188], ["activated transcription factors", "PROBLEM", 189, 220]]], ["Binding sites for a wide variety of transcription factors annotated within the RANTES promoter include IRFs, NF-kB, CCAAT/enhancer-binding protein (C/EBP), and cAMP response element-binding protein (CREB)/activating protein 1 (AP-1) [29, 65] .", [["cAMP", "CHEMICAL", 160, 164], ["RANTES", "GENE_OR_GENE_PRODUCT", 79, 85], ["NF-kB", "GENE_OR_GENE_PRODUCT", 109, 114], ["CCAAT/enhancer-binding protein", "GENE_OR_GENE_PRODUCT", 116, 146], ["C/EBP", "GENE_OR_GENE_PRODUCT", 148, 153], ["cAMP response element-binding protein (CREB)/activating protein 1", "GENE_OR_GENE_PRODUCT", 160, 225], ["AP-1", "GENE_OR_GENE_PRODUCT", 227, 231], ["transcription factors", "PROTEIN", 36, 57], ["RANTES promoter", "DNA", 79, 94], ["IRFs", "PROTEIN", 103, 107], ["NF-kB", "PROTEIN", 109, 114], ["CCAAT/enhancer-binding protein", "PROTEIN", 116, 146], ["EBP", "PROTEIN", 150, 153], ["cAMP response element-binding protein", "PROTEIN", 160, 197], ["CREB", "PROTEIN", 199, 203], ["activating protein 1", "PROTEIN", 205, 225], ["AP", "PROTEIN", 227, 229], ["Binding sites", "PROBLEM", 0, 13], ["transcription factors", "PROBLEM", 36, 57], ["the RANTES promoter", "TREATMENT", 75, 94], ["NF", "TEST", 109, 111], ["CCAAT/enhancer", "TEST", 116, 130], ["binding protein", "TEST", 131, 146], ["C/EBP", "TEST", 148, 153], ["cAMP response element", "TEST", 160, 181], ["binding protein (CREB", "TEST", 182, 203], ["activating protein", "TEST", 205, 223], ["AP", "TEST", 227, 229]]], ["These transcription factors have been shown to contribute to the differential regulation of RANTES gene expression, depending on the virus and the cell type [53, [66] [67] [68] [69] .", [["cell", "ANATOMY", 147, 151], ["RANTES", "GENE_OR_GENE_PRODUCT", 92, 98], ["cell", "CELL", 147, 151], ["transcription factors", "PROTEIN", 6, 27], ["RANTES", "PROTEIN", 92, 98], ["RANTES gene expression", "PROBLEM", 92, 114], ["the virus", "PROBLEM", 129, 138], ["the cell type", "TEST", 143, 156]]], ["We revealed in this study that TBEV-induced transcription of RANTES is mainly mediated by activation of the IRF-3 pathway.", [["TBEV", "DISEASE", 31, 35], ["TBEV", "ORGANISM", 31, 35], ["RANTES", "GENE_OR_GENE_PRODUCT", 61, 67], ["IRF-3", "GENE_OR_GENE_PRODUCT", 108, 113], ["RANTES", "PROTEIN", 61, 67], ["IRF-3", "PROTEIN", 108, 113], ["TBEV", "SPECIES", 31, 35], ["this study", "TEST", 15, 25], ["TBEV", "TEST", 31, 35]]], ["This conclusion is based on several lines of evidence: (i) mutation of the ISRE site almost completely abolished TBEVinduced promoter activation; (ii) over-expression of IRF-3, but not IRF-7 or IkB\u03b1 dominant-negative mutant, efficiently inhibited TBEV-induced RANTES production; (iii) TBEV infection triggered the phosphorylation of endogenous IRF-3 in a time-dependent manner; and (iv) addition of inhibitor targeting TBK1-IRF-3 signaling pathway considerably reduced RANTES production in T98G and CCF-CTTG1 cells.DiscussionFlavivirus infections produce virus replicative intermediate dsRNA, which could be detected by the cytoplasmic RNA sensor RIG-I and MDA5 [70, 71] .", [["T98G", "ANATOMY", 490, 494], ["CCF-CTTG1 cells", "ANATOMY", 499, 514], ["cytoplasmic", "ANATOMY", 624, 635], ["infection", "DISEASE", 290, 299], ["Flavivirus infections", "DISEASE", 525, 546], ["ISRE", "GENE_OR_GENE_PRODUCT", 75, 79], ["IRF-3", "GENE_OR_GENE_PRODUCT", 170, 175], ["IRF-7", "GENE_OR_GENE_PRODUCT", 185, 190], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 194, 198], ["TBEV", "ORGANISM", 247, 251], ["RANTES", "GENE_OR_GENE_PRODUCT", 260, 266], ["TBEV", "ORGANISM", 285, 289], ["IRF-3", "GENE_OR_GENE_PRODUCT", 344, 349], ["TBK1", "GENE_OR_GENE_PRODUCT", 419, 423], ["IRF-3", "GENE_OR_GENE_PRODUCT", 424, 429], ["RANTES", "GENE_OR_GENE_PRODUCT", 469, 475], ["T98G", "CELL", 490, 494], ["CCF-CTTG1 cells", "CELL", 499, 514], ["cytoplasmic", "ORGANISM_SUBSTANCE", 624, 635], ["RIG-I", "GENE_OR_GENE_PRODUCT", 647, 652], ["MDA5", "GENE_OR_GENE_PRODUCT", 657, 661], ["ISRE site", "DNA", 75, 84], ["TBEVinduced promoter", "DNA", 113, 133], ["IRF-3", "PROTEIN", 170, 175], ["IRF-7", "PROTEIN", 185, 190], ["IkB\u03b1 dominant-negative mutant", "PROTEIN", 194, 223], ["RANTES", "PROTEIN", 260, 266], ["endogenous IRF-3", "PROTEIN", 333, 349], ["TBK1", "PROTEIN", 419, 423], ["IRF-3", "PROTEIN", 424, 429], ["RANTES", "PROTEIN", 469, 475], ["T98G", "CELL_LINE", 490, 494], ["CCF-CTTG1 cells", "CELL_LINE", 499, 514], ["cytoplasmic RNA sensor RIG-I", "PROTEIN", 624, 652], ["MDA5", "PROTEIN", 657, 661], ["TBEV", "SPECIES", 247, 251], ["TBEV", "SPECIES", 285, 289], ["mutation of the ISRE site", "PROBLEM", 59, 84], ["IRF", "PROBLEM", 170, 173], ["IRF", "TEST", 185, 188], ["TBEV", "PROBLEM", 247, 251], ["induced RANTES production", "PROBLEM", 252, 277], ["TBEV infection", "PROBLEM", 285, 299], ["endogenous IRF", "PROBLEM", 333, 347], ["inhibitor", "TREATMENT", 399, 408], ["TBK1", "TEST", 419, 423], ["IRF", "PROBLEM", 424, 427], ["signaling pathway", "PROBLEM", 430, 447], ["reduced RANTES production", "PROBLEM", 461, 486], ["T98G", "TEST", 490, 494], ["CTTG1 cells", "PROBLEM", 503, 514], ["Flavivirus infections", "PROBLEM", 525, 546], ["virus replicative intermediate dsRNA", "PROBLEM", 555, 591], ["IRF", "OBSERVATION", 170, 173], ["endogenous IRF", "OBSERVATION", 333, 347], ["intermediate dsRNA", "OBSERVATION", 573, 591]]], ["By interacting with mitochondrial adapter protein mitochondrial antiviral signaling protein (MAVS), RIG-I/MDA5 directs the activation of TBK1 and IKK\u03b5 [72] [73] [74] .", [["mitochondrial", "ANATOMY", 20, 33], ["mitochondrial", "ANATOMY", 50, 63], ["mitochondrial", "CELLULAR_COMPONENT", 20, 33], ["mitochondrial", "CELLULAR_COMPONENT", 50, 63], ["antiviral signaling protein", "GENE_OR_GENE_PRODUCT", 64, 91], ["MAVS", "GENE_OR_GENE_PRODUCT", 93, 97], ["RIG-I", "GENE_OR_GENE_PRODUCT", 100, 105], ["MDA5", "GENE_OR_GENE_PRODUCT", 106, 110], ["TBK1", "GENE_OR_GENE_PRODUCT", 137, 141], ["IKK", "GENE_OR_GENE_PRODUCT", 146, 149], ["mitochondrial adapter protein", "PROTEIN", 20, 49], ["mitochondrial antiviral signaling protein", "PROTEIN", 50, 91], ["MAVS", "PROTEIN", 93, 97], ["RIG-I", "PROTEIN", 100, 105], ["MDA5", "PROTEIN", 106, 110], ["TBK1", "PROTEIN", 137, 141], ["IKK", "PROTEIN", 146, 149], ["TBK1", "TEST", 137, 141], ["IKK", "TEST", 146, 149]]], ["Activated TBK1 mediates IRF-3 phosphorylation, which ultimately leads to the transcription of type I IFN and other cellular genes with host defense functions.", [["cellular", "ANATOMY", 115, 123], ["TBK1", "GENE_OR_GENE_PRODUCT", 10, 14], ["IRF-3", "GENE_OR_GENE_PRODUCT", 24, 29], ["type I IFN", "GENE_OR_GENE_PRODUCT", 94, 104], ["cellular", "CELL", 115, 123], ["TBK1", "PROTEIN", 10, 14], ["IRF-3", "PROTEIN", 24, 29], ["type I IFN", "PROTEIN", 94, 104], ["cellular genes", "DNA", 115, 129], ["Activated TBK1 mediates IRF", "TREATMENT", 0, 27], ["type I IFN", "PROBLEM", 94, 104], ["cellular genes", "OBSERVATION", 115, 129], ["host defense", "OBSERVATION", 135, 147]]], ["For instance, phosphorylation of IRF-3 can directly stimulate RANTES transcription [66] .", [["IRF-3", "GENE_OR_GENE_PRODUCT", 33, 38], ["RANTES", "GENE_OR_GENE_PRODUCT", 62, 68], ["IRF-3", "PROTEIN", 33, 38], ["RANTES", "PROTEIN", 62, 68], ["phosphorylation of IRF", "PROBLEM", 14, 36]]], ["In other scenarios, IRF-3 is also of particular importance in synergistically promoting RANTES expression, together with NF-kB activation [67, 75] .", [["IRF-3", "GENE_OR_GENE_PRODUCT", 20, 25], ["RANTES", "GENE_OR_GENE_PRODUCT", 88, 94], ["NF-kB", "GENE_OR_GENE_PRODUCT", 121, 126], ["IRF-3", "PROTEIN", 20, 25], ["RANTES", "PROTEIN", 88, 94], ["NF-kB", "PROTEIN", 121, 126], ["IRF", "OBSERVATION", 20, 23]]], ["In the current study, we showed that RIG-I/MDA5-and TBK1-directed IRF-3 phosphorylation is critical for TBEV-induced RANTES expression.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 37, 42], ["MDA5", "GENE_OR_GENE_PRODUCT", 43, 47], ["TBK1", "GENE_OR_GENE_PRODUCT", 52, 56], ["IRF-3", "GENE_OR_GENE_PRODUCT", 66, 71], ["TBEV", "ORGANISM", 104, 108], ["RANTES", "GENE_OR_GENE_PRODUCT", 117, 123], ["MDA5", "PROTEIN", 43, 47], ["TBK1", "PROTEIN", 52, 56], ["IRF-3", "PROTEIN", 66, 71], ["RANTES", "PROTEIN", 117, 123], ["TBEV", "SPECIES", 104, 108], ["the current study", "TEST", 3, 20], ["RIG", "TEST", 37, 40], ["MDA5", "TEST", 43, 47], ["TBK1", "TEST", 52, 56], ["directed IRF", "PROBLEM", 57, 69], ["TBEV", "PROBLEM", 104, 108]]], ["In contrast, NF-kB pathway did not appear to play an essential role in stimulating RANTES transcription following TBEV infection, as evidenced by both transfection experiments with dominantnegative mutants of IkB\u03b1 and pretreatment studies with NF-kB inhibitor MG132.", [["TBEV infection", "DISEASE", 114, 128], ["MG132", "CHEMICAL", 260, 265], ["MG132", "CHEMICAL", 260, 265], ["NF-kB", "GENE_OR_GENE_PRODUCT", 13, 18], ["RANTES", "GENE_OR_GENE_PRODUCT", 83, 89], ["TBEV", "ORGANISM", 114, 118], ["IkB\u03b1", "GENE_OR_GENE_PRODUCT", 209, 213], ["NF-kB", "GENE_OR_GENE_PRODUCT", 244, 249], ["MG132", "SIMPLE_CHEMICAL", 260, 265], ["NF-kB", "PROTEIN", 13, 18], ["RANTES", "PROTEIN", 83, 89], ["IkB\u03b1", "PROTEIN", 209, 213], ["TBEV", "SPECIES", 114, 118], ["stimulating RANTES transcription", "TREATMENT", 71, 103], ["TBEV infection", "PROBLEM", 114, 128], ["dominantnegative mutants of IkB", "PROBLEM", 181, 212], ["pretreatment studies", "TEST", 218, 238], ["NF", "TREATMENT", 244, 246], ["kB inhibitor MG132", "TREATMENT", 247, 265]]], ["It is conceivable that the pathways leading to activation of IRF-3 may distinct from the potential pathways that stimulate NF-kB in our system.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 61, 66], ["NF-kB", "GENE_OR_GENE_PRODUCT", 123, 128], ["IRF-3", "PROTEIN", 61, 66], ["NF-kB", "PROTEIN", 123, 128], ["activation of IRF", "PROBLEM", 47, 64], ["IRF", "OBSERVATION", 61, 64]]], ["Since ISRE promoters are activated by cellular IRFs but do not require NF-kB activation, we speculate that IRF-3-mediated activation of the ISRE is a major determinant of the induction of RANTES transcription after TBEV infection.", [["cellular", "ANATOMY", 38, 46], ["TBEV infection", "DISEASE", 215, 229], ["ISRE", "GENE_OR_GENE_PRODUCT", 6, 10], ["cellular", "CELL", 38, 46], ["NF-kB", "GENE_OR_GENE_PRODUCT", 71, 76], ["IRF-3", "GENE_OR_GENE_PRODUCT", 107, 112], ["ISRE", "GENE_OR_GENE_PRODUCT", 140, 144], ["RANTES", "GENE_OR_GENE_PRODUCT", 188, 194], ["TBEV", "ORGANISM", 215, 219], ["ISRE promoters", "DNA", 6, 20], ["cellular IRFs", "PROTEIN", 38, 51], ["NF-kB", "PROTEIN", 71, 76], ["IRF-3", "PROTEIN", 107, 112], ["ISRE", "DNA", 140, 144], ["RANTES", "PROTEIN", 188, 194], ["TBEV", "SPECIES", 215, 219], ["ISRE promoters", "TREATMENT", 6, 20], ["NF-kB activation", "TREATMENT", 71, 87], ["IRF", "TEST", 107, 110], ["RANTES transcription", "TREATMENT", 188, 208], ["TBEV infection", "PROBLEM", 215, 229], ["cellular IRFs", "OBSERVATION", 38, 51]]], ["It is important to note that other IRFs, exemplified by IRF1, have been shown to contribute to RANTES induction after respiratory syncytial virus (RSV) infection [29] .", [["respiratory syncytial virus (RSV) infection", "DISEASE", 118, 161], ["IRF1", "GENE_OR_GENE_PRODUCT", 56, 60], ["RANTES", "GENE_OR_GENE_PRODUCT", 95, 101], ["respiratory syncytial virus", "ORGANISM", 118, 145], ["RSV", "ORGANISM", 147, 150], ["IRFs", "PROTEIN", 35, 39], ["IRF1", "PROTEIN", 56, 60], ["RANTES", "PROTEIN", 95, 101], ["respiratory syncytial virus", "SPECIES", 118, 145], ["RSV", "SPECIES", 147, 150], ["RANTES induction", "TREATMENT", 95, 111], ["respiratory syncytial virus (RSV) infection", "PROBLEM", 118, 161]]], ["Thus, though our results support the idea that IRF3 is involved in RANTES expression during TBEV infection, the potential role for other IRFs could not be excluded.", [["TBEV infection", "DISEASE", 92, 106], ["IRF3", "GENE_OR_GENE_PRODUCT", 47, 51], ["RANTES", "GENE_OR_GENE_PRODUCT", 67, 73], ["TBEV", "ORGANISM", 92, 96], ["IRF3", "PROTEIN", 47, 51], ["RANTES", "PROTEIN", 67, 73], ["IRFs", "PROTEIN", 137, 141], ["TBEV", "SPECIES", 92, 96], ["IRF3", "PROBLEM", 47, 51], ["TBEV infection", "PROBLEM", 92, 106], ["other IRFs", "TREATMENT", 131, 141], ["IRF3", "OBSERVATION", 47, 51], ["could not be excluded", "UNCERTAINTY", 142, 163]]], ["Future studies will be important and interesting to clarify whether a somewhat activated form of other IRFs could, possibly in synergy with IRF3 signaling, result in the induction of RANTES after TBEV infection.ConclusionsIn summary, our study shows that TBEV-induced inflammatory responses in the CNS seem to be associated with a robust production of chemokines and cytokines, of which RANTES is a strong candidate for recruiting immune cells to brain tissues.", [["CNS", "ANATOMY", 298, 301], ["immune cells", "ANATOMY", 431, 443], ["brain tissues", "ANATOMY", 447, 460], ["TBEV infection", "DISEASE", 196, 210], ["TBEV", "DISEASE", 255, 259], ["IRFs", "GENE_OR_GENE_PRODUCT", 103, 107], ["IRF3", "GENE_OR_GENE_PRODUCT", 140, 144], ["RANTES", "GENE_OR_GENE_PRODUCT", 183, 189], ["TBEV", "ORGANISM", 196, 200], ["TBEV", "ORGANISM", 255, 259], ["CNS", "ANATOMICAL_SYSTEM", 298, 301], ["RANTES", "GENE_OR_GENE_PRODUCT", 387, 393], ["immune cells", "CELL", 431, 443], ["brain tissues", "TISSUE", 447, 460], ["IRFs", "PROTEIN", 103, 107], ["IRF3", "PROTEIN", 140, 144], ["RANTES", "PROTEIN", 183, 189], ["chemokines", "PROTEIN", 352, 362], ["cytokines", "PROTEIN", 367, 376], ["RANTES", "PROTEIN", 387, 393], ["immune cells", "CELL_TYPE", 431, 443], ["TBEV", "SPECIES", 196, 200], ["TBEV", "SPECIES", 255, 259], ["Future studies", "TEST", 0, 14], ["other IRFs", "PROBLEM", 97, 107], ["IRF3 signaling", "PROBLEM", 140, 154], ["the induction of RANTES", "TREATMENT", 166, 189], ["TBEV infection", "PROBLEM", 196, 210], ["our study", "TEST", 234, 243], ["TBEV", "PROBLEM", 255, 259], ["inflammatory responses", "PROBLEM", 268, 290], ["chemokines and cytokines", "TREATMENT", 352, 376], ["recruiting immune cells to brain tissues", "PROBLEM", 420, 460], ["IRF3", "OBSERVATION", 140, 144], ["TBEV", "OBSERVATION", 255, 259], ["inflammatory", "OBSERVATION", 268, 280], ["immune cells", "OBSERVATION", 431, 443]]], ["In addition, our findings reveal the molecular pathway of TBEV-mediated induction of RANTES, involving activation of RIG-I/MDA5 and TBK1, with subsequent activation of IRF-3 resulting in increased RANTES expression.", [["TBEV", "ORGANISM", 58, 62], ["RANTES", "GENE_OR_GENE_PRODUCT", 85, 91], ["RIG-I", "GENE_OR_GENE_PRODUCT", 117, 122], ["MDA5", "GENE_OR_GENE_PRODUCT", 123, 127], ["TBK1", "GENE_OR_GENE_PRODUCT", 132, 136], ["IRF-3", "GENE_OR_GENE_PRODUCT", 168, 173], ["RANTES", "GENE_OR_GENE_PRODUCT", 197, 203], ["RANTES", "PROTEIN", 85, 91], ["RIG-I", "PROTEIN", 117, 122], ["MDA5", "PROTEIN", 123, 127], ["TBK1", "PROTEIN", 132, 136], ["IRF-3", "PROTEIN", 168, 173], ["RANTES", "PROTEIN", 197, 203], ["TBEV", "SPECIES", 58, 62], ["TBEV", "PROBLEM", 58, 62], ["TBK1", "PROBLEM", 132, 136], ["subsequent activation of IRF", "PROBLEM", 143, 171], ["increased RANTES expression", "PROBLEM", 187, 214], ["TBEV", "OBSERVATION", 58, 62], ["MDA5", "ANATOMY", 123, 127], ["IRF", "OBSERVATION", 168, 171], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["RANTES expression", "OBSERVATION", 197, 214]]], ["These findings expand the current knowledge of the role of specific chemokines during TBEV infection and render RANTES particularly interesting for further investigations in human and experimental TBE.Additional filesAdditional file 1: Figure S1 .", [["TBEV infection", "DISEASE", 86, 100], ["TBE", "DISEASE", 197, 200], ["TBEV", "ORGANISM", 86, 90], ["RANTES", "GENE_OR_GENE_PRODUCT", 112, 118], ["human", "ORGANISM", 174, 179], ["chemokines", "PROTEIN", 68, 78], ["RANTES", "PROTEIN", 112, 118], ["human", "SPECIES", 174, 179], ["TBEV", "SPECIES", 86, 90], ["human", "SPECIES", 174, 179], ["TBE", "SPECIES", 197, 200], ["specific chemokines", "TREATMENT", 59, 78], ["TBEV infection", "PROBLEM", 86, 100], ["further investigations", "TEST", 148, 170], ["TBE", "OBSERVATION", 197, 200]]], ["Expression of RANTES in TBEV-infected A549 and THP-1 cells.", [["A549", "ANATOMY", 38, 42], ["THP-1 cells", "ANATOMY", 47, 58], ["RANTES", "GENE_OR_GENE_PRODUCT", 14, 20], ["TBEV", "ORGANISM", 24, 28], ["A549", "CELL", 38, 42], ["THP-1 cells", "CELL", 47, 58], ["RANTES", "PROTEIN", 14, 20], ["TBEV-infected A549 and THP-1 cells", "CELL_LINE", 24, 58], ["TBEV", "SPECIES", 24, 28], ["RANTES", "TEST", 14, 20], ["TBEV", "TEST", 24, 28], ["RANTES", "OBSERVATION", 14, 20]]], ["A549 (A and B) and THP-1 cells (D and E) were inoculated with medium alone, TBEV, or UV-inactivated TBEV at an MOI of 1.", [["A549", "ANATOMY", 0, 4], ["THP-1 cells", "ANATOMY", 19, 30], ["UV", "CHEMICAL", 85, 87], ["A549", "CELL", 0, 4], ["A", "CELL", 6, 7], ["B", "CELL", 12, 13], ["THP-1 cells", "CELL", 19, 30], ["D and E", "CELL", 32, 39], ["TBEV", "ORGANISM", 76, 80], ["TBEV", "ORGANISM", 100, 104], ["A549", "CELL_LINE", 0, 4], ["THP-1 cells", "CELL_LINE", 19, 30], ["TBEV", "SPECIES", 76, 80], ["TBEV", "SPECIES", 100, 104], ["A549", "TEST", 0, 4], ["THP", "TEST", 19, 22], ["TBEV", "TEST", 76, 80], ["UV", "TEST", 85, 87]]], ["Total RNA was extracted from cell lysates at 6, 24, 48, and 72 h post inoculation.", [["cell lysates", "ANATOMY", 29, 41], ["cell lysates", "ORGANISM_SUBSTANCE", 29, 41], ["Total RNA", "PROBLEM", 0, 9], ["cell lysates", "TEST", 29, 41], ["inoculation", "PROBLEM", 70, 81], ["cell lysates", "OBSERVATION", 29, 41]]], ["RANTES mRNA was quantified by real-time PCR (A and D), and results were normalized to GAPDH and expressed as fold induction over medium alone at 6 h post inoculation.", [["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["GAPDH", "GENE_OR_GENE_PRODUCT", 86, 91], ["RANTES mRNA", "RNA", 0, 11], ["GAPDH", "PROTEIN", 86, 91], ["RANTES mRNA", "TEST", 0, 11], ["real-time PCR", "TEST", 30, 43], ["A and D)", "TEST", 45, 53]]], ["Supernatants were harvested at 6, 24, 48, and 72 h post inoculation, and levels of RANTES (pg/mL) released were determined by ELISA (B and E).", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["RANTES", "GENE_OR_GENE_PRODUCT", 83, 89], ["RANTES", "PROTEIN", 83, 89], ["inoculation", "TEST", 56, 67], ["RANTES", "TEST", 83, 89], ["harvested", "OBSERVATION", 18, 27]]], ["Bars represent the means \u00b1 the standard deviations of three independent experiments. * P < 0.05 versus mock control.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mock control", "TREATMENT", 103, 115]]], ["A549 (C) and THP-1 cells (F) were infected with TBEV at an MOI of 1.", [["A549", "ANATOMY", 0, 4], ["THP-1 cells", "ANATOMY", 13, 24], ["TBEV", "DISEASE", 48, 52], ["A549 (C", "CELL", 0, 7], ["THP-1 cells", "CELL", 13, 24], ["F", "CELL", 26, 27], ["TBEV", "ORGANISM", 48, 52], ["A549 (C) and THP-1 cells", "CELL_LINE", 0, 24], ["TBEV", "SPECIES", 48, 52], ["A549", "TEST", 0, 4], ["THP", "TEST", 13, 16], ["infected", "PROBLEM", 34, 42], ["TBEV", "PROBLEM", 48, 52], ["infected", "OBSERVATION", 34, 42]]], ["Supernatants were collected at indicated time points, and virus titers were determined by TCID 50 assay.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["Supernatants", "TEST", 0, 12], ["virus titers", "TEST", 58, 70]]], ["The results are presented as the means \u00b1 standard deviations obtained from three independent experiments. *P < 0.05 versus mock control.", [["mock control", "TREATMENT", 123, 135]]], ["NS = not significant.", [["NS", "TREATMENT", 0, 2], ["not", "UNCERTAINTY", 5, 8], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["Impact of BX795 or MG132 treatment on TBEV replication.", [["BX795", "CHEMICAL", 10, 15], ["MG132", "CHEMICAL", 19, 24], ["BX795", "CHEMICAL", 10, 15], ["MG132", "CHEMICAL", 19, 24], ["BX795", "SIMPLE_CHEMICAL", 10, 15], ["MG132", "SIMPLE_CHEMICAL", 19, 24], ["TBEV", "ORGANISM", 38, 42], ["TBEV", "SPECIES", 38, 42], ["BX795", "TREATMENT", 10, 15], ["MG132 treatment", "TREATMENT", 19, 34], ["TBEV replication", "TREATMENT", 38, 54]]], ["T98G or CCF-STTG1 cells were inoculated with TBEV (MOI = 1), followed by treatment with BX795 (2 \u03bcM), MG132 (3 \u03bcM), or DMSO vehicle in the absence of serum for 36 h.", [["T98G", "ANATOMY", 0, 4], ["CCF-STTG1 cells", "ANATOMY", 8, 23], ["serum", "ANATOMY", 150, 155], ["BX795", "CHEMICAL", 88, 93], ["MG132", "CHEMICAL", 102, 107], ["DMSO", "CHEMICAL", 119, 123], ["BX795", "CHEMICAL", 88, 93], ["MG132", "CHEMICAL", 102, 107], ["DMSO", "CHEMICAL", 119, 123], ["T98G", "CELL", 0, 4], ["CCF-STTG1 cells", "CELL", 8, 23], ["BX795", "SIMPLE_CHEMICAL", 88, 93], ["MG132", "SIMPLE_CHEMICAL", 102, 107], ["DMSO", "SIMPLE_CHEMICAL", 119, 123], ["serum", "ORGANISM_SUBSTANCE", 150, 155], ["T98G", "CELL_LINE", 0, 4], ["CCF-STTG1 cells", "CELL_LINE", 8, 23], ["TBEV", "SPECIES", 45, 49], ["T98G", "PROBLEM", 0, 4], ["CCF", "PROBLEM", 8, 11], ["STTG1 cells", "PROBLEM", 12, 23], ["TBEV", "PROBLEM", 45, 49], ["MOI", "TEST", 51, 54], ["MG132", "TEST", 102, 107]]], ["Supernatants were harvested, and virus infectivity was determined by estimation of the TCID 50 as described above.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["TCID 50", "DNA", 87, 94], ["virus infectivity", "PROBLEM", 33, 50], ["harvested", "OBSERVATION", 18, 27]]], ["NS = not significant.", [["NS", "TREATMENT", 0, 2], ["not", "UNCERTAINTY", 5, 8], ["significant", "OBSERVATION_MODIFIER", 9, 20]]]], "51d596f62e3861b557cab53f006ec68c82938739": [["INTRODUCTIONHeat shock proteins (HSPs) are a family of highly homologous molecular chaperons that can protect cells from damage triggered by diverse physical and chemical stresses, for example, elevation or fall of temperature, ultraviolet irradiation, medical treatment, and pathogen invasion.", [["cells", "ANATOMY", 110, 115], ["ultraviolet", "CHEMICAL", 228, 239], ["INTRODUCTIONHeat shock proteins", "GENE_OR_GENE_PRODUCT", 0, 31], ["HSPs", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 110, 115], ["INTRODUCTIONHeat shock proteins", "PROTEIN", 0, 31], ["HSPs", "PROTEIN", 33, 37], ["shock proteins", "PROBLEM", 17, 31], ["damage", "PROBLEM", 121, 127], ["elevation", "PROBLEM", 194, 203], ["fall of temperature", "PROBLEM", 207, 226], ["ultraviolet irradiation", "TREATMENT", 228, 251], ["medical treatment", "TREATMENT", 253, 270], ["pathogen invasion", "PROBLEM", 276, 293], ["pathogen", "OBSERVATION_MODIFIER", 276, 284], ["invasion", "OBSERVATION", 285, 293]]], ["The expression of HSPs is precisely regulated under stress to limit the detrimental consequences and facilitate cell recovery.", [["cell", "ANATOMY", 112, 116], ["HSPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["cell", "CELL", 112, 116], ["HSPs", "PROTEIN", 18, 22], ["HSPs", "PROBLEM", 18, 22]]], ["The HSP70 family consists of molecular chaperons of approximately 70 kDa in size that are highly conserved in all organisms (Radons, 2016) .", [["HSP70", "GENE_OR_GENE_PRODUCT", 4, 9], ["HSP70 family", "PROTEIN", 4, 16], ["molecular chaperons", "PROTEIN", 29, 48], ["70 kDa", "OBSERVATION_MODIFIER", 66, 72], ["size", "OBSERVATION_MODIFIER", 76, 80]]], ["All the HSP70 chaperons share similar domain structures, including an N-terminal ATP-binding domain (NBD), a substratebinding domain (SBD), and a C-terminal lid domain (Figure 1) , and their chaperon activity relies on the hydrolysis of ATP.", [["ATP", "CHEMICAL", 81, 84], ["ATP", "CHEMICAL", 237, 240], ["N-", "CHEMICAL", 70, 72], ["ATP", "CHEMICAL", 81, 84], ["C", "CHEMICAL", 146, 147], ["ATP", "CHEMICAL", 237, 240], ["HSP70", "GENE_OR_GENE_PRODUCT", 8, 13], ["ATP", "SIMPLE_CHEMICAL", 81, 84], ["NBD", "SIMPLE_CHEMICAL", 101, 104], ["chaperon", "GENE_OR_GENE_PRODUCT", 191, 199], ["ATP", "SIMPLE_CHEMICAL", 237, 240], ["HSP70 chaperons", "PROTEIN", 8, 23], ["N-terminal ATP-binding domain", "PROTEIN", 70, 99], ["NBD", "PROTEIN", 101, 104], ["substratebinding domain", "PROTEIN", 109, 132], ["SBD", "PROTEIN", 134, 137], ["C-terminal lid domain", "PROTEIN", 146, 167], ["Figure 1", "PROTEIN", 169, 177], ["chaperon", "PROTEIN", 191, 199], ["All the HSP70 chaperons", "TEST", 0, 23], ["similar domain structures", "PROBLEM", 30, 55], ["an N-terminal ATP-binding domain (NBD", "PROBLEM", 67, 104], ["a substratebinding domain (SBD)", "PROBLEM", 107, 138], ["a C-terminal lid domain", "PROBLEM", 144, 167], ["the hydrolysis of ATP", "TREATMENT", 219, 240]]], ["In the ATP-bound stage, HSP70s bind to the substrates with relatively low affinity.", [["ATP", "CHEMICAL", 7, 10], ["ATP", "CHEMICAL", 7, 10], ["ATP", "SIMPLE_CHEMICAL", 7, 10], ["HSP70s", "SIMPLE_CHEMICAL", 24, 30], ["HSP70s", "PROTEIN", 24, 30], ["HSP70s bind", "PROBLEM", 24, 35], ["relatively low affinity", "PROBLEM", 59, 82], ["bound stage", "OBSERVATION_MODIFIER", 11, 22]]], ["The affinity increases significantly after hydrolyzing ATP into ADP with the help of accessory proteins from the HSP40 family.", [["ATP", "CHEMICAL", 55, 58], ["ADP", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 55, 58], ["ADP", "CHEMICAL", 64, 67], ["ATP", "SIMPLE_CHEMICAL", 55, 58], ["ADP", "SIMPLE_CHEMICAL", 64, 67], ["HSP40", "GENE_OR_GENE_PRODUCT", 113, 118], ["accessory proteins", "PROTEIN", 85, 103], ["HSP40 family", "PROTEIN", 113, 125], ["hydrolyzing ATP into ADP", "TREATMENT", 43, 67]]], ["Finally, nucleotide exchange factors facilitate the dissociation of ADP to reset the cycle (Rauch et al., 2016) .", [["nucleotide", "CHEMICAL", 9, 19], ["ADP", "CHEMICAL", 68, 71], ["nucleotide", "CHEMICAL", 9, 19], ["ADP", "CHEMICAL", 68, 71], ["ADP", "SIMPLE_CHEMICAL", 68, 71], ["nucleotide exchange factors", "PROTEIN", 9, 36], ["nucleotide exchange factors", "TREATMENT", 9, 36], ["ADP", "TREATMENT", 68, 71]]], ["In the large HSP70 family, the heat shock cognate 71-kDa protein (HSC70) is constitutively expressed and plays a major role in protein quality control, such as assisting the refolding of misfolded proteins, regulating protein translocation (Sheffield et al., 1990) , and targeting protein to lysosomes or ubiquitin/proteasome machinery for degradation (Terlecky et al., 1992; Ohba, 1994) .", [["lysosomes", "ANATOMY", 292, 301], ["HSP70", "GENE_OR_GENE_PRODUCT", 13, 18], ["heat shock cognate 71-kDa", "GENE_OR_GENE_PRODUCT", 31, 56], ["HSC70", "GENE_OR_GENE_PRODUCT", 66, 71], ["lysosomes", "CELLULAR_COMPONENT", 292, 301], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 305, 314], ["HSP70 family", "PROTEIN", 13, 25], ["heat shock cognate 71-kDa protein", "PROTEIN", 31, 64], ["HSC70", "PROTEIN", 66, 71], ["misfolded proteins", "PROTEIN", 187, 205], ["ubiquitin", "PROTEIN", 305, 314], ["proteasome", "PROTEIN", 315, 325], ["the heat shock cognate", "TEST", 27, 49], ["protein quality control", "TREATMENT", 127, 150], ["misfolded proteins", "PROBLEM", 187, 205], ["ubiquitin/proteasome machinery", "TREATMENT", 305, 335], ["large", "OBSERVATION_MODIFIER", 7, 12]]], ["Besides these diverse cellular functions, HSC70 is widely reported to be involved in regulating the life cycle of various viruses, such as mediating attachment and endocytosis (Isa et al., 2004) , penetration and uncoating, transcription and replication (Du et al., 2011) , and assembly and budding (Prange et al., 1999) .", [["cellular", "ANATOMY", 22, 30], ["cellular", "CELL", 22, 30], ["HSC70", "GENE_OR_GENE_PRODUCT", 42, 47], ["HSC70", "PROTEIN", 42, 47], ["various viruses", "PROBLEM", 114, 129], ["penetration", "PROBLEM", 197, 208], ["diverse", "OBSERVATION_MODIFIER", 14, 21], ["cellular functions", "OBSERVATION", 22, 40], ["viruses", "OBSERVATION", 122, 129]]], ["More importantly, HSC70 is closely related to virus-induced host immune response through presenting antigenic peptides by MHC-II to CD4 + T cells (Auger et al., 1996) and acting as a modulator of autophagy (Beere, 2004) .", [["CD4 + T cells", "ANATOMY", 132, 145], ["HSC70", "GENE_OR_GENE_PRODUCT", 18, 23], ["MHC-II", "GENE_OR_GENE_PRODUCT", 122, 128], ["CD4", "GENE_OR_GENE_PRODUCT", 132, 135], ["HSC70", "PROTEIN", 18, 23], ["MHC-II", "PROTEIN", 122, 128], ["CD4", "PROTEIN", 132, 135], ["T cells", "CELL_TYPE", 138, 145], ["virus", "PROBLEM", 46, 51]]], ["Due to the extensive roles of HSC70 playing in the virus life cycle, it has been studied to act as the antiviral target to inhibit virus infection.", [["infection", "DISEASE", 137, 146], ["HSC70", "GENE_OR_GENE_PRODUCT", 30, 35], ["HSC70", "PROTEIN", 30, 35], ["the antiviral target", "TREATMENT", 99, 119], ["virus infection", "PROBLEM", 131, 146]]], ["Therefore, elucidating the mechanism of HSC70 involved in viral infections will redefine our understanding of the interaction between virus and host and might contribute to developing creative antivirals especially for the treatment of emerging and resurging viruses.HSC70 Participates in Viral EntryAttachment, the first crucial step to initiate infection, depends on the interaction between virus attachment proteins and cellular receptors.", [["cellular", "ANATOMY", 423, 431], ["viral infections", "DISEASE", 58, 74], ["infection", "DISEASE", 347, 356], ["HSC70", "GENE_OR_GENE_PRODUCT", 40, 45], ["HSC70", "GENE_OR_GENE_PRODUCT", 267, 272], ["cellular", "CELL", 423, 431], ["HSC70", "PROTEIN", 40, 45], ["HSC70", "PROTEIN", 267, 272], ["virus attachment proteins", "PROTEIN", 393, 418], ["cellular receptors", "PROTEIN", 423, 441], ["viral infections", "PROBLEM", 58, 74], ["the interaction between virus", "PROBLEM", 110, 139], ["creative antivirals", "TREATMENT", 184, 203], ["the treatment", "TREATMENT", 219, 232], ["resurging viruses", "PROBLEM", 249, 266], ["Viral EntryAttachment", "TREATMENT", 289, 310], ["infection", "PROBLEM", 347, 356], ["virus attachment proteins", "TREATMENT", 393, 418], ["viral infections", "OBSERVATION", 58, 74], ["Viral EntryAttachment", "OBSERVATION", 289, 310], ["infection", "OBSERVATION", 347, 356]]], ["Exploring virus-bound cell-surface molecules has always been the hot topic of virology.", [["cell", "ANATOMY", 22, 26], ["surface", "ANATOMY", 27, 34], ["cell", "CELL", 22, 26], ["virus-bound cell-surface molecules", "PROTEIN", 10, 44], ["surface molecules", "PROBLEM", 27, 44], ["bound cell", "OBSERVATION", 16, 26]]], ["HSC70 usually distributes in the cytoplasm and shuttles between cytoplasm and nucleus to participate in many biological processes.", [["cytoplasm", "ANATOMY", 33, 42], ["cytoplasm", "ANATOMY", 64, 73], ["nucleus", "ANATOMY", 78, 85], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 33, 42], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["nucleus", "CELLULAR_COMPONENT", 78, 85], ["HSC70", "PROTEIN", 0, 5], ["distributes", "OBSERVATION_MODIFIER", 14, 25], ["nucleus", "ANATOMY", 78, 85]]], ["However, the exit of HSC70 from nucleus to cytoplasm is inhibited upon stress, limiting its function to the nuclear compartment (Kodiha et al., 2005) .", [["nucleus", "ANATOMY", 32, 39], ["cytoplasm", "ANATOMY", 43, 52], ["nuclear compartment", "ANATOMY", 108, 127], ["HSC70", "GENE_OR_GENE_PRODUCT", 21, 26], ["nucleus", "CELLULAR_COMPONENT", 32, 39], ["cytoplasm", "ORGANISM_SUBSTANCE", 43, 52], ["HSC70", "PROTEIN", 21, 26]]], ["Meanwhile, studies have reported that HSC70 is also a membrane-anchored protein (Arispe et al., 2002) , and it has been proved to be expressed on the cytoplasmic membrane of several different cell lines, such as MA104, Caco-2, Hep2, BHK , C6/36 (Paingankar et al., 2010) , B cells (Mayer, 2005) , and the suckling mouse intestinal epithelial cells (Guerrero and Moreno, 2012) , and participates in virus invasion as receptor or co-receptor.HSC70 Participates in Viral EntryDengue virus (DENV), a notorious insect-borne virus, has been reported to interact with several molecules to enter host cells, such as DC-SIGN in dendritic cells (Navarro-Sanchez et al., 2003) , GRP78 (BiP) in HepG2 cells (Upanan et al., 2008) , and \u03b23 integrin in HMEC-1 cells .", [["membrane", "ANATOMY", 54, 62], ["cytoplasmic membrane", "ANATOMY", 150, 170], ["cell lines", "ANATOMY", 192, 202], ["Caco-2", "ANATOMY", 219, 225], ["BHK", "ANATOMY", 233, 236], ["C6/36", "ANATOMY", 239, 244], ["B cells", "ANATOMY", 273, 280], ["intestinal epithelial cells", "ANATOMY", 320, 347], ["cells", "ANATOMY", 593, 598], ["DC-SIGN", "ANATOMY", 608, 615], ["dendritic cells", "ANATOMY", 619, 634], ["HepG2 cells", "ANATOMY", 683, 694], ["HMEC-1 cells", "ANATOMY", 738, 750], ["HSC70", "GENE_OR_GENE_PRODUCT", 38, 43], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 150, 170], ["cell lines", "CELL", 192, 202], ["MA104", "CELL", 212, 217], ["Caco-2", "CELL", 219, 225], ["Hep2", "CELL", 227, 231], ["BHK", "CELL", 233, 236], ["C6/36", "CELL", 239, 244], ["B cells", "CELL", 273, 280], ["mouse", "ORGANISM", 314, 319], ["intestinal epithelial cells", "CELL", 320, 347], ["HSC70", "GENE_OR_GENE_PRODUCT", 440, 445], ["Viral EntryDengue virus", "ORGANISM", 462, 485], ["DENV", "ORGANISM", 487, 491], ["insect-borne virus", "ORGANISM", 506, 524], ["host cells", "CELL", 588, 598], ["DC-SIGN", "CELL", 608, 615], ["dendritic cells", "CELL", 619, 634], ["GRP78", "GENE_OR_GENE_PRODUCT", 668, 673], ["BiP", "GENE_OR_GENE_PRODUCT", 675, 678], ["HepG2 cells", "CELL", 683, 694], ["\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 723, 734], ["HMEC-1 cells", "CELL", 738, 750], ["HSC70", "PROTEIN", 38, 43], ["membrane-anchored protein", "PROTEIN", 54, 79], ["cell lines", "CELL_LINE", 192, 202], ["MA104", "CELL_LINE", 212, 217], ["Caco-2", "CELL_LINE", 219, 225], ["Hep2", "CELL_LINE", 227, 231], ["BHK", "CELL_LINE", 233, 236], ["B cells", "CELL_TYPE", 273, 280], ["suckling mouse intestinal epithelial cells", "CELL_TYPE", 305, 347], ["co-receptor", "PROTEIN", 428, 439], ["HSC70", "PROTEIN", 440, 445], ["host cells", "CELL_TYPE", 588, 598], ["DC", "CELL_TYPE", 608, 610], ["SIGN", "PROTEIN", 611, 615], ["dendritic cells", "CELL_TYPE", 619, 634], ["GRP78", "PROTEIN", 668, 673], ["BiP", "PROTEIN", 675, 678], ["HepG2 cells", "CELL_LINE", 683, 694], ["\u03b23 integrin", "PROTEIN", 723, 734], ["HMEC-1 cells", "CELL_LINE", 738, 750], ["mouse", "SPECIES", 314, 319], ["Viral EntryDengue virus", "SPECIES", 462, 485], ["insect-borne virus", "SPECIES", 506, 524], ["mouse", "SPECIES", 314, 319], ["Viral EntryDengue virus", "SPECIES", 462, 485], ["DENV", "SPECIES", 487, 491], ["HSC70", "TEST", 38, 43], ["MA104", "TEST", 212, 217], ["Caco", "TEST", 219, 223], ["Hep2", "TEST", 227, 231], ["BHK", "TEST", 233, 236], ["C6", "TEST", 239, 241], ["the suckling mouse intestinal epithelial cells", "PROBLEM", 301, 347], ["Viral EntryDengue virus", "PROBLEM", 462, 485], ["DENV", "PROBLEM", 487, 491], ["a notorious insect-borne virus", "PROBLEM", 494, 524], ["Navarro", "TEST", 636, 643], ["HepG2 cells", "TEST", 683, 694], ["cytoplasmic membrane", "OBSERVATION", 150, 170], ["different cell lines", "OBSERVATION", 182, 202], ["intestinal", "ANATOMY", 320, 330], ["epithelial cells", "OBSERVATION", 331, 347], ["Viral EntryDengue virus", "OBSERVATION", 462, 485], ["dendritic cells", "OBSERVATION", 619, 634], ["HepG2", "ANATOMY", 683, 688]]], ["HSC70 has been reported to be associated with the cell entry step of DENV through interacting with envelope glycoprotein E. HSC70 is highly expressed on the surface of C6/36 cells infected with DENV via relocation, and incubating with antibodies to HSC70 significantly blocks DENV binding to the C6/36 surface and further inhibits virus infection (Vega-Almeida et al., 2013) .", [["cell", "ANATOMY", 50, 54], ["surface", "ANATOMY", 157, 164], ["C6/36 cells", "ANATOMY", 168, 179], ["C6/36 surface", "ANATOMY", 296, 309], ["infection", "DISEASE", 337, 346], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 50, 54], ["DENV", "ORGANISM", 69, 73], ["HSC70", "GENE_OR_GENE_PRODUCT", 124, 129], ["surface", "CELLULAR_COMPONENT", 157, 164], ["C6/36 cells", "CELL", 168, 179], ["DENV", "ORGANISM", 194, 198], ["HSC70", "GENE_OR_GENE_PRODUCT", 249, 254], ["HSC70", "PROTEIN", 0, 5], ["envelope glycoprotein", "PROTEIN", 99, 120], ["HSC70", "PROTEIN", 124, 129], ["C6/36 cells", "CELL_LINE", 168, 179], ["antibodies", "PROTEIN", 235, 245], ["HSC70", "PROTEIN", 249, 254], ["DENV", "SPECIES", 69, 73], ["DENV", "SPECIES", 194, 198], ["DENV", "SPECIES", 276, 280], ["HSC70", "TEST", 0, 5], ["DENV", "PROBLEM", 69, 73], ["DENV", "PROBLEM", 194, 198], ["antibodies", "TREATMENT", 235, 245], ["blocks DENV binding", "PROBLEM", 269, 288], ["further inhibits virus infection", "PROBLEM", 314, 346], ["C6", "ANATOMY", 296, 298]]], ["Apart from being a binding receptor for DENV, HSC70 also participates in rotavirus invasion.", [["rotavirus invasion", "DISEASE", 73, 91], ["DENV", "ORGANISM", 40, 44], ["HSC70", "GENE_OR_GENE_PRODUCT", 46, 51], ["rotavirus", "ORGANISM", 73, 82], ["binding receptor", "PROTEIN", 19, 35], ["HSC70", "PROTEIN", 46, 51], ["DENV", "SPECIES", 40, 44], ["rotavirus", "SPECIES", 73, 82], ["DENV", "PROBLEM", 40, 44], ["rotavirus invasion", "PROBLEM", 73, 91], ["rotavirus invasion", "OBSERVATION", 73, 91]]], ["It is already known that the entry of rotavirus into epithelial cells is a multistep process that involves at least three interactions between virus and cellular receptors, including sialic acids, gangliosides, integrins, and HSC70 (Arias et al., 2002) .", [["epithelial cells", "ANATOMY", 53, 69], ["cellular", "ANATOMY", 153, 161], ["sialic acids", "CHEMICAL", 183, 195], ["sialic acids", "CHEMICAL", 183, 195], ["rotavirus", "ORGANISM", 38, 47], ["epithelial cells", "CELL", 53, 69], ["cellular", "CELL", 153, 161], ["sialic acids", "SIMPLE_CHEMICAL", 183, 195], ["gangliosides", "GENE_OR_GENE_PRODUCT", 197, 209], ["integrins", "GENE_OR_GENE_PRODUCT", 211, 220], ["HSC70", "GENE_OR_GENE_PRODUCT", 226, 231], ["epithelial cells", "CELL_TYPE", 53, 69], ["cellular receptors", "PROTEIN", 153, 171], ["integrins", "PROTEIN", 211, 220], ["HSC70", "PROTEIN", 226, 231], ["rotavirus", "SPECIES", 38, 47], ["rotavirus into epithelial cells", "PROBLEM", 38, 69], ["a multistep process", "PROBLEM", 73, 92], ["virus and cellular receptors", "TREATMENT", 143, 171], ["sialic acids", "TREATMENT", 183, 195], ["gangliosides", "TREATMENT", 197, 209], ["epithelial cells", "OBSERVATION", 53, 69]]], ["Although different rotavirus strains enter cells through different endocytic pathways, rotaviruses, either resistant/sensitive to neuraminidase or dependent/independent on integrin, require the involvement of HSC70, and pretreating MA104 cells with antibodies against HSC70 can inhibit rotavirus infection (Gutierrez et al., 2010) .", [["cells", "ANATOMY", 43, 48], ["MA104 cells", "ANATOMY", 232, 243], ["rotavirus infection", "DISEASE", 286, 305], ["rotavirus strains", "ORGANISM", 19, 36], ["cells", "CELL", 43, 48], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 130, 143], ["integrin", "GENE_OR_GENE_PRODUCT", 172, 180], ["HSC70", "GENE_OR_GENE_PRODUCT", 209, 214], ["MA104 cells", "CELL", 232, 243], ["HSC70", "GENE_OR_GENE_PRODUCT", 268, 273], ["rotavirus", "ORGANISM", 286, 295], ["neuraminidase", "PROTEIN", 130, 143], ["integrin", "PROTEIN", 172, 180], ["HSC70", "PROTEIN", 209, 214], ["MA104 cells", "CELL_LINE", 232, 243], ["antibodies", "PROTEIN", 249, 259], ["HSC70", "PROTEIN", 268, 273], ["rotavirus", "SPECIES", 19, 28], ["rotavirus", "SPECIES", 286, 295], ["different rotavirus strains enter cells", "PROBLEM", 9, 48], ["rotaviruses", "PROBLEM", 87, 98], ["neuraminidase", "PROBLEM", 130, 143], ["HSC70", "TEST", 209, 214], ["pretreating MA104 cells", "PROBLEM", 220, 243], ["antibodies", "TREATMENT", 249, 259], ["HSC70", "PROBLEM", 268, 273], ["rotavirus infection", "PROBLEM", 286, 305]]], ["To be infectious, rotavirus spike protein VP4 is cleaved into VP5 and VP8 subunits to promote virus entry into the cytoplasm (Ruiz et al., 1994) .", [["cytoplasm", "ANATOMY", 115, 124], ["rotavirus", "ORGANISM", 18, 27], ["VP4", "GENE_OR_GENE_PRODUCT", 42, 45], ["VP5", "GENE_OR_GENE_PRODUCT", 62, 65], ["VP8", "GENE_OR_GENE_PRODUCT", 70, 73], ["cytoplasm", "ORGANISM_SUBSTANCE", 115, 124], ["rotavirus spike protein", "PROTEIN", 18, 41], ["VP4", "PROTEIN", 42, 45], ["VP5", "PROTEIN", 62, 65], ["VP8 subunits", "PROTEIN", 70, 82], ["rotavirus", "SPECIES", 18, 27], ["infectious", "PROBLEM", 6, 16], ["rotavirus spike protein VP4", "PROBLEM", 18, 45], ["VP5 and VP8 subunits", "TREATMENT", 62, 82], ["infectious", "OBSERVATION", 6, 16], ["virus", "OBSERVATION", 94, 99]]], ["Two distinct cell surface-binding domains are present on VP5: one is the integrin-binding DGE motif located at amino acids from 308 to 310, and the other is the HSC70-binding motif located at amino acids from 642 to 658.", [["cell surface", "ANATOMY", 13, 25], ["amino acids", "CHEMICAL", 111, 122], ["amino acids", "CHEMICAL", 192, 203], ["amino acids", "CHEMICAL", 111, 122], ["amino acids", "CHEMICAL", 192, 203], ["cell", "CELL", 13, 17], ["VP5", "GENE_OR_GENE_PRODUCT", 57, 60], ["amino acids", "AMINO_ACID", 111, 122], ["HSC70", "GENE_OR_GENE_PRODUCT", 161, 166], ["amino acids", "AMINO_ACID", 192, 203], ["cell surface-binding domains", "PROTEIN", 13, 41], ["VP5", "PROTEIN", 57, 60], ["integrin-binding DGE motif", "PROTEIN", 73, 99], ["HSC70", "PROTEIN", 161, 166], ["Two distinct cell surface-binding domains", "PROBLEM", 0, 41], ["VP5", "TEST", 57, 60], ["the integrin-binding DGE motif", "PROBLEM", 69, 99], ["amino acids", "TEST", 111, 122], ["amino acids", "TEST", 192, 203], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["cell", "OBSERVATION_MODIFIER", 13, 17], ["surface", "OBSERVATION_MODIFIER", 18, 25], ["binding domains", "OBSERVATION", 26, 41]]], ["A synthetic analog containing amino acids 642-658 blocks rotavirus infectivity but not binding to the surface of MA104 cells, indicating that HSC70 serves as a post-attachment cell receptor for the rotavirus (Z\u00e1rate et al., 2003) .", [["surface", "ANATOMY", 102, 109], ["MA104 cells", "ANATOMY", 113, 124], ["post-attachment cell", "ANATOMY", 160, 180], ["amino acids 642-658", "CHEMICAL", 30, 49], ["amino acids", "CHEMICAL", 30, 41], ["amino acids", "AMINO_ACID", 30, 41], ["642-658", "AMINO_ACID", 42, 49], ["rotavirus", "ORGANISM", 57, 66], ["surface", "CELLULAR_COMPONENT", 102, 109], ["MA104 cells", "CELL", 113, 124], ["HSC70", "GENE_OR_GENE_PRODUCT", 142, 147], ["post-attachment cell receptor", "GENE_OR_GENE_PRODUCT", 160, 189], ["rotavirus", "ORGANISM", 198, 207], ["MA104 cells", "CELL_LINE", 113, 124], ["HSC70", "PROTEIN", 142, 147], ["post-attachment cell receptor", "PROTEIN", 160, 189], ["rotavirus", "SPECIES", 57, 66], ["A synthetic analog containing amino acids", "TREATMENT", 0, 41], ["blocks rotavirus infectivity", "PROBLEM", 50, 78], ["a post-attachment cell receptor", "TREATMENT", 158, 189], ["the rotavirus", "PROBLEM", 194, 207]]], ["Further study reveals that the peptide-binding domain of HSC70 involves the interaction with VP5, but its ATPbinding domain exerts a negative effect on rotavirus infection.", [["rotavirus infection", "DISEASE", 152, 171], ["HSC70", "GENE_OR_GENE_PRODUCT", 57, 62], ["VP5", "GENE_OR_GENE_PRODUCT", 93, 96], ["rotavirus", "ORGANISM", 152, 161], ["peptide-binding domain", "PROTEIN", 31, 53], ["HSC70", "PROTEIN", 57, 62], ["VP5", "PROTEIN", 93, 96], ["ATPbinding domain", "PROTEIN", 106, 123], ["rotavirus", "SPECIES", 152, 161], ["Further study", "TEST", 0, 13], ["the peptide-binding domain of HSC70", "PROBLEM", 27, 62], ["VP5", "TREATMENT", 93, 96], ["its ATPbinding domain", "PROBLEM", 102, 123], ["rotavirus infection", "PROBLEM", 152, 171], ["negative effect", "OBSERVATION_MODIFIER", 133, 148], ["rotavirus", "OBSERVATION_MODIFIER", 152, 161], ["infection", "OBSERVATION", 162, 171]]], ["In the presence of ATP, the infectivity of purified rotavirus to MA104 cells reduces 60% when incubated with soluble HSC70, indicating that ATPase activity of HSC70 partially inactivates rotavirus infectivity (P\u00e9rez-Vargas et al., 2006) .", [["MA104 cells", "ANATOMY", 65, 76], ["ATP", "CHEMICAL", 19, 22], ["ATP", "CHEMICAL", 19, 22], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["rotavirus", "ORGANISM", 52, 61], ["MA104 cells", "CELL", 65, 76], ["HSC70", "GENE_OR_GENE_PRODUCT", 117, 122], ["ATPase", "GENE_OR_GENE_PRODUCT", 140, 146], ["HSC70", "GENE_OR_GENE_PRODUCT", 159, 164], ["rotavirus", "ORGANISM", 187, 196], ["MA104 cells", "CELL_LINE", 65, 76], ["HSC70", "PROTEIN", 117, 122], ["ATPase", "PROTEIN", 140, 146], ["HSC70", "PROTEIN", 159, 164], ["rotavirus", "SPECIES", 52, 61], ["ATP", "PROBLEM", 19, 22], ["the infectivity of purified rotavirus to MA104 cells", "PROBLEM", 24, 76], ["soluble HSC70", "TEST", 109, 122], ["ATPase activity", "TEST", 140, 155], ["HSC70", "TEST", 159, 164], ["rotavirus infectivity", "PROBLEM", 187, 208]]], ["With the growing understanding of the interconversion between bound and free conformations of HSC70, a rational assumption is that a large number of ATP in the system might constrain allosteric change of HSC70 and weaken the interaction between HSC70 and VP5, resulting in the decline of virus infectivity consequently.HSC70 Involves in Viral Intracellular Trafficking and DisassemblyAfter binding cellular receptors, viruses must devise strategies to cross the membrane barrier and uncoat capsid to expose nucleic acid for gene expression.", [["Intracellular", "ANATOMY", 343, 356], ["cellular", "ANATOMY", 398, 406], ["membrane", "ANATOMY", 462, 470], ["ATP", "CHEMICAL", 149, 152], ["nucleic acid", "CHEMICAL", 507, 519], ["ATP", "CHEMICAL", 149, 152], ["HSC70", "GENE_OR_GENE_PRODUCT", 94, 99], ["ATP", "SIMPLE_CHEMICAL", 149, 152], ["HSC70", "GENE_OR_GENE_PRODUCT", 204, 209], ["HSC70", "GENE_OR_GENE_PRODUCT", 245, 250], ["VP5", "GENE_OR_GENE_PRODUCT", 255, 258], ["HSC70", "GENE_OR_GENE_PRODUCT", 319, 324], ["cellular", "CELL", 398, 406], ["membrane barrier", "CELLULAR_COMPONENT", 462, 478], ["HSC70", "PROTEIN", 94, 99], ["HSC70", "PROTEIN", 204, 209], ["HSC70", "PROTEIN", 245, 250], ["VP5", "PROTEIN", 255, 258], ["HSC70", "PROTEIN", 319, 324], ["binding cellular receptors", "PROTEIN", 390, 416], ["uncoat capsid", "PROTEIN", 483, 496], ["ATP in the system", "PROBLEM", 149, 166], ["allosteric change of HSC70", "PROBLEM", 183, 209], ["HSC70", "TEST", 245, 250], ["VP5", "TEST", 255, 258], ["virus infectivity", "PROBLEM", 288, 305], ["binding cellular receptors", "TREATMENT", 390, 416], ["viruses", "PROBLEM", 418, 425], ["the membrane barrier", "TREATMENT", 458, 478], ["nucleic acid", "TEST", 507, 519], ["large", "OBSERVATION_MODIFIER", 133, 138], ["allosteric change", "OBSERVATION", 183, 200], ["virus infectivity", "OBSERVATION", 288, 305], ["Viral Intracellular Trafficking", "OBSERVATION", 337, 368], ["cellular receptors", "OBSERVATION", 398, 416]]], ["Many enveloped viruses are internalized through clathrin-mediated endocytosis (Matlin et al., 1982) .", [["clathrin", "GENE_OR_GENE_PRODUCT", 48, 56], ["clathrin", "PROTEIN", 48, 56], ["Many enveloped viruses", "PROBLEM", 0, 22], ["enveloped", "OBSERVATION_MODIFIER", 5, 14], ["viruses", "OBSERVATION", 15, 22], ["endocytosis", "OBSERVATION_MODIFIER", 66, 77]]], ["After viral attachment, adaptor protein complex 2 (AP2) concentrates cellular receptors and recruits clathrin to the designated membrane.", [["cellular", "ANATOMY", 69, 77], ["membrane", "ANATOMY", 128, 136], ["adaptor protein complex 2", "GENE_OR_GENE_PRODUCT", 24, 49], ["AP2", "GENE_OR_GENE_PRODUCT", 51, 54], ["cellular", "CELL", 69, 77], ["clathrin", "GENE_OR_GENE_PRODUCT", 101, 109], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["adaptor protein complex 2", "PROTEIN", 24, 49], ["AP2", "PROTEIN", 51, 54], ["cellular receptors", "PROTEIN", 69, 87], ["clathrin", "PROTEIN", 101, 109], ["viral attachment", "PROBLEM", 6, 22], ["adaptor protein complex", "TREATMENT", 24, 47], ["cellular receptors", "TREATMENT", 69, 87], ["viral attachment", "OBSERVATION", 6, 22], ["membrane", "ANATOMY_MODIFIER", 128, 136]]], ["Clathrin assembles into triskelion and induces an inward curvature with the help of coat proteins.", [["Clathrin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Clathrin", "PROTEIN", 0, 8], ["coat proteins", "PROTEIN", 84, 97], ["Clathrin", "TREATMENT", 0, 8], ["an inward curvature", "PROBLEM", 47, 66], ["coat proteins", "PROBLEM", 84, 97], ["inward curvature", "OBSERVATION", 50, 66]]], ["As it gradually invaginates, the pit detaches from the membrane to form a clathrin-coated vesicle (CCV) (Brett and Traub, 2006) .", [["membrane", "ANATOMY", 55, 63], ["vesicle", "ANATOMY", 90, 97], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["clathrin", "GENE_OR_GENE_PRODUCT", 74, 82], ["vesicle", "CELLULAR_COMPONENT", 90, 97], ["clathrin", "PROTEIN", 74, 82], ["the pit detaches", "PROBLEM", 29, 45], ["pit detaches", "OBSERVATION", 33, 45], ["clathrin", "OBSERVATION", 74, 82], ["coated vesicle", "OBSERVATION", 83, 97]]], ["After detachment, clathrin is quickly removed and recycled and the vesicle goes on to fuse with the endosome.", [["vesicle", "ANATOMY", 67, 74], ["endosome", "ANATOMY", 100, 108], ["clathrin", "GENE_OR_GENE_PRODUCT", 18, 26], ["vesicle", "CELLULAR_COMPONENT", 67, 74], ["endosome", "CELLULAR_COMPONENT", 100, 108], ["clathrin", "PROTEIN", 18, 26], ["detachment", "PROBLEM", 6, 16], ["clathrin", "TREATMENT", 18, 26], ["detachment", "OBSERVATION", 6, 16]]], ["Then, viruses evolve at least three characterized mechanisms, by low pH, by receptor binding plus low pH and by receptor binding plus the action of a protease, to trigger fusion in the endosome and release viral genome (White and Whittaker, 2016) .", [["endosome", "ANATOMY", 185, 193], ["endosome", "CELLULAR_COMPONENT", 185, 193], ["protease", "PROTEIN", 150, 158], ["viral genome", "DNA", 206, 218], ["viruses", "PROBLEM", 6, 13], ["low pH", "PROBLEM", 65, 71], ["low pH", "PROBLEM", 98, 104], ["receptor binding", "PROBLEM", 112, 128], ["a protease", "TREATMENT", 148, 158], ["fusion in the endosome", "TREATMENT", 171, 193], ["viruses", "OBSERVATION", 6, 13], ["low pH", "OBSERVATION_MODIFIER", 65, 71], ["low pH", "OBSERVATION_MODIFIER", 98, 104], ["viral genome", "OBSERVATION", 206, 218]]], ["During transport among cellular compartments, HSC70 drives the clathrin assembly-disassembly cycle through providing energy (Chang et al., 2002; Xing et al., 2010) .", [["cellular compartments", "ANATOMY", 23, 44], ["cellular", "CELL", 23, 31], ["HSC70", "GENE_OR_GENE_PRODUCT", 46, 51], ["clathrin", "GENE_OR_GENE_PRODUCT", 63, 71], ["HSC70", "PROTEIN", 46, 51], ["clathrin", "PROTEIN", 63, 71]]], ["With the help of J domain proteins, such as auxilin, HSC70 binds to clathrin and dislodges triskelion in a reaction with ATP hydrolysis (Rothnie et al., 2011) .", [["ATP", "CHEMICAL", 121, 124], ["ATP", "CHEMICAL", 121, 124], ["auxilin", "GENE_OR_GENE_PRODUCT", 44, 51], ["HSC70", "GENE_OR_GENE_PRODUCT", 53, 58], ["clathrin", "GENE_OR_GENE_PRODUCT", 68, 76], ["ATP", "SIMPLE_CHEMICAL", 121, 124], ["J domain proteins", "PROTEIN", 17, 34], ["auxilin", "PROTEIN", 44, 51], ["HSC70", "PROTEIN", 53, 58], ["clathrin", "PROTEIN", 68, 76], ["J domain proteins", "TREATMENT", 17, 34], ["auxilin", "TREATMENT", 44, 51], ["HSC70 binds", "TREATMENT", 53, 64], ["a reaction", "PROBLEM", 105, 115], ["ATP hydrolysis", "TREATMENT", 121, 135]]], ["In cells overexpressing ATP-binding domain-deficient HSC70 mutants, the uncoating of CCV is inhibited and cytosolic clathrin gathers with AP1 and AP2 to form an empty \"cage\" without receptor accumulation, indicating that HSC70 broadly regulates clathrin dynamics throughout the CCV cycle (Newmyer and Schmid, 2001) .", [["cells", "ANATOMY", 3, 8], ["cytosolic", "ANATOMY", 106, 115], ["CCV", "ANATOMY", 278, 281], ["ATP", "CHEMICAL", 24, 27], ["ATP", "CHEMICAL", 24, 27], ["cells", "CELL", 3, 8], ["ATP-binding domain", "GENE_OR_GENE_PRODUCT", 24, 42], ["HSC70", "GENE_OR_GENE_PRODUCT", 53, 58], ["CCV", "GENE_OR_GENE_PRODUCT", 85, 88], ["clathrin", "GENE_OR_GENE_PRODUCT", 116, 124], ["AP1", "GENE_OR_GENE_PRODUCT", 138, 141], ["AP2", "GENE_OR_GENE_PRODUCT", 146, 149], ["HSC70", "GENE_OR_GENE_PRODUCT", 221, 226], ["clathrin", "GENE_OR_GENE_PRODUCT", 245, 253], ["ATP-binding domain", "PROTEIN", 24, 42], ["HSC70 mutants", "PROTEIN", 53, 66], ["CCV", "PROTEIN", 85, 88], ["cytosolic clathrin", "PROTEIN", 106, 124], ["AP1", "PROTEIN", 138, 141], ["AP2", "PROTEIN", 146, 149], ["HSC70", "PROTEIN", 221, 226], ["clathrin", "PROTEIN", 245, 253], ["ATP", "TEST", 24, 27], ["deficient HSC70 mutants", "PROBLEM", 43, 66], ["cytosolic clathrin", "TREATMENT", 106, 124], ["AP1 and AP2", "TEST", 138, 149], ["receptor accumulation", "PROBLEM", 182, 203]]], ["Since HSC70 contributes to the disassociation of clathrin from the vesicle coat, it undoubtedly involves the nucleocapsid disassembly of many enveloped viruses.", [["vesicle coat", "ANATOMY", 67, 79], ["HSC70", "GENE_OR_GENE_PRODUCT", 6, 11], ["clathrin", "GENE_OR_GENE_PRODUCT", 49, 57], ["vesicle", "CELLULAR_COMPONENT", 67, 74], ["nucleocapsid", "CELLULAR_COMPONENT", 109, 121], ["HSC70", "PROTEIN", 6, 11], ["clathrin", "PROTEIN", 49, 57], ["the disassociation of clathrin", "PROBLEM", 27, 57], ["vesicle coat", "ANATOMY", 67, 79], ["nucleocapsid", "OBSERVATION", 109, 121], ["enveloped", "OBSERVATION_MODIFIER", 142, 151], ["viruses", "OBSERVATION", 152, 159]]], ["Japanese encephalitis virus (JEV) initiates infection through clathrinmediated endocytosis (Nawa, 1998; Yang et al., 2013) .", [["Japanese encephalitis", "DISEASE", 0, 21], ["JEV", "DISEASE", 29, 32], ["infection", "DISEASE", 44, 53], ["Japanese encephalitis virus", "ORGANISM", 0, 27], ["JEV", "ORGANISM", 29, 32], ["Japanese encephalitis virus", "SPECIES", 0, 27], ["Japanese encephalitis virus", "SPECIES", 0, 27], ["JEV", "SPECIES", 29, 32], ["Japanese encephalitis virus (JEV)", "PROBLEM", 0, 33], ["infection through clathrinmediated endocytosis", "PROBLEM", 44, 90]]], ["In HSC70knockdown C6/36 cells, however, JEV only binds onto but cannot be taken up by cells to form acidified endosomes, let alone release viral RNA for further translation on the endoplasmic reticulum (ER) membrane (Ren et al., 2007; Chuang et al., 2015) , suggesting that HSC70 participates in JEV infection through affecting endocytosis.HSC70 Involves in Viral Intracellular Trafficking and DisassemblyIn addition to enveloped viruses, HSC70 also participates in transporting non-enveloped virus particles.", [["HSC70knockdown C6/36 cells", "ANATOMY", 3, 29], ["cells", "ANATOMY", 86, 91], ["endosomes", "ANATOMY", 110, 119], ["endoplasmic reticulum", "ANATOMY", 180, 201], ["ER) membrane", "ANATOMY", 203, 215], ["Intracellular", "ANATOMY", 364, 377], ["JEV infection", "DISEASE", 296, 309], ["HSC70knockdown C6/36 cells", "CELL", 3, 29], ["JEV", "ORGANISM", 40, 43], ["cells", "CELL", 86, 91], ["endosomes", "CELLULAR_COMPONENT", 110, 119], ["let", "GENE_OR_GENE_PRODUCT", 121, 124], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 180, 201], ["ER", "CELLULAR_COMPONENT", 203, 205], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["HSC70", "GENE_OR_GENE_PRODUCT", 274, 279], ["JEV", "ORGANISM", 296, 299], ["HSC70", "GENE_OR_GENE_PRODUCT", 340, 345], ["HSC70", "GENE_OR_GENE_PRODUCT", 439, 444], ["non-enveloped virus particles", "ORGANISM", 479, 508], ["HSC70knockdown C6/36 cells", "CELL_LINE", 3, 29], ["viral RNA", "RNA", 139, 148], ["HSC70", "PROTEIN", 274, 279], ["HSC70", "PROTEIN", 340, 345], ["HSC70", "PROTEIN", 439, 444], ["JEV", "SPECIES", 40, 43], ["JEV", "SPECIES", 296, 299], ["acidified endosomes", "PROBLEM", 100, 119], ["JEV infection", "PROBLEM", 296, 309], ["enveloped viruses", "PROBLEM", 420, 437], ["transporting non-enveloped virus particles", "PROBLEM", 466, 508], ["36 cells", "OBSERVATION_MODIFIER", 21, 29], ["endoplasmic reticulum", "ANATOMY", 180, 201], ["JEV infection", "OBSERVATION", 296, 309], ["Viral Intracellular Trafficking", "OBSERVATION", 358, 389], ["enveloped", "OBSERVATION_MODIFIER", 420, 429], ["viruses", "OBSERVATION", 430, 437]]], ["Simian virus 40 (SV40) enters cells through caveolar internalization and accumulates in ER compartment (Pelkmans et al., 2001) .", [["cells", "ANATOMY", 30, 35], ["caveolar", "ANATOMY", 44, 52], ["ER compartment", "ANATOMY", 88, 102], ["Simian virus 40", "ORGANISM", 0, 15], ["SV40", "ORGANISM", 17, 21], ["cells", "CELL", 30, 35], ["caveolar", "CELLULAR_COMPONENT", 44, 52], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["ER", "PROTEIN", 88, 90], ["Simian virus", "SPECIES", 0, 12], ["Simian virus 40", "SPECIES", 0, 15], ["Simian virus", "PROBLEM", 0, 12], ["caveolar internalization", "OBSERVATION", 44, 68]]], ["Then, SV40 hijacks ER membrane-bound J proteins DnaJB12 (B12), FIGURE 1 | Schematic representation of HSP70s structure.", [["ER membrane", "ANATOMY", 19, 30], ["B12", "CHEMICAL", 57, 60], ["SV40", "ORGANISM", 6, 10], ["ER", "GENE_OR_GENE_PRODUCT", 19, 21], ["B12", "SIMPLE_CHEMICAL", 57, 60], ["HSP70s", "GENE_OR_GENE_PRODUCT", 102, 108], ["ER", "PROTEIN", 19, 21], ["J proteins", "PROTEIN", 37, 47], ["DnaJB12", "PROTEIN", 48, 55], ["B12", "PROTEIN", 57, 60], ["HSP70s structure", "PROTEIN", 102, 118], ["SV40 hijacks ER membrane", "TEST", 6, 30], ["HSP70s structure", "PROBLEM", 102, 118], ["HSP70s structure", "OBSERVATION", 102, 118]]], ["All chaperons in the HSP70 family encompass three main structural domains, namely, an N-terminal ATP-binding domain (NBD) that exhibits ATPase activity, a substrate-binding domain (SBD) to interact with substrates, and a C-terminal lid domain to mediate co-chaperon binding.HSC70 Involves in Viral Intracellular Trafficking and DisassemblyFIGURE 2 | The broad spectrum of HSC70 functions in virus infections.", [["Intracellular", "ANATOMY", 298, 311], ["ATP", "CHEMICAL", 97, 100], ["infections", "DISEASE", 397, 407], ["N-", "CHEMICAL", 86, 88], ["ATP", "CHEMICAL", 97, 100], ["C", "CHEMICAL", 221, 222], ["HSP70", "GENE_OR_GENE_PRODUCT", 21, 26], ["ATP", "SIMPLE_CHEMICAL", 97, 100], ["NBD", "SIMPLE_CHEMICAL", 117, 120], ["ATPase", "GENE_OR_GENE_PRODUCT", 136, 142], ["co-chaperon", "GENE_OR_GENE_PRODUCT", 254, 265], ["HSC70", "GENE_OR_GENE_PRODUCT", 274, 279], ["HSC70", "GENE_OR_GENE_PRODUCT", 372, 377], ["HSP70 family", "PROTEIN", 21, 33], ["structural domains", "PROTEIN", 55, 73], ["N-terminal ATP-binding domain", "PROTEIN", 86, 115], ["NBD", "PROTEIN", 117, 120], ["ATPase", "PROTEIN", 136, 142], ["substrate-binding domain", "PROTEIN", 155, 179], ["SBD", "PROTEIN", 181, 184], ["C-terminal lid domain", "PROTEIN", 221, 242], ["co-chaperon", "PROTEIN", 254, 265], ["HSC70", "PROTEIN", 274, 279], ["HSC70", "PROTEIN", 372, 377], ["an N-terminal ATP-binding domain (NBD", "PROBLEM", 83, 120], ["ATPase activity", "PROBLEM", 136, 151], ["a substrate-binding domain (SBD)", "PROBLEM", 153, 185], ["a C-terminal lid domain", "TREATMENT", 219, 242], ["virus infections", "PROBLEM", 391, 407], ["ATPase activity", "OBSERVATION", 136, 151], ["Viral Intracellular Trafficking", "OBSERVATION", 292, 323], ["virus infections", "OBSERVATION", 391, 407]]], ["As a multitask chaperon protein, HSC70 is hijacked to be involved in many decisive aspects of virus infection.", [["infection", "DISEASE", 100, 109], ["HSC70", "GENE_OR_GENE_PRODUCT", 33, 38], ["multitask chaperon protein", "PROTEIN", 5, 31], ["HSC70", "PROTEIN", 33, 38], ["virus infection", "PROBLEM", 94, 109], ["virus infection", "OBSERVATION", 94, 109]]], ["Membrane-anchored HSC70 acts as binding receptor or post-attachment receptor to facilitate the entry of DENV and rotavirus into host cells, respectively.", [["Membrane", "ANATOMY", 0, 8], ["cells", "ANATOMY", 133, 138], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["HSC70", "GENE_OR_GENE_PRODUCT", 18, 23], ["post-attachment receptor", "GENE_OR_GENE_PRODUCT", 52, 76], ["DENV", "ORGANISM", 104, 108], ["rotavirus", "ORGANISM", 113, 122], ["host cells", "CELL", 128, 138], ["Membrane-anchored HSC70", "PROTEIN", 0, 23], ["binding receptor", "PROTEIN", 32, 48], ["post-attachment receptor", "PROTEIN", 52, 76], ["host cells", "CELL_TYPE", 128, 138], ["DENV", "SPECIES", 104, 108], ["rotavirus", "SPECIES", 113, 122], ["post-attachment receptor", "TREATMENT", 52, 76], ["DENV", "PROBLEM", 104, 108], ["rotavirus", "PROBLEM", 113, 122]]], ["After crossing the membrane barrier, HSC70 contributes to viral disassembly through uncoating clathrin from CCV or assisting in releasing capsid protein in an ATP-dependent manner.", [["membrane barrier", "ANATOMY", 19, 35], ["ATP", "CHEMICAL", 159, 162], ["ATP", "CHEMICAL", 159, 162], ["membrane barrier", "CELLULAR_COMPONENT", 19, 35], ["HSC70", "GENE_OR_GENE_PRODUCT", 37, 42], ["clathrin", "GENE_OR_GENE_PRODUCT", 94, 102], ["CCV", "GENE_OR_GENE_PRODUCT", 108, 111], ["ATP", "SIMPLE_CHEMICAL", 159, 162], ["HSC70", "PROTEIN", 37, 42], ["clathrin", "PROTEIN", 94, 102], ["CCV", "PROTEIN", 108, 111], ["capsid protein", "PROTEIN", 138, 152], ["crossing the membrane barrier", "TREATMENT", 6, 35], ["viral disassembly", "PROBLEM", 58, 75], ["uncoating clathrin", "TREATMENT", 84, 102]]], ["Subsequently, HSC70 positively or negatively participates in the replication stage of some viruses, such as MHV68, DHBV, HBV, EV-71, RABV, EBOV, and DENV, through interacting with viral proteins or viral genome.", [["HSC70", "GENE_OR_GENE_PRODUCT", 14, 19], ["MHV68", "GENE_OR_GENE_PRODUCT", 108, 113], ["DHBV", "ORGANISM", 115, 119], ["HBV", "ORGANISM", 121, 124], ["EV-71", "ORGANISM", 126, 131], ["RABV", "ORGANISM", 133, 137], ["EBOV", "ORGANISM", 139, 143], ["DENV", "ORGANISM", 149, 153], ["HSC70", "PROTEIN", 14, 19], ["viral proteins", "PROTEIN", 180, 194], ["viral genome", "DNA", 198, 210], ["MHV68", "SPECIES", 108, 113], ["DHBV", "SPECIES", 115, 119], ["HBV", "SPECIES", 121, 124], ["EV-71", "SPECIES", 126, 131], ["RABV", "SPECIES", 133, 137], ["EBOV", "SPECIES", 139, 143], ["DENV", "SPECIES", 149, 153], ["some viruses", "PROBLEM", 86, 98], ["DHBV", "PROBLEM", 115, 119], ["HBV", "TEST", 121, 124], ["EV", "TEST", 126, 128], ["RABV", "PROBLEM", 133, 137], ["EBOV", "PROBLEM", 139, 143], ["DENV", "PROBLEM", 149, 153], ["viral proteins", "PROBLEM", 180, 194], ["viral genome", "PROBLEM", 198, 210], ["some", "OBSERVATION_MODIFIER", 86, 90], ["viruses", "OBSERVATION", 91, 98], ["DENV", "OBSERVATION", 149, 153], ["viral genome", "OBSERVATION", 198, 210]]], ["Finally, HSC70 promotes viral morphogenesis generally via interacting with capsid protein.", [["HSC70", "GENE_OR_GENE_PRODUCT", 9, 14], ["HSC70", "PROTEIN", 9, 14], ["capsid protein", "PROTEIN", 75, 89], ["viral morphogenesis", "OBSERVATION", 24, 43]]], ["The up arrow means HSC70 positively regulates the viral infection stage, and conversely, down arrow means HSC70 exerts a negative effect on the viral infection stage.HSC70 Involves in Viral Intracellular Trafficking and DisassemblyDnaJB14 (B14), and DnaJC18 (C18) to recruit SGTA (small glutamine-rich tetratricopeptide repeatcontaining protein \u03b1), HSC70 (Walczak et al., 2014) , HSP105 (Ravindran et al., 2015) , and Bag2 (Dupzyk and Tsai, 2018) to form a cytosolic complex in a J domain-dependent manner and recruit Ubiquilin4 via a J domain-independent mechanism (Liu and Tsai, 2020) , to mediate SV40 ER-to-cytosol transport.", [["Intracellular", "ANATOMY", 190, 203], ["cytosolic", "ANATOMY", 457, 466], ["cytosol", "ANATOMY", 611, 618], ["infection", "DISEASE", 56, 65], ["viral infection", "DISEASE", 144, 159], ["glutamine", "CHEMICAL", 287, 296], ["glutamine", "CHEMICAL", 287, 296], ["HSC70", "GENE_OR_GENE_PRODUCT", 19, 24], ["HSC70", "GENE_OR_GENE_PRODUCT", 106, 111], ["HSC70", "GENE_OR_GENE_PRODUCT", 166, 171], ["DisassemblyDnaJB14", "GENE_OR_GENE_PRODUCT", 220, 238], ["B14", "GENE_OR_GENE_PRODUCT", 240, 243], ["DnaJC18", "GENE_OR_GENE_PRODUCT", 250, 257], ["SGTA", "GENE_OR_GENE_PRODUCT", 275, 279], ["small glutamine-rich tetratricopeptide repeatcontaining protein \u03b1", "GENE_OR_GENE_PRODUCT", 281, 346], ["HSC70", "GENE_OR_GENE_PRODUCT", 349, 354], ["Bag2", "GENE_OR_GENE_PRODUCT", 418, 422], ["Ubiquilin4", "GENE_OR_GENE_PRODUCT", 518, 528], ["SV40", "ORGANISM", 600, 604], ["ER", "GENE_OR_GENE_PRODUCT", 605, 607], ["cytosol", "CELLULAR_COMPONENT", 611, 618], ["HSC70", "PROTEIN", 19, 24], ["HSC70", "PROTEIN", 106, 111], ["HSC70", "PROTEIN", 166, 171], ["DisassemblyDnaJB14", "PROTEIN", 220, 238], ["B14", "PROTEIN", 240, 243], ["DnaJC18", "PROTEIN", 250, 257], ["SGTA", "PROTEIN", 275, 279], ["small glutamine-rich tetratricopeptide repeatcontaining protein \u03b1", "PROTEIN", 281, 346], ["HSC70", "PROTEIN", 349, 354], ["cytosolic complex", "PROTEIN", 457, 474], ["J domain", "PROTEIN", 480, 488], ["Ubiquilin4", "PROTEIN", 518, 528], ["J domain", "PROTEIN", 535, 543], ["ER", "PROTEIN", 605, 607], ["The up arrow means HSC70", "TEST", 0, 24], ["the viral infection stage", "PROBLEM", 46, 71], ["the viral infection stage", "PROBLEM", 140, 165], ["HSC70", "TEST", 166, 171], ["Viral Intracellular Trafficking", "TEST", 184, 215], ["DisassemblyDnaJB14", "TEST", 220, 238], ["SGTA", "TEST", 275, 279], ["small glutamine", "TEST", 281, 296], ["HSC70", "TEST", 349, 354], ["HSP105", "TEST", 380, 386], ["Bag2", "TEST", 418, 422], ["a cytosolic complex", "PROBLEM", 455, 474], ["a J domain", "TREATMENT", 533, 543], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65], ["negative effect", "OBSERVATION_MODIFIER", 121, 136], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159], ["Viral Intracellular Trafficking", "OBSERVATION", 184, 215]]], ["SGTA regulates the ability of HSC70 to directly interact with membrane-embedded SV40, while HSP105 and Bag2 trigger SV40 disassociate from HSC70, thereby enabling the virus to translocate across the ER membrane.", [["membrane", "ANATOMY", 62, 70], ["ER membrane", "ANATOMY", 199, 210], ["SGTA", "CHEMICAL", 0, 4], ["SGTA", "GENE_OR_GENE_PRODUCT", 0, 4], ["HSC70", "GENE_OR_GENE_PRODUCT", 30, 35], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["SV40", "GENE_OR_GENE_PRODUCT", 80, 84], ["HSP105", "GENE_OR_GENE_PRODUCT", 92, 98], ["Bag2", "GENE_OR_GENE_PRODUCT", 103, 107], ["SV40", "ORGANISM", 116, 120], ["HSC70", "GENE_OR_GENE_PRODUCT", 139, 144], ["ER", "GENE_OR_GENE_PRODUCT", 199, 201], ["membrane", "CELLULAR_COMPONENT", 202, 210], ["SGTA", "PROTEIN", 0, 4], ["HSC70", "PROTEIN", 30, 35], ["HSP105", "PROTEIN", 92, 98], ["Bag2", "PROTEIN", 103, 107], ["HSC70", "PROTEIN", 139, 144], ["ER", "PROTEIN", 199, 201], ["HSP105", "TEST", 92, 98], ["HSC70", "TEST", 139, 144], ["the virus", "PROBLEM", 163, 172]]], ["Apart from assisting SV40 transport, HSC70 contributes to the export of virus ribonucleoprotein complex (vRNP) through competing with NS2 to bind to M1, indicating important roles of HSC70 in influenza virus replication (Watanabe et al., 2014) .HSC70 Involves in Viral Intracellular Trafficking and DisassemblyBesides participating in virus intracellular trafficking, HSC70 associates with several virus uncoatings.", [["Intracellular", "ANATOMY", 269, 282], ["intracellular", "ANATOMY", 341, 354], ["influenza virus replication", "DISEASE", 192, 219], ["SV40", "ORGANISM", 21, 25], ["HSC70", "GENE_OR_GENE_PRODUCT", 37, 42], ["virus ribonucleoprotein complex", "GENE_OR_GENE_PRODUCT", 72, 103], ["vRNP", "GENE_OR_GENE_PRODUCT", 105, 109], ["NS2", "GENE_OR_GENE_PRODUCT", 134, 137], ["M1", "GENE_OR_GENE_PRODUCT", 149, 151], ["HSC70", "GENE_OR_GENE_PRODUCT", 183, 188], ["influenza virus", "ORGANISM", 192, 207], ["HSC70", "GENE_OR_GENE_PRODUCT", 245, 250], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 341, 354], ["HSC70", "GENE_OR_GENE_PRODUCT", 368, 373], ["HSC70", "PROTEIN", 37, 42], ["virus ribonucleoprotein complex", "PROTEIN", 72, 103], ["vRNP", "PROTEIN", 105, 109], ["NS2", "PROTEIN", 134, 137], ["M1", "PROTEIN", 149, 151], ["HSC70", "PROTEIN", 183, 188], ["HSC70", "PROTEIN", 245, 250], ["HSC70", "PROTEIN", 368, 373], ["influenza virus", "SPECIES", 192, 207], ["influenza virus", "SPECIES", 192, 207], ["virus ribonucleoprotein complex", "PROBLEM", 72, 103], ["NS2", "TREATMENT", 134, 137], ["HSC70 in influenza virus replication", "TREATMENT", 183, 219], ["several virus uncoatings", "PROBLEM", 390, 414], ["M1", "ANATOMY", 149, 151], ["influenza virus", "OBSERVATION", 192, 207], ["Viral Intracellular Trafficking", "OBSERVATION", 263, 294]]], ["After being trafficked to endosomes, reovirus goes through stepwise disassembly to expose the core for transcription.", [["endosomes", "ANATOMY", 26, 35], ["endosomes", "CELLULAR_COMPONENT", 26, 35], ["reovirus", "ORGANISM", 37, 45], ["reovirus", "TREATMENT", 37, 45]]], ["Studies have shown that HSC70 contributes to the removal of the \u03b4 fragment, cleaved from capsid protein \u00b51 (Bodkin et al., 1989) , in an ATPdependent manner, and further releases the transcriptionally active core into the cytoplasm.", [["cytoplasm", "ANATOMY", 222, 231], ["HSC70", "GENE_OR_GENE_PRODUCT", 24, 29], ["cytoplasm", "ORGANISM_SUBSTANCE", 222, 231], ["HSC70", "PROTEIN", 24, 29], ["\u03b4 fragment", "PROTEIN", 64, 74], ["capsid protein \u00b51", "PROTEIN", 89, 106], ["HSC70", "PROBLEM", 24, 29], ["the removal", "TREATMENT", 45, 56], ["the \u03b4 fragment", "PROBLEM", 60, 74], ["removal", "OBSERVATION_MODIFIER", 49, 56], ["fragment", "OBSERVATION", 66, 74], ["cytoplasm", "OBSERVATION_MODIFIER", 222, 231]]], ["Blocking HSC70 through specific antibodies significantly inhibits \u03b4 release and, complementing with purified HSC70, totally restores the \u03b4-release activity (Ivanovic et al., 2007) , suggesting that HSC70 plays central roles in reovirus disassembly.", [["HSC70", "GENE_OR_GENE_PRODUCT", 9, 14], ["\u03b4", "GENE_OR_GENE_PRODUCT", 66, 67], ["HSC70", "GENE_OR_GENE_PRODUCT", 109, 114], ["HSC70", "GENE_OR_GENE_PRODUCT", 198, 203], ["reovirus", "ORGANISM", 227, 235], ["HSC70", "PROTEIN", 9, 14], ["\u03b4", "PROTEIN", 66, 67], ["HSC70", "PROTEIN", 109, 114], ["HSC70", "PROTEIN", 198, 203], ["specific antibodies", "TEST", 23, 42], ["purified HSC70", "TEST", 100, 114], ["central", "ANATOMY_MODIFIER", 210, 217]]], ["Apart from animal viruses, HSC70 has been reported to be associated with cucumber necrosis virus (CNV) particles and incubation of recombinant HSC70-2 with CNV results in conformational changes or partial disassembly of virus capsid and produces higher numbers of local lesions on Chenopodium quinoa, suggesting that HSC70 plays an important role in plant virus infection (Alam and Rochon, 2017) .HSC70 Regulates Viral Genome ReplicationViruses are small intracellular parasites and thus rely heavily on host machinery to successfully replicate their genome.", [["lesions", "ANATOMY", 270, 277], ["intracellular", "ANATOMY", 455, 468], ["cucumber necrosis", "DISEASE", 73, 90], ["plant virus infection", "DISEASE", 350, 371], ["HSC70", "GENE_OR_GENE_PRODUCT", 27, 32], ["cucumber necrosis virus", "ORGANISM", 73, 96], ["HSC70-2", "GENE_OR_GENE_PRODUCT", 143, 150], ["lesions", "PATHOLOGICAL_FORMATION", 270, 277], ["Chenopodium quinoa", "ORGANISM", 281, 299], ["HSC70", "GENE_OR_GENE_PRODUCT", 317, 322], ["plant virus", "ORGANISM", 350, 361], ["HSC70", "GENE_OR_GENE_PRODUCT", 397, 402], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 455, 468], ["HSC70", "PROTEIN", 27, 32], ["HSC70", "PROTEIN", 143, 148], ["HSC70", "PROTEIN", 317, 322], ["HSC70", "PROTEIN", 397, 402], ["cucumber necrosis virus", "SPECIES", 73, 96], ["cucumber necrosis virus", "SPECIES", 73, 96], ["Chenopodium quinoa", "SPECIES", 281, 299], ["animal viruses", "PROBLEM", 11, 25], ["HSC70", "TEST", 27, 32], ["cucumber necrosis virus", "PROBLEM", 73, 96], ["recombinant HSC70", "TEST", 131, 148], ["CNV", "PROBLEM", 156, 159], ["conformational changes", "PROBLEM", 171, 193], ["partial disassembly of virus capsid", "PROBLEM", 197, 232], ["local lesions on Chenopodium quinoa", "PROBLEM", 264, 299], ["plant virus infection", "PROBLEM", 350, 371], ["Viral Genome ReplicationViruses", "TREATMENT", 413, 444], ["small intracellular parasites", "PROBLEM", 449, 478], ["animal", "OBSERVATION_MODIFIER", 11, 17], ["viruses", "OBSERVATION", 18, 25], ["reported to be associated with", "UNCERTAINTY", 42, 72], ["cucumber", "OBSERVATION_MODIFIER", 73, 81], ["necrosis", "OBSERVATION", 82, 90], ["virus capsid", "OBSERVATION", 220, 232], ["higher", "OBSERVATION_MODIFIER", 246, 252], ["numbers", "OBSERVATION_MODIFIER", 253, 260], ["local", "OBSERVATION_MODIFIER", 264, 269], ["lesions", "OBSERVATION", 270, 277], ["Chenopodium quinoa", "OBSERVATION", 281, 299], ["plant virus", "OBSERVATION", 350, 361], ["Viral Genome", "OBSERVATION", 413, 425], ["small", "OBSERVATION_MODIFIER", 449, 454], ["intracellular parasites", "OBSERVATION", 455, 478]]], ["Several studies have reported that HSC70 facilitates virus replication by interacting with viral protein or viral genome.", [["HSC70", "GENE_OR_GENE_PRODUCT", 35, 40], ["HSC70", "PROTEIN", 35, 40], ["viral protein", "PROTEIN", 91, 104], ["viral genome", "DNA", 108, 120], ["Several studies", "TEST", 0, 15], ["HSC70 facilitates virus replication", "TREATMENT", 35, 70], ["viral protein or viral genome", "PROBLEM", 91, 120], ["virus", "OBSERVATION", 53, 58], ["viral genome", "OBSERVATION", 108, 120]]], ["Murine latencyassociated nuclear antigen (mLANA) is a conserved protein of murine gammaherpesvirus 68 (MHV68), which is important for latency maintenance and acute viral replication (Virgin et al., 1997) .", [["Murine latencyassociated nuclear antigen", "GENE_OR_GENE_PRODUCT", 0, 40], ["mLANA", "GENE_OR_GENE_PRODUCT", 42, 47], ["murine gammaherpesvirus 68", "ORGANISM", 75, 101], ["MHV68", "GENE_OR_GENE_PRODUCT", 103, 108], ["Murine latencyassociated nuclear antigen", "PROTEIN", 0, 40], ["mLANA", "PROTEIN", 42, 47], ["MHV68", "PROTEIN", 103, 108], ["Murine", "SPECIES", 0, 6], ["murine", "SPECIES", 75, 81], ["murine gammaherpesvirus 68", "SPECIES", 75, 101], ["Murine latencyassociated nuclear antigen", "TEST", 0, 40], ["murine gammaherpesvirus", "TEST", 75, 98], ["latency maintenance", "TREATMENT", 134, 153], ["acute viral replication", "TREATMENT", 158, 181], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["viral replication", "OBSERVATION", 164, 181]]], ["In MHV68-infected 3T12 fibroblasts, mLANA directly interacts with HSC70 and recruits it to accumulate in the nucleus, which contribute to the formation of viral replication complexes and thereby promote viral DNA replication, the expression of late viral proteins, and ultimately virus lytic infection (Salinas et al., 2015) .", [["3T12 fibroblasts", "ANATOMY", 18, 34], ["nucleus", "ANATOMY", 109, 116], ["lytic infection", "DISEASE", 286, 301], ["MHV68", "CELL", 3, 8], ["3T12 fibroblasts", "CELL", 18, 34], ["mLANA", "GENE_OR_GENE_PRODUCT", 36, 41], ["HSC70", "GENE_OR_GENE_PRODUCT", 66, 71], ["nucleus", "CELLULAR_COMPONENT", 109, 116], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["MHV68-infected 3T12 fibroblasts", "CELL_LINE", 3, 34], ["mLANA", "PROTEIN", 36, 41], ["HSC70", "PROTEIN", 66, 71], ["viral replication complexes", "PROTEIN", 155, 182], ["late viral proteins", "PROTEIN", 244, 263], ["HSC70", "TREATMENT", 66, 71], ["viral replication complexes", "PROBLEM", 155, 182], ["viral DNA replication", "TREATMENT", 203, 224], ["late viral proteins", "PROBLEM", 244, 263], ["ultimately virus lytic infection", "PROBLEM", 269, 301], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["3T12 fibroblasts", "OBSERVATION", 18, 34], ["nucleus", "ANATOMY", 109, 116], ["viral replication", "OBSERVATION", 155, 172], ["viral DNA replication", "OBSERVATION", 203, 224], ["late", "OBSERVATION_MODIFIER", 244, 248], ["viral proteins", "OBSERVATION", 249, 263], ["lytic", "OBSERVATION_MODIFIER", 286, 291]]], ["Duck hepatitis B virus (DHBV), a small DNAcontaining virus that replicates via an RNA intermediate, has been reported to depend on HSP90 for the recognition of RNA packaging signal (\u03b5) by viral reverse transcriptase (RT), in order to initiate replication and assemble the nucleocapsid (Hu and Seeger, 1996; Hu et al., 1997) .", [["Duck hepatitis B", "DISEASE", 0, 16], ["Duck hepatitis B virus", "ORGANISM", 0, 22], ["DHBV", "ORGANISM", 24, 28], ["small DNAcontaining virus", "ORGANISM", 33, 58], ["HSP90", "GENE_OR_GENE_PRODUCT", 131, 136], ["RNA packaging signal (\u03b5)", "GENE_OR_GENE_PRODUCT", 160, 184], ["viral reverse transcriptase", "GENE_OR_GENE_PRODUCT", 188, 215], ["nucleocapsid", "CELLULAR_COMPONENT", 272, 284], ["HSP90", "PROTEIN", 131, 136], ["RNA packaging signal (\u03b5)", "PROTEIN", 160, 184], ["viral reverse transcriptase", "PROTEIN", 188, 215], ["RT", "PROTEIN", 217, 219], ["Duck hepatitis B virus", "SPECIES", 0, 22], ["Duck hepatitis B virus", "SPECIES", 0, 22], ["DHBV", "SPECIES", 24, 28], ["Duck hepatitis B virus (DHBV", "PROBLEM", 0, 28], ["a small DNAcontaining virus", "PROBLEM", 31, 58], ["HSP90", "TEST", 131, 136], ["viral reverse transcriptase", "TREATMENT", 188, 215], ["small", "OBSERVATION_MODIFIER", 33, 38], ["DNAcontaining virus", "OBSERVATION", 39, 58]]], ["Interestingly, the viral RT can be activated efficiently by just HSC70 and HSP40, without the need of HSP90 or other cofactors, in an in vitro reconstitution system (Beck and Nassal, 2003) .", [["HSC70", "GENE_OR_GENE_PRODUCT", 65, 70], ["HSP40", "GENE_OR_GENE_PRODUCT", 75, 80], ["HSP90", "GENE_OR_GENE_PRODUCT", 102, 107], ["HSC70", "PROTEIN", 65, 70], ["HSP40", "PROTEIN", 75, 80], ["HSP90", "PROTEIN", 102, 107], ["the viral RT", "TREATMENT", 15, 27], ["HSP40", "TEST", 75, 80], ["HSP90", "TREATMENT", 102, 107], ["other cofactors", "PROBLEM", 111, 126]]], ["Likewise, HSC70, especially amino acids 511-536, has been confirmed to be a supportive factor for human HBV replication, and downregulated HSC70 expression in HepG2.2.15 cells impaired HBV DNA replication by over 60% .", [["HepG2", "ANATOMY", 159, 164], ["2.15 cells", "ANATOMY", 165, 175], ["amino acids 511-536", "CHEMICAL", 28, 47], ["amino acids", "CHEMICAL", 28, 39], ["HSC70", "GENE_OR_GENE_PRODUCT", 10, 15], ["amino acids", "AMINO_ACID", 28, 39], ["511-536", "AMINO_ACID", 40, 47], ["human", "ORGANISM", 98, 103], ["HBV", "ORGANISM", 104, 107], ["HSC70", "GENE_OR_GENE_PRODUCT", 139, 144], ["HepG2", "CELL", 159, 164], ["2.15 cells", "CELL", 165, 175], ["HBV", "ORGANISM", 185, 188], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["HSC70", "PROTEIN", 10, 15], ["amino acids 511-536", "PROTEIN", 28, 47], ["HSC70", "PROTEIN", 139, 144], ["HepG2", "CELL_LINE", 159, 164], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["HBV", "SPECIES", 104, 107], ["HBV", "SPECIES", 185, 188], ["HSC70", "TEST", 10, 15], ["amino acids", "TEST", 28, 39], ["human HBV replication", "TREATMENT", 98, 119], ["impaired HBV DNA replication", "TREATMENT", 176, 204], ["HepG2", "ANATOMY", 159, 164], ["HBV DNA", "OBSERVATION", 185, 192], ["replication", "OBSERVATION_MODIFIER", 193, 204]]], ["Therefore, many studies have taken HSC70 as a therapeutic target against HBV, either by transfecting siRNA (Bian et al., 2012) or via treatment with chemical drugs (Du et al., 2011; Gao et al., 2011; Wang et al., 2011) to suppress HSC70 expression.", [["HSC70", "GENE_OR_GENE_PRODUCT", 35, 40], ["HBV", "ORGANISM", 73, 76], ["HSC70", "GENE_OR_GENE_PRODUCT", 231, 236], ["HSC70", "PROTEIN", 35, 40], ["HSC70", "PROTEIN", 231, 236], ["HBV", "SPECIES", 73, 76], ["many studies", "TEST", 11, 23], ["HBV", "PROBLEM", 73, 76], ["chemical drugs", "TREATMENT", 149, 163]]], ["Enterovirus A71 (EV-71) is a positive-stranded RNA virus, and the initiation of viral protein translation is directed by the internal ribosome entry site (IRES) in 5 -UTR in a cap-independent manner (Thompson and Sarnow, 2003) .", [["Enterovirus A71", "ORGANISM", 0, 15], ["EV-71", "ORGANISM", 17, 22], ["internal ribosome entry site", "DNA", 125, 153], ["IRES", "DNA", 155, 159], ["5 -UTR", "DNA", 164, 170], ["Enterovirus A71 (EV-71", "SPECIES", 0, 22], ["Enterovirus A71 (EV", "TEST", 0, 19], ["a positive-stranded RNA virus", "PROBLEM", 27, 56], ["viral protein translation", "TREATMENT", 80, 105], ["stranded RNA virus", "OBSERVATION", 38, 56], ["viral protein translation", "OBSERVATION", 80, 105], ["internal", "ANATOMY_MODIFIER", 125, 133], ["ribosome entry", "OBSERVATION", 134, 148]]], ["HSC70 upregulates IRES activity through interacting with 2A pro to enhance eIF4G cleavage, and the proteolytic eIF4G dramatically obstructs cellular mRNA capdependent translation and assists IRES-mediated translation, which significantly promotes viral protein expression in RD cells (Ohlmann et al., 1996; Dong et al., 2018) .HSC70 Regulates Viral Genome ReplicationChaperon activity is not limited to protein-protein interactions, and HSC70 can favor virus replication through binding regulator non-coding RNA (ncRNA).", [["cellular", "ANATOMY", 140, 148], ["RD cells", "ANATOMY", 275, 283], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["2A pro", "GENE_OR_GENE_PRODUCT", 57, 63], ["eIF4G", "GENE_OR_GENE_PRODUCT", 75, 80], ["eIF4G", "GENE_OR_GENE_PRODUCT", 111, 116], ["cellular", "CELL", 140, 148], ["RD cells", "CELL", 275, 283], ["HSC70", "GENE_OR_GENE_PRODUCT", 327, 332], ["Chaperon", "GENE_OR_GENE_PRODUCT", 367, 375], ["HSC70", "GENE_OR_GENE_PRODUCT", 437, 442], ["HSC70", "PROTEIN", 0, 5], ["IRES", "DNA", 18, 22], ["2A pro", "PROTEIN", 57, 63], ["eIF4G", "PROTEIN", 75, 80], ["proteolytic eIF4G", "PROTEIN", 99, 116], ["cellular mRNA", "RNA", 140, 153], ["IRES", "DNA", 191, 195], ["RD cells", "CELL_TYPE", 275, 283], ["HSC70", "PROTEIN", 327, 332], ["Chaperon", "PROTEIN", 367, 375], ["HSC70", "PROTEIN", 437, 442], ["binding regulator non-coding RNA", "RNA", 479, 511], ["ncRNA", "DNA", 513, 518], ["eIF4G cleavage", "TREATMENT", 75, 89], ["the proteolytic eIF4G", "TREATMENT", 95, 116], ["cellular mRNA capdependent translation", "TREATMENT", 140, 178], ["HSC70 Regulates", "TREATMENT", 327, 342], ["HSC70", "TREATMENT", 437, 442], ["virus replication", "TREATMENT", 453, 470], ["IRES activity", "OBSERVATION", 18, 31], ["viral protein expression", "OBSERVATION", 247, 271], ["Viral Genome", "OBSERVATION", 343, 355]]], ["Studies have reported that many viruses, such as human immunodeficiency virus (HIV) (Sun and Rossi, 2011) , DENV (Hussain and Asgari, 2014) , and West Nile virus (WNV) (Mazhar et al., 2011) , encode microRNA-like ncRNA to regulate virus replication.", [["human immunodeficiency virus (HIV)", "DISEASE", 49, 83], ["human immunodeficiency virus", "ORGANISM", 49, 77], ["HIV", "ORGANISM", 79, 82], ["DENV", "ORGANISM", 108, 112], ["West Nile virus", "ORGANISM", 146, 161], ["WNV", "ORGANISM", 163, 166], ["microRNA-like ncRNA", "DNA", 199, 218], ["human immunodeficiency virus (HIV", "SPECIES", 49, 82], ["West Nile virus", "SPECIES", 146, 161], ["human immunodeficiency virus", "SPECIES", 49, 77], ["HIV", "SPECIES", 79, 82], ["DENV", "SPECIES", 108, 112], ["West Nile virus", "SPECIES", 146, 161], ["WNV", "SPECIES", 163, 166], ["many viruses", "PROBLEM", 27, 39], ["human immunodeficiency virus", "PROBLEM", 49, 77], ["DENV", "PROBLEM", 108, 112], ["Asgari", "TEST", 126, 132], ["encode microRNA", "PROBLEM", 192, 207], ["virus replication", "TREATMENT", 231, 248], ["many", "OBSERVATION_MODIFIER", 27, 31], ["viruses", "OBSERVATION", 32, 39], ["virus replication", "OBSERVATION", 231, 248]]], ["Similarly, rabies virus (RABV) transcribed a small ncRNA, called leader RNA (leRNA), to inhibit virus replication in SK-N-SH cells through interfering with the interaction between genomic RNA and the nucleoprotein.", [["SK-N-SH cells", "ANATOMY", 117, 130], ["rabies virus", "ORGANISM", 11, 23], ["RABV", "ORGANISM", 25, 29], ["leRNA", "GENE_OR_GENE_PRODUCT", 77, 82], ["SK-N-SH cells", "CELL", 117, 130], ["small ncRNA", "DNA", 45, 56], ["leader RNA", "RNA", 65, 75], ["leRNA", "DNA", 77, 82], ["SK-N-SH cells", "CELL_LINE", 117, 130], ["genomic RNA", "RNA", 180, 191], ["rabies virus", "SPECIES", 11, 23], ["rabies virus", "SPECIES", 11, 23], ["RABV", "SPECIES", 25, 29], ["rabies virus (RABV", "PROBLEM", 11, 29], ["a small ncRNA", "PROBLEM", 43, 56], ["virus replication", "TREATMENT", 96, 113], ["small", "OBSERVATION_MODIFIER", 45, 50], ["ncRNA", "OBSERVATION", 51, 56]]], ["However, the expression level of HSC70 during RABV infection correlates negatively with leRNA but positively with viral genomic RNA.", [["infection", "DISEASE", 51, 60], ["HSC70", "GENE_OR_GENE_PRODUCT", 33, 38], ["RABV", "ORGANISM", 46, 50], ["leRNA", "GENE_OR_GENE_PRODUCT", 88, 93], ["HSC70", "PROTEIN", 33, 38], ["leRNA", "PROTEIN", 88, 93], ["viral genomic RNA", "RNA", 114, 131], ["RABV", "SPECIES", 46, 50], ["RABV infection", "PROBLEM", 46, 60], ["leRNA", "PROBLEM", 88, 93], ["viral genomic RNA", "PROBLEM", 114, 131], ["infection", "OBSERVATION", 51, 60], ["viral genomic RNA", "OBSERVATION", 114, 131]]], ["Further data reveals that HSC70 downregulates leRNA through interacting with its 51-59 nucleotides to promote RABV replication (Zhang et al., 2017) .", [["nucleotides", "CHEMICAL", 87, 98], ["HSC70", "GENE_OR_GENE_PRODUCT", 26, 31], ["leRNA", "GENE_OR_GENE_PRODUCT", 46, 51], ["RABV", "ORGANISM", 110, 114], ["HSC70", "PROTEIN", 26, 31], ["leRNA", "PROTEIN", 46, 51], ["51-59 nucleotides", "DNA", 81, 98], ["RABV", "SPECIES", 110, 114], ["Further data", "TEST", 0, 12], ["nucleotides", "TREATMENT", 87, 98], ["RABV replication", "TREATMENT", 110, 126], ["RABV replication", "OBSERVATION", 110, 126]]], ["The Ebola virus (EBOV) genome is flanked by the 3' leader and 5 trailer non-coding regions (NCRs), and both the NCRs play crucial roles in regulating viral replication, transcription, and progeny genome packaging.", [["Ebola", "DISEASE", 4, 9], ["Ebola virus", "ORGANISM", 4, 15], ["EBOV", "ORGANISM", 17, 21], ["3' leader", "CELLULAR_COMPONENT", 48, 57], ["NCRs", "GENE_OR_GENE_PRODUCT", 112, 116], ["Ebola virus (EBOV) genome", "DNA", 4, 29], ["3' leader", "DNA", 48, 57], ["5 trailer non-coding regions", "DNA", 62, 90], ["NCRs", "DNA", 92, 96], ["NCRs", "DNA", 112, 116], ["Ebola virus", "SPECIES", 4, 15], ["Ebola virus", "SPECIES", 4, 15], ["EBOV", "SPECIES", 17, 21], ["The Ebola virus", "PROBLEM", 0, 15], ["progeny genome packaging", "TREATMENT", 188, 212], ["Ebola virus", "OBSERVATION", 4, 15], ["viral replication", "OBSERVATION", 150, 167]]], ["HSC70 interacts with three motifs at nucleotide positions 26-30, 620-624, and 669-673 of trailer sequence to form a trailer-to-leader panhandle structure and further promotes EBOV 3E-5E-GFP minigenome replication in HEK293T cells (Joanna et al., 2016) .HSC70 Regulates Viral Genome ReplicationBesides positive regulation, HSC70 also exerts a negative effect on virus replication.", [["HEK293T cells", "ANATOMY", 216, 229], ["nucleotide", "CHEMICAL", 37, 47], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["panhandle", "CANCER", 134, 143], ["EBOV 3E-5E", "GENE_OR_GENE_PRODUCT", 175, 185], ["GFP", "GENE_OR_GENE_PRODUCT", 186, 189], ["HEK293T cells", "CELL", 216, 229], ["HSC70", "GENE_OR_GENE_PRODUCT", 253, 258], ["HSC70", "GENE_OR_GENE_PRODUCT", 322, 327], ["HSC70", "PROTEIN", 0, 5], ["nucleotide positions 26-30, 620-624, and 669-673", "DNA", 37, 85], ["trailer sequence", "DNA", 89, 105], ["trailer-to-leader panhandle structure", "DNA", 116, 153], ["HEK293T cells", "CELL_LINE", 216, 229], ["HSC70", "PROTEIN", 253, 258], ["HSC70", "PROTEIN", 322, 327], ["EBOV", "SPECIES", 175, 179], ["nucleotide positions", "TEST", 37, 57], ["trailer sequence", "TEST", 89, 105], ["a trailer", "TREATMENT", 114, 123], ["5E-GFP minigenome replication", "TREATMENT", 183, 212], ["HSC70", "TEST", 253, 258], ["HSC70", "TEST", 322, 327], ["virus replication", "TREATMENT", 361, 378], ["Viral Genome", "OBSERVATION", 269, 281], ["negative effect", "OBSERVATION_MODIFIER", 342, 357]]], ["HSC70/HSP90 has already been confirmed to be a driving force for the RNA-induced silencing complex (RISC) assembly pathway through providing ATP to load small RNA duplexes into Argonaute proteins (Iwasaki et al., 2010; Ye et al., 2012) .", [["ATP", "CHEMICAL", 141, 144], ["ATP", "CHEMICAL", 141, 144], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["HSP90", "GENE_OR_GENE_PRODUCT", 6, 11], ["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 69, 98], ["RISC", "GENE_OR_GENE_PRODUCT", 100, 104], ["ATP", "SIMPLE_CHEMICAL", 141, 144], ["Argonaute", "GENE_OR_GENE_PRODUCT", 177, 186], ["HSC70", "PROTEIN", 0, 5], ["HSP90", "PROTEIN", 6, 11], ["RNA-induced silencing complex", "PROTEIN", 69, 98], ["RISC", "PROTEIN", 100, 104], ["Argonaute proteins", "PROTEIN", 177, 195], ["HSC70/HSP90", "TEST", 0, 11], ["the RNA-induced silencing complex", "TREATMENT", 65, 98], ["ATP to load small RNA duplexes", "TREATMENT", 141, 171]]], ["Downregulating HSC70 in Huh7 cells suppresses miRNA-mediated host RNAi response and promotes the accumulation of DENV genomic RNA, suggesting a positive role of HSC70 in restricting DENV replication.", [["Huh7 cells", "ANATOMY", 24, 34], ["HSC70", "GENE_OR_GENE_PRODUCT", 15, 20], ["Huh7 cells", "CELL", 24, 34], ["HSC70", "GENE_OR_GENE_PRODUCT", 161, 166], ["DENV", "ORGANISM", 182, 186], ["HSC70", "PROTEIN", 15, 20], ["Huh7 cells", "CELL_LINE", 24, 34], ["DENV genomic RNA", "RNA", 113, 129], ["HSC70", "PROTEIN", 161, 166], ["DENV", "SPECIES", 113, 117], ["DENV", "SPECIES", 182, 186], ["Downregulating HSC70", "TREATMENT", 0, 20], ["Huh7 cells", "TEST", 24, 34], ["miRNA", "TEST", 46, 51], ["DENV genomic RNA", "PROBLEM", 113, 129], ["HSC70", "TREATMENT", 161, 166], ["restricting DENV replication", "TREATMENT", 170, 198], ["Huh7 cells", "OBSERVATION", 24, 34], ["host RNAi response", "OBSERVATION", 61, 79], ["accumulation", "OBSERVATION_MODIFIER", 97, 109], ["DENV genomic RNA", "OBSERVATION", 113, 129], ["DENV replication", "OBSERVATION", 182, 198]]], ["However, NS3, an RNAi suppressor protein encoded by DENV, inhibits the loading of miRNAs into Ago1 through interacting with HSC70 to displace TRBP and finally favors virus replication in HEK293T cells (Kakumani et al., 2015) .HSC70 Associates With Viral MorphogenesisAfter biosynthesis, viruses usually recruit several host factors to promote assembly and budding.", [["HEK293T cells", "ANATOMY", 187, 200], ["NS3", "GENE_OR_GENE_PRODUCT", 9, 12], ["Ago1", "GENE_OR_GENE_PRODUCT", 94, 98], ["HSC70", "GENE_OR_GENE_PRODUCT", 124, 129], ["TRBP", "GENE_OR_GENE_PRODUCT", 142, 146], ["HEK293T cells", "CELL", 187, 200], ["HSC70", "GENE_OR_GENE_PRODUCT", 226, 231], ["NS3", "PROTEIN", 9, 12], ["RNAi suppressor protein", "PROTEIN", 17, 40], ["Ago1", "PROTEIN", 94, 98], ["HSC70", "PROTEIN", 124, 129], ["TRBP", "PROTEIN", 142, 146], ["HEK293T cells", "CELL_LINE", 187, 200], ["HSC70", "PROTEIN", 226, 231], ["NS3", "TREATMENT", 9, 12], ["an RNAi suppressor protein", "TREATMENT", 14, 40], ["DENV", "PROBLEM", 52, 56], ["HSC70", "TREATMENT", 124, 129], ["TRBP", "TREATMENT", 142, 146], ["virus replication", "TREATMENT", 166, 183], ["Viral MorphogenesisAfter biosynthesis", "TREATMENT", 248, 285], ["viruses", "PROBLEM", 287, 294], ["Viral MorphogenesisAfter", "OBSERVATION", 248, 272]]], ["Immunogold labeling experiments suggest that HSC70 presents on the surface of hepatitis C virus (HCV) particles through interacting with the HPD (His-Pro-Arg) motif on the E2 envelope protein of the virus.", [["surface", "ANATOMY", 67, 74], ["hepatitis C", "DISEASE", 78, 89], ["His-Pro-Arg", "CHEMICAL", 146, 157], ["E2", "CHEMICAL", 172, 174], ["His-Pro-Arg", "CHEMICAL", 146, 157], ["HSC70", "GENE_OR_GENE_PRODUCT", 45, 50], ["surface", "CELLULAR_COMPONENT", 67, 74], ["hepatitis C virus", "ORGANISM", 78, 95], ["HCV", "ORGANISM", 97, 100], ["HPD", "GENE_OR_GENE_PRODUCT", 141, 144], ["HSC70", "PROTEIN", 45, 50], ["HPD (His-Pro-Arg) motif", "PROTEIN", 141, 164], ["E2 envelope protein", "PROTEIN", 172, 191], ["hepatitis C virus", "SPECIES", 78, 95], ["hepatitis C virus", "SPECIES", 78, 95], ["HCV", "SPECIES", 97, 100], ["Immunogold labeling experiments", "TEST", 0, 31], ["hepatitis C virus (HCV) particles", "PROBLEM", 78, 111], ["the HPD", "TEST", 137, 144], ["His-Pro-Arg) motif", "TREATMENT", 146, 164], ["the E2 envelope protein", "TREATMENT", 168, 191], ["the virus", "PROBLEM", 195, 204]]], ["In Huh7.5 cells, HSC70, HCV core, and E2 proteins were found to colocalize at the periphery of lipid droplets, an important site for HCV assembly and release.", [["Huh7.5 cells", "ANATOMY", 3, 15], ["lipid droplets", "ANATOMY", 95, 109], ["site", "ANATOMY", 124, 128], ["Huh7.5 cells", "CELL", 3, 15], ["HSC70", "GENE_OR_GENE_PRODUCT", 17, 22], ["HCV", "ORGANISM", 24, 27], ["E2", "GENE_OR_GENE_PRODUCT", 38, 40], ["lipid droplets", "CELLULAR_COMPONENT", 95, 109], ["Huh7.5 cells", "CELL_LINE", 3, 15], ["HSC70", "PROTEIN", 17, 22], ["E2 proteins", "PROTEIN", 38, 49], ["HCV", "SPECIES", 24, 27], ["HCV", "SPECIES", 133, 136], ["HSC70", "TEST", 17, 22], ["HCV core", "TEST", 24, 32], ["E2 proteins", "TEST", 38, 49], ["lipid droplets", "TREATMENT", 95, 109], ["HCV assembly", "TREATMENT", 133, 145], ["lipid droplets", "OBSERVATION", 95, 109], ["HCV", "OBSERVATION", 133, 136]]], ["Knockdown of HSC70 with RNA interference reduces the volume of lipid droplets and inhibits viral RNA release, without influence on virus intracellular replication level, suggesting that HSC70 might modulate HCV infectivity through contributing to assembly or budding (Parent et al., 2009) .", [["lipid droplets", "ANATOMY", 63, 77], ["intracellular", "ANATOMY", 137, 150], ["HSC70", "GENE_OR_GENE_PRODUCT", 13, 18], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 137, 150], ["HSC70", "GENE_OR_GENE_PRODUCT", 186, 191], ["HCV", "ORGANISM", 207, 210], ["HSC70", "PROTEIN", 13, 18], ["HSC70", "PROTEIN", 186, 191], ["HCV", "SPECIES", 207, 210], ["Knockdown of HSC70", "TREATMENT", 0, 18], ["RNA interference", "PROBLEM", 24, 40], ["the volume of lipid droplets", "TREATMENT", 49, 77], ["viral RNA release", "PROBLEM", 91, 108], ["virus intracellular replication level", "TEST", 131, 168], ["HSC70", "PROBLEM", 186, 191], ["HCV infectivity", "PROBLEM", 207, 222], ["RNA interference", "OBSERVATION", 24, 40], ["volume", "OBSERVATION_MODIFIER", 53, 59], ["lipid droplets", "OBSERVATION", 63, 77], ["viral RNA", "OBSERVATION", 91, 100], ["without", "UNCERTAINTY", 110, 117], ["HCV infectivity", "OBSERVATION", 207, 222]]], ["The followed research demonstrates that IMB-DM122, an inhibitor of HSC70, without activity against HCV RNA polymerase or protease and not toxic to liver cells, significantly reduces J6/JFH infectivity through interfering with the encapsidation of HSC70 (Peng et al., 2010) .", [["liver cells", "ANATOMY", 147, 158], ["IMB-DM122", "CHEMICAL", 40, 49], ["IMB-DM122", "CHEMICAL", 40, 49], ["IMB-DM122", "SIMPLE_CHEMICAL", 40, 49], ["HSC70", "GENE_OR_GENE_PRODUCT", 67, 72], ["HCV", "ORGANISM", 99, 102], ["liver cells", "CELL", 147, 158], ["J6", "GENE_OR_GENE_PRODUCT", 182, 184], ["JFH", "GENE_OR_GENE_PRODUCT", 185, 188], ["HSC70", "GENE_OR_GENE_PRODUCT", 247, 252], ["HSC70", "PROTEIN", 67, 72], ["HCV RNA polymerase", "PROTEIN", 99, 117], ["protease", "PROTEIN", 121, 129], ["liver cells", "CELL_TYPE", 147, 158], ["HSC70", "PROTEIN", 247, 252], ["HCV", "SPECIES", 99, 102], ["IMB", "TEST", 40, 43], ["an inhibitor of HSC70", "TREATMENT", 51, 72], ["HCV RNA polymerase", "PROBLEM", 99, 117], ["protease", "PROBLEM", 121, 129], ["toxic to liver cells", "PROBLEM", 138, 158], ["J6/JFH infectivity", "PROBLEM", 182, 200], ["without", "UNCERTAINTY", 74, 81], ["liver", "ANATOMY", 147, 152]]], ["Moreover, the allosteric HSC70 inhibitors block intracellular assembly, but not entry, replication, or translation, of infectious Renilla reporter JFH-1 HCV virus (Khachatoorian et al., 2016) .", [["intracellular", "ANATOMY", 48, 61], ["HSC70", "GENE_OR_GENE_PRODUCT", 25, 30], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["Renilla reporter JFH-1 HCV virus", "ORGANISM", 130, 162], ["HSC70", "PROTEIN", 25, 30], ["JFH-1 HCV virus", "SPECIES", 147, 162], ["the allosteric HSC70 inhibitors block", "TREATMENT", 10, 47], ["infectious Renilla reporter JFH", "TEST", 119, 150], ["HCV virus", "PROBLEM", 153, 162]]], ["For HBV, HSC70 not only contributes to the activation of RT but also significantly affects viral assembly.", [["HBV", "ORGANISM", 4, 7], ["HSC70", "GENE_OR_GENE_PRODUCT", 9, 14], ["HSC70", "PROTEIN", 9, 14], ["HBV", "SPECIES", 4, 7], ["HBV", "PROBLEM", 4, 7], ["the activation of RT", "PROBLEM", 39, 59], ["viral", "OBSERVATION", 91, 96]]], ["The large (L) envelop protein with its preS domain plays pivotal roles in the HBV life cycle, which largely depends on its dual topology.", [["large (L)", "GENE_OR_GENE_PRODUCT", 4, 13], ["preS", "GENE_OR_GENE_PRODUCT", 39, 43], ["large (L) envelop protein", "PROTEIN", 4, 29], ["preS domain", "PROTEIN", 39, 50], ["The large (L) envelop protein", "TREATMENT", 0, 29], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["L protein mediates viral attachment with the preS domain translocated into the post-ER lumen (e-preS) (Neurath et al., 1986) ; however, it is closely related to the viral morphogenesis with the preS domain on the cytosolic side of the ER membrane (i-preS) (Ueda et al., 1991) .", [["ER lumen", "ANATOMY", 84, 92], ["cytosolic", "ANATOMY", 213, 222], ["ER membrane", "ANATOMY", 235, 246], ["preS", "GENE_OR_GENE_PRODUCT", 45, 49], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["ER membrane", "CELLULAR_COMPONENT", 235, 246], ["L protein", "PROTEIN", 0, 9], ["preS domain", "PROTEIN", 45, 56], ["preS domain", "PROTEIN", 194, 205], ["ER", "PROTEIN", 235, 237], ["i-preS", "PROTEIN", 248, 254], ["L protein mediates", "TREATMENT", 0, 18], ["viral attachment", "PROBLEM", 19, 35], ["the preS domain", "TREATMENT", 41, 56], ["the viral morphogenesis", "PROBLEM", 161, 184], ["viral attachment", "OBSERVATION", 19, 35], ["lumen", "ANATOMY_MODIFIER", 87, 92], ["viral", "OBSERVATION", 165, 170], ["ER membrane", "ANATOMY", 235, 246]]], ["Amino acids from 70 to 94 of the L protein, named cytosolic anchorage determinant (CAD), prevents cotranslational preS translocation and contributes to the formation of i-preS.", [["cytosolic", "ANATOMY", 50, 59], ["Amino acids", "CHEMICAL", 0, 11], ["Amino acids", "CHEMICAL", 0, 11], ["Amino acids", "AMINO_ACID", 0, 11], ["cytosolic anchorage determinant", "GENE_OR_GENE_PRODUCT", 50, 81], ["preS", "GENE_OR_GENE_PRODUCT", 114, 118], ["i-preS", "GENE_OR_GENE_PRODUCT", 169, 175], ["L protein", "PROTEIN", 33, 42], ["cytosolic anchorage determinant", "PROTEIN", 50, 81], ["CAD", "PROTEIN", 83, 86], ["preS", "PROTEIN", 114, 118], ["i-preS", "PROTEIN", 169, 175], ["Amino acids", "TEST", 0, 11], ["the L protein", "TEST", 29, 42], ["CAD", "PROBLEM", 83, 86], ["cotranslational preS translocation", "PROBLEM", 98, 132], ["cytosolic anchorage", "OBSERVATION", 50, 69], ["preS translocation", "OBSERVATION", 114, 132]]], ["CAD deletion relieves the suppression of preS translocation and yields a uniform topology of L protein in COS-7 cells.", [["COS-7 cells", "ANATOMY", 106, 117], ["CAD", "DISEASE", 0, 3], ["preS", "GENE_OR_GENE_PRODUCT", 41, 45], ["COS-7 cells", "CELL", 106, 117], ["preS", "PROTEIN", 41, 45], ["L protein", "PROTEIN", 93, 102], ["COS-7 cells", "CELL_LINE", 106, 117], ["CAD deletion", "PROBLEM", 0, 12], ["preS translocation", "PROBLEM", 41, 59], ["L protein", "ANATOMY_MODIFIER", 93, 102]]], ["HSC70 selectively binds to CAD and might assist in virion formation through stabilizing the cytosolic configuration of preS (i-preS) and facilitating the contacts between L protein and viral nucleocapsid (Prange et al., 1999) .", [["virion", "ANATOMY", 51, 57], ["cytosolic", "ANATOMY", 92, 101], ["CAD", "DISEASE", 27, 30], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["virion", "CELLULAR_COMPONENT", 51, 57], ["preS", "GENE_OR_GENE_PRODUCT", 119, 123], ["i-preS", "GENE_OR_GENE_PRODUCT", 125, 131], ["L protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["HSC70", "PROTEIN", 0, 5], ["CAD", "PROTEIN", 27, 30], ["preS", "PROTEIN", 119, 123], ["i-preS", "PROTEIN", 125, 131], ["L protein", "PROTEIN", 171, 180], ["viral nucleocapsid", "PROTEIN", 185, 203], ["CAD", "PROBLEM", 27, 30], ["viral nucleocapsid", "PROBLEM", 185, 203], ["CAD", "OBSERVATION", 27, 30], ["virion", "OBSERVATION", 51, 57], ["cytosolic configuration", "OBSERVATION", 92, 115], ["viral nucleocapsid", "OBSERVATION", 185, 203]]], ["The non-enveloped human papillomavirus (HPV) consists of two capsid proteins, L1 and L2, and L2 facilitates virus assembly by recruiting L1 to nuclear substructures, named PML (promyelocytic leukemia) bodies (Swindle, 1999) .", [["nuclear substructures", "ANATOMY", 143, 164], ["PML (promyelocytic leukemia", "ANATOMY", 172, 199], ["non-enveloped human papillomavirus", "DISEASE", 4, 38], ["PML (promyelocytic leukemia)", "DISEASE", 172, 200], ["non-enveloped", "ORGANISM", 4, 17], ["human papillomavirus", "ORGANISM", 18, 38], ["HPV", "ORGANISM", 40, 43], ["L1", "GENE_OR_GENE_PRODUCT", 137, 139], ["nuclear", "CELLULAR_COMPONENT", 143, 150], ["PML", "GENE_OR_GENE_PRODUCT", 172, 175], ["promyelocytic leukemia", "CANCER", 177, 199], ["capsid proteins", "PROTEIN", 61, 76], ["L1", "PROTEIN", 78, 80], ["L2", "PROTEIN", 85, 87], ["L2", "PROTEIN", 93, 95], ["L1", "PROTEIN", 137, 139], ["human", "SPECIES", 18, 23], ["papillomavirus", "SPECIES", 24, 38], ["human papillomavirus", "SPECIES", 18, 38], ["HPV", "SPECIES", 40, 43], ["The non-enveloped human papillomavirus (HPV)", "TEST", 0, 44], ["two capsid proteins, L1 and L2", "PROBLEM", 57, 87], ["L2 facilitates virus", "PROBLEM", 93, 113], ["PML (promyelocytic leukemia) bodies", "PROBLEM", 172, 207], ["non-enveloped", "OBSERVATION_MODIFIER", 4, 17], ["human papillomavirus", "OBSERVATION", 18, 38], ["capsid proteins", "OBSERVATION", 61, 76], ["L1", "ANATOMY", 78, 80], ["L2", "ANATOMY", 85, 87], ["L2", "ANATOMY_MODIFIER", 93, 95], ["virus", "OBSERVATION", 108, 113], ["L1", "ANATOMY", 137, 139], ["PML", "OBSERVATION_MODIFIER", 172, 175], ["promyelocytic leukemia", "OBSERVATION", 177, 199]]], ["HSC70 interacts with the L2 C-terminus in the cytoplasm, and the complex then translocates to PML in COS-7 cells.", [["cytoplasm", "ANATOMY", 46, 55], ["PML", "ANATOMY", 94, 97], ["COS-7 cells", "ANATOMY", 101, 112], ["C", "CHEMICAL", 28, 29], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 46, 55], ["PML", "GENE_OR_GENE_PRODUCT", 94, 97], ["COS-7 cells", "CELL", 101, 112], ["HSC70", "PROTEIN", 0, 5], ["L2 C-terminus", "PROTEIN", 25, 38], ["PML", "PROTEIN", 94, 97], ["COS-7 cells", "CELL_LINE", 101, 112], ["L2", "ANATOMY", 25, 27], ["cytoplasm", "ANATOMY", 46, 55], ["PML", "OBSERVATION", 94, 97]]], ["The depletion of HSC70 blocks nuclear relocation of L2 and negatively regulates virus assembly, suggesting the indispensable role of HSC70 in integrating L2 into the viral capsid (Florin et al., 2004) .HSC70 Correlates With Virus-Induced Host-Protective Immune ResponseChaperone-mediated autophagy (CMA) is a type of autophagy responsible for selective degradation of cytosolic proteins bearing a certain consensus amino acid motif (KFERQ) (Dice, 1990) .", [["nuclear", "ANATOMY", 30, 37], ["cytosolic", "ANATOMY", 368, 377], ["ResponseChaperone", "CHEMICAL", 261, 278], ["CMA", "CHEMICAL", 299, 302], ["amino acid", "CHEMICAL", 415, 425], ["amino acid", "CHEMICAL", 415, 425], ["HSC70", "GENE_OR_GENE_PRODUCT", 17, 22], ["nuclear", "CELLULAR_COMPONENT", 30, 37], ["HSC70", "GENE_OR_GENE_PRODUCT", 133, 138], ["HSC70", "GENE_OR_GENE_PRODUCT", 202, 207], ["CMA", "SIMPLE_CHEMICAL", 299, 302], ["amino acid", "AMINO_ACID", 415, 425], ["HSC70", "PROTEIN", 17, 22], ["L2", "PROTEIN", 52, 54], ["HSC70", "PROTEIN", 133, 138], ["L2", "DNA", 154, 156], ["HSC70", "PROTEIN", 202, 207], ["cytosolic proteins", "PROTEIN", 368, 386], ["consensus amino acid motif", "PROTEIN", 405, 431], ["HSC70 blocks", "TREATMENT", 17, 29], ["Virus", "TEST", 224, 229], ["autophagy", "PROBLEM", 317, 326], ["cytosolic proteins", "TREATMENT", 368, 386], ["depletion", "OBSERVATION", 4, 13], ["HSC70 blocks", "OBSERVATION", 17, 29], ["L2", "ANATOMY", 52, 54], ["L2", "ANATOMY", 154, 156], ["viral capsid", "ANATOMY", 166, 178]]], ["Being a decisive component of CMA, HSC70 ensures the selectivity of target proteins and delivers the substrates to the receptor lysosome-associated membrane protein 2A (LAMP2A), in order to initiate the degradation (Kaushik and Cuervo, 2018) .", [["CMA", "SIMPLE_CHEMICAL", 30, 33], ["HSC70", "GENE_OR_GENE_PRODUCT", 35, 40], ["lysosome-associated membrane protein 2A", "GENE_OR_GENE_PRODUCT", 128, 167], ["LAMP2A", "GENE_OR_GENE_PRODUCT", 169, 175], ["HSC70", "PROTEIN", 35, 40], ["target proteins", "PROTEIN", 68, 83], ["receptor lysosome-associated membrane protein 2A", "PROTEIN", 119, 167], ["LAMP2A", "PROTEIN", 169, 175], ["the receptor lysosome", "TEST", 115, 136], ["CMA", "OBSERVATION", 30, 33]]], ["HCV infection induces lipid droplet accumulation and directly causes hepatocellular steatosis.", [["lipid droplet", "ANATOMY", 22, 35], ["hepatocellular", "ANATOMY", 69, 83], ["HCV infection", "DISEASE", 0, 13], ["steatosis", "DISEASE", 84, 93], ["HCV", "ORGANISM", 0, 3], ["lipid droplet", "SIMPLE_CHEMICAL", 22, 35], ["hepatocellular steatosis", "PATHOLOGICAL_FORMATION", 69, 93], ["HCV", "SPECIES", 0, 3], ["HCV infection", "PROBLEM", 0, 13], ["lipid droplet accumulation", "PROBLEM", 22, 48], ["hepatocellular steatosis", "PROBLEM", 69, 93], ["infection", "OBSERVATION", 4, 13], ["lipid", "OBSERVATION", 22, 27], ["droplet accumulation", "OBSERVATION", 28, 48], ["hepatocellular steatosis", "OBSERVATION", 69, 93]]], ["Long-term co-culture of free fatty acids (FFAs) and HCV in Huh7.5 cells activates CMA and downregulates IFNAR1, impairing the IFN-\u03b1-induced JAK-STAT antiviral signal pathway (Gunduz et al., 2012) .", [["Huh7.5 cells", "ANATOMY", 59, 71], ["fatty acids", "CHEMICAL", 29, 40], ["FFAs", "CHEMICAL", 42, 46], ["fatty acids", "CHEMICAL", 29, 40], ["free fatty acids", "SIMPLE_CHEMICAL", 24, 40], ["FFAs", "SIMPLE_CHEMICAL", 42, 46], ["HCV", "ORGANISM", 52, 55], ["Huh7.5 cells", "CELL", 59, 71], ["CMA", "GENE_OR_GENE_PRODUCT", 82, 85], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 104, 110], ["IFN-\u03b1-", "GENE_OR_GENE_PRODUCT", 126, 132], ["JAK", "GENE_OR_GENE_PRODUCT", 140, 143], ["STAT", "GENE_OR_GENE_PRODUCT", 144, 148], ["Huh7.5 cells", "CELL_LINE", 59, 71], ["IFNAR1", "PROTEIN", 104, 110], ["IFN", "PROTEIN", 126, 129], ["JAK", "PROTEIN", 140, 143], ["STAT", "PROTEIN", 144, 148], ["HCV", "SPECIES", 52, 55], ["free fatty acids", "TEST", 24, 40], ["FFAs", "TEST", 42, 46], ["HCV", "PROBLEM", 52, 55], ["IFNAR1", "PROBLEM", 104, 110], ["the IFN", "TEST", 122, 129], ["JAK", "TEST", 140, 143]]], ["In HCV-infected Huh7.5 cells with FFA treatment, IFNAR1 is selectively degraded through interacting with HSC70 and LAMP2A on the lysosome membrane, suggesting that HSC70 inhibits host anti-HCV immunity through mediating autophagy (Ramazan et al., 2015) .", [["Huh7.5 cells", "ANATOMY", 16, 28], ["lysosome membrane", "ANATOMY", 129, 146], ["HCV-infected", "DISEASE", 3, 15], ["FFA", "CHEMICAL", 34, 37], ["HCV", "ORGANISM", 3, 6], ["Huh7.5 cells", "CELL", 16, 28], ["FFA", "SIMPLE_CHEMICAL", 34, 37], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 49, 55], ["HSC70", "GENE_OR_GENE_PRODUCT", 105, 110], ["LAMP2A", "GENE_OR_GENE_PRODUCT", 115, 121], ["lysosome membrane", "CELLULAR_COMPONENT", 129, 146], ["HSC70", "GENE_OR_GENE_PRODUCT", 164, 169], ["Huh7.5 cells", "CELL_LINE", 16, 28], ["IFNAR1", "PROTEIN", 49, 55], ["HSC70", "PROTEIN", 105, 110], ["LAMP2A", "PROTEIN", 115, 121], ["HSC70", "PROTEIN", 164, 169], ["HCV", "SPECIES", 3, 6], ["HCV", "PROBLEM", 3, 6], ["FFA treatment", "TREATMENT", 34, 47], ["HSC70", "TEST", 105, 110], ["the lysosome membrane", "TREATMENT", 125, 146], ["HCV", "OBSERVATION", 3, 6], ["infected", "OBSERVATION_MODIFIER", 7, 15], ["Huh7.5 cells", "OBSERVATION_MODIFIER", 16, 28], ["lysosome membrane", "OBSERVATION", 129, 146]]], ["Another study suggests that HCV NS5A protein interacts with HSC70 and recruits HSC70 to hepatocyte nuclear factor 1 alpha (HNF-\u03b1), thereby promoting the CMA-dependent lysosomal degradation of HNF-\u03b1 and facilitating virus pathogenesis (Matsui et al., 2018) .", [["lysosomal", "ANATOMY", 167, 176], ["HCV", "ORGANISM", 28, 31], ["HSC70", "GENE_OR_GENE_PRODUCT", 60, 65], ["HSC70", "GENE_OR_GENE_PRODUCT", 79, 84], ["hepatocyte nuclear factor 1 alpha", "GENE_OR_GENE_PRODUCT", 88, 121], ["HNF-\u03b1", "GENE_OR_GENE_PRODUCT", 123, 128], ["CMA", "SIMPLE_CHEMICAL", 153, 156], ["lysosomal", "CELLULAR_COMPONENT", 167, 176], ["HNF-\u03b1", "GENE_OR_GENE_PRODUCT", 192, 197], ["HCV NS5A protein", "PROTEIN", 28, 44], ["HSC70", "PROTEIN", 60, 65], ["HSC70", "PROTEIN", 79, 84], ["hepatocyte nuclear factor 1 alpha", "PROTEIN", 88, 121], ["HNF", "PROTEIN", 123, 126], ["\u03b1", "PROTEIN", 127, 128], ["HNF", "PROTEIN", 192, 195], ["\u03b1", "PROTEIN", 196, 197], ["HCV", "SPECIES", 28, 31], ["Another study", "TEST", 0, 13], ["HCV NS5A protein interacts", "PROBLEM", 28, 54], ["HSC70", "TEST", 60, 65], ["HSC70", "TEST", 79, 84], ["hepatocyte nuclear factor", "TEST", 88, 113], ["alpha (HNF", "TEST", 116, 126], ["the CMA", "PROBLEM", 149, 156], ["dependent lysosomal degradation of HNF", "PROBLEM", 157, 195], ["facilitating virus pathogenesis", "PROBLEM", 202, 233], ["HCV", "OBSERVATION", 28, 31], ["lysosomal degradation", "OBSERVATION", 167, 188]]], ["Interestingly, HSC70 can directly participate in cellular host innate immunity by the DNA-dependent protein kinase (DNA-PK) DNA sensing pathway, which induces a robust and broad antiviral response via a non-classical DNA sensing pathway.", [["cellular", "ANATOMY", 49, 57], ["HSC70", "GENE_OR_GENE_PRODUCT", 15, 20], ["cellular", "CELL", 49, 57], ["DNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 86, 114], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["-PK", "GENE_OR_GENE_PRODUCT", 119, 122], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["HSC70", "PROTEIN", 15, 20], ["DNA-dependent protein kinase", "PROTEIN", 86, 114], ["the DNA", "TEST", 82, 89], ["dependent protein kinase", "PROBLEM", 90, 114], ["DNA", "TEST", 116, 119], ["DNA sensing pathway", "TEST", 124, 143], ["a non-classical DNA sensing pathway", "TREATMENT", 201, 236], ["antiviral response", "OBSERVATION", 178, 196]]], ["Invasive viral DNA activates DNA-PK and further triggers phosphorylation of HSC70 on Ser 638 and IRF3 on Ser 386 to regulate downstream IFN expression.", [["Ser", "CHEMICAL", 85, 88], ["Ser", "CHEMICAL", 105, 108], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["-PK", "GENE_OR_GENE_PRODUCT", 32, 35], ["HSC70", "GENE_OR_GENE_PRODUCT", 76, 81], ["Ser 638", "AMINO_ACID", 85, 92], ["IRF3", "GENE_OR_GENE_PRODUCT", 97, 101], ["Ser 386", "AMINO_ACID", 105, 112], ["IFN", "GENE_OR_GENE_PRODUCT", 136, 139], ["HSC70", "PROTEIN", 76, 81], ["Ser 638", "PROTEIN", 85, 92], ["IRF3", "PROTEIN", 97, 101], ["IFN", "PROTEIN", 136, 139], ["Invasive viral DNA", "TEST", 0, 18], ["further triggers phosphorylation", "TEST", 40, 72], ["HSC70", "TEST", 76, 81], ["Ser", "TEST", 85, 88]]], ["E1A oncogene of human adenovirus 5 restricts host antiviral response through antagonizing HSC70 and IRF3 phosphorylation (Burleigh et al., 2020) .", [["E1A", "GENE_OR_GENE_PRODUCT", 0, 3], ["human adenovirus 5", "ORGANISM", 16, 34], ["HSC70", "GENE_OR_GENE_PRODUCT", 90, 95], ["IRF3", "GENE_OR_GENE_PRODUCT", 100, 104], ["E1A oncogene", "DNA", 0, 12], ["HSC70", "PROTEIN", 90, 95], ["IRF3", "PROTEIN", 100, 104], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["E1A oncogene of human adenovirus", "TREATMENT", 0, 32], ["antagonizing HSC70", "TREATMENT", 77, 95], ["IRF3 phosphorylation", "TREATMENT", 100, 120]]], ["Besides being involved in innate immunity, HSC70 also has a role in host adaptive immunity through antigen processing and presentation.", [["HSC70", "GENE_OR_GENE_PRODUCT", 43, 48], ["HSC70", "PROTEIN", 43, 48]]], ["HSC70 presents peptide antigens to CD4 + T cells, with a potential to regulate T and B cell activation and the final secretion of antibodies by plasma cells (Dengjel et al., 2005; Deffit and Blum, 2015) .", [["CD4 + T cells", "ANATOMY", 35, 48], ["B cell", "ANATOMY", 85, 91], ["plasma cells", "ANATOMY", 144, 156], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 35, 38], ["T", "CELL", 79, 80], ["B cell", "CELL", 85, 91], ["plasma cells", "CELL", 144, 156], ["HSC70", "PROTEIN", 0, 5], ["CD4", "PROTEIN", 35, 38], ["T cells", "CELL_TYPE", 41, 48], ["antibodies", "PROTEIN", 130, 140], ["plasma cells", "CELL_TYPE", 144, 156], ["HSC70", "TEST", 0, 5], ["T cells", "PROBLEM", 41, 48], ["B cell activation", "TEST", 85, 102]]], ["HSV-2 could block transporter associated with antigen processing (TAP) function in infected cells to interfere with viral peptide presentation by MHC-I to CD8 + T cells and induces immune evasion (Laing et al., 2010) .", [["cells", "ANATOMY", 92, 97], ["CD8 + T cells", "ANATOMY", 155, 168], ["HSV-2", "ORGANISM", 0, 5], ["TAP", "GENE_OR_GENE_PRODUCT", 66, 69], ["cells", "CELL", 92, 97], ["MHC-I", "GENE_OR_GENE_PRODUCT", 146, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 155, 158], ["TAP", "PROTEIN", 66, 69], ["infected cells", "CELL_TYPE", 83, 97], ["MHC", "PROTEIN", 146, 149], ["CD8", "PROTEIN", 155, 158], ["T cells", "CELL_TYPE", 161, 168], ["HSV", "PROBLEM", 0, 3], ["antigen processing", "PROBLEM", 46, 64], ["infected cells", "PROBLEM", 83, 97], ["infected cells", "OBSERVATION", 83, 97]]], ["However, HSC70-based HSV-2 peptide vaccine elicits robust CD4 + and CD8 + T cell response with good safety profile, indicating that HSC70 might facilitate CD4 + T cell to recognize the antigen and boost host antiviral immune, and the research finding has been applied to the phase I clinical trial (Wald et al., 2011) .DISCUSSIONAs a multitask chaperone protein, HSC70 acts as a main or substeersman, being involved in many different cellular biological processes.", [["CD4 +", "ANATOMY", 58, 63], ["CD8 + T cell", "ANATOMY", 68, 80], ["CD4 + T cell", "ANATOMY", 155, 167], ["cellular", "ANATOMY", 434, 442], ["HSC70", "GENE_OR_GENE_PRODUCT", 9, 14], ["HSV-2 peptide", "ORGANISM", 21, 34], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 68, 71], ["HSC70", "GENE_OR_GENE_PRODUCT", 132, 137], ["CD4", "GENE_OR_GENE_PRODUCT", 155, 158], ["HSC70", "GENE_OR_GENE_PRODUCT", 363, 368], ["cellular", "CELL", 434, 442], ["HSC70", "PROTEIN", 9, 14], ["CD4", "PROTEIN", 58, 61], ["CD8", "PROTEIN", 68, 71], ["HSC70", "PROTEIN", 132, 137], ["CD4", "PROTEIN", 155, 158], ["multitask chaperone protein", "PROTEIN", 334, 361], ["HSC70", "PROTEIN", 363, 368], ["HSC70", "TEST", 9, 14], ["HSV", "TEST", 21, 24], ["CD4", "TEST", 58, 61], ["CD8", "TEST", 68, 71], ["HSC70", "TEST", 132, 137], ["CD4 + T cell", "PROBLEM", 155, 167], ["the antigen", "TEST", 181, 192], ["boost host antiviral immune", "TREATMENT", 197, 224], ["cellular biological processes", "OBSERVATION", 434, 463]]], ["With virus infection, however, these physiological functions are interrupted and HSC70 is hijacked to assist virus propagation.", [["infection", "DISEASE", 11, 20], ["HSC70", "GENE_OR_GENE_PRODUCT", 81, 86], ["HSC70", "PROTEIN", 81, 86], ["virus infection", "PROBLEM", 5, 20], ["HSC70", "TEST", 81, 86], ["virus", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20]]], ["Many studies have demonstrated that HSC70 is a major target utilized by either enveloped or non-enveloped DNA or RNA virus to participate in different infective stages.", [["HSC70", "GENE_OR_GENE_PRODUCT", 36, 41], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["HSC70", "PROTEIN", 36, 41], ["non-enveloped DNA", "DNA", 92, 109], ["Many studies", "TEST", 0, 12], ["HSC70", "TEST", 36, 41], ["non-enveloped DNA", "PROBLEM", 92, 109], ["RNA virus", "PROBLEM", 113, 122], ["different infective stages", "PROBLEM", 141, 167], ["infective", "OBSERVATION_MODIFIER", 151, 160]]], ["However, HSC70 is not only coerced into facilitating virus infection but also acts as a resister to eliminate virus by boosting cellular antiviral innate and adaptive immune response.", [["cellular", "ANATOMY", 128, 136], ["infection", "DISEASE", 59, 68], ["HSC70", "GENE_OR_GENE_PRODUCT", 9, 14], ["cellular", "CELL", 128, 136], ["HSC70", "PROTEIN", 9, 14], ["HSC70", "TEST", 9, 14], ["facilitating virus infection", "PROBLEM", 40, 68], ["virus", "PROBLEM", 110, 115], ["virus", "OBSERVATION", 53, 58]]], ["Therefore, this review summarizes the diverse roles of HSC70 in virus infections (Figure 2) , to deepen the understanding of the interaction between virus and host and promote the further study of viral pathogenesis.DISCUSSIONHSC70 is an important housekeeping protein, mostly responsible for maintaining protein homeostasis in nonstressed conditions and involved in rapidly inducible cell protection following stress situations.", [["cell", "ANATOMY", 385, 389], ["infections", "DISEASE", 70, 80], ["HSC70", "GENE_OR_GENE_PRODUCT", 55, 60], ["cell", "CELL", 385, 389], ["HSC70", "PROTEIN", 55, 60], ["DISCUSSIONHSC70", "PROTEIN", 216, 231], ["housekeeping protein", "PROTEIN", 248, 268], ["HSC70 in virus infections", "PROBLEM", 55, 80], ["the interaction between virus", "PROBLEM", 125, 154], ["the further study", "TEST", 176, 193], ["viral pathogenesis", "PROBLEM", 197, 215], ["rapidly inducible cell protection", "TREATMENT", 367, 400], ["stress situations", "PROBLEM", 411, 428], ["inducible cell protection", "OBSERVATION", 375, 400]]], ["In contrast, HSC70 generally promotes, but rarely inhibits, virus infection through interacting with viral protein or viral gene, suggesting that many viruses benefit from host-defensive response to facilitate selfreplication and it might be a potential antiviral target to limit virus infections.", [["infection", "DISEASE", 66, 75], ["infections", "DISEASE", 286, 296], ["HSC70", "GENE_OR_GENE_PRODUCT", 13, 18], ["HSC70", "PROTEIN", 13, 18], ["viral protein", "PROTEIN", 101, 114], ["viral gene", "DNA", 118, 128], ["virus infection", "PROBLEM", 60, 75], ["viral protein or viral gene", "PROBLEM", 101, 128], ["many viruses", "PROBLEM", 146, 158], ["selfreplication", "TREATMENT", 210, 225], ["a potential antiviral target", "TREATMENT", 242, 270], ["virus infections", "PROBLEM", 280, 296], ["viruses", "OBSERVATION", 151, 158]]], ["Based on the fact that constitutive deletion of HSC70 is embryonically lethal in mice (Cazale et al., 2009 ) and knockdown with siRNA induces cell death (Wang et al., 2017) , allosteric regulation of HSC70 by compound or inhibitor is a better option to perturb its function.", [["cell", "ANATOMY", 142, 146], ["death", "DISEASE", 147, 152], ["HSC70", "GENE_OR_GENE_PRODUCT", 48, 53], ["mice", "ORGANISM", 81, 85], ["cell", "CELL", 142, 146], ["HSC70", "GENE_OR_GENE_PRODUCT", 200, 205], ["HSC70", "PROTEIN", 48, 53], ["HSC70", "PROTEIN", 200, 205], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["constitutive deletion of HSC70", "PROBLEM", 23, 53], ["cell death", "PROBLEM", 142, 152], ["allosteric regulation of HSC70", "TREATMENT", 175, 205], ["inhibitor", "TREATMENT", 221, 230]]], ["Studies have shown that the tylophorine analog, such as DCB-3503 and rac-cryptopleurine, specifically binds to the NBD of HSC70 and stimulates ATP hydrolysis in the presence of the poly U/UC motif of HCV RNA and thus inhibits viral translation consequently (Wang et al., 2018) .", [["tylophorine", "CHEMICAL", 28, 39], ["DCB-3503", "CHEMICAL", 56, 64], ["rac-cryptopleurine", "CHEMICAL", 69, 87], ["ATP", "CHEMICAL", 143, 146], ["poly U", "CHEMICAL", 181, 187], ["tylophorine", "CHEMICAL", 28, 39], ["DCB-3503", "CHEMICAL", 56, 64], ["rac-cryptopleurine", "CHEMICAL", 69, 87], ["ATP", "CHEMICAL", 143, 146], ["tylophorine", "SIMPLE_CHEMICAL", 28, 39], ["DCB-3503", "SIMPLE_CHEMICAL", 56, 64], ["rac-cryptopleurine", "SIMPLE_CHEMICAL", 69, 87], ["HSC70", "GENE_OR_GENE_PRODUCT", 122, 127], ["ATP", "SIMPLE_CHEMICAL", 143, 146], ["HCV", "ORGANISM", 200, 203], ["NBD", "PROTEIN", 115, 118], ["HSC70", "PROTEIN", 122, 127], ["poly U/UC motif", "RNA", 181, 196], ["HCV RNA", "RNA", 200, 207], ["HCV", "SPECIES", 200, 203], ["the tylophorine analog", "PROBLEM", 24, 46], ["DCB", "TEST", 56, 59], ["rac-cryptopleurine", "TREATMENT", 69, 87], ["the NBD of HSC70", "TEST", 111, 127], ["ATP hydrolysis", "PROBLEM", 143, 157], ["the poly U/UC motif", "TREATMENT", 177, 196], ["HCV RNA", "PROBLEM", 200, 207], ["viral translation", "PROBLEM", 226, 243], ["ATP hydrolysis", "OBSERVATION", 143, 157]]], ["As an ATP analog, adenosine derivative compound VER-155008 acts as a competitive inhibitor to bind the HSP70 family and induces conformational changes of HSC70, making it impossible for HSC70 to interact with infectious bursal disease virus (IBDV) VP2 protein and eventually inhibiting virus replication (Chen et al., 2020) .", [["ATP", "CHEMICAL", 6, 9], ["adenosine", "CHEMICAL", 18, 27], ["VER-155008", "CHEMICAL", 48, 58], ["infectious bursal disease", "DISEASE", 209, 234], ["ATP", "CHEMICAL", 6, 9], ["adenosine", "CHEMICAL", 18, 27], ["VER-155008", "CHEMICAL", 48, 58], ["ATP", "SIMPLE_CHEMICAL", 6, 9], ["adenosine derivative", "SIMPLE_CHEMICAL", 18, 38], ["VER-155008", "SIMPLE_CHEMICAL", 48, 58], ["HSP70", "GENE_OR_GENE_PRODUCT", 103, 108], ["HSC70", "GENE_OR_GENE_PRODUCT", 154, 159], ["HSC70", "GENE_OR_GENE_PRODUCT", 186, 191], ["infectious bursal disease virus", "ORGANISM", 209, 240], ["IBDV", "ORGANISM", 242, 246], ["VP2", "GENE_OR_GENE_PRODUCT", 248, 251], ["HSP70 family", "PROTEIN", 103, 115], ["HSC70", "PROTEIN", 154, 159], ["HSC70", "PROTEIN", 186, 191], ["infectious bursal disease virus (IBDV) VP2 protein", "PROTEIN", 209, 259], ["infectious bursal disease virus", "SPECIES", 209, 240], ["IBDV", "SPECIES", 242, 246], ["an ATP analog", "TREATMENT", 3, 16], ["adenosine derivative compound VER", "TREATMENT", 18, 51], ["a competitive inhibitor", "TREATMENT", 67, 90], ["conformational changes of HSC70", "PROBLEM", 128, 159], ["HSC70", "TREATMENT", 186, 191], ["infectious bursal disease virus", "PROBLEM", 209, 240], ["IBDV) VP2 protein", "TREATMENT", 242, 259]]], ["Therefore, HSC70 is a promising target for antivirals and needs to be further studied.DISCUSSIONMoreover, since HSC70 assists in the release and recycle of clathrin to form the endosome, preparing for membrane fusion, and transporting exogenous cargos to the subcellular sites, it is no doubt to play an integral role in virus invasion.", [["endosome", "ANATOMY", 177, 185], ["membrane", "ANATOMY", 201, 209], ["subcellular sites", "ANATOMY", 259, 276], ["HSC70", "GENE_OR_GENE_PRODUCT", 11, 16], ["HSC70", "GENE_OR_GENE_PRODUCT", 112, 117], ["clathrin", "GENE_OR_GENE_PRODUCT", 156, 164], ["endosome", "CELLULAR_COMPONENT", 177, 185], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["HSC70", "PROTEIN", 11, 16], ["HSC70", "PROTEIN", 112, 117], ["clathrin", "PROTEIN", 156, 164], ["antivirals", "TREATMENT", 43, 53], ["clathrin", "TREATMENT", 156, 164], ["membrane fusion", "TREATMENT", 201, 216], ["transporting exogenous cargos", "TREATMENT", 222, 251], ["virus invasion", "PROBLEM", 321, 335], ["no doubt", "UNCERTAINTY", 284, 292], ["virus invasion", "OBSERVATION", 321, 335]]], ["It is widely believed that coronaviruses enter the host cells via two routes, the particularly important endocytic pathway and the nonendosomal pathway (Yang and Shen, 2020) .", [["cells", "ANATOMY", 56, 61], ["coronaviruses", "ORGANISM", 27, 40], ["host cells", "CELL", 51, 61], ["host cells", "CELL_TYPE", 51, 61], ["coronaviruses", "PROBLEM", 27, 40], ["coronaviruses", "OBSERVATION", 27, 40], ["host cells", "OBSERVATION", 51, 61]]], ["However, whether HSC70 participates in coronavirus infection through influencing cell entry is still unknown.DISCUSSIONAlthough being initially characterized as a chaperon to stabilize protein homeostasis, the multifunctional roles of HSC70 in cellular biological processes make it possible to participate in different stages of virus life cycle.", [["cell", "ANATOMY", 81, 85], ["cellular", "ANATOMY", 244, 252], ["coronavirus infection", "DISEASE", 39, 60], ["HSC70", "GENE_OR_GENE_PRODUCT", 17, 22], ["coronavirus", "ORGANISM", 39, 50], ["cell", "CELL", 81, 85], ["HSC70", "GENE_OR_GENE_PRODUCT", 235, 240], ["cellular", "CELL", 244, 252], ["HSC70", "PROTEIN", 17, 22], ["HSC70", "PROTEIN", 235, 240], ["coronavirus", "SPECIES", 39, 50], ["coronavirus infection", "PROBLEM", 39, 60], ["influencing cell entry", "PROBLEM", 69, 91], ["protein homeostasis", "PROBLEM", 185, 204], ["virus life cycle", "TREATMENT", 329, 345], ["coronavirus infection", "OBSERVATION", 39, 60]]], ["As our understanding deepens, the underlying molecular mechanism of HSC70-regulating virus pathogenesis will be gradually elucidated, and the related antiviral drugs will be further developed.AUTHOR CONTRIBUTIONSZW and JW searched references and wrote the manuscript.", [["HSC70", "GENE_OR_GENE_PRODUCT", 68, 73], ["HSC70", "PROTEIN", 68, 73], ["HSC70-regulating virus pathogenesis", "PROBLEM", 68, 103], ["the related antiviral drugs", "TREATMENT", 138, 165]]], ["YL, XY, JZ, and YC contributed to revision of the manuscript.", [["revision", "TREATMENT", 34, 42], ["revision", "OBSERVATION", 34, 42]]], ["The funders had no role in the collection, analysis, and interpretation of data, or the decision to submit the work for publication.", [["analysis", "TEST", 43, 51], ["no role", "UNCERTAINTY", 16, 23]]]], "PMC7336133": [["Introduction to Red BiotechnologyBiotechnology derives from the Greek words \u2013 bios \u2013 life, technos \u2013 technology and logos \u2013 language, proof \u2013 that is biotechnology deals with the technical usage of living organisms for various purposes such as food, medicine, pharmaceuticals, recycling.", [["Red Biotechnology", "PROTEIN", 16, 33]]], ["Other categories are also in use, the division into plant biotechnology, animal biotechnology, biotechnology of microorganisms and its colonies, cell culture biotechnologies, biotechnology of subcellular systems.", [["colonies", "ANATOMY", 135, 143], ["cell", "ANATOMY", 145, 149], ["subcellular", "ANATOMY", 192, 203], ["cell", "CELL", 145, 149], ["microorganisms", "PROBLEM", 112, 126], ["its colonies", "PROBLEM", 131, 143], ["cell culture biotechnologies", "TEST", 145, 173], ["subcellular systems", "ANATOMY", 192, 211]]], ["The word \u2018biotechnology\u2019 was used for the first time by the director of the cattle utilization cooperative and Hungarian great land owner Karl Ereky and latter Hungarian Food minister.", [["cattle", "ORGANISM", 76, 82], ["cattle", "SPECIES", 76, 82]]], ["He published a book with the title: \u201cBiotechnology of the meat, fat and milk production in agricultural large concerns for scientific sophisticated farmers\u201d in 1919 in Berlin.", [["meat", "ANATOMY", 58, 62], ["fat", "ANATOMY", 64, 67], ["milk", "ANATOMY", 72, 76], ["meat", "ORGANISM_SUBDIVISION", 58, 62], ["fat", "TISSUE", 64, 67], ["milk", "ORGANISM_SUBSTANCE", 72, 76], ["fat", "ANATOMY", 64, 67]]], ["That was nothing new, but the word was new.Introduction to Red BiotechnologySo lets immerse in the world of biotechnology which is as colourful and fascinating as life itself.Introduction to Red BiotechnologyRed biotechnology deals with biotechnological techniques such as gene therapy (replacing a defective gene causing diseases by a healthy gene), stem cell research (to fight off leukaemia), genetic engineering (changing the genetic makeup of genes to produce improved organisms) and the development of new drugs and vaccines in medicine.Introduction to Red BiotechnologyAnother inventive application is tissue engineering.", [["stem cell", "ANATOMY", 351, 360], ["leukaemia", "ANATOMY", 384, 393], ["tissue", "ANATOMY", 609, 615], ["leukaemia", "DISEASE", 384, 393], ["stem cell", "CELL", 351, 360], ["leukaemia", "CANCER", 384, 393], ["tissue", "TISSUE", 609, 615], ["Red Biotechnology", "PROTEIN", 59, 76], ["Red Biotechnology", "PROTEIN", 191, 208], ["Red Biotechnology", "PROTEIN", 559, 576], ["Red biotechnology", "TREATMENT", 208, 225], ["biotechnological techniques", "TREATMENT", 237, 264], ["gene therapy", "TREATMENT", 273, 285], ["a defective gene", "TREATMENT", 297, 313], ["diseases", "PROBLEM", 322, 330], ["stem cell research", "TEST", 351, 369], ["leukaemia", "PROBLEM", 384, 393], ["genetic engineering", "TREATMENT", 396, 415], ["new drugs", "TREATMENT", 508, 517], ["vaccines in medicine", "TREATMENT", 522, 542], ["Another inventive application", "TREATMENT", 576, 605], ["new", "OBSERVATION_MODIFIER", 17, 20]]], ["That means that cells are cultivated for tissue implantation.", [["cells", "ANATOMY", 16, 21], ["tissue", "ANATOMY", 41, 47], ["cells", "CELL", 16, 21], ["tissue", "TISSUE", 41, 47], ["tissue implantation", "TREATMENT", 41, 60]]], ["This leads to the production of artificial skin, cartilage and spinal disc replacement.Introduction to Red BiotechnologyFurthermore red biotechnology finds also its application in the field of research about mutations and amplifications of genes to cure degenerative diseases such as Parkinson.Introduction to Red BiotechnologyIt is commonly known that certain drugs are not so effective for every patient because of its genetic disposition and metabolism.", [["skin", "ANATOMY", 43, 47], ["cartilage", "ANATOMY", 49, 58], ["spinal disc", "ANATOMY", 63, 74], ["degenerative diseases", "DISEASE", 254, 275], ["Parkinson", "DISEASE", 284, 293], ["skin", "ORGAN", 43, 47], ["cartilage", "TISSUE", 49, 58], ["spinal disc", "MULTI-TISSUE_STRUCTURE", 63, 74], ["patient", "ORGANISM", 398, 405], ["Red Biotechnology", "PROTEIN", 310, 327], ["patient", "SPECIES", 398, 405], ["artificial skin, cartilage and spinal disc replacement", "TREATMENT", 32, 86], ["mutations", "PROBLEM", 208, 217], ["amplifications of genes", "PROBLEM", 222, 245], ["cure degenerative diseases", "PROBLEM", 249, 275], ["Parkinson", "PROBLEM", 284, 293], ["artificial", "ANATOMY_MODIFIER", 32, 42], ["skin", "ANATOMY", 43, 47], ["cartilage", "ANATOMY", 49, 58], ["spinal disc", "ANATOMY", 63, 74], ["replacement", "OBSERVATION_MODIFIER", 75, 86], ["degenerative", "OBSERVATION_MODIFIER", 254, 266], ["diseases", "OBSERVATION", 267, 275]]], ["Therefore knowing the genetic disposition of a patient implies a better treatment by the analysis of the genes.Introduction to Red BiotechnologyIn conclusion red biotechnology means an immense progress in medicine which still has to be developed further.Introduction to Red BiotechnologyBy analysing some texts about red biotechnology pupils can gain a better inside.Introduction to Red BiotechnologyListen to the youtube video: www.youtube.com/watch?v=hv1U19J3yfwIntroduction to Red BiotechnologyIntroduction to red biotechnology and biopharmaceuticalsIntroduction to Red BiotechnologyNote five keywords and explain them more closely.Parkinson\u2019s Disease: Vitamin B3 Has a Positive Effect on Nerve Cells ::: Red Biotechnology (Tab. #!start#1.2#!sep#Tab2#!sep#table#!end#)Parkinson\u2019s disease is one of the most common neurodegenerative diseases in the world.", [["Nerve Cells", "ANATOMY", 692, 703], ["Parkinson\u2019s Disease", "DISEASE", 635, 654], ["Vitamin B3", "CHEMICAL", 656, 666], ["#!start#1.2#!sep#Tab2#!sep#table#!end#)Parkinson\u2019s disease", "DISEASE", 732, 790], ["neurodegenerative diseases", "DISEASE", 817, 843], ["Vitamin B3", "CHEMICAL", 656, 666], ["patient", "ORGANISM", 47, 54], ["Vitamin B3", "SIMPLE_CHEMICAL", 656, 666], ["Nerve Cells", "CELL", 692, 703], ["Red Biotechnology", "PROTEIN", 127, 144], ["patient", "SPECIES", 47, 54], ["a better treatment", "TREATMENT", 63, 81], ["the analysis", "TEST", 85, 97], ["biopharmaceuticals", "TREATMENT", 535, 553], ["Parkinson\u2019s Disease", "PROBLEM", 635, 654], ["Vitamin B3", "TREATMENT", 656, 666], ["Red Biotechnology", "TREATMENT", 708, 725], ["disease", "PROBLEM", 783, 790], ["neurodegenerative diseases", "PROBLEM", 817, 843], ["disease", "OBSERVATION", 783, 790], ["most common", "OBSERVATION_MODIFIER", 805, 816], ["neurodegenerative", "OBSERVATION_MODIFIER", 817, 834], ["diseases", "OBSERVATION", 835, 843]]], ["There are around 4.3 million sufferers worldwide.", [["4.3 million", "OBSERVATION_MODIFIER", 17, 28]]], ["It is characterised by motor impairments that result from the death of certain nerve cells in the brain.", [["nerve cells", "ANATOMY", 79, 90], ["brain", "ANATOMY", 98, 103], ["motor impairments", "DISEASE", 23, 40], ["death", "DISEASE", 62, 67], ["nerve cells", "CELL", 79, 90], ["brain", "ORGAN", 98, 103], ["nerve cells", "CELL_TYPE", 79, 90], ["motor impairments", "PROBLEM", 23, 40], ["the death of certain nerve cells in the brain", "PROBLEM", 58, 103], ["motor impairments", "OBSERVATION", 23, 40], ["nerve cells", "OBSERVATION", 79, 90], ["brain", "ANATOMY", 98, 103]]], ["Therapies are not yet available.", [["Therapies", "TREATMENT", 0, 9]]], ["However, researchers at the University of T\u00fcbingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.", [["nerve cells", "ANATOMY", 120, 131], ["vitamin B3", "CHEMICAL", 76, 86], ["vitamin B3", "CHEMICAL", 76, 86], ["vitamin B3", "SIMPLE_CHEMICAL", 76, 86], ["nerve cells", "CELL", 120, 131], ["damaged nerve cells", "CELL_TYPE", 112, 131], ["vitamin B3", "PROBLEM", 76, 86], ["damaged nerve cells", "PROBLEM", 112, 131], ["positive effect", "OBSERVATION_MODIFIER", 93, 108], ["nerve cells", "OBSERVATION", 120, 131]]], ["Vitamin B3 application will now be examined to determine whether it could be a new therapeutic approach for treating Parkinson\u2019s.Parkinson\u2019s Disease: Vitamin B3 Has a Positive Effect on Nerve Cells ::: Red Biotechnology (Tab. #!start#1.2#!sep#Tab2#!sep#table#!end#)Parkinson\u2019s is the second most common neurodegenerative disease after Alzheimer\u2019s.", [["Nerve Cells", "ANATOMY", 186, 197], ["Vitamin B3", "CHEMICAL", 0, 10], ["Parkinson\u2019s", "DISEASE", 117, 128], ["Parkinson\u2019s Disease", "DISEASE", 129, 148], ["Vitamin B3", "CHEMICAL", 150, 160], ["neurodegenerative disease", "DISEASE", 303, 328], ["Alzheimer\u2019s", "DISEASE", 335, 346], ["Vitamin B3", "CHEMICAL", 0, 10], ["Vitamin B3", "CHEMICAL", 150, 160], ["Vitamin B3", "SIMPLE_CHEMICAL", 0, 10], ["Vitamin B3", "SIMPLE_CHEMICAL", 150, 160], ["Nerve Cells", "CELL", 186, 197], ["Vitamin B3 application", "TREATMENT", 0, 22], ["a new therapeutic approach", "TREATMENT", 77, 103], ["Parkinson\u2019s", "PROBLEM", 117, 128], ["Parkinson\u2019s Disease", "PROBLEM", 129, 148], ["Vitamin B3", "TREATMENT", 150, 160], ["neurodegenerative disease", "PROBLEM", 303, 328], ["Alzheimer\u2019s", "PROBLEM", 335, 346], ["neurodegenerative", "OBSERVATION_MODIFIER", 303, 320], ["disease", "OBSERVATION", 321, 328]]], ["The disease affects around two percent of people over 60 worldwide, and the numbers are rising.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["The disease affects", "PROBLEM", 0, 19], ["disease", "OBSERVATION", 4, 11], ["rising", "OBSERVATION_MODIFIER", 88, 94]]], ["Between 250,000 and 280,000 people have the disease in Germany alone.", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34], ["disease", "OBSERVATION", 44, 51]]], ["Typical symptoms of this still incurable disease include motor impairments such as unsteady hands, stiff muscles and slow movements.", [["muscles", "ANATOMY", 105, 112], ["motor impairments", "DISEASE", 57, 74], ["hands", "ORGANISM_SUBDIVISION", 92, 97], ["muscles", "ORGANISM_SUBDIVISION", 105, 112], ["Typical symptoms", "PROBLEM", 0, 16], ["this still incurable disease", "PROBLEM", 20, 48], ["motor impairments", "PROBLEM", 57, 74], ["unsteady hands, stiff muscles", "PROBLEM", 83, 112], ["slow movements", "PROBLEM", 117, 131], ["motor impairments", "OBSERVATION", 57, 74], ["stiff muscles", "ANATOMY", 99, 112]]], ["The disease is caused by the loss of dopamine-containing nerve cells in a certain brain region called the black substance (substantia nigra).", [["nerve cells", "ANATOMY", 57, 68], ["brain", "ANATOMY", 82, 87], ["substantia nigra", "ANATOMY", 123, 139], ["dopamine", "CHEMICAL", 37, 45], ["dopamine", "CHEMICAL", 37, 45], ["dopamine", "SIMPLE_CHEMICAL", 37, 45], ["nerve cells", "CELL", 57, 68], ["brain", "ORGAN", 82, 87], ["substantia nigra", "ORGANISM", 123, 139], ["nerve cells", "CELL_TYPE", 57, 68], ["The disease", "PROBLEM", 0, 11], ["the loss of dopamine", "PROBLEM", 25, 45], ["nerve cells", "PROBLEM", 57, 68], ["disease", "OBSERVATION", 4, 11], ["loss", "OBSERVATION_MODIFIER", 29, 33], ["nerve cells", "OBSERVATION", 57, 68], ["brain", "ANATOMY", 82, 87], ["black substance", "OBSERVATION", 106, 121]]], ["Little is yet known why these nerve cells die.Parkinson\u2019s Disease: Vitamin B3 Has a Positive Effect on Nerve Cells ::: Red Biotechnology (Tab. #!start#1.2#!sep#Tab2#!sep#table#!end#)For many years, junior professor Dr. Dr. Michela Deleidi and her research group at the Hertie Institute for Clinical Brain Research and the University of T\u00fcbingen have been studying how Parkinson\u2019s disease develops.", [["nerve cells", "ANATOMY", 30, 41], ["Nerve Cells", "ANATOMY", 103, 114], ["Parkinson\u2019s Disease", "DISEASE", 46, 65], ["Vitamin B3", "CHEMICAL", 67, 77], ["Parkinson\u2019s disease", "DISEASE", 368, 387], ["Vitamin B3", "CHEMICAL", 67, 77], ["nerve cells", "CELL", 30, 41], ["Vitamin B3", "SIMPLE_CHEMICAL", 67, 77], ["Nerve Cells", "CELL", 103, 114], ["nerve cells", "CELL_TYPE", 30, 41], ["Tab", "PROTEIN", 138, 141], ["Parkinson\u2019s Disease", "PROBLEM", 46, 65], ["Vitamin B3", "TREATMENT", 67, 77], ["Parkinson\u2019s disease", "PROBLEM", 368, 387]]], ["\u201cSome time ago, we came up with the idea that the disease is caused by damaged nerve cells with a dysfunctional energy metabolism, and hence damaged mitochondria,\u201d explains Deleid1.", [["nerve cells", "ANATOMY", 79, 90], ["mitochondria", "ANATOMY", 149, 161], ["nerve cells", "CELL", 79, 90], ["mitochondria", "CELLULAR_COMPONENT", 149, 161], ["Deleid1", "GENE_OR_GENE_PRODUCT", 173, 180], ["damaged nerve cells", "CELL_TYPE", 71, 90], ["Deleid1", "PROTEIN", 173, 180], ["the disease", "PROBLEM", 46, 57], ["damaged nerve cells", "PROBLEM", 71, 90], ["a dysfunctional energy metabolism", "PROBLEM", 96, 129], ["disease", "OBSERVATION", 50, 57], ["nerve cells", "OBSERVATION", 79, 90]]], ["\u201cAnd indeed, in one of our studies, we found that the mitochondria in the affected nerve cells of Parkinson\u2019s patients did not work properly.", [["mitochondria", "ANATOMY", 54, 66], ["nerve cells", "ANATOMY", 83, 94], ["Parkinson\u2019s", "DISEASE", 98, 109], ["mitochondria", "CELLULAR_COMPONENT", 54, 66], ["nerve cells", "CELL", 83, 94], ["patients", "ORGANISM", 110, 118], ["affected nerve cells", "CELL_TYPE", 74, 94], ["patients", "SPECIES", 110, 118], ["our studies", "TEST", 23, 34], ["the mitochondria", "PROBLEM", 50, 66], ["affected nerve", "ANATOMY", 74, 88]]], ["So we then decided to look for a way to repair and improve mitochondrial function.\u201dParkinson\u2019s Disease: Vitamin B3 Has a Positive Effect on Nerve Cells ::: Red Biotechnology (Tab. #!start#1.2#!sep#Tab2#!sep#table#!end#)In search of a \u201cmitochondrial rescue\u201d, as Deleidi calls it, the researchers came across vitamin B3.", [["mitochondrial", "ANATOMY", 59, 72], ["Nerve Cells", "ANATOMY", 140, 151], ["mitochondrial", "ANATOMY", 235, 248], ["Parkinson\u2019s Disease", "DISEASE", 83, 102], ["Vitamin B3", "CHEMICAL", 104, 114], ["vitamin B3", "CHEMICAL", 307, 317], ["Vitamin B3", "CHEMICAL", 104, 114], ["vitamin B3", "CHEMICAL", 307, 317], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["Vitamin B3", "SIMPLE_CHEMICAL", 104, 114], ["Nerve Cells", "CELL", 140, 151], ["mitochondrial", "CELLULAR_COMPONENT", 235, 248], ["vitamin B3", "SIMPLE_CHEMICAL", 307, 317], ["Tab", "PROTEIN", 175, 178], ["repair", "TREATMENT", 40, 46], ["Parkinson\u2019s Disease", "PROBLEM", 83, 102], ["Vitamin B3", "TREATMENT", 104, 114], ["vitamin B3", "TREATMENT", 307, 317], ["mitochondrial function", "OBSERVATION", 59, 81]]], ["\u201cIt has long been known that vitamin B3 plays a role in central metabolic processes, and some studies have shown that the vitamin plays a role in maintaining healthy mitochondria,\u201d says the neurologist.", [["mitochondria", "ANATOMY", 166, 178], ["vitamin B3", "CHEMICAL", 29, 39], ["vitamin", "CHEMICAL", 122, 129], ["vitamin B3", "CHEMICAL", 29, 39], ["vitamin", "CHEMICAL", 122, 129], ["vitamin B3", "GENE_OR_GENE_PRODUCT", 29, 39], ["vitamin", "SIMPLE_CHEMICAL", 122, 129], ["mitochondria", "CELLULAR_COMPONENT", 166, 178], ["vitamin B3", "TREATMENT", 29, 39], ["some studies", "TEST", 89, 101]]], ["\u201cSo it was natural for us to look at the vitamin and its potential role in the treatment of Parkinson\u2019s.\u201dParkinson\u2019s Disease: Vitamin B3 Has a Positive Effect on Nerve Cells ::: Red Biotechnology (Tab. #!start#1.2#!sep#Tab2#!sep#table#!end#)", [["Nerve Cells", "ANATOMY", 162, 173], ["vitamin", "CHEMICAL", 41, 48], ["Parkinson\u2019s", "DISEASE", 92, 103], ["Parkinson\u2019s Disease", "DISEASE", 105, 124], ["Vitamin B3", "CHEMICAL", 126, 136], ["vitamin", "CHEMICAL", 41, 48], ["Vitamin B3", "CHEMICAL", 126, 136], ["vitamin", "SIMPLE_CHEMICAL", 41, 48], ["Vitamin B3", "SIMPLE_CHEMICAL", 126, 136], ["Nerve Cells", "CELL", 162, 173], ["Tab", "PROTEIN", 197, 200], ["the vitamin", "TREATMENT", 37, 48], ["Parkinson\u2019s", "PROBLEM", 92, 103], ["Parkinson\u2019s Disease", "PROBLEM", 105, 124], ["Vitamin B3", "TREATMENT", 126, 136], ["Parkinson", "OBSERVATION", 92, 101]]]], "PMC7262179": []}